Needs of Veterans With Personality Disorder Diagnoses in Community-Based Mental Health Care

Article Type
Changed
Tue, 05/20/2025 - 13:25
Display Headline

Needs of Veterans With Personality Disorder Diagnoses in Community-Based Mental Health Care

Personality disorders (PDs) are enduring patterns of internal experience and behavior that differ from cultural norms and expectations, are inflexible and pervasive, have their onset in adolescence or early adulthood, and lead to distress or impairment. Ten PDs are included in the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition): paranoid, schizoid, schizotypal, borderline, antisocial, histrionic, narcissistic, avoidant, dependent, and obsessive-compulsive.1 These disorders impose a high burden on patients, families, health care systems, and broader economic systems.2,3 Up to 1 in 7 persons in the community and 50% of those receiving outpatient mental health treatment experience a PD.4,5 These conditions are associated with an increased risk of adverse events, including suicide attempt and death by suicide, criminal-legal involvement, homelessness, substance use, underemployment, relational issues, and high utilization of psychiatric services.6-9 PDs are routinely underassessed, underdocumented, and undertreated in clinical settings, and consistently receive less research funding than other, less prevalent forms of psychopathology. 10-12 As a result, there is limited understanding of clinical needs of individuals experiencing PDs.

MILITARY VETERANS WITH PERSONALITY DISORDERS

Underacknowledgment of PDs and their associated difficulties may be especially pronounced in veteran populations. Due to longstanding etiological theories that implicate childhood trauma and adolescent onset in pathology development, PDs are traditionally considered pre-existing conditions or developmental abnormalities by the US Department of Defense and US Department of Veterans Affairs (VA). As a result, PDs are therefore deemed incompatible with military service and ineligible for service-connected disability benefits.13-15 Such determinations allowed PD pathology to be used as grounds for discharge for 26,000 service members from 2001 to 2007, or 2.6% of total enlisted discharges during that period.13,15,16

Despite this structural discrimination, recent research suggests veterans may be more likely to experience PD pathology than the general population.17 For example, a 2021 epidemiological survey in a community-based veteran sample found elevated rates of borderline, antisocial, and schizotypal PDs (6%-13%).6 In contrast, only 0.8% to 5.0% of veteran electronic health records (EHRs) have a documented PD diagnosis.8,18,19 Such elevations in PD pathology within veteran samples imply either a disproportionately high prevalence among enlistees (and therefore missed during recruitment procedures) or onset following military service, possibly due to exposure to traumatic events and/ or occupational stress.17 Due to the relative infancy of research in this area and a lack of longitudinal studies, etiology and course of illness for personality pathology in veterans remains largely unclear.

Structural underacknowledgment of PDs among military personnel has contributed to their underrepresentation in research on veteran populations. PD-focused research with veterans is rare, despite a rapid increase in broader empirical attention paid to these conditions in nonveteran samples.20 A recent meta-analysis of veterans with PDs identified 27 studies that included basic prevalence statistics. PDs were rarely a primary focus for these studies, and most were limited to veterans seen in Veterans Health Administration (VHA) settings.17 The literature also paints a bleak picture, suggesting veterans who experience PDs are at higher risk for suicide attempt and death by suicide, criminal-legal involvement, and homelessness. They also tend to experience more severe comorbid psychopathological symptoms and more often use high-intensity mental health services (eg, care within emergency departments or psychiatric inpatient settings) than veterans without PD pathology.6,8,18,19,21 However, PD pathology does not appear to impede the effectiveness of treatment for veterans.22-24 The implications of PD pathology on broader psychosocial functioning and health care needs certify a need for additional research that examines patterns of personality pathology, particularly in veterans outside the VHA.

METHODS

This study aims to enhance understanding of veterans affected by PDs and offer insight and guidance for treatment of these conditions in federal and nonfederal treatment settings. Previous research has been largely limited to VHA care-receiving samples; the longstanding stigma against PDs by the US military and VA may contribute to biased diagnosis and documentation of PDs in these settings. A large sample of veterans receiving community-based mental health care was therefore used to explore aims of the current study. This study specifically examined demographic patterns, diagnostic comorbidity, psychosocial outcomes, and treatment care settings among veterans with and without a PD diagnosis. Consistent with previous research, we hypothesized that veterans with a PD diagnosis would have more severe mental health comorbidities, poorer psychosocial outcomes, and receive care in higher intensity settings relative to veterans without a diagnosis.

Data for the sample were drawn from the Mental Health Client-Level Data, a publicly available national dataset of nearly 7 million patients who received mental health treatment services provided or funded through state mental health agencies in 2022.25 The analytic sample included about 2.5 million patients for whom veteran status and data around the presence or absence of a PD diagnosis were available. Of these patients, 104,198 were identified as veterans. Veteran patients were identified as predominantly male (63%), White (71%), non-Hispanic (90%), and never married (54%).

Measures

The parent dataset included demographic, clinical, and psychosocial outcome information reported by treatment facilities to individual state administrative systems for each patient who received services. To protect patient privacy, only nonprotected health information is included, and efforts were made throughout compilation of the parent dataset to ensure patient privacy (eg, limiting detail of information disseminated for public access). Because the parent dataset does not include protected health information, studies using these data are considered exempt from institutional review board oversight.

Demographic information. This study reviewed veteran status, sex, race, ethnicity, age, education, and marital status. Veteran status was defined by whether the patient was aged ≥ 18 years and had previously served (but was not currently serving) in the military. Patients with a history of service in the National Guard or Military Reserves were only classified as veterans if they had been called or ordered to active duty while serving. Sex was operationalized dichotomously as male or female; no patients were identified as intersex, transgender, or other gender identities.

Clinical information. Up to 3 mental health diagnoses were reported for each patient and included the following disorders: personality, trauma and attention-deficit/hyperactivity, stressor, anxiety, conduct, delirium/dementia, bipolar, depressive, oppositional defiant, pervasive developmental, schizophrenia or other psychotic, and alcohol or substance use. Mental health diagnosis categories were generated for the parent dataset by grouping diagnostic codes corresponding to each category. To protect patient privacy, more detailed diagnostic information was not available as part of the parent dataset. Although the American Psychiatric Association recognizes 10 distinct PDs, the exact nature of PD diagnoses was not included within the parent dataset. PD diagnoses were coded to reflect the presence or absence of any such diagnosis.

A substance use problem designation was also provided for patients according to various identification methods, including substance use disorder (SUD) diagnosis, substance use screening results, enrollment in a substance use program, substance use survey, service claims information, and other related sources of information. A severe mental illness or serious emotional disturbance designation was provided for patients meeting state definitions of these designations. Context(s) of service provision were coded as inpatient state psychiatric hospital, community-based program, residential treatment center, judicial institution, or other psychiatric inpatient setting.

Psychosocial outcome information. Patient employment and residential status were also included in analyses. Each reflected status at the time of discharge from services or end of reporting period; employment status was only provided for patients receiving treatment in community-based programs.

Data Analysis

Descriptive statistics and X2 analyses were used to compare demographic, clinical, and psychosocial outcome variables between patients with and without PD diagnoses. These analyses were calculated for both the 104,198 veterans and the 2,222,306 nonveterans aged ≥ 18 years in the dataset. Given the sample size, a conservative α of .01 was used to determine statistical significance.

RESULTS

In this sample of persons receiving state-funded mental health care, veterans were significantly less likely than nonveterans to have a documented PD diagnosis (2.1% vs 3.6%, X2 [1] = 647.49; P < .01). PD diagnoses were more common among White (risk ratio [RR], 1.11), non-Hispanic (RR, 1.03) veterans who were in middle to late adulthood (RR, 1.16-1.40), more educated (RR, 1.35), and divorced or widowed (RR, 1.43), and less common among Black/African American (RR, 0.78) or Puerto Rican (RR, 0.32) veterans who were in early adulthood (RR, 0.31-0.79), less educated (RR, 0.64-0.89), and currently married (RR, 0.89) or never married (RR, 0.86). Veteran men and women were equally likely to have a PD diagnosis (RR, 1.03) (Table 1). Among nonveterans, men were less likely than women to have a PD diagnosis (RR, 0.79), and PD diagnoses were most common among persons in middle adulthood (RR, 1.06-1.15) (eAppendix 1).

0425FED-MH-PD-012T10425FED-MH-PD-012_eA1

Veterans with a PD diagnosis were more likely than those without a diagnosis to have more diagnoses (RR, 2.96-8.49) and to have comorbid trauma or related stressor (RR, 1.33), or bipolar (RR, 1.56) or psychotic (RR, 1.15) disorder diagnoses, but less likely to have comorbid depressive disorder (RR, 0.82). Although veterans with and without a PD diagnosis were similarly likely to have a comorbid SUD (RR, 1.13), those with a PD diagnosis were significantly less likely to be assigned a substance use problem designation (RR, 0.78). PD diagnosis was also more common among veterans who received services in state psychiatric hospitals (RR, 3.05), community-based clinics (RR, 1.06), and judicial institutions (RR, 6.33) and less common among those who received services in other psychiatric inpatient settings (RR, 0.30). No differences were observed for residential treatment settings (RR, 0.79). Among nonveterans, a PD diagnosis was associated with slightly greater odds of a substance use designation (RR, 1.03) (eAppendix 2).

0425FED-MH-PD-012_eA2

Veterans with a PD diagnosis were also less likely to have full-time employment (RR, 0.73) and more likely to have undifferentiated employment (RR, 2.00) or to be removed from the labor force (RR, 1.35). Veterans with a PD diagnosis were also more likely to reside in nontraditional living conditions (RR, 1.42) and less likely to be residing in a private residence (RR, 0.98), compared with those without PD diagnosis. The rates of homelessness were similar for veterans with and without a PD diagnosis (RR, 0.90) (Table 2). These patterns were similar among nonveterans.

0425FED-MH-PD-012T2

DISCUSSION

This study examined the rate and correlates of PD diagnosis among a large, community-based sample of veterans receiving state-funded mental health care. About 2% of veterans in this sample had a PD diagnosis, with diagnoses more common among veterans who were White, non-Hispanic, aged ≥ 45 years, with higher education, divorced or widowed, also diagnosed with trauma-related, bipolar, and/or psychotic disorders, underemployed, nontraditionally housed, and receiving treatment in state psychiatric hospital, community-based clinic, or judicial system settings.

The observed rate of PD diagnosis in this study aligns with what is typically observed in VHA EHRs.8,18,19 However, the rate is notably lower than prevalence estimates for psychiatric outpatient settings (about 50%) and in meta-analyses of prevalence among veterans (0.8%-23% for each of the 10 PDs).4,17,26 Longstanding stigma against PDs may contribute to underdiagnosis. For example, many clinicians are concerned that documentation or disclosure of a PD will interfere with the patient’s ability to access treatment due to stigma and discrimination.27,28 These fears are not unfounded; even among clinicians, PDs are commonly considered untreatable, and many individuals with PDs are denied access to evidence-based treatments due to the diagnosis.29 In a 2016 survey of community psychiatrists, nearly 1 in 4 reported that they avoid taking patients with a borderline PD diagnosis in their caseloads.28 To date, no studies have been conducted to explore clinicians’ willingness to accept patients with other PDs or, specifically, among veterans.

Despite such widespread stigma, research suggests clinicians' negative attitudes toward PDs can be decreased through antistigma campaigns.30 However, it remains unclear if such efforts also contribute to an increase in clinicians’ willingness to document PD diagnoses. Without accurate identification and documentation, the field’s understanding of PDs will remain limited.

In the current study, veterans with PD diagnoses tended to present with more complex and severe psychiatric comorbidities compared to veterans without such diagnoses. Observed comorbidity of PDs (particularly borderline PD) with trauma-related and bipolar disorders is well established.8 Conversely, co-occurring personality and psychotic disorders—which comprise 16% of veterans with a PD diagnosis in the sample in this study—are not consistently examined in the literature. A 2022 examination of veterans receiving VHA care suggested 12% and 13% of those with a PD diagnosis documented in their EHR also had documented schizophrenia or another psychotic disorder, respectively. PD diagnoses were associated with 6.88- and 9.80-fold increases in risk for comorbid schizophrenia and other psychotic disorder diagnoses, respectively.8 Similarly, a recent longitudinal study of nearly 2 million Swedish individuals suggested borderline PD is specifically associated with a > 24-times greater risk of having a comorbid psychotic disorder.31 It is therefore possible that the comorbidity between personality and psychotic disorders is quite common despite its relative lack of attention in empirical research.

Veterans with PD diagnoses in this study were also more likely to experience substandard housing, employment challenges, and receive treatment through judicial institutions than those without a PD diagnosis. Such findings are consistent with previous research demonstrating the substantial psychosocial challenges associated with PD diagnosis, even after controlling for comorbid conditions.7,9 Veterans with PDs may benefit from specialized case management and support to facilitate stable housing and employment and to mitigate the risk of judicial involvement. Some research suggests veterans with PDs may be less likely to gain competitive employment after participating in VA therapeutic and supportive employment services programs, suggesting standard programming may be less suitable for this population.32 Similarly, other research suggests individuals with PDs may benefit more from specialized, intensive services than standard clinical case management.33 Future research may therefore benefit from clarifying the degree to which adaptations to standard programming could yield beneficial effects for persons with PD diagnoses.

Implications

Cumulatively, the results of this study attest to the necessity for transdiagnostic treatment planning that includes close collaboration between psychotherapeutic, pharmacological, and case management services. Some psychotherapy models for PDs, such as dialectical behavior therapy (DBT), which includes a combination of group skills training, individual therapy, as-needed phone coaching, and therapist consultation, may be successfully adapted to include this collaboration.34-36 However, implementation of such comprehensive programming often requires extensive clinician training and coordination of resources, which poses implementation challenges.37-39 In 2021, the VHA began large-scale implementation of PD-specific psychotherapy for veterans with recent suicidal self-directed violence and borderline PD, including DBT, though to date results remain unclear.40 Generalist approaches, such as good psychiatric management (GPM), which emphasizes emotional validation, practical problem solving, realistic goal setting, and relationship functioning within the context of standard care appointments, may be more easily implemented in community care settings due to lesser training and resource requirements and can also be adapted to include needed elements of care coordination.41,42 Both DBT and GPM were initially developed for the treatment of borderline PD. Although DBT has also demonstrated some effectiveness in the treatment of antisocial PD, potential applications of DBT and GPM to other PDs remain largely underdeveloped.43-46

There are no widely accepted medications for the treatment of PDs. Pharmacotherapy for these conditions typically consists of individualized approaches informed by personal experience that attempt to balance targeting of specific symptoms while minimizing polypharmacy and potential risks (eg, overdose or addiction).47,48 Despite this, pharmacotherapy is often considered a necessary component in the treatment of bipolar and psychotic disorders, both common comorbidities of PDs found in veterans in this study.49,50 Careful consideration of complex comorbidities and pharmacotherapy needs is warranted in the treatment of veterans with PDs. Future research may benefit from clarifying clinical guidelines around pharmacotherapy, particularly for observed comorbidities of PDs to trauma, bipolar, and psychotic disorders.

It is important to note the discrepancies in the results of this study surrounding patient substance use. The results suggest a negligible or inverse association between the likelihood of a PD diagnosis and difficulties with substance use among the veterans in this study. However, the unexpectedly low rate of SUD diagnoses (< 6%) suggests that they were likely underdocumented. Research suggests a strong association between personality and SUDs in both veteran and civilian samples.6,51 Results suggesting a lower prevalence of substance use difficulties among treatment-seeking veterans with PDs should be interpreted with great caution.

Demographically, PD diagnoses were more common among veterans who were White, non-Hispanic, and aged ≥ 45 years, and less common among veterans who were Black/ African American, mixed/unspecified race, Puerto Rican or other non-Mexican Hispanic ethnicity, or aged < 35 years. No significant sex-based differences were observed. These patterns are consistent with research suggesting individuals who identify as Black may be less likely than individuals who identify as White to report PD symptoms, meet criteria for a PD, and have a PD diagnosed even when it is warranted.52

The findings observed in this study with respect to age, however, are notably inconsistent with the literature. Previous research typically suggests a negative association between age and PD pathology; however, a 2020 review of PDs in older adults by Penders et al suggests a prevalence of 11% to 15% in this population.53,54 Research into PDs most often focuses on adolescent and early adulthood developmental periods, limiting insight into the phenomenology of PDs in middle to late adulthood.55 Further, most research into PDs among geriatric populations has focused on psychometric assessment rather than practical treatment guidance.54 However, in this study, elevated risk for PD diagnoses was salient throughout middle to late adulthood among veterans; similar, albeit less pronounced patterns were also observed for elevated risk of PD diagnosis in middle adulthood among nonveterans. Such findings suggest clarifying the phenomenology and treatment needs of individuals with PDs in middle to late adulthood may have particularly salient implications for the mental health care of veterans affected by these conditions. As the veteran population advances in age, these needs will present unique challenges if health care systems are unprepared to effectively address them.

Limitations

This study is characterized by several strengths, most notably its use of a large dataset recently collected on a national scale. Few studies outside of the VHA system include samples of > 100,000 treatment-seeking veterans collected on a national scale. Nevertheless, results should be understood within the context of several methodological limitations. However, the dataset was limited to the first 3 diagnoses documented in patients’ EHRs, and many patients had no listed diagnoses. Patients with complex comorbidities may have > 3 diagnoses; for these individuals, data provided an incomplete picture of clinical presentation. This is especially relevant for individuals with PDs, who tend to meet criteria for a range of comorbid conditions.8,10 The now dated practice of listing PDs on Axis II also increases the chance of clinicians listing PDs after conditions traditionally listed on Axis I (eg, major depressive disorder) in patient charts.56 This study’s inclusion of only the first 3 listed diagnoses likely underestimated true PD diagnosis prevalence.

The results of this study must be interpreted as reflecting the prevalence and correlates of receiving a PD diagnosis rather than meeting diagnostic criteria for a PD. Relatedly, PD diagnoses were reported as a single construct, limiting insight into prevalence and correlates of individual PD diagnoses (eg, borderline vs paranoid PDs). Meta-analyses estimates suggest PD prevalence among veterans is likely much higher than observed in this study.17 Stigma continues to discourage clinicians from documenting and disclosing PD diagnoses even when warranted.27,28 Continued research should aim to clarify conditions (eg, patient presentation, stigma, or institutional culture) contributing to documentation of PD diagnoses. Given the cross-sectional nature of this study, results cannot speak to longitudinal treatment outcomes or prognosis of persons receiving a PD diagnosis.

Despite its large sample size and national representation, the sampling strategy of this study could have contributed to idiosyncrasies in the dataset. Restriction of data to the persons receiving state-funded mental health services introduces a notable bias to the composition of the sample, which is likely comprised of a disproportionately high number of Medicaid recipients, students, and individuals with chronic illnesses and underrepresentation of persons who pay for mental health services using private insurance or private pay arrangements. As such, although socioeconomic information was not provided within this dataset, one can presume a generally lower socioeconomic status among study participants compared to the community at large. This study also included a proportionally small sample of veterans (3.6% compared to about 6.2% in the broader US population), suggesting veterans may have been underrepresented or underidentified in surveyed mental health care settings.57 This study also did not include data around service in active-duty military, national guard, or military reserves; a greater proportion of the sample likely had a history of military service than was represented by veteran status designation. Further, the proportionally high sample of individuals with severe mental illness suggests a likely overrepresentation of such conditions in surveyed settings.

Institutional differences in the practice of assigning diagnoses likely limited statistical power to detect potentially meaningful associations and effects. Structural influences, such as stigma and institutional culture, may have notable effects on documentation practices, particularly for PDs. Future research should aim to replicate observed associations using more controlled diagnostic procedures.

Lastly, even with the use of a more conservative α and a focus on effect sizes to guide interpretation of results, use of multiple bivariate analyses can be presumed to have increased the likelihood of type I error. Given the limited prior research in this area, an exploratory approach to statistical analysis was considered warranted to maximize opportunity for identifying areas in need of additional empirical attention. Continued research using more conservative statistical approaches (eg, multivariate analyses) is needed to determine replicability and generalizability of observed results.

CONCLUSIONS

This study examined the prevalence and correlates of PD diagnoses in a national sample of veterans receiving community-based, state-funded mental health care. About 2% received a PD diagnosis, with diagnoses most common among veterans who were White, non-Hispanic, aged ≥ 45 years, also diagnosed with trauma-based, bipolar, and/or psychotic disorders, underemployed, nontraditionally housed, and receiving treatment in a state psychiatric hospital or judicial system setting. The results attest to a necessity for transdiagnostic treatment planning and care coordination for this population, with particular attention to psychosocial stressors.

References
  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text revision. American Psychiatric Association; 2022.
  2. Hastrup LH, Jennum P, Ibsen R, Kjellberg J, Simonsen E. Societal costs of borderline personality disorders: a matched-controlled nationwide study of patients and spouses. Acta Psychiatr Scand. 2019;140(5):458-467. doi:10.1111/acps.13094
  3. Sveen CA, Pedersen G, Ulvestad DA, Zahl KE, Wilberg T, Kvarstein EH. Societal costs of personality disorders: a cross-sectional multicenter study of treatment-seeking patients in mental health services in Norway. J Clin Psychol. 2023;79(8):1752-1769. doi:10.1002/jclp.23504
  4. Beckwith H, Moran PF, Reilly J. Personality disorder prevalence in psychiatric outpatients: a systematic literature review. Personal Ment Health. 2014;8(2):91-101. doi:10.1002/pmh.1252
  5. Eaton NR, Greene AL. Personality disorders: community prevalence and socio-demographic correlates. Curr Opin Psychol. 2018;21:28-32. doi:10.1016/j.copsyc. 2017.09.001
  6. Edwards ER, Barnes S, Govindarajulu U, Geraci J, Tsai J. Mental health and substance use patterns associated with lifetime suicide attempt, incarceration, and homelessness: a latent class analysis of a nationally representative sample of U.S. veterans. Psychol Serv. 2021;18(4):619-631. doi:10.1037/ser0000488
  7. Moran P, Romaniuk H, Coffey C, et al. The influence of personality disorder on the future mental health and social adjustment of young adults: a population-based cohort study. Lancet Psychiatry. 2016;3(7):636-645. doi:10.1016/S2215-0366(16)30029-3
  8. Nelson SM, Griffin CA, Hein TC, Bowersox N, McCarthy JF. Personality disorder and suicide risk among patients in the Veterans Affairs health system. Personal Disord. 2022;13(6):563-571. doi:10.1037/per0000521
  9. Skodol AE. Impact of personality pathology on psychosocial functioning. Curr Opin Psychol. 2018;21;33-38. doi:10.1016/j.copsyc.2017.09.006
  10. Tyrer P, Reed GM, Crawford MJ. Classification, assessment, prevalence, and effect of personality disorder. Lancet. 2015;385(9969):717-726. doi:10.1016/S0140-6736(14)61995-4
  11. Fitzpatrick S, Goss S, Di Bartolomeo A, Varma S, Tissera T, Earle E. Follow the money: is borderline personality disorder research underfunded in Canada? Can Psychol. 2024;65(1):46-57. doi:10.1037/cap0000375
  12. Zimmerman M, Gazarian D. Is research on borderline personality disorder underfunded by the National Institute of Health? Psychiatry Res. 2014;220(3):941-944. doi:10.1016/j.psychres.2014.09.021
  13. Leroux TC. U.S. military discharges and pre-existing personality disorders: a health policy review. Adm Policy Ment Health. 2015;42(6):748-755. doi:10.1007/s10488-014-0611-z
  14. Monahan MC, Keener JK. Fitness-for-duty evaluations. In Kennedy CH, Zillmer EA, eds. Military Psychology: Clinical and Operational Applications. 2nd ed. Guilford Publications; 2012:25-49.
  15. Hearing Before the Committee on Veterans’ Affairs, 111th Congress 2nd Sess (2010). Personality disorder discharges: impact on veterans benefits. Accessed March 4, 2025. https://www.govinfo.gov/content/pkg/CHRG-111hhrg61755/html/CHRG-111hhrg61755.htm
  16. Ader M, Cuthbert R, Hoechst K, Simon EH, Strassburger Z, Wishnie M. Casting troops aside: the United States military’s illegal personality disorder discharge problem. Vietnam Veterans of America. March 2012. Accessed February 28, 2025. https://law.yale.edu/sites/default/files/documents/pdf/Clinics/VLSC_CastingTroopsAside.pdf
  17. Edwards ER, Tran H, Wrobleski J, Rabhan Y, Yin J, Chiodi C, Goodman M, Geraci J. Prevalence of personality disorders across veteran samples: A meta-analysis. J Pers Disord. 2022;36(3):339-358. doi:10.1521/ pedi.2022.36.3.339
  18. Holliday R, Desai A, Edwards E, Borges L. Personal i ty disorder diagnosis among just ice -involved veterans: an investigation of VA-using veterans. J Nerv Ment Dis. 2023;211(5):402-406 doi:10.1097/ NMD.0000000000001627
  19. McCarthy JF, Bossarte RM, Katz IR, et al. Predictive modeling and concentration of the risk of suicide: implications for preventive interventions in the US Department of Veterans Affairs. Am J Public Health. 2015;105(9):1935-1942. doi:10.2105/AJPH.2015.302737
  20. Liu Y, Chen C, Zhou Y, Zhang N, Liu S. Twenty years of research on borderline personality disorder: a scientometric analysis of hotspots, bursts, and research trends. Front Psych. 2024;15:1361535. doi:10.3389/ fpsyt.2024.1361535
  21. Williams R, Holliday R, Clem M, Anderson E, Morris EE, Surís A. Borderline personality disorder and military sexual trauma: analysis of previous traumatization and current psychiatric presentation. J Interpers Violence. 2017;32(15):2223-2236. doi:10.1177/0886260515596149
  22. Holder N, Holliday R, Pai A, Surís A. Role of borderline personality disorder in the treatment of military sexual trauma-related posttraumatic stress disorder with cognitive processing therapy. Behav Med. 2017;43(3):184-190. doi:10.1080/08964289.2016.1276430
  23. Ralevski E, Ball S, Nich C, Limoncelli D, Petrakis I. The impact of personality disorders on alcohol-use outcomes in a pharmacotherapy trial for alcohol dependence and comorbid Axis I disorders. Am J Addict. 2007;16(6):443- 449. doi:10.1080/10550490701643336
  24. Walter KH, Bolte TA, Owens GP, Chard KM. The impact of personality disorders on treatment outcome for veterans in a posttraumatic stress disorder residential treatment program. Cognit Ther Res. 2012;36(5):576-584. doi:10.1007/s10608-011-9393-8
  25. Substance Abuse and Mental Health Services. Mental health client-level data (MH-CLD), 2022. Accessed February 28, 2025. https://www.datafiles.samhsa.gov/dataset/mental-health-client-level-data-2022-mh-cld-2022-ds0001
  26. Zimmerman M, Rothschild L, Chelminski I. The prevalence of DSM-IV personality disorders in psychiatric outpatients. Am J Psychiatry. 2005;162(10):1911-1918. doi:10.1176/appi.ajp.162.10.1911
  27. Campbell K, Clarke KA, Massey D, Lakeman R. Borderline personality disorder: To diagnose or not to diagnose? That is the question. Int J Mental Health Nurs. 2020;29(5):972-981. doi:10.1111/inm.12737
  28. Sisti D, Segal AG, Siegel AM, Johnson R, Gunderson J. Diagnosing, disclosing, and documenting borderline personality disorder: a survey of psychiatrists’ practices. J Pers Disord. 2016;30(6):848-856. doi:10.1521/ pedi_2015_29_228
  29. Klein P, Fairweather AK, Lawn S. Structural stigma and its impact on healthcare for borderline personality disorder: a scoping review. Int J Ment Health Syst. 2022;16(1):48. doi:10.1186/s13033-022-00558-3
  30. Knaak S, Szeto AC, Fitch K, Modgill G, Patten S. Stigma towards borderline personality disorder: effectiveness and generalizability of an anti-stigma program for healthcare providers using a pre-post randomized design. Borderline Personal Disord Emot Dysregul. 2015;2:9. doi:10.1186/s40479-015-0030-0
  31. Tate AE, Sahlin H, Liu S, et al. Borderline personality disorder: associations with psychiatric disorders, somatic illnesses, trauma, and adverse behaviors. Mol Psychiatry. 2022;27:2514-2521. doi:10.1038/s41380- 022-01503-z
  32. Abraham KM, Yosef M, Resnick SG, Zivin K. Competitive employment outcomes among veterans in VHA Therapeutic and Supported Employment Services programs. Psychiatr Serv. 2017;68(9)938-946. doi:10.1176/appi. ps201600412
  33. Frisman LK, Mueser KT, Covell NH, et al. Use of integrated dual disorder treatment via Assertive Community Treatment versus clinical case management for persons with co-occurring disorders and antisocial personality disorder. J Nerv Ment Dis. 2009;197(11):822-828. doi:10.1097/NMD.0b013e3181beac52
  34. Edwards ER, Kober H, Rinne GR, Griffin SA, Axelrod S, Cooney EB. Skills]homework completion and phone coaching as predictors of therapeutic change and outcomes in completers of a DBT intensive outpatient programme. Psychol Psychother. 2021;94(3):504-522. doi:10.1111/papt.12325
  35. Linehan MM, Dimeff LA, Reynolds SK, et al. Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend. 2002;67(1):13-26. doi:10.1016/s0376-8716(02)00011-x
  36. Linehan MM, Korslund KE, Harned MS, et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry. 2015;72(5):475-482.doi:10.1001 /jamapsychiatry.2014.3039
  37. Carmel A, Rose ML, Fruzzetti AE. Barriers and solutions to implementing dialectical behavior therapy in a public behavioral health system. Adm Policy Ment Health. 2014;41(5):608-614. doi:10.1007/s10488-013-0504-6
  38. Decker SE, Matthieu MM, Smith BN, Landes SJ. Barriers and facilitators to dialectical behavior therapy skills groups in the Veterans Health Administration. Mil Med. 2024;189(5-6):1055-1063. doi:10.1093/milmed/ usad123
  39. Landes SJ, Rodriguez AL, Smith BN, et al. Barriers, facilitators, and benefits of implementation of dialectical behavior therapy in routine care: results from a national program evaluation survey in the Veterans Health Administration. Transl Behav Med. 2017;7(4):832-844. doi:10.1007/s13142-017-0465-5
  40. Walker J, Betthauser LM, Green K, Landes SJ, Stacy M. Suicide Prevention 2.0 Clinical Telehealth Program: Evidence- Based Treatment in the Veterans Health Administration. April 28, 2024. Accessed February 28, 2025. https://www.youtube.com/watch?v=fFsDzkg0SR0
  41. Gunderson J, Masland S, Choi-Kain L. Good psychiatric management: a review. Curr Opin Psychol. 2018;21:127- 131. doi:10.1016/j.copsyc.2017.12.006
  42. Kramer U. Good-enough therapy: a review of the empirical basis of good psychiatric management. Am J Psychother. 2025;78(1): 11-15. doi:10.1176/appi .psychotherapy.20230041
  43. Visdómine-Lozano JC. Contextualist perspectives in the treatment of antisocial behaviors and offending: a comparative review of FAP, ACT, DBT, and MDT. Trauma Violence Abuse. 2022;23(1):241-254. doi:10.1177/1524838020939509
  44. Drago A, Marogna C, Jørgen Søgaard H. A review of characteristics and treatments of the avoidant personality disorder. Could the DBT be an option? Int J Psychol Psychoanal. 2016;2(1):013.
  45. Finch EF, Choi-Kain LW, Iliakis EA, Eisen JL, Pinto A. Good psychiatric management for obsessive–compulsive personality disorder. Curr Behav Neurosci Rep. 2021;8:160-171. doi:10.1007/s40473-021-00239-4
  46. Miller TW, Kraus RF. Modified dialectical behavior therapy and problem solving for obsessive-compulsive personality disorder. Journal Contemp Psychother. 2007;37:79-85. doi:10.1007/s10879-006-9039-4
  47. Bozzatello P, Rocca P, De Rosa ML, Bellino S. Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough? Expert Opin Pharmacother. 2020;21(1):47-61.doi:10.1080/14656566 .2019.1686482
  48. Sand P, Derviososki E, Kollia S, Strand J, Di Leone F. Psychiatrists’ perspectives on prescription decisions for patients with personality disorders. J Pers Disord. 2024;38(3):225-240. doi:10.1521/pedi.2024.38.3.225
  49. Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. J Clin Psychiatry. 2003;64 Suppl 12:5-19.
  50. Nierenberg AA, Agustini B, Köhler-Forsberg O, et al. Diagnosis and treatment of bipolar disorder: a review. JAMA. 2023;330(14):1370-1380. doi:10.1001 /jama.2023.18588
  51. Köck P, Walter M. Personality disorder and substance use disorder–an update. Ment Health Prev. 2018;12:82- 89. doi:10.1016/J.MHP.2018.10.003
  52. Garb HN. Race bias and gender bias in the diagnosis of psychological disorders. Clin Psych Rev. 2021;90:102087. doi:10.1016/j.cpr.2021.102087
  53. Debast I, van Alphen SPJ, Rossi G, et al. Personality traits and personality disorders in late middle and old age: do they remain stable? A literature review. Clin Gerontol. 2014;37(3):253-271.doi:10.1080/07317115 .2014.885917
  54. Penders KAP, Peeters IGP, Metsemakers JFM, van Alphen SPJ. Personality disorders in older adults: a review of epidemiology, assessment, and treatment. Curr Psychiatry Rep. 2020;22(3):1-14. doi:10.1007/s11920-020- 1133-x
  55. Videler AC, Hutsebaut J, Schulkens JEM, Sobczak S, van Alphen SPJ. A life span perspective on borderline personality disorder. Curr Psychiatry Rep. 2019;21(7) :1-8. doi:10.1007/s11920-019-1040-1
  56. Wakefield JC. DSM-5 and the general definition of personality disorder. Clin Soc Work J. 2013;41(2):168-183. doi:10.1007/s10615-012-0402-5
  57. US Census Bureau. 2022 American Community Survey 1-year. Accessed February 28, 2025. https://data.census.gov/table/ACSST1Y2022.S2101?q=Veterans&y=2022comparison
Article PDF
Author and Disclosure Information

Emily R. Edwards, PhDa,b,c; Ashley L. Greene, PhDa; Suzanne E. Decker, PhDb,d; Hugh D. Leonard, PhDe; Marianne Goodman, MDa,c

Author affiliations 
aVISN 2 Mental Illness Research Education, and Clinical Center, Bronx, New York 
bYale School of Medicine, New Haven, Connecticut cIcahn School of Medicine at Mount Sinai, New York City, New York 
dVISN 1 Mental Illness Research Education, and Clinical Center, West Haven, Connecticut 
eMann-Grandstaff Department of Veterans Affairs Medical Center, Spokane, Washington

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Correspondence: Emily Edwards ([email protected])

Fed Pract. 2025;42(suppl 1). Published online April 2. doi:10.12788/fp.0572

Issue
Federal Practitioner - 42(4)s
Publications
Topics
Page Number
S12-S23
Sections
Author and Disclosure Information

Emily R. Edwards, PhDa,b,c; Ashley L. Greene, PhDa; Suzanne E. Decker, PhDb,d; Hugh D. Leonard, PhDe; Marianne Goodman, MDa,c

Author affiliations 
aVISN 2 Mental Illness Research Education, and Clinical Center, Bronx, New York 
bYale School of Medicine, New Haven, Connecticut cIcahn School of Medicine at Mount Sinai, New York City, New York 
dVISN 1 Mental Illness Research Education, and Clinical Center, West Haven, Connecticut 
eMann-Grandstaff Department of Veterans Affairs Medical Center, Spokane, Washington

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Correspondence: Emily Edwards ([email protected])

Fed Pract. 2025;42(suppl 1). Published online April 2. doi:10.12788/fp.0572

Author and Disclosure Information

Emily R. Edwards, PhDa,b,c; Ashley L. Greene, PhDa; Suzanne E. Decker, PhDb,d; Hugh D. Leonard, PhDe; Marianne Goodman, MDa,c

Author affiliations 
aVISN 2 Mental Illness Research Education, and Clinical Center, Bronx, New York 
bYale School of Medicine, New Haven, Connecticut cIcahn School of Medicine at Mount Sinai, New York City, New York 
dVISN 1 Mental Illness Research Education, and Clinical Center, West Haven, Connecticut 
eMann-Grandstaff Department of Veterans Affairs Medical Center, Spokane, Washington

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Correspondence: Emily Edwards ([email protected])

Fed Pract. 2025;42(suppl 1). Published online April 2. doi:10.12788/fp.0572

Article PDF
Article PDF

Personality disorders (PDs) are enduring patterns of internal experience and behavior that differ from cultural norms and expectations, are inflexible and pervasive, have their onset in adolescence or early adulthood, and lead to distress or impairment. Ten PDs are included in the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition): paranoid, schizoid, schizotypal, borderline, antisocial, histrionic, narcissistic, avoidant, dependent, and obsessive-compulsive.1 These disorders impose a high burden on patients, families, health care systems, and broader economic systems.2,3 Up to 1 in 7 persons in the community and 50% of those receiving outpatient mental health treatment experience a PD.4,5 These conditions are associated with an increased risk of adverse events, including suicide attempt and death by suicide, criminal-legal involvement, homelessness, substance use, underemployment, relational issues, and high utilization of psychiatric services.6-9 PDs are routinely underassessed, underdocumented, and undertreated in clinical settings, and consistently receive less research funding than other, less prevalent forms of psychopathology. 10-12 As a result, there is limited understanding of clinical needs of individuals experiencing PDs.

MILITARY VETERANS WITH PERSONALITY DISORDERS

Underacknowledgment of PDs and their associated difficulties may be especially pronounced in veteran populations. Due to longstanding etiological theories that implicate childhood trauma and adolescent onset in pathology development, PDs are traditionally considered pre-existing conditions or developmental abnormalities by the US Department of Defense and US Department of Veterans Affairs (VA). As a result, PDs are therefore deemed incompatible with military service and ineligible for service-connected disability benefits.13-15 Such determinations allowed PD pathology to be used as grounds for discharge for 26,000 service members from 2001 to 2007, or 2.6% of total enlisted discharges during that period.13,15,16

Despite this structural discrimination, recent research suggests veterans may be more likely to experience PD pathology than the general population.17 For example, a 2021 epidemiological survey in a community-based veteran sample found elevated rates of borderline, antisocial, and schizotypal PDs (6%-13%).6 In contrast, only 0.8% to 5.0% of veteran electronic health records (EHRs) have a documented PD diagnosis.8,18,19 Such elevations in PD pathology within veteran samples imply either a disproportionately high prevalence among enlistees (and therefore missed during recruitment procedures) or onset following military service, possibly due to exposure to traumatic events and/ or occupational stress.17 Due to the relative infancy of research in this area and a lack of longitudinal studies, etiology and course of illness for personality pathology in veterans remains largely unclear.

Structural underacknowledgment of PDs among military personnel has contributed to their underrepresentation in research on veteran populations. PD-focused research with veterans is rare, despite a rapid increase in broader empirical attention paid to these conditions in nonveteran samples.20 A recent meta-analysis of veterans with PDs identified 27 studies that included basic prevalence statistics. PDs were rarely a primary focus for these studies, and most were limited to veterans seen in Veterans Health Administration (VHA) settings.17 The literature also paints a bleak picture, suggesting veterans who experience PDs are at higher risk for suicide attempt and death by suicide, criminal-legal involvement, and homelessness. They also tend to experience more severe comorbid psychopathological symptoms and more often use high-intensity mental health services (eg, care within emergency departments or psychiatric inpatient settings) than veterans without PD pathology.6,8,18,19,21 However, PD pathology does not appear to impede the effectiveness of treatment for veterans.22-24 The implications of PD pathology on broader psychosocial functioning and health care needs certify a need for additional research that examines patterns of personality pathology, particularly in veterans outside the VHA.

METHODS

This study aims to enhance understanding of veterans affected by PDs and offer insight and guidance for treatment of these conditions in federal and nonfederal treatment settings. Previous research has been largely limited to VHA care-receiving samples; the longstanding stigma against PDs by the US military and VA may contribute to biased diagnosis and documentation of PDs in these settings. A large sample of veterans receiving community-based mental health care was therefore used to explore aims of the current study. This study specifically examined demographic patterns, diagnostic comorbidity, psychosocial outcomes, and treatment care settings among veterans with and without a PD diagnosis. Consistent with previous research, we hypothesized that veterans with a PD diagnosis would have more severe mental health comorbidities, poorer psychosocial outcomes, and receive care in higher intensity settings relative to veterans without a diagnosis.

Data for the sample were drawn from the Mental Health Client-Level Data, a publicly available national dataset of nearly 7 million patients who received mental health treatment services provided or funded through state mental health agencies in 2022.25 The analytic sample included about 2.5 million patients for whom veteran status and data around the presence or absence of a PD diagnosis were available. Of these patients, 104,198 were identified as veterans. Veteran patients were identified as predominantly male (63%), White (71%), non-Hispanic (90%), and never married (54%).

Measures

The parent dataset included demographic, clinical, and psychosocial outcome information reported by treatment facilities to individual state administrative systems for each patient who received services. To protect patient privacy, only nonprotected health information is included, and efforts were made throughout compilation of the parent dataset to ensure patient privacy (eg, limiting detail of information disseminated for public access). Because the parent dataset does not include protected health information, studies using these data are considered exempt from institutional review board oversight.

Demographic information. This study reviewed veteran status, sex, race, ethnicity, age, education, and marital status. Veteran status was defined by whether the patient was aged ≥ 18 years and had previously served (but was not currently serving) in the military. Patients with a history of service in the National Guard or Military Reserves were only classified as veterans if they had been called or ordered to active duty while serving. Sex was operationalized dichotomously as male or female; no patients were identified as intersex, transgender, or other gender identities.

Clinical information. Up to 3 mental health diagnoses were reported for each patient and included the following disorders: personality, trauma and attention-deficit/hyperactivity, stressor, anxiety, conduct, delirium/dementia, bipolar, depressive, oppositional defiant, pervasive developmental, schizophrenia or other psychotic, and alcohol or substance use. Mental health diagnosis categories were generated for the parent dataset by grouping diagnostic codes corresponding to each category. To protect patient privacy, more detailed diagnostic information was not available as part of the parent dataset. Although the American Psychiatric Association recognizes 10 distinct PDs, the exact nature of PD diagnoses was not included within the parent dataset. PD diagnoses were coded to reflect the presence or absence of any such diagnosis.

A substance use problem designation was also provided for patients according to various identification methods, including substance use disorder (SUD) diagnosis, substance use screening results, enrollment in a substance use program, substance use survey, service claims information, and other related sources of information. A severe mental illness or serious emotional disturbance designation was provided for patients meeting state definitions of these designations. Context(s) of service provision were coded as inpatient state psychiatric hospital, community-based program, residential treatment center, judicial institution, or other psychiatric inpatient setting.

Psychosocial outcome information. Patient employment and residential status were also included in analyses. Each reflected status at the time of discharge from services or end of reporting period; employment status was only provided for patients receiving treatment in community-based programs.

Data Analysis

Descriptive statistics and X2 analyses were used to compare demographic, clinical, and psychosocial outcome variables between patients with and without PD diagnoses. These analyses were calculated for both the 104,198 veterans and the 2,222,306 nonveterans aged ≥ 18 years in the dataset. Given the sample size, a conservative α of .01 was used to determine statistical significance.

RESULTS

In this sample of persons receiving state-funded mental health care, veterans were significantly less likely than nonveterans to have a documented PD diagnosis (2.1% vs 3.6%, X2 [1] = 647.49; P < .01). PD diagnoses were more common among White (risk ratio [RR], 1.11), non-Hispanic (RR, 1.03) veterans who were in middle to late adulthood (RR, 1.16-1.40), more educated (RR, 1.35), and divorced or widowed (RR, 1.43), and less common among Black/African American (RR, 0.78) or Puerto Rican (RR, 0.32) veterans who were in early adulthood (RR, 0.31-0.79), less educated (RR, 0.64-0.89), and currently married (RR, 0.89) or never married (RR, 0.86). Veteran men and women were equally likely to have a PD diagnosis (RR, 1.03) (Table 1). Among nonveterans, men were less likely than women to have a PD diagnosis (RR, 0.79), and PD diagnoses were most common among persons in middle adulthood (RR, 1.06-1.15) (eAppendix 1).

0425FED-MH-PD-012T10425FED-MH-PD-012_eA1

Veterans with a PD diagnosis were more likely than those without a diagnosis to have more diagnoses (RR, 2.96-8.49) and to have comorbid trauma or related stressor (RR, 1.33), or bipolar (RR, 1.56) or psychotic (RR, 1.15) disorder diagnoses, but less likely to have comorbid depressive disorder (RR, 0.82). Although veterans with and without a PD diagnosis were similarly likely to have a comorbid SUD (RR, 1.13), those with a PD diagnosis were significantly less likely to be assigned a substance use problem designation (RR, 0.78). PD diagnosis was also more common among veterans who received services in state psychiatric hospitals (RR, 3.05), community-based clinics (RR, 1.06), and judicial institutions (RR, 6.33) and less common among those who received services in other psychiatric inpatient settings (RR, 0.30). No differences were observed for residential treatment settings (RR, 0.79). Among nonveterans, a PD diagnosis was associated with slightly greater odds of a substance use designation (RR, 1.03) (eAppendix 2).

0425FED-MH-PD-012_eA2

Veterans with a PD diagnosis were also less likely to have full-time employment (RR, 0.73) and more likely to have undifferentiated employment (RR, 2.00) or to be removed from the labor force (RR, 1.35). Veterans with a PD diagnosis were also more likely to reside in nontraditional living conditions (RR, 1.42) and less likely to be residing in a private residence (RR, 0.98), compared with those without PD diagnosis. The rates of homelessness were similar for veterans with and without a PD diagnosis (RR, 0.90) (Table 2). These patterns were similar among nonveterans.

0425FED-MH-PD-012T2

DISCUSSION

This study examined the rate and correlates of PD diagnosis among a large, community-based sample of veterans receiving state-funded mental health care. About 2% of veterans in this sample had a PD diagnosis, with diagnoses more common among veterans who were White, non-Hispanic, aged ≥ 45 years, with higher education, divorced or widowed, also diagnosed with trauma-related, bipolar, and/or psychotic disorders, underemployed, nontraditionally housed, and receiving treatment in state psychiatric hospital, community-based clinic, or judicial system settings.

The observed rate of PD diagnosis in this study aligns with what is typically observed in VHA EHRs.8,18,19 However, the rate is notably lower than prevalence estimates for psychiatric outpatient settings (about 50%) and in meta-analyses of prevalence among veterans (0.8%-23% for each of the 10 PDs).4,17,26 Longstanding stigma against PDs may contribute to underdiagnosis. For example, many clinicians are concerned that documentation or disclosure of a PD will interfere with the patient’s ability to access treatment due to stigma and discrimination.27,28 These fears are not unfounded; even among clinicians, PDs are commonly considered untreatable, and many individuals with PDs are denied access to evidence-based treatments due to the diagnosis.29 In a 2016 survey of community psychiatrists, nearly 1 in 4 reported that they avoid taking patients with a borderline PD diagnosis in their caseloads.28 To date, no studies have been conducted to explore clinicians’ willingness to accept patients with other PDs or, specifically, among veterans.

Despite such widespread stigma, research suggests clinicians' negative attitudes toward PDs can be decreased through antistigma campaigns.30 However, it remains unclear if such efforts also contribute to an increase in clinicians’ willingness to document PD diagnoses. Without accurate identification and documentation, the field’s understanding of PDs will remain limited.

In the current study, veterans with PD diagnoses tended to present with more complex and severe psychiatric comorbidities compared to veterans without such diagnoses. Observed comorbidity of PDs (particularly borderline PD) with trauma-related and bipolar disorders is well established.8 Conversely, co-occurring personality and psychotic disorders—which comprise 16% of veterans with a PD diagnosis in the sample in this study—are not consistently examined in the literature. A 2022 examination of veterans receiving VHA care suggested 12% and 13% of those with a PD diagnosis documented in their EHR also had documented schizophrenia or another psychotic disorder, respectively. PD diagnoses were associated with 6.88- and 9.80-fold increases in risk for comorbid schizophrenia and other psychotic disorder diagnoses, respectively.8 Similarly, a recent longitudinal study of nearly 2 million Swedish individuals suggested borderline PD is specifically associated with a > 24-times greater risk of having a comorbid psychotic disorder.31 It is therefore possible that the comorbidity between personality and psychotic disorders is quite common despite its relative lack of attention in empirical research.

Veterans with PD diagnoses in this study were also more likely to experience substandard housing, employment challenges, and receive treatment through judicial institutions than those without a PD diagnosis. Such findings are consistent with previous research demonstrating the substantial psychosocial challenges associated with PD diagnosis, even after controlling for comorbid conditions.7,9 Veterans with PDs may benefit from specialized case management and support to facilitate stable housing and employment and to mitigate the risk of judicial involvement. Some research suggests veterans with PDs may be less likely to gain competitive employment after participating in VA therapeutic and supportive employment services programs, suggesting standard programming may be less suitable for this population.32 Similarly, other research suggests individuals with PDs may benefit more from specialized, intensive services than standard clinical case management.33 Future research may therefore benefit from clarifying the degree to which adaptations to standard programming could yield beneficial effects for persons with PD diagnoses.

Implications

Cumulatively, the results of this study attest to the necessity for transdiagnostic treatment planning that includes close collaboration between psychotherapeutic, pharmacological, and case management services. Some psychotherapy models for PDs, such as dialectical behavior therapy (DBT), which includes a combination of group skills training, individual therapy, as-needed phone coaching, and therapist consultation, may be successfully adapted to include this collaboration.34-36 However, implementation of such comprehensive programming often requires extensive clinician training and coordination of resources, which poses implementation challenges.37-39 In 2021, the VHA began large-scale implementation of PD-specific psychotherapy for veterans with recent suicidal self-directed violence and borderline PD, including DBT, though to date results remain unclear.40 Generalist approaches, such as good psychiatric management (GPM), which emphasizes emotional validation, practical problem solving, realistic goal setting, and relationship functioning within the context of standard care appointments, may be more easily implemented in community care settings due to lesser training and resource requirements and can also be adapted to include needed elements of care coordination.41,42 Both DBT and GPM were initially developed for the treatment of borderline PD. Although DBT has also demonstrated some effectiveness in the treatment of antisocial PD, potential applications of DBT and GPM to other PDs remain largely underdeveloped.43-46

There are no widely accepted medications for the treatment of PDs. Pharmacotherapy for these conditions typically consists of individualized approaches informed by personal experience that attempt to balance targeting of specific symptoms while minimizing polypharmacy and potential risks (eg, overdose or addiction).47,48 Despite this, pharmacotherapy is often considered a necessary component in the treatment of bipolar and psychotic disorders, both common comorbidities of PDs found in veterans in this study.49,50 Careful consideration of complex comorbidities and pharmacotherapy needs is warranted in the treatment of veterans with PDs. Future research may benefit from clarifying clinical guidelines around pharmacotherapy, particularly for observed comorbidities of PDs to trauma, bipolar, and psychotic disorders.

It is important to note the discrepancies in the results of this study surrounding patient substance use. The results suggest a negligible or inverse association between the likelihood of a PD diagnosis and difficulties with substance use among the veterans in this study. However, the unexpectedly low rate of SUD diagnoses (< 6%) suggests that they were likely underdocumented. Research suggests a strong association between personality and SUDs in both veteran and civilian samples.6,51 Results suggesting a lower prevalence of substance use difficulties among treatment-seeking veterans with PDs should be interpreted with great caution.

Demographically, PD diagnoses were more common among veterans who were White, non-Hispanic, and aged ≥ 45 years, and less common among veterans who were Black/ African American, mixed/unspecified race, Puerto Rican or other non-Mexican Hispanic ethnicity, or aged < 35 years. No significant sex-based differences were observed. These patterns are consistent with research suggesting individuals who identify as Black may be less likely than individuals who identify as White to report PD symptoms, meet criteria for a PD, and have a PD diagnosed even when it is warranted.52

The findings observed in this study with respect to age, however, are notably inconsistent with the literature. Previous research typically suggests a negative association between age and PD pathology; however, a 2020 review of PDs in older adults by Penders et al suggests a prevalence of 11% to 15% in this population.53,54 Research into PDs most often focuses on adolescent and early adulthood developmental periods, limiting insight into the phenomenology of PDs in middle to late adulthood.55 Further, most research into PDs among geriatric populations has focused on psychometric assessment rather than practical treatment guidance.54 However, in this study, elevated risk for PD diagnoses was salient throughout middle to late adulthood among veterans; similar, albeit less pronounced patterns were also observed for elevated risk of PD diagnosis in middle adulthood among nonveterans. Such findings suggest clarifying the phenomenology and treatment needs of individuals with PDs in middle to late adulthood may have particularly salient implications for the mental health care of veterans affected by these conditions. As the veteran population advances in age, these needs will present unique challenges if health care systems are unprepared to effectively address them.

Limitations

This study is characterized by several strengths, most notably its use of a large dataset recently collected on a national scale. Few studies outside of the VHA system include samples of > 100,000 treatment-seeking veterans collected on a national scale. Nevertheless, results should be understood within the context of several methodological limitations. However, the dataset was limited to the first 3 diagnoses documented in patients’ EHRs, and many patients had no listed diagnoses. Patients with complex comorbidities may have > 3 diagnoses; for these individuals, data provided an incomplete picture of clinical presentation. This is especially relevant for individuals with PDs, who tend to meet criteria for a range of comorbid conditions.8,10 The now dated practice of listing PDs on Axis II also increases the chance of clinicians listing PDs after conditions traditionally listed on Axis I (eg, major depressive disorder) in patient charts.56 This study’s inclusion of only the first 3 listed diagnoses likely underestimated true PD diagnosis prevalence.

The results of this study must be interpreted as reflecting the prevalence and correlates of receiving a PD diagnosis rather than meeting diagnostic criteria for a PD. Relatedly, PD diagnoses were reported as a single construct, limiting insight into prevalence and correlates of individual PD diagnoses (eg, borderline vs paranoid PDs). Meta-analyses estimates suggest PD prevalence among veterans is likely much higher than observed in this study.17 Stigma continues to discourage clinicians from documenting and disclosing PD diagnoses even when warranted.27,28 Continued research should aim to clarify conditions (eg, patient presentation, stigma, or institutional culture) contributing to documentation of PD diagnoses. Given the cross-sectional nature of this study, results cannot speak to longitudinal treatment outcomes or prognosis of persons receiving a PD diagnosis.

Despite its large sample size and national representation, the sampling strategy of this study could have contributed to idiosyncrasies in the dataset. Restriction of data to the persons receiving state-funded mental health services introduces a notable bias to the composition of the sample, which is likely comprised of a disproportionately high number of Medicaid recipients, students, and individuals with chronic illnesses and underrepresentation of persons who pay for mental health services using private insurance or private pay arrangements. As such, although socioeconomic information was not provided within this dataset, one can presume a generally lower socioeconomic status among study participants compared to the community at large. This study also included a proportionally small sample of veterans (3.6% compared to about 6.2% in the broader US population), suggesting veterans may have been underrepresented or underidentified in surveyed mental health care settings.57 This study also did not include data around service in active-duty military, national guard, or military reserves; a greater proportion of the sample likely had a history of military service than was represented by veteran status designation. Further, the proportionally high sample of individuals with severe mental illness suggests a likely overrepresentation of such conditions in surveyed settings.

Institutional differences in the practice of assigning diagnoses likely limited statistical power to detect potentially meaningful associations and effects. Structural influences, such as stigma and institutional culture, may have notable effects on documentation practices, particularly for PDs. Future research should aim to replicate observed associations using more controlled diagnostic procedures.

Lastly, even with the use of a more conservative α and a focus on effect sizes to guide interpretation of results, use of multiple bivariate analyses can be presumed to have increased the likelihood of type I error. Given the limited prior research in this area, an exploratory approach to statistical analysis was considered warranted to maximize opportunity for identifying areas in need of additional empirical attention. Continued research using more conservative statistical approaches (eg, multivariate analyses) is needed to determine replicability and generalizability of observed results.

CONCLUSIONS

This study examined the prevalence and correlates of PD diagnoses in a national sample of veterans receiving community-based, state-funded mental health care. About 2% received a PD diagnosis, with diagnoses most common among veterans who were White, non-Hispanic, aged ≥ 45 years, also diagnosed with trauma-based, bipolar, and/or psychotic disorders, underemployed, nontraditionally housed, and receiving treatment in a state psychiatric hospital or judicial system setting. The results attest to a necessity for transdiagnostic treatment planning and care coordination for this population, with particular attention to psychosocial stressors.

Personality disorders (PDs) are enduring patterns of internal experience and behavior that differ from cultural norms and expectations, are inflexible and pervasive, have their onset in adolescence or early adulthood, and lead to distress or impairment. Ten PDs are included in the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition): paranoid, schizoid, schizotypal, borderline, antisocial, histrionic, narcissistic, avoidant, dependent, and obsessive-compulsive.1 These disorders impose a high burden on patients, families, health care systems, and broader economic systems.2,3 Up to 1 in 7 persons in the community and 50% of those receiving outpatient mental health treatment experience a PD.4,5 These conditions are associated with an increased risk of adverse events, including suicide attempt and death by suicide, criminal-legal involvement, homelessness, substance use, underemployment, relational issues, and high utilization of psychiatric services.6-9 PDs are routinely underassessed, underdocumented, and undertreated in clinical settings, and consistently receive less research funding than other, less prevalent forms of psychopathology. 10-12 As a result, there is limited understanding of clinical needs of individuals experiencing PDs.

MILITARY VETERANS WITH PERSONALITY DISORDERS

Underacknowledgment of PDs and their associated difficulties may be especially pronounced in veteran populations. Due to longstanding etiological theories that implicate childhood trauma and adolescent onset in pathology development, PDs are traditionally considered pre-existing conditions or developmental abnormalities by the US Department of Defense and US Department of Veterans Affairs (VA). As a result, PDs are therefore deemed incompatible with military service and ineligible for service-connected disability benefits.13-15 Such determinations allowed PD pathology to be used as grounds for discharge for 26,000 service members from 2001 to 2007, or 2.6% of total enlisted discharges during that period.13,15,16

Despite this structural discrimination, recent research suggests veterans may be more likely to experience PD pathology than the general population.17 For example, a 2021 epidemiological survey in a community-based veteran sample found elevated rates of borderline, antisocial, and schizotypal PDs (6%-13%).6 In contrast, only 0.8% to 5.0% of veteran electronic health records (EHRs) have a documented PD diagnosis.8,18,19 Such elevations in PD pathology within veteran samples imply either a disproportionately high prevalence among enlistees (and therefore missed during recruitment procedures) or onset following military service, possibly due to exposure to traumatic events and/ or occupational stress.17 Due to the relative infancy of research in this area and a lack of longitudinal studies, etiology and course of illness for personality pathology in veterans remains largely unclear.

Structural underacknowledgment of PDs among military personnel has contributed to their underrepresentation in research on veteran populations. PD-focused research with veterans is rare, despite a rapid increase in broader empirical attention paid to these conditions in nonveteran samples.20 A recent meta-analysis of veterans with PDs identified 27 studies that included basic prevalence statistics. PDs were rarely a primary focus for these studies, and most were limited to veterans seen in Veterans Health Administration (VHA) settings.17 The literature also paints a bleak picture, suggesting veterans who experience PDs are at higher risk for suicide attempt and death by suicide, criminal-legal involvement, and homelessness. They also tend to experience more severe comorbid psychopathological symptoms and more often use high-intensity mental health services (eg, care within emergency departments or psychiatric inpatient settings) than veterans without PD pathology.6,8,18,19,21 However, PD pathology does not appear to impede the effectiveness of treatment for veterans.22-24 The implications of PD pathology on broader psychosocial functioning and health care needs certify a need for additional research that examines patterns of personality pathology, particularly in veterans outside the VHA.

METHODS

This study aims to enhance understanding of veterans affected by PDs and offer insight and guidance for treatment of these conditions in federal and nonfederal treatment settings. Previous research has been largely limited to VHA care-receiving samples; the longstanding stigma against PDs by the US military and VA may contribute to biased diagnosis and documentation of PDs in these settings. A large sample of veterans receiving community-based mental health care was therefore used to explore aims of the current study. This study specifically examined demographic patterns, diagnostic comorbidity, psychosocial outcomes, and treatment care settings among veterans with and without a PD diagnosis. Consistent with previous research, we hypothesized that veterans with a PD diagnosis would have more severe mental health comorbidities, poorer psychosocial outcomes, and receive care in higher intensity settings relative to veterans without a diagnosis.

Data for the sample were drawn from the Mental Health Client-Level Data, a publicly available national dataset of nearly 7 million patients who received mental health treatment services provided or funded through state mental health agencies in 2022.25 The analytic sample included about 2.5 million patients for whom veteran status and data around the presence or absence of a PD diagnosis were available. Of these patients, 104,198 were identified as veterans. Veteran patients were identified as predominantly male (63%), White (71%), non-Hispanic (90%), and never married (54%).

Measures

The parent dataset included demographic, clinical, and psychosocial outcome information reported by treatment facilities to individual state administrative systems for each patient who received services. To protect patient privacy, only nonprotected health information is included, and efforts were made throughout compilation of the parent dataset to ensure patient privacy (eg, limiting detail of information disseminated for public access). Because the parent dataset does not include protected health information, studies using these data are considered exempt from institutional review board oversight.

Demographic information. This study reviewed veteran status, sex, race, ethnicity, age, education, and marital status. Veteran status was defined by whether the patient was aged ≥ 18 years and had previously served (but was not currently serving) in the military. Patients with a history of service in the National Guard or Military Reserves were only classified as veterans if they had been called or ordered to active duty while serving. Sex was operationalized dichotomously as male or female; no patients were identified as intersex, transgender, or other gender identities.

Clinical information. Up to 3 mental health diagnoses were reported for each patient and included the following disorders: personality, trauma and attention-deficit/hyperactivity, stressor, anxiety, conduct, delirium/dementia, bipolar, depressive, oppositional defiant, pervasive developmental, schizophrenia or other psychotic, and alcohol or substance use. Mental health diagnosis categories were generated for the parent dataset by grouping diagnostic codes corresponding to each category. To protect patient privacy, more detailed diagnostic information was not available as part of the parent dataset. Although the American Psychiatric Association recognizes 10 distinct PDs, the exact nature of PD diagnoses was not included within the parent dataset. PD diagnoses were coded to reflect the presence or absence of any such diagnosis.

A substance use problem designation was also provided for patients according to various identification methods, including substance use disorder (SUD) diagnosis, substance use screening results, enrollment in a substance use program, substance use survey, service claims information, and other related sources of information. A severe mental illness or serious emotional disturbance designation was provided for patients meeting state definitions of these designations. Context(s) of service provision were coded as inpatient state psychiatric hospital, community-based program, residential treatment center, judicial institution, or other psychiatric inpatient setting.

Psychosocial outcome information. Patient employment and residential status were also included in analyses. Each reflected status at the time of discharge from services or end of reporting period; employment status was only provided for patients receiving treatment in community-based programs.

Data Analysis

Descriptive statistics and X2 analyses were used to compare demographic, clinical, and psychosocial outcome variables between patients with and without PD diagnoses. These analyses were calculated for both the 104,198 veterans and the 2,222,306 nonveterans aged ≥ 18 years in the dataset. Given the sample size, a conservative α of .01 was used to determine statistical significance.

RESULTS

In this sample of persons receiving state-funded mental health care, veterans were significantly less likely than nonveterans to have a documented PD diagnosis (2.1% vs 3.6%, X2 [1] = 647.49; P < .01). PD diagnoses were more common among White (risk ratio [RR], 1.11), non-Hispanic (RR, 1.03) veterans who were in middle to late adulthood (RR, 1.16-1.40), more educated (RR, 1.35), and divorced or widowed (RR, 1.43), and less common among Black/African American (RR, 0.78) or Puerto Rican (RR, 0.32) veterans who were in early adulthood (RR, 0.31-0.79), less educated (RR, 0.64-0.89), and currently married (RR, 0.89) or never married (RR, 0.86). Veteran men and women were equally likely to have a PD diagnosis (RR, 1.03) (Table 1). Among nonveterans, men were less likely than women to have a PD diagnosis (RR, 0.79), and PD diagnoses were most common among persons in middle adulthood (RR, 1.06-1.15) (eAppendix 1).

0425FED-MH-PD-012T10425FED-MH-PD-012_eA1

Veterans with a PD diagnosis were more likely than those without a diagnosis to have more diagnoses (RR, 2.96-8.49) and to have comorbid trauma or related stressor (RR, 1.33), or bipolar (RR, 1.56) or psychotic (RR, 1.15) disorder diagnoses, but less likely to have comorbid depressive disorder (RR, 0.82). Although veterans with and without a PD diagnosis were similarly likely to have a comorbid SUD (RR, 1.13), those with a PD diagnosis were significantly less likely to be assigned a substance use problem designation (RR, 0.78). PD diagnosis was also more common among veterans who received services in state psychiatric hospitals (RR, 3.05), community-based clinics (RR, 1.06), and judicial institutions (RR, 6.33) and less common among those who received services in other psychiatric inpatient settings (RR, 0.30). No differences were observed for residential treatment settings (RR, 0.79). Among nonveterans, a PD diagnosis was associated with slightly greater odds of a substance use designation (RR, 1.03) (eAppendix 2).

0425FED-MH-PD-012_eA2

Veterans with a PD diagnosis were also less likely to have full-time employment (RR, 0.73) and more likely to have undifferentiated employment (RR, 2.00) or to be removed from the labor force (RR, 1.35). Veterans with a PD diagnosis were also more likely to reside in nontraditional living conditions (RR, 1.42) and less likely to be residing in a private residence (RR, 0.98), compared with those without PD diagnosis. The rates of homelessness were similar for veterans with and without a PD diagnosis (RR, 0.90) (Table 2). These patterns were similar among nonveterans.

0425FED-MH-PD-012T2

DISCUSSION

This study examined the rate and correlates of PD diagnosis among a large, community-based sample of veterans receiving state-funded mental health care. About 2% of veterans in this sample had a PD diagnosis, with diagnoses more common among veterans who were White, non-Hispanic, aged ≥ 45 years, with higher education, divorced or widowed, also diagnosed with trauma-related, bipolar, and/or psychotic disorders, underemployed, nontraditionally housed, and receiving treatment in state psychiatric hospital, community-based clinic, or judicial system settings.

The observed rate of PD diagnosis in this study aligns with what is typically observed in VHA EHRs.8,18,19 However, the rate is notably lower than prevalence estimates for psychiatric outpatient settings (about 50%) and in meta-analyses of prevalence among veterans (0.8%-23% for each of the 10 PDs).4,17,26 Longstanding stigma against PDs may contribute to underdiagnosis. For example, many clinicians are concerned that documentation or disclosure of a PD will interfere with the patient’s ability to access treatment due to stigma and discrimination.27,28 These fears are not unfounded; even among clinicians, PDs are commonly considered untreatable, and many individuals with PDs are denied access to evidence-based treatments due to the diagnosis.29 In a 2016 survey of community psychiatrists, nearly 1 in 4 reported that they avoid taking patients with a borderline PD diagnosis in their caseloads.28 To date, no studies have been conducted to explore clinicians’ willingness to accept patients with other PDs or, specifically, among veterans.

Despite such widespread stigma, research suggests clinicians' negative attitudes toward PDs can be decreased through antistigma campaigns.30 However, it remains unclear if such efforts also contribute to an increase in clinicians’ willingness to document PD diagnoses. Without accurate identification and documentation, the field’s understanding of PDs will remain limited.

In the current study, veterans with PD diagnoses tended to present with more complex and severe psychiatric comorbidities compared to veterans without such diagnoses. Observed comorbidity of PDs (particularly borderline PD) with trauma-related and bipolar disorders is well established.8 Conversely, co-occurring personality and psychotic disorders—which comprise 16% of veterans with a PD diagnosis in the sample in this study—are not consistently examined in the literature. A 2022 examination of veterans receiving VHA care suggested 12% and 13% of those with a PD diagnosis documented in their EHR also had documented schizophrenia or another psychotic disorder, respectively. PD diagnoses were associated with 6.88- and 9.80-fold increases in risk for comorbid schizophrenia and other psychotic disorder diagnoses, respectively.8 Similarly, a recent longitudinal study of nearly 2 million Swedish individuals suggested borderline PD is specifically associated with a > 24-times greater risk of having a comorbid psychotic disorder.31 It is therefore possible that the comorbidity between personality and psychotic disorders is quite common despite its relative lack of attention in empirical research.

Veterans with PD diagnoses in this study were also more likely to experience substandard housing, employment challenges, and receive treatment through judicial institutions than those without a PD diagnosis. Such findings are consistent with previous research demonstrating the substantial psychosocial challenges associated with PD diagnosis, even after controlling for comorbid conditions.7,9 Veterans with PDs may benefit from specialized case management and support to facilitate stable housing and employment and to mitigate the risk of judicial involvement. Some research suggests veterans with PDs may be less likely to gain competitive employment after participating in VA therapeutic and supportive employment services programs, suggesting standard programming may be less suitable for this population.32 Similarly, other research suggests individuals with PDs may benefit more from specialized, intensive services than standard clinical case management.33 Future research may therefore benefit from clarifying the degree to which adaptations to standard programming could yield beneficial effects for persons with PD diagnoses.

Implications

Cumulatively, the results of this study attest to the necessity for transdiagnostic treatment planning that includes close collaboration between psychotherapeutic, pharmacological, and case management services. Some psychotherapy models for PDs, such as dialectical behavior therapy (DBT), which includes a combination of group skills training, individual therapy, as-needed phone coaching, and therapist consultation, may be successfully adapted to include this collaboration.34-36 However, implementation of such comprehensive programming often requires extensive clinician training and coordination of resources, which poses implementation challenges.37-39 In 2021, the VHA began large-scale implementation of PD-specific psychotherapy for veterans with recent suicidal self-directed violence and borderline PD, including DBT, though to date results remain unclear.40 Generalist approaches, such as good psychiatric management (GPM), which emphasizes emotional validation, practical problem solving, realistic goal setting, and relationship functioning within the context of standard care appointments, may be more easily implemented in community care settings due to lesser training and resource requirements and can also be adapted to include needed elements of care coordination.41,42 Both DBT and GPM were initially developed for the treatment of borderline PD. Although DBT has also demonstrated some effectiveness in the treatment of antisocial PD, potential applications of DBT and GPM to other PDs remain largely underdeveloped.43-46

There are no widely accepted medications for the treatment of PDs. Pharmacotherapy for these conditions typically consists of individualized approaches informed by personal experience that attempt to balance targeting of specific symptoms while minimizing polypharmacy and potential risks (eg, overdose or addiction).47,48 Despite this, pharmacotherapy is often considered a necessary component in the treatment of bipolar and psychotic disorders, both common comorbidities of PDs found in veterans in this study.49,50 Careful consideration of complex comorbidities and pharmacotherapy needs is warranted in the treatment of veterans with PDs. Future research may benefit from clarifying clinical guidelines around pharmacotherapy, particularly for observed comorbidities of PDs to trauma, bipolar, and psychotic disorders.

It is important to note the discrepancies in the results of this study surrounding patient substance use. The results suggest a negligible or inverse association between the likelihood of a PD diagnosis and difficulties with substance use among the veterans in this study. However, the unexpectedly low rate of SUD diagnoses (< 6%) suggests that they were likely underdocumented. Research suggests a strong association between personality and SUDs in both veteran and civilian samples.6,51 Results suggesting a lower prevalence of substance use difficulties among treatment-seeking veterans with PDs should be interpreted with great caution.

Demographically, PD diagnoses were more common among veterans who were White, non-Hispanic, and aged ≥ 45 years, and less common among veterans who were Black/ African American, mixed/unspecified race, Puerto Rican or other non-Mexican Hispanic ethnicity, or aged < 35 years. No significant sex-based differences were observed. These patterns are consistent with research suggesting individuals who identify as Black may be less likely than individuals who identify as White to report PD symptoms, meet criteria for a PD, and have a PD diagnosed even when it is warranted.52

The findings observed in this study with respect to age, however, are notably inconsistent with the literature. Previous research typically suggests a negative association between age and PD pathology; however, a 2020 review of PDs in older adults by Penders et al suggests a prevalence of 11% to 15% in this population.53,54 Research into PDs most often focuses on adolescent and early adulthood developmental periods, limiting insight into the phenomenology of PDs in middle to late adulthood.55 Further, most research into PDs among geriatric populations has focused on psychometric assessment rather than practical treatment guidance.54 However, in this study, elevated risk for PD diagnoses was salient throughout middle to late adulthood among veterans; similar, albeit less pronounced patterns were also observed for elevated risk of PD diagnosis in middle adulthood among nonveterans. Such findings suggest clarifying the phenomenology and treatment needs of individuals with PDs in middle to late adulthood may have particularly salient implications for the mental health care of veterans affected by these conditions. As the veteran population advances in age, these needs will present unique challenges if health care systems are unprepared to effectively address them.

Limitations

This study is characterized by several strengths, most notably its use of a large dataset recently collected on a national scale. Few studies outside of the VHA system include samples of > 100,000 treatment-seeking veterans collected on a national scale. Nevertheless, results should be understood within the context of several methodological limitations. However, the dataset was limited to the first 3 diagnoses documented in patients’ EHRs, and many patients had no listed diagnoses. Patients with complex comorbidities may have > 3 diagnoses; for these individuals, data provided an incomplete picture of clinical presentation. This is especially relevant for individuals with PDs, who tend to meet criteria for a range of comorbid conditions.8,10 The now dated practice of listing PDs on Axis II also increases the chance of clinicians listing PDs after conditions traditionally listed on Axis I (eg, major depressive disorder) in patient charts.56 This study’s inclusion of only the first 3 listed diagnoses likely underestimated true PD diagnosis prevalence.

The results of this study must be interpreted as reflecting the prevalence and correlates of receiving a PD diagnosis rather than meeting diagnostic criteria for a PD. Relatedly, PD diagnoses were reported as a single construct, limiting insight into prevalence and correlates of individual PD diagnoses (eg, borderline vs paranoid PDs). Meta-analyses estimates suggest PD prevalence among veterans is likely much higher than observed in this study.17 Stigma continues to discourage clinicians from documenting and disclosing PD diagnoses even when warranted.27,28 Continued research should aim to clarify conditions (eg, patient presentation, stigma, or institutional culture) contributing to documentation of PD diagnoses. Given the cross-sectional nature of this study, results cannot speak to longitudinal treatment outcomes or prognosis of persons receiving a PD diagnosis.

Despite its large sample size and national representation, the sampling strategy of this study could have contributed to idiosyncrasies in the dataset. Restriction of data to the persons receiving state-funded mental health services introduces a notable bias to the composition of the sample, which is likely comprised of a disproportionately high number of Medicaid recipients, students, and individuals with chronic illnesses and underrepresentation of persons who pay for mental health services using private insurance or private pay arrangements. As such, although socioeconomic information was not provided within this dataset, one can presume a generally lower socioeconomic status among study participants compared to the community at large. This study also included a proportionally small sample of veterans (3.6% compared to about 6.2% in the broader US population), suggesting veterans may have been underrepresented or underidentified in surveyed mental health care settings.57 This study also did not include data around service in active-duty military, national guard, or military reserves; a greater proportion of the sample likely had a history of military service than was represented by veteran status designation. Further, the proportionally high sample of individuals with severe mental illness suggests a likely overrepresentation of such conditions in surveyed settings.

Institutional differences in the practice of assigning diagnoses likely limited statistical power to detect potentially meaningful associations and effects. Structural influences, such as stigma and institutional culture, may have notable effects on documentation practices, particularly for PDs. Future research should aim to replicate observed associations using more controlled diagnostic procedures.

Lastly, even with the use of a more conservative α and a focus on effect sizes to guide interpretation of results, use of multiple bivariate analyses can be presumed to have increased the likelihood of type I error. Given the limited prior research in this area, an exploratory approach to statistical analysis was considered warranted to maximize opportunity for identifying areas in need of additional empirical attention. Continued research using more conservative statistical approaches (eg, multivariate analyses) is needed to determine replicability and generalizability of observed results.

CONCLUSIONS

This study examined the prevalence and correlates of PD diagnoses in a national sample of veterans receiving community-based, state-funded mental health care. About 2% received a PD diagnosis, with diagnoses most common among veterans who were White, non-Hispanic, aged ≥ 45 years, also diagnosed with trauma-based, bipolar, and/or psychotic disorders, underemployed, nontraditionally housed, and receiving treatment in a state psychiatric hospital or judicial system setting. The results attest to a necessity for transdiagnostic treatment planning and care coordination for this population, with particular attention to psychosocial stressors.

References
  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text revision. American Psychiatric Association; 2022.
  2. Hastrup LH, Jennum P, Ibsen R, Kjellberg J, Simonsen E. Societal costs of borderline personality disorders: a matched-controlled nationwide study of patients and spouses. Acta Psychiatr Scand. 2019;140(5):458-467. doi:10.1111/acps.13094
  3. Sveen CA, Pedersen G, Ulvestad DA, Zahl KE, Wilberg T, Kvarstein EH. Societal costs of personality disorders: a cross-sectional multicenter study of treatment-seeking patients in mental health services in Norway. J Clin Psychol. 2023;79(8):1752-1769. doi:10.1002/jclp.23504
  4. Beckwith H, Moran PF, Reilly J. Personality disorder prevalence in psychiatric outpatients: a systematic literature review. Personal Ment Health. 2014;8(2):91-101. doi:10.1002/pmh.1252
  5. Eaton NR, Greene AL. Personality disorders: community prevalence and socio-demographic correlates. Curr Opin Psychol. 2018;21:28-32. doi:10.1016/j.copsyc. 2017.09.001
  6. Edwards ER, Barnes S, Govindarajulu U, Geraci J, Tsai J. Mental health and substance use patterns associated with lifetime suicide attempt, incarceration, and homelessness: a latent class analysis of a nationally representative sample of U.S. veterans. Psychol Serv. 2021;18(4):619-631. doi:10.1037/ser0000488
  7. Moran P, Romaniuk H, Coffey C, et al. The influence of personality disorder on the future mental health and social adjustment of young adults: a population-based cohort study. Lancet Psychiatry. 2016;3(7):636-645. doi:10.1016/S2215-0366(16)30029-3
  8. Nelson SM, Griffin CA, Hein TC, Bowersox N, McCarthy JF. Personality disorder and suicide risk among patients in the Veterans Affairs health system. Personal Disord. 2022;13(6):563-571. doi:10.1037/per0000521
  9. Skodol AE. Impact of personality pathology on psychosocial functioning. Curr Opin Psychol. 2018;21;33-38. doi:10.1016/j.copsyc.2017.09.006
  10. Tyrer P, Reed GM, Crawford MJ. Classification, assessment, prevalence, and effect of personality disorder. Lancet. 2015;385(9969):717-726. doi:10.1016/S0140-6736(14)61995-4
  11. Fitzpatrick S, Goss S, Di Bartolomeo A, Varma S, Tissera T, Earle E. Follow the money: is borderline personality disorder research underfunded in Canada? Can Psychol. 2024;65(1):46-57. doi:10.1037/cap0000375
  12. Zimmerman M, Gazarian D. Is research on borderline personality disorder underfunded by the National Institute of Health? Psychiatry Res. 2014;220(3):941-944. doi:10.1016/j.psychres.2014.09.021
  13. Leroux TC. U.S. military discharges and pre-existing personality disorders: a health policy review. Adm Policy Ment Health. 2015;42(6):748-755. doi:10.1007/s10488-014-0611-z
  14. Monahan MC, Keener JK. Fitness-for-duty evaluations. In Kennedy CH, Zillmer EA, eds. Military Psychology: Clinical and Operational Applications. 2nd ed. Guilford Publications; 2012:25-49.
  15. Hearing Before the Committee on Veterans’ Affairs, 111th Congress 2nd Sess (2010). Personality disorder discharges: impact on veterans benefits. Accessed March 4, 2025. https://www.govinfo.gov/content/pkg/CHRG-111hhrg61755/html/CHRG-111hhrg61755.htm
  16. Ader M, Cuthbert R, Hoechst K, Simon EH, Strassburger Z, Wishnie M. Casting troops aside: the United States military’s illegal personality disorder discharge problem. Vietnam Veterans of America. March 2012. Accessed February 28, 2025. https://law.yale.edu/sites/default/files/documents/pdf/Clinics/VLSC_CastingTroopsAside.pdf
  17. Edwards ER, Tran H, Wrobleski J, Rabhan Y, Yin J, Chiodi C, Goodman M, Geraci J. Prevalence of personality disorders across veteran samples: A meta-analysis. J Pers Disord. 2022;36(3):339-358. doi:10.1521/ pedi.2022.36.3.339
  18. Holliday R, Desai A, Edwards E, Borges L. Personal i ty disorder diagnosis among just ice -involved veterans: an investigation of VA-using veterans. J Nerv Ment Dis. 2023;211(5):402-406 doi:10.1097/ NMD.0000000000001627
  19. McCarthy JF, Bossarte RM, Katz IR, et al. Predictive modeling and concentration of the risk of suicide: implications for preventive interventions in the US Department of Veterans Affairs. Am J Public Health. 2015;105(9):1935-1942. doi:10.2105/AJPH.2015.302737
  20. Liu Y, Chen C, Zhou Y, Zhang N, Liu S. Twenty years of research on borderline personality disorder: a scientometric analysis of hotspots, bursts, and research trends. Front Psych. 2024;15:1361535. doi:10.3389/ fpsyt.2024.1361535
  21. Williams R, Holliday R, Clem M, Anderson E, Morris EE, Surís A. Borderline personality disorder and military sexual trauma: analysis of previous traumatization and current psychiatric presentation. J Interpers Violence. 2017;32(15):2223-2236. doi:10.1177/0886260515596149
  22. Holder N, Holliday R, Pai A, Surís A. Role of borderline personality disorder in the treatment of military sexual trauma-related posttraumatic stress disorder with cognitive processing therapy. Behav Med. 2017;43(3):184-190. doi:10.1080/08964289.2016.1276430
  23. Ralevski E, Ball S, Nich C, Limoncelli D, Petrakis I. The impact of personality disorders on alcohol-use outcomes in a pharmacotherapy trial for alcohol dependence and comorbid Axis I disorders. Am J Addict. 2007;16(6):443- 449. doi:10.1080/10550490701643336
  24. Walter KH, Bolte TA, Owens GP, Chard KM. The impact of personality disorders on treatment outcome for veterans in a posttraumatic stress disorder residential treatment program. Cognit Ther Res. 2012;36(5):576-584. doi:10.1007/s10608-011-9393-8
  25. Substance Abuse and Mental Health Services. Mental health client-level data (MH-CLD), 2022. Accessed February 28, 2025. https://www.datafiles.samhsa.gov/dataset/mental-health-client-level-data-2022-mh-cld-2022-ds0001
  26. Zimmerman M, Rothschild L, Chelminski I. The prevalence of DSM-IV personality disorders in psychiatric outpatients. Am J Psychiatry. 2005;162(10):1911-1918. doi:10.1176/appi.ajp.162.10.1911
  27. Campbell K, Clarke KA, Massey D, Lakeman R. Borderline personality disorder: To diagnose or not to diagnose? That is the question. Int J Mental Health Nurs. 2020;29(5):972-981. doi:10.1111/inm.12737
  28. Sisti D, Segal AG, Siegel AM, Johnson R, Gunderson J. Diagnosing, disclosing, and documenting borderline personality disorder: a survey of psychiatrists’ practices. J Pers Disord. 2016;30(6):848-856. doi:10.1521/ pedi_2015_29_228
  29. Klein P, Fairweather AK, Lawn S. Structural stigma and its impact on healthcare for borderline personality disorder: a scoping review. Int J Ment Health Syst. 2022;16(1):48. doi:10.1186/s13033-022-00558-3
  30. Knaak S, Szeto AC, Fitch K, Modgill G, Patten S. Stigma towards borderline personality disorder: effectiveness and generalizability of an anti-stigma program for healthcare providers using a pre-post randomized design. Borderline Personal Disord Emot Dysregul. 2015;2:9. doi:10.1186/s40479-015-0030-0
  31. Tate AE, Sahlin H, Liu S, et al. Borderline personality disorder: associations with psychiatric disorders, somatic illnesses, trauma, and adverse behaviors. Mol Psychiatry. 2022;27:2514-2521. doi:10.1038/s41380- 022-01503-z
  32. Abraham KM, Yosef M, Resnick SG, Zivin K. Competitive employment outcomes among veterans in VHA Therapeutic and Supported Employment Services programs. Psychiatr Serv. 2017;68(9)938-946. doi:10.1176/appi. ps201600412
  33. Frisman LK, Mueser KT, Covell NH, et al. Use of integrated dual disorder treatment via Assertive Community Treatment versus clinical case management for persons with co-occurring disorders and antisocial personality disorder. J Nerv Ment Dis. 2009;197(11):822-828. doi:10.1097/NMD.0b013e3181beac52
  34. Edwards ER, Kober H, Rinne GR, Griffin SA, Axelrod S, Cooney EB. Skills]homework completion and phone coaching as predictors of therapeutic change and outcomes in completers of a DBT intensive outpatient programme. Psychol Psychother. 2021;94(3):504-522. doi:10.1111/papt.12325
  35. Linehan MM, Dimeff LA, Reynolds SK, et al. Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend. 2002;67(1):13-26. doi:10.1016/s0376-8716(02)00011-x
  36. Linehan MM, Korslund KE, Harned MS, et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry. 2015;72(5):475-482.doi:10.1001 /jamapsychiatry.2014.3039
  37. Carmel A, Rose ML, Fruzzetti AE. Barriers and solutions to implementing dialectical behavior therapy in a public behavioral health system. Adm Policy Ment Health. 2014;41(5):608-614. doi:10.1007/s10488-013-0504-6
  38. Decker SE, Matthieu MM, Smith BN, Landes SJ. Barriers and facilitators to dialectical behavior therapy skills groups in the Veterans Health Administration. Mil Med. 2024;189(5-6):1055-1063. doi:10.1093/milmed/ usad123
  39. Landes SJ, Rodriguez AL, Smith BN, et al. Barriers, facilitators, and benefits of implementation of dialectical behavior therapy in routine care: results from a national program evaluation survey in the Veterans Health Administration. Transl Behav Med. 2017;7(4):832-844. doi:10.1007/s13142-017-0465-5
  40. Walker J, Betthauser LM, Green K, Landes SJ, Stacy M. Suicide Prevention 2.0 Clinical Telehealth Program: Evidence- Based Treatment in the Veterans Health Administration. April 28, 2024. Accessed February 28, 2025. https://www.youtube.com/watch?v=fFsDzkg0SR0
  41. Gunderson J, Masland S, Choi-Kain L. Good psychiatric management: a review. Curr Opin Psychol. 2018;21:127- 131. doi:10.1016/j.copsyc.2017.12.006
  42. Kramer U. Good-enough therapy: a review of the empirical basis of good psychiatric management. Am J Psychother. 2025;78(1): 11-15. doi:10.1176/appi .psychotherapy.20230041
  43. Visdómine-Lozano JC. Contextualist perspectives in the treatment of antisocial behaviors and offending: a comparative review of FAP, ACT, DBT, and MDT. Trauma Violence Abuse. 2022;23(1):241-254. doi:10.1177/1524838020939509
  44. Drago A, Marogna C, Jørgen Søgaard H. A review of characteristics and treatments of the avoidant personality disorder. Could the DBT be an option? Int J Psychol Psychoanal. 2016;2(1):013.
  45. Finch EF, Choi-Kain LW, Iliakis EA, Eisen JL, Pinto A. Good psychiatric management for obsessive–compulsive personality disorder. Curr Behav Neurosci Rep. 2021;8:160-171. doi:10.1007/s40473-021-00239-4
  46. Miller TW, Kraus RF. Modified dialectical behavior therapy and problem solving for obsessive-compulsive personality disorder. Journal Contemp Psychother. 2007;37:79-85. doi:10.1007/s10879-006-9039-4
  47. Bozzatello P, Rocca P, De Rosa ML, Bellino S. Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough? Expert Opin Pharmacother. 2020;21(1):47-61.doi:10.1080/14656566 .2019.1686482
  48. Sand P, Derviososki E, Kollia S, Strand J, Di Leone F. Psychiatrists’ perspectives on prescription decisions for patients with personality disorders. J Pers Disord. 2024;38(3):225-240. doi:10.1521/pedi.2024.38.3.225
  49. Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. J Clin Psychiatry. 2003;64 Suppl 12:5-19.
  50. Nierenberg AA, Agustini B, Köhler-Forsberg O, et al. Diagnosis and treatment of bipolar disorder: a review. JAMA. 2023;330(14):1370-1380. doi:10.1001 /jama.2023.18588
  51. Köck P, Walter M. Personality disorder and substance use disorder–an update. Ment Health Prev. 2018;12:82- 89. doi:10.1016/J.MHP.2018.10.003
  52. Garb HN. Race bias and gender bias in the diagnosis of psychological disorders. Clin Psych Rev. 2021;90:102087. doi:10.1016/j.cpr.2021.102087
  53. Debast I, van Alphen SPJ, Rossi G, et al. Personality traits and personality disorders in late middle and old age: do they remain stable? A literature review. Clin Gerontol. 2014;37(3):253-271.doi:10.1080/07317115 .2014.885917
  54. Penders KAP, Peeters IGP, Metsemakers JFM, van Alphen SPJ. Personality disorders in older adults: a review of epidemiology, assessment, and treatment. Curr Psychiatry Rep. 2020;22(3):1-14. doi:10.1007/s11920-020- 1133-x
  55. Videler AC, Hutsebaut J, Schulkens JEM, Sobczak S, van Alphen SPJ. A life span perspective on borderline personality disorder. Curr Psychiatry Rep. 2019;21(7) :1-8. doi:10.1007/s11920-019-1040-1
  56. Wakefield JC. DSM-5 and the general definition of personality disorder. Clin Soc Work J. 2013;41(2):168-183. doi:10.1007/s10615-012-0402-5
  57. US Census Bureau. 2022 American Community Survey 1-year. Accessed February 28, 2025. https://data.census.gov/table/ACSST1Y2022.S2101?q=Veterans&y=2022comparison
References
  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text revision. American Psychiatric Association; 2022.
  2. Hastrup LH, Jennum P, Ibsen R, Kjellberg J, Simonsen E. Societal costs of borderline personality disorders: a matched-controlled nationwide study of patients and spouses. Acta Psychiatr Scand. 2019;140(5):458-467. doi:10.1111/acps.13094
  3. Sveen CA, Pedersen G, Ulvestad DA, Zahl KE, Wilberg T, Kvarstein EH. Societal costs of personality disorders: a cross-sectional multicenter study of treatment-seeking patients in mental health services in Norway. J Clin Psychol. 2023;79(8):1752-1769. doi:10.1002/jclp.23504
  4. Beckwith H, Moran PF, Reilly J. Personality disorder prevalence in psychiatric outpatients: a systematic literature review. Personal Ment Health. 2014;8(2):91-101. doi:10.1002/pmh.1252
  5. Eaton NR, Greene AL. Personality disorders: community prevalence and socio-demographic correlates. Curr Opin Psychol. 2018;21:28-32. doi:10.1016/j.copsyc. 2017.09.001
  6. Edwards ER, Barnes S, Govindarajulu U, Geraci J, Tsai J. Mental health and substance use patterns associated with lifetime suicide attempt, incarceration, and homelessness: a latent class analysis of a nationally representative sample of U.S. veterans. Psychol Serv. 2021;18(4):619-631. doi:10.1037/ser0000488
  7. Moran P, Romaniuk H, Coffey C, et al. The influence of personality disorder on the future mental health and social adjustment of young adults: a population-based cohort study. Lancet Psychiatry. 2016;3(7):636-645. doi:10.1016/S2215-0366(16)30029-3
  8. Nelson SM, Griffin CA, Hein TC, Bowersox N, McCarthy JF. Personality disorder and suicide risk among patients in the Veterans Affairs health system. Personal Disord. 2022;13(6):563-571. doi:10.1037/per0000521
  9. Skodol AE. Impact of personality pathology on psychosocial functioning. Curr Opin Psychol. 2018;21;33-38. doi:10.1016/j.copsyc.2017.09.006
  10. Tyrer P, Reed GM, Crawford MJ. Classification, assessment, prevalence, and effect of personality disorder. Lancet. 2015;385(9969):717-726. doi:10.1016/S0140-6736(14)61995-4
  11. Fitzpatrick S, Goss S, Di Bartolomeo A, Varma S, Tissera T, Earle E. Follow the money: is borderline personality disorder research underfunded in Canada? Can Psychol. 2024;65(1):46-57. doi:10.1037/cap0000375
  12. Zimmerman M, Gazarian D. Is research on borderline personality disorder underfunded by the National Institute of Health? Psychiatry Res. 2014;220(3):941-944. doi:10.1016/j.psychres.2014.09.021
  13. Leroux TC. U.S. military discharges and pre-existing personality disorders: a health policy review. Adm Policy Ment Health. 2015;42(6):748-755. doi:10.1007/s10488-014-0611-z
  14. Monahan MC, Keener JK. Fitness-for-duty evaluations. In Kennedy CH, Zillmer EA, eds. Military Psychology: Clinical and Operational Applications. 2nd ed. Guilford Publications; 2012:25-49.
  15. Hearing Before the Committee on Veterans’ Affairs, 111th Congress 2nd Sess (2010). Personality disorder discharges: impact on veterans benefits. Accessed March 4, 2025. https://www.govinfo.gov/content/pkg/CHRG-111hhrg61755/html/CHRG-111hhrg61755.htm
  16. Ader M, Cuthbert R, Hoechst K, Simon EH, Strassburger Z, Wishnie M. Casting troops aside: the United States military’s illegal personality disorder discharge problem. Vietnam Veterans of America. March 2012. Accessed February 28, 2025. https://law.yale.edu/sites/default/files/documents/pdf/Clinics/VLSC_CastingTroopsAside.pdf
  17. Edwards ER, Tran H, Wrobleski J, Rabhan Y, Yin J, Chiodi C, Goodman M, Geraci J. Prevalence of personality disorders across veteran samples: A meta-analysis. J Pers Disord. 2022;36(3):339-358. doi:10.1521/ pedi.2022.36.3.339
  18. Holliday R, Desai A, Edwards E, Borges L. Personal i ty disorder diagnosis among just ice -involved veterans: an investigation of VA-using veterans. J Nerv Ment Dis. 2023;211(5):402-406 doi:10.1097/ NMD.0000000000001627
  19. McCarthy JF, Bossarte RM, Katz IR, et al. Predictive modeling and concentration of the risk of suicide: implications for preventive interventions in the US Department of Veterans Affairs. Am J Public Health. 2015;105(9):1935-1942. doi:10.2105/AJPH.2015.302737
  20. Liu Y, Chen C, Zhou Y, Zhang N, Liu S. Twenty years of research on borderline personality disorder: a scientometric analysis of hotspots, bursts, and research trends. Front Psych. 2024;15:1361535. doi:10.3389/ fpsyt.2024.1361535
  21. Williams R, Holliday R, Clem M, Anderson E, Morris EE, Surís A. Borderline personality disorder and military sexual trauma: analysis of previous traumatization and current psychiatric presentation. J Interpers Violence. 2017;32(15):2223-2236. doi:10.1177/0886260515596149
  22. Holder N, Holliday R, Pai A, Surís A. Role of borderline personality disorder in the treatment of military sexual trauma-related posttraumatic stress disorder with cognitive processing therapy. Behav Med. 2017;43(3):184-190. doi:10.1080/08964289.2016.1276430
  23. Ralevski E, Ball S, Nich C, Limoncelli D, Petrakis I. The impact of personality disorders on alcohol-use outcomes in a pharmacotherapy trial for alcohol dependence and comorbid Axis I disorders. Am J Addict. 2007;16(6):443- 449. doi:10.1080/10550490701643336
  24. Walter KH, Bolte TA, Owens GP, Chard KM. The impact of personality disorders on treatment outcome for veterans in a posttraumatic stress disorder residential treatment program. Cognit Ther Res. 2012;36(5):576-584. doi:10.1007/s10608-011-9393-8
  25. Substance Abuse and Mental Health Services. Mental health client-level data (MH-CLD), 2022. Accessed February 28, 2025. https://www.datafiles.samhsa.gov/dataset/mental-health-client-level-data-2022-mh-cld-2022-ds0001
  26. Zimmerman M, Rothschild L, Chelminski I. The prevalence of DSM-IV personality disorders in psychiatric outpatients. Am J Psychiatry. 2005;162(10):1911-1918. doi:10.1176/appi.ajp.162.10.1911
  27. Campbell K, Clarke KA, Massey D, Lakeman R. Borderline personality disorder: To diagnose or not to diagnose? That is the question. Int J Mental Health Nurs. 2020;29(5):972-981. doi:10.1111/inm.12737
  28. Sisti D, Segal AG, Siegel AM, Johnson R, Gunderson J. Diagnosing, disclosing, and documenting borderline personality disorder: a survey of psychiatrists’ practices. J Pers Disord. 2016;30(6):848-856. doi:10.1521/ pedi_2015_29_228
  29. Klein P, Fairweather AK, Lawn S. Structural stigma and its impact on healthcare for borderline personality disorder: a scoping review. Int J Ment Health Syst. 2022;16(1):48. doi:10.1186/s13033-022-00558-3
  30. Knaak S, Szeto AC, Fitch K, Modgill G, Patten S. Stigma towards borderline personality disorder: effectiveness and generalizability of an anti-stigma program for healthcare providers using a pre-post randomized design. Borderline Personal Disord Emot Dysregul. 2015;2:9. doi:10.1186/s40479-015-0030-0
  31. Tate AE, Sahlin H, Liu S, et al. Borderline personality disorder: associations with psychiatric disorders, somatic illnesses, trauma, and adverse behaviors. Mol Psychiatry. 2022;27:2514-2521. doi:10.1038/s41380- 022-01503-z
  32. Abraham KM, Yosef M, Resnick SG, Zivin K. Competitive employment outcomes among veterans in VHA Therapeutic and Supported Employment Services programs. Psychiatr Serv. 2017;68(9)938-946. doi:10.1176/appi. ps201600412
  33. Frisman LK, Mueser KT, Covell NH, et al. Use of integrated dual disorder treatment via Assertive Community Treatment versus clinical case management for persons with co-occurring disorders and antisocial personality disorder. J Nerv Ment Dis. 2009;197(11):822-828. doi:10.1097/NMD.0b013e3181beac52
  34. Edwards ER, Kober H, Rinne GR, Griffin SA, Axelrod S, Cooney EB. Skills]homework completion and phone coaching as predictors of therapeutic change and outcomes in completers of a DBT intensive outpatient programme. Psychol Psychother. 2021;94(3):504-522. doi:10.1111/papt.12325
  35. Linehan MM, Dimeff LA, Reynolds SK, et al. Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend. 2002;67(1):13-26. doi:10.1016/s0376-8716(02)00011-x
  36. Linehan MM, Korslund KE, Harned MS, et al. Dialectical behavior therapy for high suicide risk in individuals with borderline personality disorder: a randomized clinical trial and component analysis. JAMA Psychiatry. 2015;72(5):475-482.doi:10.1001 /jamapsychiatry.2014.3039
  37. Carmel A, Rose ML, Fruzzetti AE. Barriers and solutions to implementing dialectical behavior therapy in a public behavioral health system. Adm Policy Ment Health. 2014;41(5):608-614. doi:10.1007/s10488-013-0504-6
  38. Decker SE, Matthieu MM, Smith BN, Landes SJ. Barriers and facilitators to dialectical behavior therapy skills groups in the Veterans Health Administration. Mil Med. 2024;189(5-6):1055-1063. doi:10.1093/milmed/ usad123
  39. Landes SJ, Rodriguez AL, Smith BN, et al. Barriers, facilitators, and benefits of implementation of dialectical behavior therapy in routine care: results from a national program evaluation survey in the Veterans Health Administration. Transl Behav Med. 2017;7(4):832-844. doi:10.1007/s13142-017-0465-5
  40. Walker J, Betthauser LM, Green K, Landes SJ, Stacy M. Suicide Prevention 2.0 Clinical Telehealth Program: Evidence- Based Treatment in the Veterans Health Administration. April 28, 2024. Accessed February 28, 2025. https://www.youtube.com/watch?v=fFsDzkg0SR0
  41. Gunderson J, Masland S, Choi-Kain L. Good psychiatric management: a review. Curr Opin Psychol. 2018;21:127- 131. doi:10.1016/j.copsyc.2017.12.006
  42. Kramer U. Good-enough therapy: a review of the empirical basis of good psychiatric management. Am J Psychother. 2025;78(1): 11-15. doi:10.1176/appi .psychotherapy.20230041
  43. Visdómine-Lozano JC. Contextualist perspectives in the treatment of antisocial behaviors and offending: a comparative review of FAP, ACT, DBT, and MDT. Trauma Violence Abuse. 2022;23(1):241-254. doi:10.1177/1524838020939509
  44. Drago A, Marogna C, Jørgen Søgaard H. A review of characteristics and treatments of the avoidant personality disorder. Could the DBT be an option? Int J Psychol Psychoanal. 2016;2(1):013.
  45. Finch EF, Choi-Kain LW, Iliakis EA, Eisen JL, Pinto A. Good psychiatric management for obsessive–compulsive personality disorder. Curr Behav Neurosci Rep. 2021;8:160-171. doi:10.1007/s40473-021-00239-4
  46. Miller TW, Kraus RF. Modified dialectical behavior therapy and problem solving for obsessive-compulsive personality disorder. Journal Contemp Psychother. 2007;37:79-85. doi:10.1007/s10879-006-9039-4
  47. Bozzatello P, Rocca P, De Rosa ML, Bellino S. Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough? Expert Opin Pharmacother. 2020;21(1):47-61.doi:10.1080/14656566 .2019.1686482
  48. Sand P, Derviososki E, Kollia S, Strand J, Di Leone F. Psychiatrists’ perspectives on prescription decisions for patients with personality disorders. J Pers Disord. 2024;38(3):225-240. doi:10.1521/pedi.2024.38.3.225
  49. Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. J Clin Psychiatry. 2003;64 Suppl 12:5-19.
  50. Nierenberg AA, Agustini B, Köhler-Forsberg O, et al. Diagnosis and treatment of bipolar disorder: a review. JAMA. 2023;330(14):1370-1380. doi:10.1001 /jama.2023.18588
  51. Köck P, Walter M. Personality disorder and substance use disorder–an update. Ment Health Prev. 2018;12:82- 89. doi:10.1016/J.MHP.2018.10.003
  52. Garb HN. Race bias and gender bias in the diagnosis of psychological disorders. Clin Psych Rev. 2021;90:102087. doi:10.1016/j.cpr.2021.102087
  53. Debast I, van Alphen SPJ, Rossi G, et al. Personality traits and personality disorders in late middle and old age: do they remain stable? A literature review. Clin Gerontol. 2014;37(3):253-271.doi:10.1080/07317115 .2014.885917
  54. Penders KAP, Peeters IGP, Metsemakers JFM, van Alphen SPJ. Personality disorders in older adults: a review of epidemiology, assessment, and treatment. Curr Psychiatry Rep. 2020;22(3):1-14. doi:10.1007/s11920-020- 1133-x
  55. Videler AC, Hutsebaut J, Schulkens JEM, Sobczak S, van Alphen SPJ. A life span perspective on borderline personality disorder. Curr Psychiatry Rep. 2019;21(7) :1-8. doi:10.1007/s11920-019-1040-1
  56. Wakefield JC. DSM-5 and the general definition of personality disorder. Clin Soc Work J. 2013;41(2):168-183. doi:10.1007/s10615-012-0402-5
  57. US Census Bureau. 2022 American Community Survey 1-year. Accessed February 28, 2025. https://data.census.gov/table/ACSST1Y2022.S2101?q=Veterans&y=2022comparison
Issue
Federal Practitioner - 42(4)s
Issue
Federal Practitioner - 42(4)s
Page Number
S12-S23
Page Number
S12-S23
Publications
Publications
Topics
Article Type
Display Headline

Needs of Veterans With Personality Disorder Diagnoses in Community-Based Mental Health Care

Display Headline

Needs of Veterans With Personality Disorder Diagnoses in Community-Based Mental Health Care

Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Thu, 04/03/2025 - 13:13
Un-Gate On Date
Thu, 04/03/2025 - 13:13
Use ProPublica
CFC Schedule Remove Status
Thu, 04/03/2025 - 13:13
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Thu, 04/03/2025 - 13:13

COVID-19 Impact on Veterans Health Administration Nurses: A Retrospective Survey

Article Type
Changed
Mon, 03/31/2025 - 12:24
Display Headline

COVID-19 Impact on Veterans Health Administration Nurses: A Retrospective Survey

On March 11, 2020, the World Health Organization designated COVID- 19 as a pandemic.1 Pandemics have historically impacted physical and mental health across all populations, but especially health care workers (HCWs).2 Nurses and other HCWs were profoundly impacted by the pandemic.3-8

Throughout the pandemic, nurses continued to provide care while working in short-staffed workplaces, facing increased exposure to COVID-19, and witnessing COVID—19–related morbidity and mortality.9 Many nurses were mandated to cross-train in unfamiliar clinical settings and adjust to new and prolonged shift schedules. Physical and emotional exhaustion associated with managing care for individuals with COVID-19, shortage of personal protective equipment (PPE), risk of infection, fear of secondary transmission to family members, feelings of being rejected by others, and social isolation, led to HCWs’ increased vulnerability to psychological impacts of the pandemic.8,10

A meta-analysis of 65 studies with > 79,000 participants found HCWs experienced significant levels of anxiety, depression, stress, insomnia, and other mental health issues, such as posttraumatic stress disorder (PTSD). Female HCWs, nurses, and frontline responders experienced a higher incidence of psychological impact.11 Other meta-analyses revealed that nurses’ compassion satisfaction, compassion fatigue, and burnout levels were significantly impacted with increased levels of burnout among nurses who had a friend or family member diagnosed with COVID- 19 or experienced prolonged threat of exposure to the virus.12,13 A study of 350 nurses found high rates of perceived transgressions by others, and betrayal.8 Nurse leaders and staff nurses had to persevere as moral distress became pervasive among nursing staff, which led to complex and often unsustainable circumstances. 14 The themes identified in the literature about the pandemic’s impact as well as witnessing nurse colleagues’ distress with patient mortality and death of coworkers during the early phase of the COVID-19 pandemic compelled a group of Veterans Health Administration (VHA) nurses to form a research team to understand the scope of impact and identify possible solutions.

Since published studies on the impact of pandemics on HCWs, including nurses, primarily focused on inpatient settings, the investigators of this study sought to capture the experiences of outpatient and inpatient nurses providing care in the US Department of Veterans Affairs (VA) Sierra Pacific Network (Veterans Integrated Service Network [VISN] 21), which has facilities in northern California, Hawaii, and Nevada.15-19 The purpose of this study was to identify the impact of COVID-19 on nurses caring for veterans in both outpatient and inpatient settings at VISN 21 facilities from March 2020 to September 2022, to inform leadership about the extent the virus affected nurses, and identify strategies that address current and future impacts of pandemics.

METHODS

This retrospective descriptive survey adapted the Pandemic Impact Survey by Purcell et al, which included the Moral Injury Events Scale, Primary Care PTSD Screener, the Patient Health Questionnaire-2 for depression, and a modified burnout scale.20-24 The survey of 70 Likert-scale questions was intended to measure nurses’ needs, burnout, moral distress, depression and stress symptoms, work-related factors, and intent to remain working in their current position. A nurse was defined broadly and included those employed as licensed vocational nurses (LVN), licensed practical nurses (LPN), registered nurses (RN), nurses with advanced degrees, advanced practice registered nurses (APRNs), and nurses with other certifications or licenses.

The VA Pacific Islands Research and Development Committee reviewed and approved the institutional review board-exempted study. The VISN 21 union was notified; only limited demographic information and broad VA tenure categories were collected to protect privacy. The principal investigator redacted facility identifier data after each facility had participated.

The survey was placed in REDCAP and a confidential link was emailed to all VISN 21 inpatient and outpatient nurses during March 2023. Because a comprehensive VISN 21 list of nurse email addresses was unavailable, the email was distributed by nursing leadership at each facility. Nurses received an email reminder at the 2-week halfway point, prompting them to complete the survey. The email indicated the purpose and voluntary nature of the study and cautioned nurses that they might experience stress while answering survey questions. Stress management resources were provided.

Descriptive statistics were used to report the results. Data were aggregated for analyzing and reporting purposes.

RESULTS

In March 2023, 860 of 5586 nurses (15%) responded to the survey. Respondents included 344 clinical inpatient nurses (40%) and 516 clinical outpatient nurses (60%); 688 (80%) were RNs, 129 (15%) were LPNs/LVNs, and 43 (5%) were APRNs. Of 849 respondents to provide their age, 15 (2%) were < 30 years, 163 (19%) were 30 to 39 years, 232 (27%) were 40 to 49 years, 259 (30%) were 50 to 59 years, and 180 (21%) were ≥ 60 years.

The survey found that 688 nurses reported job satisfaction (80%) and 75% of all respondents (66% among inpatient nurses) reported feeling happy with the care they delivered. Both inpatient and outpatient nurses indicated they could rely on staff. Sixty percent (n = 516) of the nurses indicated that facility management considered workplace health and safety and supervisors showed concern for subordinates, although inpatient nurses reported a lower percentage (Table 1).

FDP04203121_T1

Two hundred fifty-eight nurses (30%) reported having nurse colleagues who died and 52 (6%) had ≥ 3 colleagues who died. Among respondents, 292 had ≥ 3 patients who died after contracting COVID-19 and 232 (27%) had a significant person in their life die. More than one-half (54%; n = 464) of nurses had to limit contact with a family member who had COVID-19. Most nurses reported concerns about their colleagues (91%), were concerned about bringing COVID-19 home (82%), and stayed away from family during the pandemic (56%) (Table 2).

FDP04203121_T2

A total of 593 nurses (69%) reported feeling overwhelmed from the workload associated with the pandemic, 490 (57%) felt frustrated with role changes, 447 (52%) were stressed because of short staffing, and 327 (38%) felt stressed because of being assigned or floated to different patient care areas. Among inpatient nurses, 158 (46%) reported stress related to being floated. Coworker absenteeism caused challenges for 697 nurses (81%) (Table 3).

FDP04203121_T3

Nurses suggested a number of changes that could improve working conditions, including flexible scheduling (54%) and more hours of leave, which was requested by 43% of outpatient/inpatient nurses and 53% of inpatient alone nurses. Access to COVID-19 testing and PPE was endorsed as a workplace need by 439 nurses; the need for access to PPE was reported by 43% of inpatient-only nurses vs 29% of outpatient/inpatient nurses. The need for adequate staffing was reported by 54% of nurses although the rate was higher among those working inpatient settings (66%) (Table 4).

FDP04203121_T4

Four hundred sixty-four nurses (54%) felt tense and irritable at home because of work and 447 had ≥ 1 symptoms of burnout (Table 5). In terms of moral distress, > 30% of nurses witnessed morally incongruent situations, 10% felt their own moral code was violated, and > 30% felt betrayed by others (Table 6). Among respondents, 16% to 21% of nurses reported depressive symptoms (eAppendix). About 50% of nurses intended to stay in their current position while 20% indicated an intention to leave for another VA position.

FDP04203121_T5FDP04203121_T6FDP04203128_A1

DISCUSSION

This study identified the impact of COVID-19 on nurses who work in VISN 21. The survey included a significant number of nurses who work in outpatient settings, which differed from most other published studies to date.15-19 This study found that inpatient and outpatient nurses were similarly impacted by the COVID-19 pandemic, although there were differences. A high percentage of nurses reported job satisfaction despite the personal and professional impact of the pandemic.

Caring for veterans can result in a therapeutic relationship with a deep appreciation of veterans’ service and sensitivity to their needs.25 Some nurses reported that they feel it is a privilege to care for veterans.

Most nurses who participated in this study felt they could rely on their colleagues and were concerned about their health and wellbeing. Kissel et al explored protective factors for nurses during the pandemic and found participants often reported that their coworkers were positive safeguards.17 At least 50% of respondents reported that management considered workplace safety and was concerned about their welfare. Previous research has found that a positive working organization that promoted safety and concern for staff were protective factors against stress among HCWs.26 A literature review of 3 coronavirus outbreaks illustrated the support from supervisors and colleagues promoted resiliency and reduced stress disorders.3

Similar to other studies, study respondents experienced profound losses, including the deaths of colleagues, patients, and family. In 2021 Howell reported that HCWs experienced increased stress, fear, anxiety, and other negative emotions following news of colleagues’ deaths from COVID-19.27 Kissel et al reported that nurses frequently described pandemic-related physical and psychological harm and witnessing distress that they had not been previously exposed to.17

Our findings illustrate the tightrope nurses walked while caring for patients and concerns about the health of their colleagues and family. Consistent with our findings, Howell found that HCWs were afraid of contracting the infection at work and then unknowingly giving it to others such as patients, coworkers, and household members. 27 Murat et al reported that some nurses chose to live separately during the pandemic to avoid spreading COVID-19 to relatives.19 Several researchers found that concerns about family and children were prevalent and led to fear, anxiety, and burnout among nurses.18,28,29 Shah et al suggested that nurses experiencing death in the workplace and within their family may have resulted in fear and anxiety about returning to work.29 Garcia and Calvo argued that nurses may have been stigmatized as carriers of COVID-19.16 In addition, the loss of prepandemic workplace rituals may have impacted performance, team connection, and functioning, and led to increased turnover and decreased attachment to the organization.30

This study described the significant workplace issues nurses endured during the pandemic, including being overwhelmed with additional and/or multiple roles and frustrated and stressed with role changes and short staffing. Nurses endorsed workplace challenges in the context of coworker absenteeism and reassignments to different areas, such as intensive care units (ICUs).17 Researchers also reported that displaced team members experienced loneliness and isolation when they were removed from their usual place of work and experienced distress caring for patients beyond their perceived competency or comfort.17,31 Nurses also experienced rapid organizational changes, resource scarcity, high patient-to-nurse ratios, inconsistent or limited communications, and the absence of protocols for prolonged mass casualty events.17 These challenges, such as significant uncertainty and rapidly changing working conditions, were shared experiences suggested to be similar to “tumbling into chaos,” and likened to the overwhelming situations faced during patient surges to a medical “war zone.”17

Study respondents indicated that nurses wanted better access to critical supplies, PPE, and COVID-19 testing; more flexible scheduling; longer leave times; and staffing that was appropriate to the patient volumes. These findings aligned with previous research. Howell found that HCWs, especially nurses, worried about childcare because of school closures and increased work hours.27 Nurses felt that hospital support was inaccessible or inadequate and worried about access to essential resources.17-19,27 Studies also found excessive workloads, and many nurses needed mental or financial assistance from the hospital in addition to more rest and less work.18,28 An editorial highlighted the potential adverse effects that a lack of PPE could have on staff ’s mental health because of perceptions of institutional betrayal, which occurs when trusted and powerful organizations seemingly act in ways that can harm those dependent on them for safety and well-being.32

Consistent with other research, this study found that a majority of nurses experienced significant burnout symptoms. The number of nurses reporting symptoms of burnout increased during the pandemic with ICU nurses reporting the highest levels.17,33 Soto-Rubio et al emphasized that working conditions experienced by nurses, such as interpersonal conflict, lack of trust in administration, workload, and role conflict, contributed to burnout during COVID-19.34 Other studies found that nurses experienced burnout caused by uncertainty, intense work, and extra duties contributed to higher burnout scores.18,19 It is not surprising that researchers have indicated that nurses experiencing burnout might display depressive and stress-related symptoms, insomnia, and concentration and memory problems.19

The results of this study indicate that one-third of participating nurses were experiencing moral distress. Burton et al described COVID-19 as an environment in which nurses witnessed, experienced, and at times had to participate in acts that involved ethical violations in care, institutional betrayal, and traumatic strain.9 Of note, our findings revealed that both inpatient and outpatient nurses experienced moral distress. Interestingly, Mantri et al found that COVID-19 increased moral injury but not burnout among health professionals, which differed from the results of this study.35

The findings of this study indicate that many nurses experienced depressive symptoms. A systematic review found a similar percentage of HCWs experienced depression while caring for patients with COVID- 19, though a Chinese study found a higher percentage.36,37 Previous research also found that the most difficult aspect of the COVID- 19 pandemic for nurses was coping with mental disorders such as depression, and that many experienced difficulty sleeping/ had poor sleep quality, believed a similar disaster would occur in the future, were irritated or angered easily, and experienced emotional exhaustion.15,19 The long-term mental and physical ramifications of caring for individuals with COVID-19 remain unknown. However, previous research suggests a high prevalence of depression, insomnia, anxiety, and distress, which could impair nurses’ professional performance.29

This study reported that a majority of nurses intended to stay in their current position and about 20% intended to leave for another position within the VA. Similar findings conducted early in the pandemic indicated that most participants did not intend to quit nursing.19

This study’s findings suggest the COVID-19 pandemic had an adverse impact on VISN 21 nurses. It is critical to develop, implement, and adopt adequate measures as early as possible to support the health care system, especially nurses.18

Implications

Before the COVID-19 pandemic, discussing burnout and moral anguish was common, primarily in critical care.14 However, these experiences became more widespread throughout nursing settings during the pandemic. Nurse leaders have been identified as responsible for ensuring the environmental safety and personal well-being of their colleagues during and after pandemics.14

Studies of HCW experiences during COVID-19 provide many insights into future preparedness, strategies to best handle another pandemic during its acute stage, and techniques to address issues that might persist. This study and others suggest that comprehensive interventions in preparation for, during, and after a pandemic are needed. We break down strategies into pandemic and postpandemic interventions based on a synthesis of the literature and the research team’s knowledge and expertise.3,14-16,27,29,36,38-44

Pandemic interventions. During a pandemic, it is important that nurses are adequately cared for to ensure they can continue to provide quality care for others. Resources supporting emotional well-being and addressing moral distress offered during a pandemic are essential. Implementing meaningful strategies could enhance nurses’ health and wellbeing. It is essential that leaders provide nurses a safe work environment/experience during a pandemic by instituting meaningful resources. In addition, developing best practices for leadership are critical.

Postpandemic interventions. Personal experiences of depression, burnout, and moral distress have not spontaneously resolved as the pandemic receded. Providing postpandemic interventions to lessen ongoing and lingering depressive, burnout, and moral distress symptoms experienced by frontline workers are critical. These interventions might prevent long-term health issues and the exodus of nurses.

Postpandemic interventions should include the integration of pandemic planning into new or existing educational or training programs for staff. Promotion and support of mental health services by health system leadership for nursing personnel implemented as a usual service will play an important role in preparing for future pandemics. A key role in preparation is developing and maintaining cooperation and ongoing mutual understanding, respect, and communication between leadership and nursing staff.

Future Research

This study’s findings inform VHA leadership and society about how a large group of nurses were impacted by COVID-19 while caring for patients in inpatient and outpatient settings and could provide a basis for extending this research to other groups of nurses or health care personnel. Future research might be helpful in identifying the impact of COVID-19 on nursing leadership. During conversations with nursing leadership, a common theme identified was that nurses did not feel that leadership was fully prepared for the level of emergency the pandemic created both personally and professionally; leadership expressed experiences similar to nurses providing direct care and felt powerless to help their nursing staff. Other areas of research could include identifying underlying factors contributing to burnout and moral distress and describing nurses’ expectations of or needs from leadership to best manage burnout and moral distress.

Limitations

Experiences of nurses who stopped working were not captured and information about their experiences might have different results. The survey distribution was limited to 2 emails (an initial email and a second at midpoint) sent at the discretion of the nurse executive of each facility. The study timeline was long because of complex regulatory protective processes inherent in the VHA system for researchers to include initial institutional review board review process, union notifications, and each facility’s response to the survey. Although 860 nurses participated, this was 15% of the 5586 VISN 21 nurses at the time of the study. Many clinical inpatient nurses do not have regular access to email, which might have impacted participation rate.

CONCLUSIONS

This study identified the impact COVID-19 had on nurses who worked in a large hospital system. The research team outlined strategies to be employed during and after the pandemic, such as preplanning for future pandemics to provide a framework for a comprehensive pandemic response protocol.

This study adds to generalized knowledge because it captured voices of inpatient and outpatient nurses, the latter had not been previously studied. As nurses and health care organizations move beyond the pandemic with a significant number of nurses continuing to experience effects, there is a need to institute interventions to assist nurses in healing and begin preparations for future pandemics.

References
  1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
  2. Liu X, Kakade M, Fuller CJ, et al. Depression after exposure to stressful events: lessons learned from the severe acute respiratory syndrome epidemic. Compr Psychiatry. 2012;53(1):15-23. doi:10.1016/j.comppsych.2011.02.003
  3. Carmassi C, Foghi C, Dell’Oste V, et al. PTSD symptoms in healthcare workers facing the three coronavirus outbreaks: What can we expect after the COVID-19 pandemic. Psychiatry Res. 2020;292:113312. doi:10.1016/j.psychres.2020.113312
  4. De Kock JH, Latham HA, Leslie SJ, et al. A rapid review of the impact of COVID-19 on the mental health of healthcare workers: implications for supporting psychological well-being. BMC Public Health. 2021;21(1):104. doi:10.1186/s12889-020-10070-3
  5. Gualano MR, Sinigaglia T, Lo Moro G, et al. The burden of burnout among healthcare professionals of intensive care units and emergency departments during the covid-19 pandemic: a systematic review. Int J Environ Res Public Health. 2021;18(15):8172. doi:10.3390/ijerph18158172
  6. Sirois FM, Owens J. Factors associated with psychological distress in health-care workers during an infectious disease outbreak: a rapid systematic review of the evidence. Front Psychiatry. 2020;11;589545. doi:10.3389/fpsyt.2020.589545
  7. Talevi D, Socci V, Carai M, et al. Mental health outcomes of the COVID-19 pandemic. Riv Psichiatr. 2020;55(3);137-144. doi:10.1708/3382.33569
  8. Amsalem D, Lazarov A, Markowitz JC, et al. Psychiatric symptoms and moral injury among US healthcare workers in the COVID-19 era. BMC Psychiatry. 2021;21(1):546. doi:10.1186/s12888-021-03565-9
  9. Burton CW, Jenkins DK, Chan G.K, Zellner KL, Zalta AK. A mixed methods study of moral distress among frontline nurses during the COVID-19 pandemic. Psychol Trauma. 2023;16(4):568-575. doi:10.1037/tra0001493
  10. Stawicki SP, Jeanmonod R, Miller AC, et al. The 2019- 2020 novel coronavirus (Severe acute respiratory syndrome coronavirus 2) Pandemic:a Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group consensus paper. J Glob Infect Dis. 2020;12(2):47- 93. doi:10.4103/jgid.jgid_86_20
  11. Batra K, Singh TP, Sharma M, Batra R, Schvaneveldt N. Investigating the psychological impact of COVID- 19 among healthcare workers: a meta-analysis. Int J Environ Res Public Health. 2020;17(23):9096. doi:10.3390/ijerph17239096
  12. Xie W, Chen L, Feng F, et al. The prevalence of compassion satisfaction and compassion fatigue among nurses: a systematic review and meta-analysis. Int J Nurs Stud. 2021;120:103973. doi:10.1016/j.ijnurstu.2021.103973
  13. Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Nurses’ burnout and associated risk factors during the COVID-19 pandemic: a systematic review and meta-analysis. J Adv Nurs. 2021;77(8):3286-3302. doi:10.1111/jan.14839
  14. Hofmeyer A, Taylor R. Strategies and resources for nurse leaders to use to lead with empathy and prudence so they understand and address sources of anxiety among nurses practicing in the era of COVID-19. J Clin Nurs. 2021;30(1- 2):298-305. doi:10.1111/jocn.15520
  15. Chen R, Sun C, Chen JJ, et al. A large-scale survey on trauma, burnout, and posttraumatic growth among nurses during the COVID-19 pandemic. Int J Ment Health Nurs. 2021;30(1):102-116. doi:10.1111/inm.12796
  16. García G, Calvo J. The threat of COVID-19 and its influence on nursing staff burnout. J Adv Nurs. 2021;77(2):832-844. doi:10.1111/jan.14642
  17. Kissel KA, Filipek C, Jenkins J. Impact of the COVID- 19 pandemic on nurses working in intensive care units: a scoping review. Crit Care Nurse. 2023;43(2):55-63. doi:10.4037/ccn2023196
  18. Lin YY, Pan YA, Hsieh YL, et al. COVID-19 pandemic is associated with an adverse impact on burnout and mood disorder in healthcare professionals. Int J Environ Res and Public Health. 2021;18(7):3654. doi:10.3390/ijerph18073654
  19. Murat M, Köse S, Savas¸er S. Determination of stress, depression and burnout levels of front-line nurses during the COVID-19 pandemic. Int J Ment Health Nurs. 2021;30(2):533-543. doi:10.1111/inm.12818
  20. Purcell N, Bertenthal D, Usman H, et al. Moral injury and mental health in healthcare workers are linked to organizational culture and modifiable workplace conditions: results of a national, mixed-methods study conducted at Veterans Affairs (VA) medical centers during the COVID- 19 pandemic. PLOS Ment Health. 2024;1(7):e0000085. doi:10.1371/journal.pmen.0000085
  21. Nash WP, Marino Carper TL, Mills MA, Au T, Goldsmith A, Litz BT. Psychometric evaluation of the Moral Injury Events Scale. Mil Med. 2013;178(6):646-652. doi:10.7205/MILMED-D-13-00017
  22. Prins A, Bovin MJ, Smolenski DJ, et al. The Primary Care PTSD Screen for DSM-5 (PC-PTSD-5): development and evaluation within a veteran primary care sample. J Gen Intern Med. 2016;31(10):1206-1211. doi:10.1007/s11606-016-3703-5
  23. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284-1292. doi:10.1097/01.MLR.0000093487.78664.3C
  24. Rohland BM, Kruse GR, Rohrer JE. Validation of a single- item measure of burnout against the Maslach Burnout Inventory among physicians. Stress and Health. 2004;20(2):75-79. doi:10.1002/smi.1002
  25. Carlson J. Baccalaureate nursing faculty competencies and teaching strategies to enhance the care of the veteran population: perspectives of Veteran Affairs Nursing Academy (VANA) faculty. J Prof Nurs. 2016;32(4):314-323. doi:10.1016/j.profnurs.2016.01.006
  26. Denning M, Goh ET, Tan B, et al. Determinants of burnout and other aspects of psychological well-being in healthcare workers during the Covid-19 pandemic: a multinational cross-sectional study. PloS One. 2021;16(4):e0238666. doi:10.1371/journal.pone.0238666
  27. Howell BAM. Battling burnout at the frontlines of health care amid COVID-19. AACN Adv Crit Care. 2021;32(2):195- 203. doi:10.4037/aacnacc2021454
  28. Afshari D, Nourollahi-Darabad M, Chinisaz N. Demographic predictors of resilience among nurses during the COVID-19 pandemic. Work. 2021;68(2):297-303. doi:10.3233/WOR-203376
  29. Shah M, Roggenkamp M, Ferrer L, Burger V, Brassil KJ. Mental health and COVID-19: the psychological implications of a pandemic for nurses. Clin J Oncol Nurs. 2021;25(1), 69-75. doi:10.1188/21.CJON.69-75
  30. Griner T, Souza M, Girard A, Hain P, High H, Williams M. COVID-19’s impact on nurses’ workplace rituals. Nurs Lead. 2021;19(4):425-430. doi:10.1016/j.mnl.2021.06.008
  31. Koren A, Alam MAU, Koneru S, DeVito A, Abdallah L, Liu B. Nursing perspectives on the impacts of COVID- 19: social media content analysis. JMIR Form Res. 2021;5(12):e31358. doi:10.2196/31358
  32. Gold JA. Covid-19: adverse mental health outcomes for healthcare workers. BMJ. 2020;5:369:m1815. doi: 10.1136/bmj.m1815. doi:10.1136/bmj.m1815
  33. Slusarz R, Cwiekala-Lewis K, Wysokinski M, Filipska- Blejder K, Fidecki W, Biercewicz M. Characteristics of occupational burnout among nurses of various specialties and in the time of the COVID-19 pandemic-review. Int J Environ Res Public Health. 2022;19(21):13775. doi:10.3390/ijerph192113775
  34. Soto-Rubio A, Giménez-Espert MDC, Prado-Gascó V. Effect of emotional intelligence and psychosocial risks on burnout, job satisfaction, and nurses’ health during the COVID-19 pandemic. Int J Environ Res Public Health. 2020;17(21):7998. doi:10.3390/ijerph17217998
  35. Mantri S, Song YK, Lawson JM, Berger EJ, Koenig HG. Moral injury and burnout in health care professionals during the COVID-19 pandemic. J Nerv Ment Dis. 2021;209(10):720-726. doi:10.1097/NMD.0000000000001367
  36. Salari N, Khazaie H, Hosseinian-Far A, et al. The prevalence of stress, anxiety and depression within front-line healthcare workers caring for COVID-19 patients: a systematic review and meta-regression. Hum Resour Health 2020;18(1):100. doi:10.1186/s12960-020-00544-1
  37. Lai J, Ma S, Wang Y, et al. Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019. JAMA Netw Open. 2020;3(3):e203976. doi:10.1001/jamanetworkopen.2020.3976
  38. Chesak SS, Cutshall SM, Bowe CL, Montanari KM, Bhagra A. Stress management interventions for nurses: critical literature review. J Holist Nurs. 2019;37(3):288-295. doi:10.1177/0898010119842693
  39. Cooper AL, Brown JA, Leslie GD. Nurse resilience for clinical practice: an integrative review. J Adv Nurs. 2021;77(6):2623-2640. doi:10.1111/jan.14763
  40. Melnyk BM, Kelly SA, Stephens J, et al. Interventions to improve mental health, well-being, physical health, and lifestyle behaviors in physicians and nurses: a systematic review. Am J Health Promot. 2020;34(8):929-941. doi:10.1177/0890117120920451
  41. Cho H, Sagherian K, Steege LM. Hospital staff nurse perceptions of resources and resource needs during the COVID-19 pandemic. Nurs Outlook. 2023;71(3):101984. doi:10.1016/j.outlook.2023.101984
  42. Bachem R, Tsur N, Levin Y, Abu-Raiya H, Maercker A. Negative affect, fatalism, and perceived institutional betrayal in times of the coronavirus pandemic: a cross-cultural investigation of control beliefs. Front Psychiatry. 2020;11:589914. doi:10.3389/fpsyt.2020.589914
  43. Shanafelt T, Ripp J, Trockel M. Understanding and addressing sources of anxiety among health care professionals during the COVID-19 pandemic. JAMA. 2020;323(21):2133. doi:10.1001/jama.2020.5893
  44. Schuster M, Dwyer PA. Post-traumatic stress disorder in nurses: an integrative review. J Clin Nurs. 2020;29(15- 16):2769-2787. doi:10.1111/jocn.15288
Article PDF
Author and Disclosure Information

Judy Carlson, EdD, MSN, APRN, BCNa; Tymeeka Davis, DNP, RN-BC, PCCN, CNLb; Tracie Citron, MS, APRN, AGAC-NP, ACNS-BCc; Amalia Garcia, BSN, RN, CCMc; Kelly Presser, MSN, RN, CNLd; Saida Adem, MSN, APRNc; Arlene Perry, MSEd, MS, RN, CMCN, IQCIb; Anna Farrell, MSN, RN, CMGT-BCe; Shakalee Exantus, MSN, RNb; Brandy Mebane, BSN, RNb; Kasey Redding, MSN, RN, CPNa; Natalie Purcell, PhDf

Author affiliations
aVeterans Affairs Pacific Islands Health Care System, Honolulu, Hawaii
bVeterans Affairs Southern Nevada Healthcare System, Las Vegas
cVeterans Affairs San Francisco Health Care System, California
dVeterans Affairs Sierra Nevada Health Care System, Reno
eVeterans Affairs Northern California Health Care System, Sacramento
fVeterans Affairs Palo Alto Health Care System, California

Author disclosures The authors report no actual or potential conflicts of interest regarding this article.

Correspondence: Judy Carlson ([email protected])

Fed Pract. 2025;42(3). Published online March 17. doi:10.12788/fp.0555

Issue
Federal Practitioner - 42(3)
Publications
Topics
Page Number
120-127
Sections
Author and Disclosure Information

Judy Carlson, EdD, MSN, APRN, BCNa; Tymeeka Davis, DNP, RN-BC, PCCN, CNLb; Tracie Citron, MS, APRN, AGAC-NP, ACNS-BCc; Amalia Garcia, BSN, RN, CCMc; Kelly Presser, MSN, RN, CNLd; Saida Adem, MSN, APRNc; Arlene Perry, MSEd, MS, RN, CMCN, IQCIb; Anna Farrell, MSN, RN, CMGT-BCe; Shakalee Exantus, MSN, RNb; Brandy Mebane, BSN, RNb; Kasey Redding, MSN, RN, CPNa; Natalie Purcell, PhDf

Author affiliations
aVeterans Affairs Pacific Islands Health Care System, Honolulu, Hawaii
bVeterans Affairs Southern Nevada Healthcare System, Las Vegas
cVeterans Affairs San Francisco Health Care System, California
dVeterans Affairs Sierra Nevada Health Care System, Reno
eVeterans Affairs Northern California Health Care System, Sacramento
fVeterans Affairs Palo Alto Health Care System, California

Author disclosures The authors report no actual or potential conflicts of interest regarding this article.

Correspondence: Judy Carlson ([email protected])

Fed Pract. 2025;42(3). Published online March 17. doi:10.12788/fp.0555

Author and Disclosure Information

Judy Carlson, EdD, MSN, APRN, BCNa; Tymeeka Davis, DNP, RN-BC, PCCN, CNLb; Tracie Citron, MS, APRN, AGAC-NP, ACNS-BCc; Amalia Garcia, BSN, RN, CCMc; Kelly Presser, MSN, RN, CNLd; Saida Adem, MSN, APRNc; Arlene Perry, MSEd, MS, RN, CMCN, IQCIb; Anna Farrell, MSN, RN, CMGT-BCe; Shakalee Exantus, MSN, RNb; Brandy Mebane, BSN, RNb; Kasey Redding, MSN, RN, CPNa; Natalie Purcell, PhDf

Author affiliations
aVeterans Affairs Pacific Islands Health Care System, Honolulu, Hawaii
bVeterans Affairs Southern Nevada Healthcare System, Las Vegas
cVeterans Affairs San Francisco Health Care System, California
dVeterans Affairs Sierra Nevada Health Care System, Reno
eVeterans Affairs Northern California Health Care System, Sacramento
fVeterans Affairs Palo Alto Health Care System, California

Author disclosures The authors report no actual or potential conflicts of interest regarding this article.

Correspondence: Judy Carlson ([email protected])

Fed Pract. 2025;42(3). Published online March 17. doi:10.12788/fp.0555

Article PDF
Article PDF

On March 11, 2020, the World Health Organization designated COVID- 19 as a pandemic.1 Pandemics have historically impacted physical and mental health across all populations, but especially health care workers (HCWs).2 Nurses and other HCWs were profoundly impacted by the pandemic.3-8

Throughout the pandemic, nurses continued to provide care while working in short-staffed workplaces, facing increased exposure to COVID-19, and witnessing COVID—19–related morbidity and mortality.9 Many nurses were mandated to cross-train in unfamiliar clinical settings and adjust to new and prolonged shift schedules. Physical and emotional exhaustion associated with managing care for individuals with COVID-19, shortage of personal protective equipment (PPE), risk of infection, fear of secondary transmission to family members, feelings of being rejected by others, and social isolation, led to HCWs’ increased vulnerability to psychological impacts of the pandemic.8,10

A meta-analysis of 65 studies with > 79,000 participants found HCWs experienced significant levels of anxiety, depression, stress, insomnia, and other mental health issues, such as posttraumatic stress disorder (PTSD). Female HCWs, nurses, and frontline responders experienced a higher incidence of psychological impact.11 Other meta-analyses revealed that nurses’ compassion satisfaction, compassion fatigue, and burnout levels were significantly impacted with increased levels of burnout among nurses who had a friend or family member diagnosed with COVID- 19 or experienced prolonged threat of exposure to the virus.12,13 A study of 350 nurses found high rates of perceived transgressions by others, and betrayal.8 Nurse leaders and staff nurses had to persevere as moral distress became pervasive among nursing staff, which led to complex and often unsustainable circumstances. 14 The themes identified in the literature about the pandemic’s impact as well as witnessing nurse colleagues’ distress with patient mortality and death of coworkers during the early phase of the COVID-19 pandemic compelled a group of Veterans Health Administration (VHA) nurses to form a research team to understand the scope of impact and identify possible solutions.

Since published studies on the impact of pandemics on HCWs, including nurses, primarily focused on inpatient settings, the investigators of this study sought to capture the experiences of outpatient and inpatient nurses providing care in the US Department of Veterans Affairs (VA) Sierra Pacific Network (Veterans Integrated Service Network [VISN] 21), which has facilities in northern California, Hawaii, and Nevada.15-19 The purpose of this study was to identify the impact of COVID-19 on nurses caring for veterans in both outpatient and inpatient settings at VISN 21 facilities from March 2020 to September 2022, to inform leadership about the extent the virus affected nurses, and identify strategies that address current and future impacts of pandemics.

METHODS

This retrospective descriptive survey adapted the Pandemic Impact Survey by Purcell et al, which included the Moral Injury Events Scale, Primary Care PTSD Screener, the Patient Health Questionnaire-2 for depression, and a modified burnout scale.20-24 The survey of 70 Likert-scale questions was intended to measure nurses’ needs, burnout, moral distress, depression and stress symptoms, work-related factors, and intent to remain working in their current position. A nurse was defined broadly and included those employed as licensed vocational nurses (LVN), licensed practical nurses (LPN), registered nurses (RN), nurses with advanced degrees, advanced practice registered nurses (APRNs), and nurses with other certifications or licenses.

The VA Pacific Islands Research and Development Committee reviewed and approved the institutional review board-exempted study. The VISN 21 union was notified; only limited demographic information and broad VA tenure categories were collected to protect privacy. The principal investigator redacted facility identifier data after each facility had participated.

The survey was placed in REDCAP and a confidential link was emailed to all VISN 21 inpatient and outpatient nurses during March 2023. Because a comprehensive VISN 21 list of nurse email addresses was unavailable, the email was distributed by nursing leadership at each facility. Nurses received an email reminder at the 2-week halfway point, prompting them to complete the survey. The email indicated the purpose and voluntary nature of the study and cautioned nurses that they might experience stress while answering survey questions. Stress management resources were provided.

Descriptive statistics were used to report the results. Data were aggregated for analyzing and reporting purposes.

RESULTS

In March 2023, 860 of 5586 nurses (15%) responded to the survey. Respondents included 344 clinical inpatient nurses (40%) and 516 clinical outpatient nurses (60%); 688 (80%) were RNs, 129 (15%) were LPNs/LVNs, and 43 (5%) were APRNs. Of 849 respondents to provide their age, 15 (2%) were < 30 years, 163 (19%) were 30 to 39 years, 232 (27%) were 40 to 49 years, 259 (30%) were 50 to 59 years, and 180 (21%) were ≥ 60 years.

The survey found that 688 nurses reported job satisfaction (80%) and 75% of all respondents (66% among inpatient nurses) reported feeling happy with the care they delivered. Both inpatient and outpatient nurses indicated they could rely on staff. Sixty percent (n = 516) of the nurses indicated that facility management considered workplace health and safety and supervisors showed concern for subordinates, although inpatient nurses reported a lower percentage (Table 1).

FDP04203121_T1

Two hundred fifty-eight nurses (30%) reported having nurse colleagues who died and 52 (6%) had ≥ 3 colleagues who died. Among respondents, 292 had ≥ 3 patients who died after contracting COVID-19 and 232 (27%) had a significant person in their life die. More than one-half (54%; n = 464) of nurses had to limit contact with a family member who had COVID-19. Most nurses reported concerns about their colleagues (91%), were concerned about bringing COVID-19 home (82%), and stayed away from family during the pandemic (56%) (Table 2).

FDP04203121_T2

A total of 593 nurses (69%) reported feeling overwhelmed from the workload associated with the pandemic, 490 (57%) felt frustrated with role changes, 447 (52%) were stressed because of short staffing, and 327 (38%) felt stressed because of being assigned or floated to different patient care areas. Among inpatient nurses, 158 (46%) reported stress related to being floated. Coworker absenteeism caused challenges for 697 nurses (81%) (Table 3).

FDP04203121_T3

Nurses suggested a number of changes that could improve working conditions, including flexible scheduling (54%) and more hours of leave, which was requested by 43% of outpatient/inpatient nurses and 53% of inpatient alone nurses. Access to COVID-19 testing and PPE was endorsed as a workplace need by 439 nurses; the need for access to PPE was reported by 43% of inpatient-only nurses vs 29% of outpatient/inpatient nurses. The need for adequate staffing was reported by 54% of nurses although the rate was higher among those working inpatient settings (66%) (Table 4).

FDP04203121_T4

Four hundred sixty-four nurses (54%) felt tense and irritable at home because of work and 447 had ≥ 1 symptoms of burnout (Table 5). In terms of moral distress, > 30% of nurses witnessed morally incongruent situations, 10% felt their own moral code was violated, and > 30% felt betrayed by others (Table 6). Among respondents, 16% to 21% of nurses reported depressive symptoms (eAppendix). About 50% of nurses intended to stay in their current position while 20% indicated an intention to leave for another VA position.

FDP04203121_T5FDP04203121_T6FDP04203128_A1

DISCUSSION

This study identified the impact of COVID-19 on nurses who work in VISN 21. The survey included a significant number of nurses who work in outpatient settings, which differed from most other published studies to date.15-19 This study found that inpatient and outpatient nurses were similarly impacted by the COVID-19 pandemic, although there were differences. A high percentage of nurses reported job satisfaction despite the personal and professional impact of the pandemic.

Caring for veterans can result in a therapeutic relationship with a deep appreciation of veterans’ service and sensitivity to their needs.25 Some nurses reported that they feel it is a privilege to care for veterans.

Most nurses who participated in this study felt they could rely on their colleagues and were concerned about their health and wellbeing. Kissel et al explored protective factors for nurses during the pandemic and found participants often reported that their coworkers were positive safeguards.17 At least 50% of respondents reported that management considered workplace safety and was concerned about their welfare. Previous research has found that a positive working organization that promoted safety and concern for staff were protective factors against stress among HCWs.26 A literature review of 3 coronavirus outbreaks illustrated the support from supervisors and colleagues promoted resiliency and reduced stress disorders.3

Similar to other studies, study respondents experienced profound losses, including the deaths of colleagues, patients, and family. In 2021 Howell reported that HCWs experienced increased stress, fear, anxiety, and other negative emotions following news of colleagues’ deaths from COVID-19.27 Kissel et al reported that nurses frequently described pandemic-related physical and psychological harm and witnessing distress that they had not been previously exposed to.17

Our findings illustrate the tightrope nurses walked while caring for patients and concerns about the health of their colleagues and family. Consistent with our findings, Howell found that HCWs were afraid of contracting the infection at work and then unknowingly giving it to others such as patients, coworkers, and household members. 27 Murat et al reported that some nurses chose to live separately during the pandemic to avoid spreading COVID-19 to relatives.19 Several researchers found that concerns about family and children were prevalent and led to fear, anxiety, and burnout among nurses.18,28,29 Shah et al suggested that nurses experiencing death in the workplace and within their family may have resulted in fear and anxiety about returning to work.29 Garcia and Calvo argued that nurses may have been stigmatized as carriers of COVID-19.16 In addition, the loss of prepandemic workplace rituals may have impacted performance, team connection, and functioning, and led to increased turnover and decreased attachment to the organization.30

This study described the significant workplace issues nurses endured during the pandemic, including being overwhelmed with additional and/or multiple roles and frustrated and stressed with role changes and short staffing. Nurses endorsed workplace challenges in the context of coworker absenteeism and reassignments to different areas, such as intensive care units (ICUs).17 Researchers also reported that displaced team members experienced loneliness and isolation when they were removed from their usual place of work and experienced distress caring for patients beyond their perceived competency or comfort.17,31 Nurses also experienced rapid organizational changes, resource scarcity, high patient-to-nurse ratios, inconsistent or limited communications, and the absence of protocols for prolonged mass casualty events.17 These challenges, such as significant uncertainty and rapidly changing working conditions, were shared experiences suggested to be similar to “tumbling into chaos,” and likened to the overwhelming situations faced during patient surges to a medical “war zone.”17

Study respondents indicated that nurses wanted better access to critical supplies, PPE, and COVID-19 testing; more flexible scheduling; longer leave times; and staffing that was appropriate to the patient volumes. These findings aligned with previous research. Howell found that HCWs, especially nurses, worried about childcare because of school closures and increased work hours.27 Nurses felt that hospital support was inaccessible or inadequate and worried about access to essential resources.17-19,27 Studies also found excessive workloads, and many nurses needed mental or financial assistance from the hospital in addition to more rest and less work.18,28 An editorial highlighted the potential adverse effects that a lack of PPE could have on staff ’s mental health because of perceptions of institutional betrayal, which occurs when trusted and powerful organizations seemingly act in ways that can harm those dependent on them for safety and well-being.32

Consistent with other research, this study found that a majority of nurses experienced significant burnout symptoms. The number of nurses reporting symptoms of burnout increased during the pandemic with ICU nurses reporting the highest levels.17,33 Soto-Rubio et al emphasized that working conditions experienced by nurses, such as interpersonal conflict, lack of trust in administration, workload, and role conflict, contributed to burnout during COVID-19.34 Other studies found that nurses experienced burnout caused by uncertainty, intense work, and extra duties contributed to higher burnout scores.18,19 It is not surprising that researchers have indicated that nurses experiencing burnout might display depressive and stress-related symptoms, insomnia, and concentration and memory problems.19

The results of this study indicate that one-third of participating nurses were experiencing moral distress. Burton et al described COVID-19 as an environment in which nurses witnessed, experienced, and at times had to participate in acts that involved ethical violations in care, institutional betrayal, and traumatic strain.9 Of note, our findings revealed that both inpatient and outpatient nurses experienced moral distress. Interestingly, Mantri et al found that COVID-19 increased moral injury but not burnout among health professionals, which differed from the results of this study.35

The findings of this study indicate that many nurses experienced depressive symptoms. A systematic review found a similar percentage of HCWs experienced depression while caring for patients with COVID- 19, though a Chinese study found a higher percentage.36,37 Previous research also found that the most difficult aspect of the COVID- 19 pandemic for nurses was coping with mental disorders such as depression, and that many experienced difficulty sleeping/ had poor sleep quality, believed a similar disaster would occur in the future, were irritated or angered easily, and experienced emotional exhaustion.15,19 The long-term mental and physical ramifications of caring for individuals with COVID-19 remain unknown. However, previous research suggests a high prevalence of depression, insomnia, anxiety, and distress, which could impair nurses’ professional performance.29

This study reported that a majority of nurses intended to stay in their current position and about 20% intended to leave for another position within the VA. Similar findings conducted early in the pandemic indicated that most participants did not intend to quit nursing.19

This study’s findings suggest the COVID-19 pandemic had an adverse impact on VISN 21 nurses. It is critical to develop, implement, and adopt adequate measures as early as possible to support the health care system, especially nurses.18

Implications

Before the COVID-19 pandemic, discussing burnout and moral anguish was common, primarily in critical care.14 However, these experiences became more widespread throughout nursing settings during the pandemic. Nurse leaders have been identified as responsible for ensuring the environmental safety and personal well-being of their colleagues during and after pandemics.14

Studies of HCW experiences during COVID-19 provide many insights into future preparedness, strategies to best handle another pandemic during its acute stage, and techniques to address issues that might persist. This study and others suggest that comprehensive interventions in preparation for, during, and after a pandemic are needed. We break down strategies into pandemic and postpandemic interventions based on a synthesis of the literature and the research team’s knowledge and expertise.3,14-16,27,29,36,38-44

Pandemic interventions. During a pandemic, it is important that nurses are adequately cared for to ensure they can continue to provide quality care for others. Resources supporting emotional well-being and addressing moral distress offered during a pandemic are essential. Implementing meaningful strategies could enhance nurses’ health and wellbeing. It is essential that leaders provide nurses a safe work environment/experience during a pandemic by instituting meaningful resources. In addition, developing best practices for leadership are critical.

Postpandemic interventions. Personal experiences of depression, burnout, and moral distress have not spontaneously resolved as the pandemic receded. Providing postpandemic interventions to lessen ongoing and lingering depressive, burnout, and moral distress symptoms experienced by frontline workers are critical. These interventions might prevent long-term health issues and the exodus of nurses.

Postpandemic interventions should include the integration of pandemic planning into new or existing educational or training programs for staff. Promotion and support of mental health services by health system leadership for nursing personnel implemented as a usual service will play an important role in preparing for future pandemics. A key role in preparation is developing and maintaining cooperation and ongoing mutual understanding, respect, and communication between leadership and nursing staff.

Future Research

This study’s findings inform VHA leadership and society about how a large group of nurses were impacted by COVID-19 while caring for patients in inpatient and outpatient settings and could provide a basis for extending this research to other groups of nurses or health care personnel. Future research might be helpful in identifying the impact of COVID-19 on nursing leadership. During conversations with nursing leadership, a common theme identified was that nurses did not feel that leadership was fully prepared for the level of emergency the pandemic created both personally and professionally; leadership expressed experiences similar to nurses providing direct care and felt powerless to help their nursing staff. Other areas of research could include identifying underlying factors contributing to burnout and moral distress and describing nurses’ expectations of or needs from leadership to best manage burnout and moral distress.

Limitations

Experiences of nurses who stopped working were not captured and information about their experiences might have different results. The survey distribution was limited to 2 emails (an initial email and a second at midpoint) sent at the discretion of the nurse executive of each facility. The study timeline was long because of complex regulatory protective processes inherent in the VHA system for researchers to include initial institutional review board review process, union notifications, and each facility’s response to the survey. Although 860 nurses participated, this was 15% of the 5586 VISN 21 nurses at the time of the study. Many clinical inpatient nurses do not have regular access to email, which might have impacted participation rate.

CONCLUSIONS

This study identified the impact COVID-19 had on nurses who worked in a large hospital system. The research team outlined strategies to be employed during and after the pandemic, such as preplanning for future pandemics to provide a framework for a comprehensive pandemic response protocol.

This study adds to generalized knowledge because it captured voices of inpatient and outpatient nurses, the latter had not been previously studied. As nurses and health care organizations move beyond the pandemic with a significant number of nurses continuing to experience effects, there is a need to institute interventions to assist nurses in healing and begin preparations for future pandemics.

On March 11, 2020, the World Health Organization designated COVID- 19 as a pandemic.1 Pandemics have historically impacted physical and mental health across all populations, but especially health care workers (HCWs).2 Nurses and other HCWs were profoundly impacted by the pandemic.3-8

Throughout the pandemic, nurses continued to provide care while working in short-staffed workplaces, facing increased exposure to COVID-19, and witnessing COVID—19–related morbidity and mortality.9 Many nurses were mandated to cross-train in unfamiliar clinical settings and adjust to new and prolonged shift schedules. Physical and emotional exhaustion associated with managing care for individuals with COVID-19, shortage of personal protective equipment (PPE), risk of infection, fear of secondary transmission to family members, feelings of being rejected by others, and social isolation, led to HCWs’ increased vulnerability to psychological impacts of the pandemic.8,10

A meta-analysis of 65 studies with > 79,000 participants found HCWs experienced significant levels of anxiety, depression, stress, insomnia, and other mental health issues, such as posttraumatic stress disorder (PTSD). Female HCWs, nurses, and frontline responders experienced a higher incidence of psychological impact.11 Other meta-analyses revealed that nurses’ compassion satisfaction, compassion fatigue, and burnout levels were significantly impacted with increased levels of burnout among nurses who had a friend or family member diagnosed with COVID- 19 or experienced prolonged threat of exposure to the virus.12,13 A study of 350 nurses found high rates of perceived transgressions by others, and betrayal.8 Nurse leaders and staff nurses had to persevere as moral distress became pervasive among nursing staff, which led to complex and often unsustainable circumstances. 14 The themes identified in the literature about the pandemic’s impact as well as witnessing nurse colleagues’ distress with patient mortality and death of coworkers during the early phase of the COVID-19 pandemic compelled a group of Veterans Health Administration (VHA) nurses to form a research team to understand the scope of impact and identify possible solutions.

Since published studies on the impact of pandemics on HCWs, including nurses, primarily focused on inpatient settings, the investigators of this study sought to capture the experiences of outpatient and inpatient nurses providing care in the US Department of Veterans Affairs (VA) Sierra Pacific Network (Veterans Integrated Service Network [VISN] 21), which has facilities in northern California, Hawaii, and Nevada.15-19 The purpose of this study was to identify the impact of COVID-19 on nurses caring for veterans in both outpatient and inpatient settings at VISN 21 facilities from March 2020 to September 2022, to inform leadership about the extent the virus affected nurses, and identify strategies that address current and future impacts of pandemics.

METHODS

This retrospective descriptive survey adapted the Pandemic Impact Survey by Purcell et al, which included the Moral Injury Events Scale, Primary Care PTSD Screener, the Patient Health Questionnaire-2 for depression, and a modified burnout scale.20-24 The survey of 70 Likert-scale questions was intended to measure nurses’ needs, burnout, moral distress, depression and stress symptoms, work-related factors, and intent to remain working in their current position. A nurse was defined broadly and included those employed as licensed vocational nurses (LVN), licensed practical nurses (LPN), registered nurses (RN), nurses with advanced degrees, advanced practice registered nurses (APRNs), and nurses with other certifications or licenses.

The VA Pacific Islands Research and Development Committee reviewed and approved the institutional review board-exempted study. The VISN 21 union was notified; only limited demographic information and broad VA tenure categories were collected to protect privacy. The principal investigator redacted facility identifier data after each facility had participated.

The survey was placed in REDCAP and a confidential link was emailed to all VISN 21 inpatient and outpatient nurses during March 2023. Because a comprehensive VISN 21 list of nurse email addresses was unavailable, the email was distributed by nursing leadership at each facility. Nurses received an email reminder at the 2-week halfway point, prompting them to complete the survey. The email indicated the purpose and voluntary nature of the study and cautioned nurses that they might experience stress while answering survey questions. Stress management resources were provided.

Descriptive statistics were used to report the results. Data were aggregated for analyzing and reporting purposes.

RESULTS

In March 2023, 860 of 5586 nurses (15%) responded to the survey. Respondents included 344 clinical inpatient nurses (40%) and 516 clinical outpatient nurses (60%); 688 (80%) were RNs, 129 (15%) were LPNs/LVNs, and 43 (5%) were APRNs. Of 849 respondents to provide their age, 15 (2%) were < 30 years, 163 (19%) were 30 to 39 years, 232 (27%) were 40 to 49 years, 259 (30%) were 50 to 59 years, and 180 (21%) were ≥ 60 years.

The survey found that 688 nurses reported job satisfaction (80%) and 75% of all respondents (66% among inpatient nurses) reported feeling happy with the care they delivered. Both inpatient and outpatient nurses indicated they could rely on staff. Sixty percent (n = 516) of the nurses indicated that facility management considered workplace health and safety and supervisors showed concern for subordinates, although inpatient nurses reported a lower percentage (Table 1).

FDP04203121_T1

Two hundred fifty-eight nurses (30%) reported having nurse colleagues who died and 52 (6%) had ≥ 3 colleagues who died. Among respondents, 292 had ≥ 3 patients who died after contracting COVID-19 and 232 (27%) had a significant person in their life die. More than one-half (54%; n = 464) of nurses had to limit contact with a family member who had COVID-19. Most nurses reported concerns about their colleagues (91%), were concerned about bringing COVID-19 home (82%), and stayed away from family during the pandemic (56%) (Table 2).

FDP04203121_T2

A total of 593 nurses (69%) reported feeling overwhelmed from the workload associated with the pandemic, 490 (57%) felt frustrated with role changes, 447 (52%) were stressed because of short staffing, and 327 (38%) felt stressed because of being assigned or floated to different patient care areas. Among inpatient nurses, 158 (46%) reported stress related to being floated. Coworker absenteeism caused challenges for 697 nurses (81%) (Table 3).

FDP04203121_T3

Nurses suggested a number of changes that could improve working conditions, including flexible scheduling (54%) and more hours of leave, which was requested by 43% of outpatient/inpatient nurses and 53% of inpatient alone nurses. Access to COVID-19 testing and PPE was endorsed as a workplace need by 439 nurses; the need for access to PPE was reported by 43% of inpatient-only nurses vs 29% of outpatient/inpatient nurses. The need for adequate staffing was reported by 54% of nurses although the rate was higher among those working inpatient settings (66%) (Table 4).

FDP04203121_T4

Four hundred sixty-four nurses (54%) felt tense and irritable at home because of work and 447 had ≥ 1 symptoms of burnout (Table 5). In terms of moral distress, > 30% of nurses witnessed morally incongruent situations, 10% felt their own moral code was violated, and > 30% felt betrayed by others (Table 6). Among respondents, 16% to 21% of nurses reported depressive symptoms (eAppendix). About 50% of nurses intended to stay in their current position while 20% indicated an intention to leave for another VA position.

FDP04203121_T5FDP04203121_T6FDP04203128_A1

DISCUSSION

This study identified the impact of COVID-19 on nurses who work in VISN 21. The survey included a significant number of nurses who work in outpatient settings, which differed from most other published studies to date.15-19 This study found that inpatient and outpatient nurses were similarly impacted by the COVID-19 pandemic, although there were differences. A high percentage of nurses reported job satisfaction despite the personal and professional impact of the pandemic.

Caring for veterans can result in a therapeutic relationship with a deep appreciation of veterans’ service and sensitivity to their needs.25 Some nurses reported that they feel it is a privilege to care for veterans.

Most nurses who participated in this study felt they could rely on their colleagues and were concerned about their health and wellbeing. Kissel et al explored protective factors for nurses during the pandemic and found participants often reported that their coworkers were positive safeguards.17 At least 50% of respondents reported that management considered workplace safety and was concerned about their welfare. Previous research has found that a positive working organization that promoted safety and concern for staff were protective factors against stress among HCWs.26 A literature review of 3 coronavirus outbreaks illustrated the support from supervisors and colleagues promoted resiliency and reduced stress disorders.3

Similar to other studies, study respondents experienced profound losses, including the deaths of colleagues, patients, and family. In 2021 Howell reported that HCWs experienced increased stress, fear, anxiety, and other negative emotions following news of colleagues’ deaths from COVID-19.27 Kissel et al reported that nurses frequently described pandemic-related physical and psychological harm and witnessing distress that they had not been previously exposed to.17

Our findings illustrate the tightrope nurses walked while caring for patients and concerns about the health of their colleagues and family. Consistent with our findings, Howell found that HCWs were afraid of contracting the infection at work and then unknowingly giving it to others such as patients, coworkers, and household members. 27 Murat et al reported that some nurses chose to live separately during the pandemic to avoid spreading COVID-19 to relatives.19 Several researchers found that concerns about family and children were prevalent and led to fear, anxiety, and burnout among nurses.18,28,29 Shah et al suggested that nurses experiencing death in the workplace and within their family may have resulted in fear and anxiety about returning to work.29 Garcia and Calvo argued that nurses may have been stigmatized as carriers of COVID-19.16 In addition, the loss of prepandemic workplace rituals may have impacted performance, team connection, and functioning, and led to increased turnover and decreased attachment to the organization.30

This study described the significant workplace issues nurses endured during the pandemic, including being overwhelmed with additional and/or multiple roles and frustrated and stressed with role changes and short staffing. Nurses endorsed workplace challenges in the context of coworker absenteeism and reassignments to different areas, such as intensive care units (ICUs).17 Researchers also reported that displaced team members experienced loneliness and isolation when they were removed from their usual place of work and experienced distress caring for patients beyond their perceived competency or comfort.17,31 Nurses also experienced rapid organizational changes, resource scarcity, high patient-to-nurse ratios, inconsistent or limited communications, and the absence of protocols for prolonged mass casualty events.17 These challenges, such as significant uncertainty and rapidly changing working conditions, were shared experiences suggested to be similar to “tumbling into chaos,” and likened to the overwhelming situations faced during patient surges to a medical “war zone.”17

Study respondents indicated that nurses wanted better access to critical supplies, PPE, and COVID-19 testing; more flexible scheduling; longer leave times; and staffing that was appropriate to the patient volumes. These findings aligned with previous research. Howell found that HCWs, especially nurses, worried about childcare because of school closures and increased work hours.27 Nurses felt that hospital support was inaccessible or inadequate and worried about access to essential resources.17-19,27 Studies also found excessive workloads, and many nurses needed mental or financial assistance from the hospital in addition to more rest and less work.18,28 An editorial highlighted the potential adverse effects that a lack of PPE could have on staff ’s mental health because of perceptions of institutional betrayal, which occurs when trusted and powerful organizations seemingly act in ways that can harm those dependent on them for safety and well-being.32

Consistent with other research, this study found that a majority of nurses experienced significant burnout symptoms. The number of nurses reporting symptoms of burnout increased during the pandemic with ICU nurses reporting the highest levels.17,33 Soto-Rubio et al emphasized that working conditions experienced by nurses, such as interpersonal conflict, lack of trust in administration, workload, and role conflict, contributed to burnout during COVID-19.34 Other studies found that nurses experienced burnout caused by uncertainty, intense work, and extra duties contributed to higher burnout scores.18,19 It is not surprising that researchers have indicated that nurses experiencing burnout might display depressive and stress-related symptoms, insomnia, and concentration and memory problems.19

The results of this study indicate that one-third of participating nurses were experiencing moral distress. Burton et al described COVID-19 as an environment in which nurses witnessed, experienced, and at times had to participate in acts that involved ethical violations in care, institutional betrayal, and traumatic strain.9 Of note, our findings revealed that both inpatient and outpatient nurses experienced moral distress. Interestingly, Mantri et al found that COVID-19 increased moral injury but not burnout among health professionals, which differed from the results of this study.35

The findings of this study indicate that many nurses experienced depressive symptoms. A systematic review found a similar percentage of HCWs experienced depression while caring for patients with COVID- 19, though a Chinese study found a higher percentage.36,37 Previous research also found that the most difficult aspect of the COVID- 19 pandemic for nurses was coping with mental disorders such as depression, and that many experienced difficulty sleeping/ had poor sleep quality, believed a similar disaster would occur in the future, were irritated or angered easily, and experienced emotional exhaustion.15,19 The long-term mental and physical ramifications of caring for individuals with COVID-19 remain unknown. However, previous research suggests a high prevalence of depression, insomnia, anxiety, and distress, which could impair nurses’ professional performance.29

This study reported that a majority of nurses intended to stay in their current position and about 20% intended to leave for another position within the VA. Similar findings conducted early in the pandemic indicated that most participants did not intend to quit nursing.19

This study’s findings suggest the COVID-19 pandemic had an adverse impact on VISN 21 nurses. It is critical to develop, implement, and adopt adequate measures as early as possible to support the health care system, especially nurses.18

Implications

Before the COVID-19 pandemic, discussing burnout and moral anguish was common, primarily in critical care.14 However, these experiences became more widespread throughout nursing settings during the pandemic. Nurse leaders have been identified as responsible for ensuring the environmental safety and personal well-being of their colleagues during and after pandemics.14

Studies of HCW experiences during COVID-19 provide many insights into future preparedness, strategies to best handle another pandemic during its acute stage, and techniques to address issues that might persist. This study and others suggest that comprehensive interventions in preparation for, during, and after a pandemic are needed. We break down strategies into pandemic and postpandemic interventions based on a synthesis of the literature and the research team’s knowledge and expertise.3,14-16,27,29,36,38-44

Pandemic interventions. During a pandemic, it is important that nurses are adequately cared for to ensure they can continue to provide quality care for others. Resources supporting emotional well-being and addressing moral distress offered during a pandemic are essential. Implementing meaningful strategies could enhance nurses’ health and wellbeing. It is essential that leaders provide nurses a safe work environment/experience during a pandemic by instituting meaningful resources. In addition, developing best practices for leadership are critical.

Postpandemic interventions. Personal experiences of depression, burnout, and moral distress have not spontaneously resolved as the pandemic receded. Providing postpandemic interventions to lessen ongoing and lingering depressive, burnout, and moral distress symptoms experienced by frontline workers are critical. These interventions might prevent long-term health issues and the exodus of nurses.

Postpandemic interventions should include the integration of pandemic planning into new or existing educational or training programs for staff. Promotion and support of mental health services by health system leadership for nursing personnel implemented as a usual service will play an important role in preparing for future pandemics. A key role in preparation is developing and maintaining cooperation and ongoing mutual understanding, respect, and communication between leadership and nursing staff.

Future Research

This study’s findings inform VHA leadership and society about how a large group of nurses were impacted by COVID-19 while caring for patients in inpatient and outpatient settings and could provide a basis for extending this research to other groups of nurses or health care personnel. Future research might be helpful in identifying the impact of COVID-19 on nursing leadership. During conversations with nursing leadership, a common theme identified was that nurses did not feel that leadership was fully prepared for the level of emergency the pandemic created both personally and professionally; leadership expressed experiences similar to nurses providing direct care and felt powerless to help their nursing staff. Other areas of research could include identifying underlying factors contributing to burnout and moral distress and describing nurses’ expectations of or needs from leadership to best manage burnout and moral distress.

Limitations

Experiences of nurses who stopped working were not captured and information about their experiences might have different results. The survey distribution was limited to 2 emails (an initial email and a second at midpoint) sent at the discretion of the nurse executive of each facility. The study timeline was long because of complex regulatory protective processes inherent in the VHA system for researchers to include initial institutional review board review process, union notifications, and each facility’s response to the survey. Although 860 nurses participated, this was 15% of the 5586 VISN 21 nurses at the time of the study. Many clinical inpatient nurses do not have regular access to email, which might have impacted participation rate.

CONCLUSIONS

This study identified the impact COVID-19 had on nurses who worked in a large hospital system. The research team outlined strategies to be employed during and after the pandemic, such as preplanning for future pandemics to provide a framework for a comprehensive pandemic response protocol.

This study adds to generalized knowledge because it captured voices of inpatient and outpatient nurses, the latter had not been previously studied. As nurses and health care organizations move beyond the pandemic with a significant number of nurses continuing to experience effects, there is a need to institute interventions to assist nurses in healing and begin preparations for future pandemics.

References
  1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
  2. Liu X, Kakade M, Fuller CJ, et al. Depression after exposure to stressful events: lessons learned from the severe acute respiratory syndrome epidemic. Compr Psychiatry. 2012;53(1):15-23. doi:10.1016/j.comppsych.2011.02.003
  3. Carmassi C, Foghi C, Dell’Oste V, et al. PTSD symptoms in healthcare workers facing the three coronavirus outbreaks: What can we expect after the COVID-19 pandemic. Psychiatry Res. 2020;292:113312. doi:10.1016/j.psychres.2020.113312
  4. De Kock JH, Latham HA, Leslie SJ, et al. A rapid review of the impact of COVID-19 on the mental health of healthcare workers: implications for supporting psychological well-being. BMC Public Health. 2021;21(1):104. doi:10.1186/s12889-020-10070-3
  5. Gualano MR, Sinigaglia T, Lo Moro G, et al. The burden of burnout among healthcare professionals of intensive care units and emergency departments during the covid-19 pandemic: a systematic review. Int J Environ Res Public Health. 2021;18(15):8172. doi:10.3390/ijerph18158172
  6. Sirois FM, Owens J. Factors associated with psychological distress in health-care workers during an infectious disease outbreak: a rapid systematic review of the evidence. Front Psychiatry. 2020;11;589545. doi:10.3389/fpsyt.2020.589545
  7. Talevi D, Socci V, Carai M, et al. Mental health outcomes of the COVID-19 pandemic. Riv Psichiatr. 2020;55(3);137-144. doi:10.1708/3382.33569
  8. Amsalem D, Lazarov A, Markowitz JC, et al. Psychiatric symptoms and moral injury among US healthcare workers in the COVID-19 era. BMC Psychiatry. 2021;21(1):546. doi:10.1186/s12888-021-03565-9
  9. Burton CW, Jenkins DK, Chan G.K, Zellner KL, Zalta AK. A mixed methods study of moral distress among frontline nurses during the COVID-19 pandemic. Psychol Trauma. 2023;16(4):568-575. doi:10.1037/tra0001493
  10. Stawicki SP, Jeanmonod R, Miller AC, et al. The 2019- 2020 novel coronavirus (Severe acute respiratory syndrome coronavirus 2) Pandemic:a Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group consensus paper. J Glob Infect Dis. 2020;12(2):47- 93. doi:10.4103/jgid.jgid_86_20
  11. Batra K, Singh TP, Sharma M, Batra R, Schvaneveldt N. Investigating the psychological impact of COVID- 19 among healthcare workers: a meta-analysis. Int J Environ Res Public Health. 2020;17(23):9096. doi:10.3390/ijerph17239096
  12. Xie W, Chen L, Feng F, et al. The prevalence of compassion satisfaction and compassion fatigue among nurses: a systematic review and meta-analysis. Int J Nurs Stud. 2021;120:103973. doi:10.1016/j.ijnurstu.2021.103973
  13. Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Nurses’ burnout and associated risk factors during the COVID-19 pandemic: a systematic review and meta-analysis. J Adv Nurs. 2021;77(8):3286-3302. doi:10.1111/jan.14839
  14. Hofmeyer A, Taylor R. Strategies and resources for nurse leaders to use to lead with empathy and prudence so they understand and address sources of anxiety among nurses practicing in the era of COVID-19. J Clin Nurs. 2021;30(1- 2):298-305. doi:10.1111/jocn.15520
  15. Chen R, Sun C, Chen JJ, et al. A large-scale survey on trauma, burnout, and posttraumatic growth among nurses during the COVID-19 pandemic. Int J Ment Health Nurs. 2021;30(1):102-116. doi:10.1111/inm.12796
  16. García G, Calvo J. The threat of COVID-19 and its influence on nursing staff burnout. J Adv Nurs. 2021;77(2):832-844. doi:10.1111/jan.14642
  17. Kissel KA, Filipek C, Jenkins J. Impact of the COVID- 19 pandemic on nurses working in intensive care units: a scoping review. Crit Care Nurse. 2023;43(2):55-63. doi:10.4037/ccn2023196
  18. Lin YY, Pan YA, Hsieh YL, et al. COVID-19 pandemic is associated with an adverse impact on burnout and mood disorder in healthcare professionals. Int J Environ Res and Public Health. 2021;18(7):3654. doi:10.3390/ijerph18073654
  19. Murat M, Köse S, Savas¸er S. Determination of stress, depression and burnout levels of front-line nurses during the COVID-19 pandemic. Int J Ment Health Nurs. 2021;30(2):533-543. doi:10.1111/inm.12818
  20. Purcell N, Bertenthal D, Usman H, et al. Moral injury and mental health in healthcare workers are linked to organizational culture and modifiable workplace conditions: results of a national, mixed-methods study conducted at Veterans Affairs (VA) medical centers during the COVID- 19 pandemic. PLOS Ment Health. 2024;1(7):e0000085. doi:10.1371/journal.pmen.0000085
  21. Nash WP, Marino Carper TL, Mills MA, Au T, Goldsmith A, Litz BT. Psychometric evaluation of the Moral Injury Events Scale. Mil Med. 2013;178(6):646-652. doi:10.7205/MILMED-D-13-00017
  22. Prins A, Bovin MJ, Smolenski DJ, et al. The Primary Care PTSD Screen for DSM-5 (PC-PTSD-5): development and evaluation within a veteran primary care sample. J Gen Intern Med. 2016;31(10):1206-1211. doi:10.1007/s11606-016-3703-5
  23. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284-1292. doi:10.1097/01.MLR.0000093487.78664.3C
  24. Rohland BM, Kruse GR, Rohrer JE. Validation of a single- item measure of burnout against the Maslach Burnout Inventory among physicians. Stress and Health. 2004;20(2):75-79. doi:10.1002/smi.1002
  25. Carlson J. Baccalaureate nursing faculty competencies and teaching strategies to enhance the care of the veteran population: perspectives of Veteran Affairs Nursing Academy (VANA) faculty. J Prof Nurs. 2016;32(4):314-323. doi:10.1016/j.profnurs.2016.01.006
  26. Denning M, Goh ET, Tan B, et al. Determinants of burnout and other aspects of psychological well-being in healthcare workers during the Covid-19 pandemic: a multinational cross-sectional study. PloS One. 2021;16(4):e0238666. doi:10.1371/journal.pone.0238666
  27. Howell BAM. Battling burnout at the frontlines of health care amid COVID-19. AACN Adv Crit Care. 2021;32(2):195- 203. doi:10.4037/aacnacc2021454
  28. Afshari D, Nourollahi-Darabad M, Chinisaz N. Demographic predictors of resilience among nurses during the COVID-19 pandemic. Work. 2021;68(2):297-303. doi:10.3233/WOR-203376
  29. Shah M, Roggenkamp M, Ferrer L, Burger V, Brassil KJ. Mental health and COVID-19: the psychological implications of a pandemic for nurses. Clin J Oncol Nurs. 2021;25(1), 69-75. doi:10.1188/21.CJON.69-75
  30. Griner T, Souza M, Girard A, Hain P, High H, Williams M. COVID-19’s impact on nurses’ workplace rituals. Nurs Lead. 2021;19(4):425-430. doi:10.1016/j.mnl.2021.06.008
  31. Koren A, Alam MAU, Koneru S, DeVito A, Abdallah L, Liu B. Nursing perspectives on the impacts of COVID- 19: social media content analysis. JMIR Form Res. 2021;5(12):e31358. doi:10.2196/31358
  32. Gold JA. Covid-19: adverse mental health outcomes for healthcare workers. BMJ. 2020;5:369:m1815. doi: 10.1136/bmj.m1815. doi:10.1136/bmj.m1815
  33. Slusarz R, Cwiekala-Lewis K, Wysokinski M, Filipska- Blejder K, Fidecki W, Biercewicz M. Characteristics of occupational burnout among nurses of various specialties and in the time of the COVID-19 pandemic-review. Int J Environ Res Public Health. 2022;19(21):13775. doi:10.3390/ijerph192113775
  34. Soto-Rubio A, Giménez-Espert MDC, Prado-Gascó V. Effect of emotional intelligence and psychosocial risks on burnout, job satisfaction, and nurses’ health during the COVID-19 pandemic. Int J Environ Res Public Health. 2020;17(21):7998. doi:10.3390/ijerph17217998
  35. Mantri S, Song YK, Lawson JM, Berger EJ, Koenig HG. Moral injury and burnout in health care professionals during the COVID-19 pandemic. J Nerv Ment Dis. 2021;209(10):720-726. doi:10.1097/NMD.0000000000001367
  36. Salari N, Khazaie H, Hosseinian-Far A, et al. The prevalence of stress, anxiety and depression within front-line healthcare workers caring for COVID-19 patients: a systematic review and meta-regression. Hum Resour Health 2020;18(1):100. doi:10.1186/s12960-020-00544-1
  37. Lai J, Ma S, Wang Y, et al. Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019. JAMA Netw Open. 2020;3(3):e203976. doi:10.1001/jamanetworkopen.2020.3976
  38. Chesak SS, Cutshall SM, Bowe CL, Montanari KM, Bhagra A. Stress management interventions for nurses: critical literature review. J Holist Nurs. 2019;37(3):288-295. doi:10.1177/0898010119842693
  39. Cooper AL, Brown JA, Leslie GD. Nurse resilience for clinical practice: an integrative review. J Adv Nurs. 2021;77(6):2623-2640. doi:10.1111/jan.14763
  40. Melnyk BM, Kelly SA, Stephens J, et al. Interventions to improve mental health, well-being, physical health, and lifestyle behaviors in physicians and nurses: a systematic review. Am J Health Promot. 2020;34(8):929-941. doi:10.1177/0890117120920451
  41. Cho H, Sagherian K, Steege LM. Hospital staff nurse perceptions of resources and resource needs during the COVID-19 pandemic. Nurs Outlook. 2023;71(3):101984. doi:10.1016/j.outlook.2023.101984
  42. Bachem R, Tsur N, Levin Y, Abu-Raiya H, Maercker A. Negative affect, fatalism, and perceived institutional betrayal in times of the coronavirus pandemic: a cross-cultural investigation of control beliefs. Front Psychiatry. 2020;11:589914. doi:10.3389/fpsyt.2020.589914
  43. Shanafelt T, Ripp J, Trockel M. Understanding and addressing sources of anxiety among health care professionals during the COVID-19 pandemic. JAMA. 2020;323(21):2133. doi:10.1001/jama.2020.5893
  44. Schuster M, Dwyer PA. Post-traumatic stress disorder in nurses: an integrative review. J Clin Nurs. 2020;29(15- 16):2769-2787. doi:10.1111/jocn.15288
References
  1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
  2. Liu X, Kakade M, Fuller CJ, et al. Depression after exposure to stressful events: lessons learned from the severe acute respiratory syndrome epidemic. Compr Psychiatry. 2012;53(1):15-23. doi:10.1016/j.comppsych.2011.02.003
  3. Carmassi C, Foghi C, Dell’Oste V, et al. PTSD symptoms in healthcare workers facing the three coronavirus outbreaks: What can we expect after the COVID-19 pandemic. Psychiatry Res. 2020;292:113312. doi:10.1016/j.psychres.2020.113312
  4. De Kock JH, Latham HA, Leslie SJ, et al. A rapid review of the impact of COVID-19 on the mental health of healthcare workers: implications for supporting psychological well-being. BMC Public Health. 2021;21(1):104. doi:10.1186/s12889-020-10070-3
  5. Gualano MR, Sinigaglia T, Lo Moro G, et al. The burden of burnout among healthcare professionals of intensive care units and emergency departments during the covid-19 pandemic: a systematic review. Int J Environ Res Public Health. 2021;18(15):8172. doi:10.3390/ijerph18158172
  6. Sirois FM, Owens J. Factors associated with psychological distress in health-care workers during an infectious disease outbreak: a rapid systematic review of the evidence. Front Psychiatry. 2020;11;589545. doi:10.3389/fpsyt.2020.589545
  7. Talevi D, Socci V, Carai M, et al. Mental health outcomes of the COVID-19 pandemic. Riv Psichiatr. 2020;55(3);137-144. doi:10.1708/3382.33569
  8. Amsalem D, Lazarov A, Markowitz JC, et al. Psychiatric symptoms and moral injury among US healthcare workers in the COVID-19 era. BMC Psychiatry. 2021;21(1):546. doi:10.1186/s12888-021-03565-9
  9. Burton CW, Jenkins DK, Chan G.K, Zellner KL, Zalta AK. A mixed methods study of moral distress among frontline nurses during the COVID-19 pandemic. Psychol Trauma. 2023;16(4):568-575. doi:10.1037/tra0001493
  10. Stawicki SP, Jeanmonod R, Miller AC, et al. The 2019- 2020 novel coronavirus (Severe acute respiratory syndrome coronavirus 2) Pandemic:a Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group consensus paper. J Glob Infect Dis. 2020;12(2):47- 93. doi:10.4103/jgid.jgid_86_20
  11. Batra K, Singh TP, Sharma M, Batra R, Schvaneveldt N. Investigating the psychological impact of COVID- 19 among healthcare workers: a meta-analysis. Int J Environ Res Public Health. 2020;17(23):9096. doi:10.3390/ijerph17239096
  12. Xie W, Chen L, Feng F, et al. The prevalence of compassion satisfaction and compassion fatigue among nurses: a systematic review and meta-analysis. Int J Nurs Stud. 2021;120:103973. doi:10.1016/j.ijnurstu.2021.103973
  13. Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Nurses’ burnout and associated risk factors during the COVID-19 pandemic: a systematic review and meta-analysis. J Adv Nurs. 2021;77(8):3286-3302. doi:10.1111/jan.14839
  14. Hofmeyer A, Taylor R. Strategies and resources for nurse leaders to use to lead with empathy and prudence so they understand and address sources of anxiety among nurses practicing in the era of COVID-19. J Clin Nurs. 2021;30(1- 2):298-305. doi:10.1111/jocn.15520
  15. Chen R, Sun C, Chen JJ, et al. A large-scale survey on trauma, burnout, and posttraumatic growth among nurses during the COVID-19 pandemic. Int J Ment Health Nurs. 2021;30(1):102-116. doi:10.1111/inm.12796
  16. García G, Calvo J. The threat of COVID-19 and its influence on nursing staff burnout. J Adv Nurs. 2021;77(2):832-844. doi:10.1111/jan.14642
  17. Kissel KA, Filipek C, Jenkins J. Impact of the COVID- 19 pandemic on nurses working in intensive care units: a scoping review. Crit Care Nurse. 2023;43(2):55-63. doi:10.4037/ccn2023196
  18. Lin YY, Pan YA, Hsieh YL, et al. COVID-19 pandemic is associated with an adverse impact on burnout and mood disorder in healthcare professionals. Int J Environ Res and Public Health. 2021;18(7):3654. doi:10.3390/ijerph18073654
  19. Murat M, Köse S, Savas¸er S. Determination of stress, depression and burnout levels of front-line nurses during the COVID-19 pandemic. Int J Ment Health Nurs. 2021;30(2):533-543. doi:10.1111/inm.12818
  20. Purcell N, Bertenthal D, Usman H, et al. Moral injury and mental health in healthcare workers are linked to organizational culture and modifiable workplace conditions: results of a national, mixed-methods study conducted at Veterans Affairs (VA) medical centers during the COVID- 19 pandemic. PLOS Ment Health. 2024;1(7):e0000085. doi:10.1371/journal.pmen.0000085
  21. Nash WP, Marino Carper TL, Mills MA, Au T, Goldsmith A, Litz BT. Psychometric evaluation of the Moral Injury Events Scale. Mil Med. 2013;178(6):646-652. doi:10.7205/MILMED-D-13-00017
  22. Prins A, Bovin MJ, Smolenski DJ, et al. The Primary Care PTSD Screen for DSM-5 (PC-PTSD-5): development and evaluation within a veteran primary care sample. J Gen Intern Med. 2016;31(10):1206-1211. doi:10.1007/s11606-016-3703-5
  23. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284-1292. doi:10.1097/01.MLR.0000093487.78664.3C
  24. Rohland BM, Kruse GR, Rohrer JE. Validation of a single- item measure of burnout against the Maslach Burnout Inventory among physicians. Stress and Health. 2004;20(2):75-79. doi:10.1002/smi.1002
  25. Carlson J. Baccalaureate nursing faculty competencies and teaching strategies to enhance the care of the veteran population: perspectives of Veteran Affairs Nursing Academy (VANA) faculty. J Prof Nurs. 2016;32(4):314-323. doi:10.1016/j.profnurs.2016.01.006
  26. Denning M, Goh ET, Tan B, et al. Determinants of burnout and other aspects of psychological well-being in healthcare workers during the Covid-19 pandemic: a multinational cross-sectional study. PloS One. 2021;16(4):e0238666. doi:10.1371/journal.pone.0238666
  27. Howell BAM. Battling burnout at the frontlines of health care amid COVID-19. AACN Adv Crit Care. 2021;32(2):195- 203. doi:10.4037/aacnacc2021454
  28. Afshari D, Nourollahi-Darabad M, Chinisaz N. Demographic predictors of resilience among nurses during the COVID-19 pandemic. Work. 2021;68(2):297-303. doi:10.3233/WOR-203376
  29. Shah M, Roggenkamp M, Ferrer L, Burger V, Brassil KJ. Mental health and COVID-19: the psychological implications of a pandemic for nurses. Clin J Oncol Nurs. 2021;25(1), 69-75. doi:10.1188/21.CJON.69-75
  30. Griner T, Souza M, Girard A, Hain P, High H, Williams M. COVID-19’s impact on nurses’ workplace rituals. Nurs Lead. 2021;19(4):425-430. doi:10.1016/j.mnl.2021.06.008
  31. Koren A, Alam MAU, Koneru S, DeVito A, Abdallah L, Liu B. Nursing perspectives on the impacts of COVID- 19: social media content analysis. JMIR Form Res. 2021;5(12):e31358. doi:10.2196/31358
  32. Gold JA. Covid-19: adverse mental health outcomes for healthcare workers. BMJ. 2020;5:369:m1815. doi: 10.1136/bmj.m1815. doi:10.1136/bmj.m1815
  33. Slusarz R, Cwiekala-Lewis K, Wysokinski M, Filipska- Blejder K, Fidecki W, Biercewicz M. Characteristics of occupational burnout among nurses of various specialties and in the time of the COVID-19 pandemic-review. Int J Environ Res Public Health. 2022;19(21):13775. doi:10.3390/ijerph192113775
  34. Soto-Rubio A, Giménez-Espert MDC, Prado-Gascó V. Effect of emotional intelligence and psychosocial risks on burnout, job satisfaction, and nurses’ health during the COVID-19 pandemic. Int J Environ Res Public Health. 2020;17(21):7998. doi:10.3390/ijerph17217998
  35. Mantri S, Song YK, Lawson JM, Berger EJ, Koenig HG. Moral injury and burnout in health care professionals during the COVID-19 pandemic. J Nerv Ment Dis. 2021;209(10):720-726. doi:10.1097/NMD.0000000000001367
  36. Salari N, Khazaie H, Hosseinian-Far A, et al. The prevalence of stress, anxiety and depression within front-line healthcare workers caring for COVID-19 patients: a systematic review and meta-regression. Hum Resour Health 2020;18(1):100. doi:10.1186/s12960-020-00544-1
  37. Lai J, Ma S, Wang Y, et al. Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019. JAMA Netw Open. 2020;3(3):e203976. doi:10.1001/jamanetworkopen.2020.3976
  38. Chesak SS, Cutshall SM, Bowe CL, Montanari KM, Bhagra A. Stress management interventions for nurses: critical literature review. J Holist Nurs. 2019;37(3):288-295. doi:10.1177/0898010119842693
  39. Cooper AL, Brown JA, Leslie GD. Nurse resilience for clinical practice: an integrative review. J Adv Nurs. 2021;77(6):2623-2640. doi:10.1111/jan.14763
  40. Melnyk BM, Kelly SA, Stephens J, et al. Interventions to improve mental health, well-being, physical health, and lifestyle behaviors in physicians and nurses: a systematic review. Am J Health Promot. 2020;34(8):929-941. doi:10.1177/0890117120920451
  41. Cho H, Sagherian K, Steege LM. Hospital staff nurse perceptions of resources and resource needs during the COVID-19 pandemic. Nurs Outlook. 2023;71(3):101984. doi:10.1016/j.outlook.2023.101984
  42. Bachem R, Tsur N, Levin Y, Abu-Raiya H, Maercker A. Negative affect, fatalism, and perceived institutional betrayal in times of the coronavirus pandemic: a cross-cultural investigation of control beliefs. Front Psychiatry. 2020;11:589914. doi:10.3389/fpsyt.2020.589914
  43. Shanafelt T, Ripp J, Trockel M. Understanding and addressing sources of anxiety among health care professionals during the COVID-19 pandemic. JAMA. 2020;323(21):2133. doi:10.1001/jama.2020.5893
  44. Schuster M, Dwyer PA. Post-traumatic stress disorder in nurses: an integrative review. J Clin Nurs. 2020;29(15- 16):2769-2787. doi:10.1111/jocn.15288
Issue
Federal Practitioner - 42(3)
Issue
Federal Practitioner - 42(3)
Page Number
120-127
Page Number
120-127
Publications
Publications
Topics
Article Type
Display Headline

COVID-19 Impact on Veterans Health Administration Nurses: A Retrospective Survey

Display Headline

COVID-19 Impact on Veterans Health Administration Nurses: A Retrospective Survey

Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 03/11/2025 - 14:03
Un-Gate On Date
Tue, 03/11/2025 - 14:03
Use ProPublica
CFC Schedule Remove Status
Tue, 03/11/2025 - 14:03
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Tue, 03/11/2025 - 14:03

Comorbidities and Lifestyle Risk Factors Associated With Scabies Infestation

Article Type
Changed
Tue, 03/04/2025 - 14:56
Display Headline

Comorbidities and Lifestyle Risk Factors Associated With Scabies Infestation

To the Editor:

Scabies infestation, which has been recognized as a neglected tropical disease by the World Health Organization since 2017, is caused by the human itch mite (Sarcoptes scabiei var hominis).1 Infected individuals experience a pruritic papular rash when the mite burrows into the epidermis, where it lives and lays eggs.2,3 Infected individuals also may develop bacterial superinfections if the skin barrier becomes compromised, leading to systemic complications and considerable morbidity.3

In countries with high human development indices, scabies outbreaks are linked to densely populated living conditions, such as those found in nursing homes or prisons.3,4 Scabies also is transmitted via sexual contact in adults. Beyond immunosuppression, little is known about other comorbid conditions or lifestyle risk factors associated with scabies infestation.2 Because scabies can mimic a range of other dermatologic conditions such as folliculitis, atopic dermatitis, and arthropod bites, misdiagnosis is common and can lead to delayed treatment and increased transmission risk.4 In this study, we sought to examine comorbid conditions and/or lifestyle risk factors associated with scabies infestation.

A matched case-control study was performed using the Registered Tier dataset of the National Institutes of Health All of Us Research Program Curated Data Repository version 7, which includes more than 400,000 unique participants aged 18 years or older from across the United States. The All of Us Research Program excludes adults who are unable to consent independently as well as incarcerated populations and children younger than 18 years. Participants diagnosed with scabies were identified using SNOMED code 62752005 and compared to a control group matched 1:4 based on age, sex, and selfidentified race. SNOMED codes also were used to identify various comorbidities and lifestyle risk factors, including depression, bipolar disorder, anxiety, schizophrenia, peripheral vascular disease (PVD), HIV, type 2 diabetes mellitus (T2DM), unsheltered status, tobacco use, difficulty with activities of daily living, insurance status, and any recent travel history. Logistic regression models were used to calculate odds ratios (ORs) and estimate effect sizes, with statistical significance set at P<.05.

We identified 691 cases of scabies infestation and 2073 controls. The average age of the patients diagnosed with scabies was 55.1 years. Seventy percent (481/691) identified as female and 32.4% (224/491) identified as Black or African American. Matched controls were similar for all analyzed demographic characteristics (P=1.0)(eTable 1). Patients diagnosed with scabies were more likely to be unsheltered (OR, 2.33 [95% CI, 1.91-2.85]), use tobacco (OR 1.77 [95% CI, 1.48-2.11]) and have a comorbid diagnosis of HIV (OR, 3.08 [95% CI, 2.03-4.66]), T2DM (OR, 2.05 [95% CI, 1.57- 2.66]) or PVD (OR, 2.06 [95% CI, 1.43-2.97]) compared with controls (P<.001). Psychiatric comorbidities were more common in the patients diagnosed with scabies, including depression (OR, 3.07 [95% CI, 2.54-3.72]), anxiety (OR, 2.48 [95% CI, 2.06-2.98]), bipolar disorder (OR, 3.08 [95% CI, 2.34-4.05]), and schizophrenia (OR, 4.68 [95% CI, 2.93-7.49])(P<.001). Difficulties with activities of daily living, including running errands alone (OR, 2.32 [95% CI, 1.43-3.76]) and concentrating (OR, 5.78; 95% CI, 3.86-8.64), were more prevalent in the scabies group compared to controls (both P<.05). In a multivariate logistic regression model including unsheltered status as a covariate, all associations remained statistically significant (P<.05)(eTable 2).

CT115003083-eTable1CT115003083-eTable2

This large diverse study demonstrated an association between scabies infestation and unsheltered status. Previous studies have shown that unsheltered populations are at increased risk for many dermatologic conditions, perhaps due to decreased access to health care and social support, lack of access to hygiene facilities (eg, public showers), and increased prevalence of substance use and psychiatric disorders among this population.5 In a cross-sectional analysis of hospitalized patients, 8.6% of unsheltered patients (n=197) had an ectoparasitic disease (including scabies) compared with 1.0% of patients with stable housing (n=1018), with a 9.43-fold increased risk for ectoparasitic infestation among unsheltered patients (95% CI, 3.79-23.47; P<.001).6 Increased attention to public health initiatives among unsheltered populations— including access to hygiene facilities and increased dermatologic services—are needed, as ectoparasitic infections are both preventable and treatable, and these initiatives could reduce morbidity associated with superimposed bacterial infections for which unsheltered patients are at increased risk.6

Our results also showed that individuals diagnosed with scabies were more likely than the controls to have been diagnosed with HIV, T2DM, and PVD. Our findings are similar to those of a systematic review of immunosuppressive factors associated with crusted scabies (a severe form of scabies infestation) in which 10.2% and 15.7% of patients (n=683) had comorbid HIV and T2DM, respectively.7 A functioning cell-mediated response to scabies mite antigens limits proliferation of the human itch mite; thus, infection with HIV/AIDS, which induces the destruction of CD4+ T cells, limits the immune system’s ability to mount an effective response against these antigens. The association of scabies with T2DM likely is multifactorial; for example, chronic hyperglycemia may lead to immune system impairment, and peripheral neuropathy may reduce the itch sensation, allowing scabies mites to proliferate without removal by scratching.7 In a descriptive epidemiologic study in Japan, 11.7% of patients with scabies (N=857) had comorbid PVD.8 Peripheral vascular disease can lead to the development of ulcers, gangrene, and stasis dermatitis, all of which compromise the skin barrier and increase susceptibility to infection.9 Notably, these associations remained even when unsheltered status was considered as a confounding variable. Because individuals with HIV, T2DM, and PVD may be at higher risk for serious complications of scabies infestation (eg, secondary bacterial infections, invasive group A streptococcal infections), prompt detection and treatment of scabies are crucial in curbing morbidity in these at-risk populations.

Our study also demonstrated that psychiatric comorbidities including depression, anxiety, bipolar disorder, and schizophrenia were associated with scabies infestation, even when controlling for unsheltered status, which may have a bidirectional relationship with mental health disorders.10 In a cross-sectional study of 83 adult patients diagnosed with scabies, 72.2% (60/83) reported moderate to extremely large effect of scabies infestation on quality of life using the Dermatology Life Quality Index, and these scores positively correlated with increased Beck Depression Scale and Beck Anxiety Scale scores (rs=0.448 and rs=0.456 0.456, respectively; both P=.000). The results of this study suggest that scabies negatively impacts quality of life, which might increase symptoms of depression and anxiety.11

Studies are needed to assess whether patients with pre-existing depression and anxiety face increased risk for scabies infestation. In a retrospective case-control study using data from the National Health Insurance Research Database of Taiwan, 0.8% (58/7096) of patients with scabies (n=7096) and 0.4% of controls (n=28,375) were newly diagnosed with bipolar disorder over a 7-year period, indicating a 1.55-fold increased risk for bipolar disorder in patients with scabies compared to those without (95% CI, 1.12-2.09; P<.05).12 Future studies are needed to determine whether the relationship between bipolar disorder and scabies is bidirectional, with pre-existing bipolar disorder evaluated as a risk factor for subsequent scabies infestation. Increased difficulties with activities of daily living, including running errands independently and concentrating, were associated with scabies. These difficulties may reflect sequelae of psychiatric illness or pruritus associated with scabies affecting daily living.

Physician awareness of comorbidities and lifestyle risk factors associated with scabies infestation may improve diagnosis and prevent treatment delays. In a retrospective study at a single dermatology outpatient clinic, 45.3% of patients with scabies (n=428) had previously been misdiagnosed with another dermatologic condition, and the most common erroneous diagnosis was atopic dermatitis.13 Our study provides a framework of comorbidities and lifestyle risk factors associated with scabies infestation that dermatologists can use to stratify patients who may be at greater risk for this condition, allowing dermatologists to select appropriate treatment when clinical signs are ambiguous.

Limitations of our study included the potential for miscoding in the database, lack of information about treatment regimens employed (if any), and lack of information about the temporal relationship between associations.

In summary, it is recommended that patients with pruritus and other characteristic clinical findings of scabies receive appropriate workup for scabies regardless of risk factors; however, the medical and psychiatric comorbidities and lifestyle risk factors identified in this study may help to identify at-risk patients. Our study showed that unsheltered patients are at increased risk for scabies, potentially due to unique dermatologic challenges and lack of access to health care and hygiene facilities. Positive correlations between scabies and HIV, T2DM, and PVD suggest that patients with chronic immunocompromising illnesses who live in group homes or other crowded quarters and present with symptoms could be evaluated for scabies infestation to prevent widespread and difficult- to-control outbreaks in these communities. Based on our findings, scabies also should be included in the differential diagnosis for patients with psychiatric illness and suggestive symptoms. Early identification and treatment of scabies infestation could prevent misdiagnosis and treatment delays.

References
  1. World Health Organization. Scabies fact sheet. May 31, 2023. Accessed February 13, 2025. https://www.who.int/news-room/fact-sheets/detail/scabies
  2. Chandler DJ, Fuller LC. A review of scabies: an infestation more than skin deep. Dermatology. 2019;235:79-90. doi:10.1159/000495290
  3. Schneider S, Wu J, Tizek L, et al. Prevalence of scabies worldwidean updated systematic literature review in 2022. J Eur Acad Dermatol Venereol. 2023;37:1749-1757. doi:10.1111/jdv.19167
  4. Thomas C, Coates SJ, Engelman D, et al. Ectoparasites: Scabies. J Am Acad Dermatol. 2020;82:533-548. doi:10.1016/j.jaad.2019.05.109
  5. Henry T, Khachemoune A. Dermatologic conditions and risk factors in people experiencing homelessness (PEH): systematic review. Arch Dermatol Res. 2023;315:2795-2803. doi:10.1007/s00403-023-02722-2
  6. Zakaria A, Amerson EH, Kim-Lim P, et al. Characterization of dermatological diagnoses among hospitalized patients experiencing homelessness. Clin Exp Dermatol. 2022;47:117-120. doi:10.1111/ced.14828
  7. Bergamin G, Hudson J, Currie BJ, et al. A systematic review of immunosuppressive risk factors and comorbidities associated with the development of crusted scabies. Int J Infect Dis. 2024;143:107036. doi:10.1016/j.ijid.2024.107036
  8. Yamaguchi Y, Murata F, Maeda M, et al. Investigating the epidemiology and outbreaks of scabies in Japanese households, residential care facilities, and hospitals using claims data: the Longevity Improvement & Fair Evidence (LIFE) study. IJID Reg. 2024;11:100353. doi:10.1016 /j.ijregi.2024.03.008
  9. Raja A, Karch J, Shih AF, et al. Part II: Cutaneous manifestations of peripheral vascular disease. J Am Acad Dermatol. 2023;89:211-226. doi:10.1016/j.jaad.2021.05.077
  10. Barry R, Anderson J, Tran L, et al. Prevalence of mental health disorders among individuals experiencing homelessness: a systematic review and meta-analysis. JAMA Psychiatry. 2024;81:691-699. doi:10.1001 /jamapsychiatry.2024.0426
  11. Koc Y.ld.r.m S, Demirel Og. ut N, Erbag. c. E, et al. Scabies affects quality of life in correlation with depression and anxiety. Dermatol Pract Concept. 2023;13:E2023144. doi:10.5826/dpc.1302a144
  12. Lin CY, Chang FW, Yang JJ, et al. Increased risk of bipolar disorder in patients with scabies: a nationwide population-based matched-cohort study. Psychiatry Res. 2017;257:14-20. doi:10.1016 /j.psychres.2017.07.013
  13. Anderson KL, Strowd LC. Epidemiology, diagnosis, and treatment of scabies in a dermatology office. J Am Board Fam Med. 2017;30:78-84. doi:10.3122/jabfm.2017.01.160190
Article PDF
Author and Disclosure Information

Rachel C. Hill and Fernando Vicente are from Weill Cornell Medical College, New York, New York. Dr. Lipner is from the Department of Dermatology, Weill Cornell Medicine, New York.

Rachel C. Hill and Fernando Vicente have no relevant financial disclosures to report. Dr. Lipner has served as a consultant for BelleTorus Corporation and Moberg Pharmaceuticals.

Correspondence: Shari R. Lipner, MD, PhD, Weill Cornell Medicine, Department of Dermatology, 1305 York Ave, New York, NY 10021 ([email protected]).

Cutis. 2025 March;115(3):83-85, E1-E2. doi:10.12788/cutis.1179

Issue
Cutis - 115(3)
Publications
Topics
Page Number
83-85
Sections
Author and Disclosure Information

Rachel C. Hill and Fernando Vicente are from Weill Cornell Medical College, New York, New York. Dr. Lipner is from the Department of Dermatology, Weill Cornell Medicine, New York.

Rachel C. Hill and Fernando Vicente have no relevant financial disclosures to report. Dr. Lipner has served as a consultant for BelleTorus Corporation and Moberg Pharmaceuticals.

Correspondence: Shari R. Lipner, MD, PhD, Weill Cornell Medicine, Department of Dermatology, 1305 York Ave, New York, NY 10021 ([email protected]).

Cutis. 2025 March;115(3):83-85, E1-E2. doi:10.12788/cutis.1179

Author and Disclosure Information

Rachel C. Hill and Fernando Vicente are from Weill Cornell Medical College, New York, New York. Dr. Lipner is from the Department of Dermatology, Weill Cornell Medicine, New York.

Rachel C. Hill and Fernando Vicente have no relevant financial disclosures to report. Dr. Lipner has served as a consultant for BelleTorus Corporation and Moberg Pharmaceuticals.

Correspondence: Shari R. Lipner, MD, PhD, Weill Cornell Medicine, Department of Dermatology, 1305 York Ave, New York, NY 10021 ([email protected]).

Cutis. 2025 March;115(3):83-85, E1-E2. doi:10.12788/cutis.1179

Article PDF
Article PDF

To the Editor:

Scabies infestation, which has been recognized as a neglected tropical disease by the World Health Organization since 2017, is caused by the human itch mite (Sarcoptes scabiei var hominis).1 Infected individuals experience a pruritic papular rash when the mite burrows into the epidermis, where it lives and lays eggs.2,3 Infected individuals also may develop bacterial superinfections if the skin barrier becomes compromised, leading to systemic complications and considerable morbidity.3

In countries with high human development indices, scabies outbreaks are linked to densely populated living conditions, such as those found in nursing homes or prisons.3,4 Scabies also is transmitted via sexual contact in adults. Beyond immunosuppression, little is known about other comorbid conditions or lifestyle risk factors associated with scabies infestation.2 Because scabies can mimic a range of other dermatologic conditions such as folliculitis, atopic dermatitis, and arthropod bites, misdiagnosis is common and can lead to delayed treatment and increased transmission risk.4 In this study, we sought to examine comorbid conditions and/or lifestyle risk factors associated with scabies infestation.

A matched case-control study was performed using the Registered Tier dataset of the National Institutes of Health All of Us Research Program Curated Data Repository version 7, which includes more than 400,000 unique participants aged 18 years or older from across the United States. The All of Us Research Program excludes adults who are unable to consent independently as well as incarcerated populations and children younger than 18 years. Participants diagnosed with scabies were identified using SNOMED code 62752005 and compared to a control group matched 1:4 based on age, sex, and selfidentified race. SNOMED codes also were used to identify various comorbidities and lifestyle risk factors, including depression, bipolar disorder, anxiety, schizophrenia, peripheral vascular disease (PVD), HIV, type 2 diabetes mellitus (T2DM), unsheltered status, tobacco use, difficulty with activities of daily living, insurance status, and any recent travel history. Logistic regression models were used to calculate odds ratios (ORs) and estimate effect sizes, with statistical significance set at P<.05.

We identified 691 cases of scabies infestation and 2073 controls. The average age of the patients diagnosed with scabies was 55.1 years. Seventy percent (481/691) identified as female and 32.4% (224/491) identified as Black or African American. Matched controls were similar for all analyzed demographic characteristics (P=1.0)(eTable 1). Patients diagnosed with scabies were more likely to be unsheltered (OR, 2.33 [95% CI, 1.91-2.85]), use tobacco (OR 1.77 [95% CI, 1.48-2.11]) and have a comorbid diagnosis of HIV (OR, 3.08 [95% CI, 2.03-4.66]), T2DM (OR, 2.05 [95% CI, 1.57- 2.66]) or PVD (OR, 2.06 [95% CI, 1.43-2.97]) compared with controls (P<.001). Psychiatric comorbidities were more common in the patients diagnosed with scabies, including depression (OR, 3.07 [95% CI, 2.54-3.72]), anxiety (OR, 2.48 [95% CI, 2.06-2.98]), bipolar disorder (OR, 3.08 [95% CI, 2.34-4.05]), and schizophrenia (OR, 4.68 [95% CI, 2.93-7.49])(P<.001). Difficulties with activities of daily living, including running errands alone (OR, 2.32 [95% CI, 1.43-3.76]) and concentrating (OR, 5.78; 95% CI, 3.86-8.64), were more prevalent in the scabies group compared to controls (both P<.05). In a multivariate logistic regression model including unsheltered status as a covariate, all associations remained statistically significant (P<.05)(eTable 2).

CT115003083-eTable1CT115003083-eTable2

This large diverse study demonstrated an association between scabies infestation and unsheltered status. Previous studies have shown that unsheltered populations are at increased risk for many dermatologic conditions, perhaps due to decreased access to health care and social support, lack of access to hygiene facilities (eg, public showers), and increased prevalence of substance use and psychiatric disorders among this population.5 In a cross-sectional analysis of hospitalized patients, 8.6% of unsheltered patients (n=197) had an ectoparasitic disease (including scabies) compared with 1.0% of patients with stable housing (n=1018), with a 9.43-fold increased risk for ectoparasitic infestation among unsheltered patients (95% CI, 3.79-23.47; P<.001).6 Increased attention to public health initiatives among unsheltered populations— including access to hygiene facilities and increased dermatologic services—are needed, as ectoparasitic infections are both preventable and treatable, and these initiatives could reduce morbidity associated with superimposed bacterial infections for which unsheltered patients are at increased risk.6

Our results also showed that individuals diagnosed with scabies were more likely than the controls to have been diagnosed with HIV, T2DM, and PVD. Our findings are similar to those of a systematic review of immunosuppressive factors associated with crusted scabies (a severe form of scabies infestation) in which 10.2% and 15.7% of patients (n=683) had comorbid HIV and T2DM, respectively.7 A functioning cell-mediated response to scabies mite antigens limits proliferation of the human itch mite; thus, infection with HIV/AIDS, which induces the destruction of CD4+ T cells, limits the immune system’s ability to mount an effective response against these antigens. The association of scabies with T2DM likely is multifactorial; for example, chronic hyperglycemia may lead to immune system impairment, and peripheral neuropathy may reduce the itch sensation, allowing scabies mites to proliferate without removal by scratching.7 In a descriptive epidemiologic study in Japan, 11.7% of patients with scabies (N=857) had comorbid PVD.8 Peripheral vascular disease can lead to the development of ulcers, gangrene, and stasis dermatitis, all of which compromise the skin barrier and increase susceptibility to infection.9 Notably, these associations remained even when unsheltered status was considered as a confounding variable. Because individuals with HIV, T2DM, and PVD may be at higher risk for serious complications of scabies infestation (eg, secondary bacterial infections, invasive group A streptococcal infections), prompt detection and treatment of scabies are crucial in curbing morbidity in these at-risk populations.

Our study also demonstrated that psychiatric comorbidities including depression, anxiety, bipolar disorder, and schizophrenia were associated with scabies infestation, even when controlling for unsheltered status, which may have a bidirectional relationship with mental health disorders.10 In a cross-sectional study of 83 adult patients diagnosed with scabies, 72.2% (60/83) reported moderate to extremely large effect of scabies infestation on quality of life using the Dermatology Life Quality Index, and these scores positively correlated with increased Beck Depression Scale and Beck Anxiety Scale scores (rs=0.448 and rs=0.456 0.456, respectively; both P=.000). The results of this study suggest that scabies negatively impacts quality of life, which might increase symptoms of depression and anxiety.11

Studies are needed to assess whether patients with pre-existing depression and anxiety face increased risk for scabies infestation. In a retrospective case-control study using data from the National Health Insurance Research Database of Taiwan, 0.8% (58/7096) of patients with scabies (n=7096) and 0.4% of controls (n=28,375) were newly diagnosed with bipolar disorder over a 7-year period, indicating a 1.55-fold increased risk for bipolar disorder in patients with scabies compared to those without (95% CI, 1.12-2.09; P<.05).12 Future studies are needed to determine whether the relationship between bipolar disorder and scabies is bidirectional, with pre-existing bipolar disorder evaluated as a risk factor for subsequent scabies infestation. Increased difficulties with activities of daily living, including running errands independently and concentrating, were associated with scabies. These difficulties may reflect sequelae of psychiatric illness or pruritus associated with scabies affecting daily living.

Physician awareness of comorbidities and lifestyle risk factors associated with scabies infestation may improve diagnosis and prevent treatment delays. In a retrospective study at a single dermatology outpatient clinic, 45.3% of patients with scabies (n=428) had previously been misdiagnosed with another dermatologic condition, and the most common erroneous diagnosis was atopic dermatitis.13 Our study provides a framework of comorbidities and lifestyle risk factors associated with scabies infestation that dermatologists can use to stratify patients who may be at greater risk for this condition, allowing dermatologists to select appropriate treatment when clinical signs are ambiguous.

Limitations of our study included the potential for miscoding in the database, lack of information about treatment regimens employed (if any), and lack of information about the temporal relationship between associations.

In summary, it is recommended that patients with pruritus and other characteristic clinical findings of scabies receive appropriate workup for scabies regardless of risk factors; however, the medical and psychiatric comorbidities and lifestyle risk factors identified in this study may help to identify at-risk patients. Our study showed that unsheltered patients are at increased risk for scabies, potentially due to unique dermatologic challenges and lack of access to health care and hygiene facilities. Positive correlations between scabies and HIV, T2DM, and PVD suggest that patients with chronic immunocompromising illnesses who live in group homes or other crowded quarters and present with symptoms could be evaluated for scabies infestation to prevent widespread and difficult- to-control outbreaks in these communities. Based on our findings, scabies also should be included in the differential diagnosis for patients with psychiatric illness and suggestive symptoms. Early identification and treatment of scabies infestation could prevent misdiagnosis and treatment delays.

To the Editor:

Scabies infestation, which has been recognized as a neglected tropical disease by the World Health Organization since 2017, is caused by the human itch mite (Sarcoptes scabiei var hominis).1 Infected individuals experience a pruritic papular rash when the mite burrows into the epidermis, where it lives and lays eggs.2,3 Infected individuals also may develop bacterial superinfections if the skin barrier becomes compromised, leading to systemic complications and considerable morbidity.3

In countries with high human development indices, scabies outbreaks are linked to densely populated living conditions, such as those found in nursing homes or prisons.3,4 Scabies also is transmitted via sexual contact in adults. Beyond immunosuppression, little is known about other comorbid conditions or lifestyle risk factors associated with scabies infestation.2 Because scabies can mimic a range of other dermatologic conditions such as folliculitis, atopic dermatitis, and arthropod bites, misdiagnosis is common and can lead to delayed treatment and increased transmission risk.4 In this study, we sought to examine comorbid conditions and/or lifestyle risk factors associated with scabies infestation.

A matched case-control study was performed using the Registered Tier dataset of the National Institutes of Health All of Us Research Program Curated Data Repository version 7, which includes more than 400,000 unique participants aged 18 years or older from across the United States. The All of Us Research Program excludes adults who are unable to consent independently as well as incarcerated populations and children younger than 18 years. Participants diagnosed with scabies were identified using SNOMED code 62752005 and compared to a control group matched 1:4 based on age, sex, and selfidentified race. SNOMED codes also were used to identify various comorbidities and lifestyle risk factors, including depression, bipolar disorder, anxiety, schizophrenia, peripheral vascular disease (PVD), HIV, type 2 diabetes mellitus (T2DM), unsheltered status, tobacco use, difficulty with activities of daily living, insurance status, and any recent travel history. Logistic regression models were used to calculate odds ratios (ORs) and estimate effect sizes, with statistical significance set at P<.05.

We identified 691 cases of scabies infestation and 2073 controls. The average age of the patients diagnosed with scabies was 55.1 years. Seventy percent (481/691) identified as female and 32.4% (224/491) identified as Black or African American. Matched controls were similar for all analyzed demographic characteristics (P=1.0)(eTable 1). Patients diagnosed with scabies were more likely to be unsheltered (OR, 2.33 [95% CI, 1.91-2.85]), use tobacco (OR 1.77 [95% CI, 1.48-2.11]) and have a comorbid diagnosis of HIV (OR, 3.08 [95% CI, 2.03-4.66]), T2DM (OR, 2.05 [95% CI, 1.57- 2.66]) or PVD (OR, 2.06 [95% CI, 1.43-2.97]) compared with controls (P<.001). Psychiatric comorbidities were more common in the patients diagnosed with scabies, including depression (OR, 3.07 [95% CI, 2.54-3.72]), anxiety (OR, 2.48 [95% CI, 2.06-2.98]), bipolar disorder (OR, 3.08 [95% CI, 2.34-4.05]), and schizophrenia (OR, 4.68 [95% CI, 2.93-7.49])(P<.001). Difficulties with activities of daily living, including running errands alone (OR, 2.32 [95% CI, 1.43-3.76]) and concentrating (OR, 5.78; 95% CI, 3.86-8.64), were more prevalent in the scabies group compared to controls (both P<.05). In a multivariate logistic regression model including unsheltered status as a covariate, all associations remained statistically significant (P<.05)(eTable 2).

CT115003083-eTable1CT115003083-eTable2

This large diverse study demonstrated an association between scabies infestation and unsheltered status. Previous studies have shown that unsheltered populations are at increased risk for many dermatologic conditions, perhaps due to decreased access to health care and social support, lack of access to hygiene facilities (eg, public showers), and increased prevalence of substance use and psychiatric disorders among this population.5 In a cross-sectional analysis of hospitalized patients, 8.6% of unsheltered patients (n=197) had an ectoparasitic disease (including scabies) compared with 1.0% of patients with stable housing (n=1018), with a 9.43-fold increased risk for ectoparasitic infestation among unsheltered patients (95% CI, 3.79-23.47; P<.001).6 Increased attention to public health initiatives among unsheltered populations— including access to hygiene facilities and increased dermatologic services—are needed, as ectoparasitic infections are both preventable and treatable, and these initiatives could reduce morbidity associated with superimposed bacterial infections for which unsheltered patients are at increased risk.6

Our results also showed that individuals diagnosed with scabies were more likely than the controls to have been diagnosed with HIV, T2DM, and PVD. Our findings are similar to those of a systematic review of immunosuppressive factors associated with crusted scabies (a severe form of scabies infestation) in which 10.2% and 15.7% of patients (n=683) had comorbid HIV and T2DM, respectively.7 A functioning cell-mediated response to scabies mite antigens limits proliferation of the human itch mite; thus, infection with HIV/AIDS, which induces the destruction of CD4+ T cells, limits the immune system’s ability to mount an effective response against these antigens. The association of scabies with T2DM likely is multifactorial; for example, chronic hyperglycemia may lead to immune system impairment, and peripheral neuropathy may reduce the itch sensation, allowing scabies mites to proliferate without removal by scratching.7 In a descriptive epidemiologic study in Japan, 11.7% of patients with scabies (N=857) had comorbid PVD.8 Peripheral vascular disease can lead to the development of ulcers, gangrene, and stasis dermatitis, all of which compromise the skin barrier and increase susceptibility to infection.9 Notably, these associations remained even when unsheltered status was considered as a confounding variable. Because individuals with HIV, T2DM, and PVD may be at higher risk for serious complications of scabies infestation (eg, secondary bacterial infections, invasive group A streptococcal infections), prompt detection and treatment of scabies are crucial in curbing morbidity in these at-risk populations.

Our study also demonstrated that psychiatric comorbidities including depression, anxiety, bipolar disorder, and schizophrenia were associated with scabies infestation, even when controlling for unsheltered status, which may have a bidirectional relationship with mental health disorders.10 In a cross-sectional study of 83 adult patients diagnosed with scabies, 72.2% (60/83) reported moderate to extremely large effect of scabies infestation on quality of life using the Dermatology Life Quality Index, and these scores positively correlated with increased Beck Depression Scale and Beck Anxiety Scale scores (rs=0.448 and rs=0.456 0.456, respectively; both P=.000). The results of this study suggest that scabies negatively impacts quality of life, which might increase symptoms of depression and anxiety.11

Studies are needed to assess whether patients with pre-existing depression and anxiety face increased risk for scabies infestation. In a retrospective case-control study using data from the National Health Insurance Research Database of Taiwan, 0.8% (58/7096) of patients with scabies (n=7096) and 0.4% of controls (n=28,375) were newly diagnosed with bipolar disorder over a 7-year period, indicating a 1.55-fold increased risk for bipolar disorder in patients with scabies compared to those without (95% CI, 1.12-2.09; P<.05).12 Future studies are needed to determine whether the relationship between bipolar disorder and scabies is bidirectional, with pre-existing bipolar disorder evaluated as a risk factor for subsequent scabies infestation. Increased difficulties with activities of daily living, including running errands independently and concentrating, were associated with scabies. These difficulties may reflect sequelae of psychiatric illness or pruritus associated with scabies affecting daily living.

Physician awareness of comorbidities and lifestyle risk factors associated with scabies infestation may improve diagnosis and prevent treatment delays. In a retrospective study at a single dermatology outpatient clinic, 45.3% of patients with scabies (n=428) had previously been misdiagnosed with another dermatologic condition, and the most common erroneous diagnosis was atopic dermatitis.13 Our study provides a framework of comorbidities and lifestyle risk factors associated with scabies infestation that dermatologists can use to stratify patients who may be at greater risk for this condition, allowing dermatologists to select appropriate treatment when clinical signs are ambiguous.

Limitations of our study included the potential for miscoding in the database, lack of information about treatment regimens employed (if any), and lack of information about the temporal relationship between associations.

In summary, it is recommended that patients with pruritus and other characteristic clinical findings of scabies receive appropriate workup for scabies regardless of risk factors; however, the medical and psychiatric comorbidities and lifestyle risk factors identified in this study may help to identify at-risk patients. Our study showed that unsheltered patients are at increased risk for scabies, potentially due to unique dermatologic challenges and lack of access to health care and hygiene facilities. Positive correlations between scabies and HIV, T2DM, and PVD suggest that patients with chronic immunocompromising illnesses who live in group homes or other crowded quarters and present with symptoms could be evaluated for scabies infestation to prevent widespread and difficult- to-control outbreaks in these communities. Based on our findings, scabies also should be included in the differential diagnosis for patients with psychiatric illness and suggestive symptoms. Early identification and treatment of scabies infestation could prevent misdiagnosis and treatment delays.

References
  1. World Health Organization. Scabies fact sheet. May 31, 2023. Accessed February 13, 2025. https://www.who.int/news-room/fact-sheets/detail/scabies
  2. Chandler DJ, Fuller LC. A review of scabies: an infestation more than skin deep. Dermatology. 2019;235:79-90. doi:10.1159/000495290
  3. Schneider S, Wu J, Tizek L, et al. Prevalence of scabies worldwidean updated systematic literature review in 2022. J Eur Acad Dermatol Venereol. 2023;37:1749-1757. doi:10.1111/jdv.19167
  4. Thomas C, Coates SJ, Engelman D, et al. Ectoparasites: Scabies. J Am Acad Dermatol. 2020;82:533-548. doi:10.1016/j.jaad.2019.05.109
  5. Henry T, Khachemoune A. Dermatologic conditions and risk factors in people experiencing homelessness (PEH): systematic review. Arch Dermatol Res. 2023;315:2795-2803. doi:10.1007/s00403-023-02722-2
  6. Zakaria A, Amerson EH, Kim-Lim P, et al. Characterization of dermatological diagnoses among hospitalized patients experiencing homelessness. Clin Exp Dermatol. 2022;47:117-120. doi:10.1111/ced.14828
  7. Bergamin G, Hudson J, Currie BJ, et al. A systematic review of immunosuppressive risk factors and comorbidities associated with the development of crusted scabies. Int J Infect Dis. 2024;143:107036. doi:10.1016/j.ijid.2024.107036
  8. Yamaguchi Y, Murata F, Maeda M, et al. Investigating the epidemiology and outbreaks of scabies in Japanese households, residential care facilities, and hospitals using claims data: the Longevity Improvement & Fair Evidence (LIFE) study. IJID Reg. 2024;11:100353. doi:10.1016 /j.ijregi.2024.03.008
  9. Raja A, Karch J, Shih AF, et al. Part II: Cutaneous manifestations of peripheral vascular disease. J Am Acad Dermatol. 2023;89:211-226. doi:10.1016/j.jaad.2021.05.077
  10. Barry R, Anderson J, Tran L, et al. Prevalence of mental health disorders among individuals experiencing homelessness: a systematic review and meta-analysis. JAMA Psychiatry. 2024;81:691-699. doi:10.1001 /jamapsychiatry.2024.0426
  11. Koc Y.ld.r.m S, Demirel Og. ut N, Erbag. c. E, et al. Scabies affects quality of life in correlation with depression and anxiety. Dermatol Pract Concept. 2023;13:E2023144. doi:10.5826/dpc.1302a144
  12. Lin CY, Chang FW, Yang JJ, et al. Increased risk of bipolar disorder in patients with scabies: a nationwide population-based matched-cohort study. Psychiatry Res. 2017;257:14-20. doi:10.1016 /j.psychres.2017.07.013
  13. Anderson KL, Strowd LC. Epidemiology, diagnosis, and treatment of scabies in a dermatology office. J Am Board Fam Med. 2017;30:78-84. doi:10.3122/jabfm.2017.01.160190
References
  1. World Health Organization. Scabies fact sheet. May 31, 2023. Accessed February 13, 2025. https://www.who.int/news-room/fact-sheets/detail/scabies
  2. Chandler DJ, Fuller LC. A review of scabies: an infestation more than skin deep. Dermatology. 2019;235:79-90. doi:10.1159/000495290
  3. Schneider S, Wu J, Tizek L, et al. Prevalence of scabies worldwidean updated systematic literature review in 2022. J Eur Acad Dermatol Venereol. 2023;37:1749-1757. doi:10.1111/jdv.19167
  4. Thomas C, Coates SJ, Engelman D, et al. Ectoparasites: Scabies. J Am Acad Dermatol. 2020;82:533-548. doi:10.1016/j.jaad.2019.05.109
  5. Henry T, Khachemoune A. Dermatologic conditions and risk factors in people experiencing homelessness (PEH): systematic review. Arch Dermatol Res. 2023;315:2795-2803. doi:10.1007/s00403-023-02722-2
  6. Zakaria A, Amerson EH, Kim-Lim P, et al. Characterization of dermatological diagnoses among hospitalized patients experiencing homelessness. Clin Exp Dermatol. 2022;47:117-120. doi:10.1111/ced.14828
  7. Bergamin G, Hudson J, Currie BJ, et al. A systematic review of immunosuppressive risk factors and comorbidities associated with the development of crusted scabies. Int J Infect Dis. 2024;143:107036. doi:10.1016/j.ijid.2024.107036
  8. Yamaguchi Y, Murata F, Maeda M, et al. Investigating the epidemiology and outbreaks of scabies in Japanese households, residential care facilities, and hospitals using claims data: the Longevity Improvement & Fair Evidence (LIFE) study. IJID Reg. 2024;11:100353. doi:10.1016 /j.ijregi.2024.03.008
  9. Raja A, Karch J, Shih AF, et al. Part II: Cutaneous manifestations of peripheral vascular disease. J Am Acad Dermatol. 2023;89:211-226. doi:10.1016/j.jaad.2021.05.077
  10. Barry R, Anderson J, Tran L, et al. Prevalence of mental health disorders among individuals experiencing homelessness: a systematic review and meta-analysis. JAMA Psychiatry. 2024;81:691-699. doi:10.1001 /jamapsychiatry.2024.0426
  11. Koc Y.ld.r.m S, Demirel Og. ut N, Erbag. c. E, et al. Scabies affects quality of life in correlation with depression and anxiety. Dermatol Pract Concept. 2023;13:E2023144. doi:10.5826/dpc.1302a144
  12. Lin CY, Chang FW, Yang JJ, et al. Increased risk of bipolar disorder in patients with scabies: a nationwide population-based matched-cohort study. Psychiatry Res. 2017;257:14-20. doi:10.1016 /j.psychres.2017.07.013
  13. Anderson KL, Strowd LC. Epidemiology, diagnosis, and treatment of scabies in a dermatology office. J Am Board Fam Med. 2017;30:78-84. doi:10.3122/jabfm.2017.01.160190
Issue
Cutis - 115(3)
Issue
Cutis - 115(3)
Page Number
83-85
Page Number
83-85
Publications
Publications
Topics
Article Type
Display Headline

Comorbidities and Lifestyle Risk Factors Associated With Scabies Infestation

Display Headline

Comorbidities and Lifestyle Risk Factors Associated With Scabies Infestation

Sections
Inside the Article

PRACTICE POINTS

  • Scabies infestation is caused by the human itch mite (Sarcoptes scabiei var hominis) and can be spread via sexual contact in adults.
  • Crowded living conditions are associated with scabies infestation in countries with high human development indices, such as the United States.
  • Patients with certain comorbid conditions or lifestyle risk factors should be screened for scabies infestation when presenting with pruritus and other characteristic clinical findings.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Mon, 03/03/2025 - 12:54
Un-Gate On Date
Mon, 03/03/2025 - 12:54
Use ProPublica
CFC Schedule Remove Status
Mon, 03/03/2025 - 12:54
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Mon, 03/03/2025 - 12:54

Utilization and Cost of Veterans Health Administration Referrals to Community Care-Based Physical Therapy

Article Type
Changed
Wed, 03/05/2025 - 08:20
Display Headline

Utilization and Cost of Veterans Health Administration Referrals to Community Care-Based Physical Therapy

 

The Veterans Health Administration (VHA) is the largest US integrated health system, providing care to veterans through VHA and non-VHA practitioners and facilities.1,2 Providing high-quality, timely, and veteran-centric care remains a priority for the VHA. Legislative efforts have expanded opportunities for eligible veterans to receive care in the community purchased by VHA, known as community care (CC).1 The Veterans Access, Choice, and Accountability Act of 2014 came in response to reports of long wait times and drive times for patients.3-5 The MISSION Act of 2018 expanded access to CC by streamlining it and broadening eligibility criteria, especially for veterans in rural communities who often experience more barriers in accessing care than veterans living in urban communities.1,6-10 Since the implementation of the Choice and MISSION Acts, > 2.7 million veterans have received care through community practitioners within the VHA CC network.11

Background

Increased access to CC could benefit veterans living in rural communities by increasing care options and circumventing challenges to accessing VHA care (ie, geographic, transportation, and distance barriers, practitioner and specialist shortages, and hospital closures). 5,9,10,12,13 However, health care system deficits in rural areas could also limit CC effectiveness for veterans living in those communities. 3 Other challenges posed by using CC include care coordination, information sharing, care continuity, delayed payments to CC practitioners, and mixed findings regarding CC quality.5,8,13,14 VHA practitioners are specifically trained to meet the multifaceted needs unique to veterans’ health and subculture, training CC practitioners may not receive.5,15

CC offers services for primary care and a broad range of specialties, including rehabilitation services such as physical therapy (PT).6 PT is used for the effective treatment of various conditions veterans experience and promote wellbeing and independence.16 US Department of Veterans Affairs (VA) databases reveal a high prevalence of veterans receiving PT services through CC; PT is one of the most frequently used CC outpatient specialty services by veterans living in rural communities.14,17

Telerehabitltation Enterprisewide Initiative

VHA has greatly invested in delivering care virtually, especially for veterans living in rural communities.18 In 2017, the VHA Office of Rural Health funded the Telerehabilitation Enterprise-Wide Initiative (TR-EWI) in partnership with the Physical Medicine and Rehabilitation Services national program office to increase access to specialized rehabilitation services for veterans living in rural communities by leveraging telehealth technologies.18-21 This alternative mode of health care delivery allows clinicians to overcome access barriers by delivering rehabilitation therapies directly to veterans' homes or nearby community-based outpatient clinics. TR-EWI was conceived as a hub-and-spoke model, where rehabilitation expertise at the hub was virtually delivered to spoke sites that did not have in-house expertise. In subsequent years, the TR-EWI also evolved to provide targeted telerehabilitation programs within rural-serving community-based outpatient clinics, including PT as a predominant service.19,20

As TR-EWI progressed—and in conjunction with the uptake of telehealth across VHA during the COVID-19 pandemic—there has been increased focus on PT telerehabilitation, especially for the 4.6 million veterans in rural communities.18,22,23 Because health care delivery system deficits in rural areas could limit the effective use of CC, many TR-EWI sites hope to reduce their CC referrals by providing telehealth PT services to veterans who might otherwise need to be referred to CC. This strategy aligns with VHA goals of providing high-quality and timely care. To better understand opportunities for programs like TR-EWI to provide rehabilitation services for veterans and reduce care sent to the community, research that examines CC referral trends for PT over time is warranted.

This study examines CC from a rehabilitation perspective with a focus on CC referral trends for PT, specifically for Veterans Integrated Service Networks (VISNs) where TREWI sites are located. The study’s objectives were to describe rehabilitation PT services being referred to CC and examine associated CC costs for PT services. Two research questions guided the study. First, what are the utilization trends for CC PT referrals from fiscal year (FY) 2019 to FY 2022? Secondly, what is the cost breakdown of CC for PT referrals from FY 2020 to FY 2022?

Methods

This study was conducted by a multidisciplinary team comprised of public health, disability, rehabilitation counseling, and PT professionals. It was deemed a quality improvement project under VA guidance and followed the SQUIRE guidelines for quality improvement reporting.24,25 The study used the VA Common Operating Platform (Palantir) to obtain individual-level CC referral data from the HealthShare Referral Manager (HSRM) database and consult data from the Computerized Patient Record System. Palantir is used to store and integrate VA data derived from the VA Corporate Data Warehouse and VHA Support Service Center. Referrals are authorizations for care to be delivered by a CC practitioner.

TR-EWI is comprised of 7 sites: VISN 2, VISN 4, VISN 8, VISN 12, VISN 15, VISN 19, and VISN 22. Each site provides telerehabilitation services with an emphasis on reaching veterans living in rural communities. We joined the referrals and consults cubes in Palantir to extract PT referrals for FY 2019 to FY 2022 for the 7 VISNs with TR-EWI sites and obtain referral-specific information and demographic characteristics. 26 Data were extracted in October 2022.

The VHA Community Care Referral Dashboard (CC Dashboard) provided nonindividual level CC cost data.27 The CC Dashboard provides insights into the costs of CC services for VHA enrollees by category of care, standardized episode of care, and eligibility. Data are based on nationallevel HSRM referrals that are not suspended or linked to a canceled or discontinued consult. Data were aggregated by VISN. The dashboard only includes referrals dating back to FY 2020; therefore, PT data from FY 2020 through FY 2022 for VISNs with TR-EWI sites were collected. Data were extracted in December 2022.

This study examined CC referrals, station name, eligibility types, clinical diagnoses (International Classification of Diseases, Tenth Revision codes), and demographic information in the Palantir dataset. Six eligibility criteria can qualify a veteran to receive CC.28 Within clinical diagnoses, the variable of interest was the provisional diagnosis. Patient demographics included age, gender, and rurality of residence, as determined by the Rural-Urban Commuting Area system.29,30 Rural and highly rural categories were combined for analysis. For the CC cost dataset, this study examined CC referrals, referral cost, and eligibility type.

Analysis

For the first research question, we examined referral data from FY 2019 to FY 2022 using the Palantir dataset, performed descriptive statistical analysis for all variables, and analyzed data to identify trends. Descriptive statistics were completed using IBM SPSS Statistics for Windows Version 29.0.0.0.

A qualitative analysis of provisional diagnosis data revealed what is being referred to CC for PT. A preliminary overview of provisional diagnosis data was conducted to familiarize coders with the data. We developed a coding framework to categorize diagnoses based on anatomical location, body structure, and clinical areas of interest. Data were reviewed individually and grouped into categories within the coding framework before meeting as a team to achieve group consensus on categorization. We then totaled the frequency of occurrence for provisional diagnoses within each category. Qualitative analyses were completed using Microsoft Excel.

For the second research question, the study used the CC cost dataset to examine the cost breakdown of CC PT referrals from FY 2020 to FY 2022. We calculated the number and cost of PT referrals across eligibility groups for each FY and VISN. Data were analyzed using SPSS to identify cost trends.

Results

There were 344,406 referrals to CC for PT from FY 2019 to FY 2022 for the 7 VISNs analyzed (Table 1). Of these, 22.5% were from FY 2019, 19.1% from FY 2020, 28.2% from FY 2021, and 30.3% from FY 2022. VISN 8 and VISN 22 reported the most overall PT referrals, with VISN 8 comprising 22.2% and VISN 22 comprising 18.1% of all referrals. VISN 2 reported the least overall referrals (3.7%). VISN 4 and VISN 12 had decreases in referrals over time. VISN 2 and VISN 15 had decreases in referrals from FY 2019 to FY 2021 and slight increases from FY 2021 to FY 2022. VISN 19 and VISN 22 both saw slight increases from FY 2019 to FY 2020 and substantial increases from FY 2020 to FY 2022, with FY 2022 accounting for 40.0% and 42.3% of all referrals for VISN 19 and VISN 20, respectively (Figure 1).

0225FED-ePT-T10225FED-ePT-F1

For FY 2019 and FY 2020, VISN 8 had the highest percentage of referrals (26.7% and 23.2%, respectively), whereas VISN 22 was among the lowest (7.3% and 11.4%, respectively). However, for FY 2021 and FY 2022, VISN 22 reported the highest percentage of referrals (23.5% and 25.3%, respectively) compared to all other VISNs. VISN 2 consistently reported the lowest percentage of referrals across all years.

There were 56 stations analyzed across the 7 VISNs (Appendix 1). Nine stations each accounted for ≥ 3.0% of the total PT referrals and only 2 stations accounted for > 5.0% of referrals. Orlando, Florida (6.0%), Philadelphia, Pennsylvania (5.2%), Tampa, Florida (4.9%), Aurora, Colorado (4.9%), and Gainesville, Florida (4.4%) reported the top 5 highest referrals, with 3 being from VISN 8 (Orlando, Tampa, Gainesville). Stations with the lowest reported referrals were all in VISN 2 in New York: The Bronx, (0%), New York Harbor (0%), Hudson Valley (0.1%) and Finger Lakes (0.2%).

0225FED-ePT-A1
Rurality

Urban stations comprised 56.2% and rural stations comprised 39.8% of PT CC referrals, while 0.2% of referrals were from insular isle US territories: Guam, American Samoa, Northern Marianas, and the Virgin Islands. The sample had missing or unknown data for 3.8% of referrals. FY 2022 had the largest difference in rural and urban referrals. Additionally, there was an overall trend of more referrals over time for rural and urban, with a large increase in rural (+40.0%) and urban (+62.7%) referrals from FY 2020 to FY 2021 and a modest increase from FY 2021 to FY 2022 (+5.2% for rural and +9.1% for urban). There was a decrease in rural (-7.0%) and urban (-3.5%) referrals from FY 2019 to FY 2020 (Figure 2).

0225FED-ePT-F2

There were differences in referrals by rurality and VISN (Table 2). VISN 12, VISN 15, and VISN 19 reported more rural than urban referrals, whereas VISN 4, VISN 8, and VISN 22 reported more urban than rural referrals. VISN 2 reported similar numbers for both, with slightly more urban than rural referrals. When reviewing trends over time for each FY, VISN 12, VISN 15, and VISN 19 reported more rural than urban referrals and VISN 4, VISN 8, and VISN 22 had more urban than rural referrals. In FY 2019 and FY 2020, VISN 2 reported slightly more urban than rural referrals but almost the same number of referrals in FY 2021 and FY 2022 (Appendix 2).

0225FED-ePT-T20225FED-ePT-A2
Demographics

The mean (SD) age was 61.2 (15.8) years (range, 20-105). Most PT CC referrals were for veterans aged 70 to 79 years (26.9%), followed by 60 to 69 years (20.7%), and 50 to 59 years (16.4%) (Appendix 3). Trends were consistent across VISNs. There was less of a difference between rural and urban referral percentages as the population aged. Veterans aged < 49 years residing in more urban areas accounted for more referrals to CC compared to their rural counterparts. This difference was less apparent in the 70 to 79 years and 80 to 89 years age brackets.

0225FED-ePT-A3

Most PT CC referrals (81.2%) were male and 14.8% were female. About 3.6% of referral data were missing sex information, and there was a smaller difference between male veterans living in rural communities and male veterans living in urban communities compared with female veterans. A total of 42.9% of male veterans resided in rural areas compared to 56.8% in urban areas; 32.7% of female veterans resided in rural areas compared to 66.9% in urban areas (Appendix 3).

Other Criteria

Of the 334,406 referrals, 114,983 (34.4%) had eligibility data, mostly from FY 2021 and FY 2022 (Table 3). Available eligibility data were likely affected by the MISSION Act and new regulations for reporting CC eligibility. Distance (33.4%) was the most common eligibility criteria, followed by timeliness of care (28.8%), and best medical interest (19.8%); 40.4% were rural and 59.5% were urban. Distance (55.4%) was most common for rural veterans, while timeliness of care (39.7%) was most common for urban veterans. For both groups, the second most common eligibility reason was best medical interest (Appendix 4).

0225FED-ePT-T30225FED-ePT-A4

Bone, joint, or soft tissue disorders were common diagnoses, with 25.2% located in the lower back, 14.7% in the shoulder, and 12.8% in the knee (Appendix 5). Amputations of the upper and lower limbs, fractures, cancer-related diagnoses, integumentary system disorders, thoracic and abdominal injuries and disorders, and other medical and mental health conditions each accounted for < 1% of the total diagnoses.

0225FED-ePT-A5
Costs

At time of analysis, the CC Dashboard had cost data available for 200,204 CC PT referrals from FY 2020 to FY 2022. The difference in referral numbers for the 2 datasets is likely attributed to several factors: CC cost data is exclusively from the HSRM, whereas Palantir includes other data sources; how VA cleans data pulled into Palantir; how the CC Dashboard algorithm populates data; and variances based on timing of reporting and/or if referrals are eventually canceled.

The total cost of PT CC referrals from FY 2020 to FY 2022 in selected VISNs was about $220,615,399 (Appendix 6). Appendix 7 details the methodology for determining the average standardized episode- of-care cost by VISN and how referral costs are calculated. Data show a continuous increase in total estimated cost from $46.8 million in FY 2020 to $92.1 million in FY 2022. From FY 2020 to FY 2022, aggregate costs ranged from $6,758,053 in VISN 2 to $47,209,162 in VISN 8 (Figure 3). The total referral cost for PT was highest at VISN 4 in FY 2020 ($10,447,140) and highest at VISN 22 in FY 2021 ($18,835,657) and FY 2022 ($22,962,438) (Figure 4). For referral costs from FY 2020 to FY 2022, distance accounted for $75,561,948 (34.3%), timeliness of care accounted for $60,413,496 (27.3%), and best medical interest accounted for $46,291,390 (21.0%) (Table 4).

0225FED-ePT-A70225FED-ePT-A6

 

0225FED-ePT-F30225FED-ePT-F40225FED-ePT-T4

Overall costs were primarily driven by specific VISNs within each eligibility type (Appendix 8; Figure 5). VISN 19, VISN 22, and VISN 15 accounted for the highest referral costs for distance; VISN 22, VISN 8, and VISN 19 accounted for the secondhighest referral cost, timeliness of care; and VISN 4, VISN 8, and VISN 12 accounted for the third-highest referral cost, best medical interest (Figure 5). VISN 2, VISN 4, VISN 12, VISN 15, and VISN 22 had service unavailable as an eligibility type with 1 of the top 3 associated referral costs, which was higher in cost than timeliness of care for VISN 2, VISN 4, VISN 12, and VISN 15.

0225FED-ePT-A280225FED-ePT-F5

Discussion

This study examines the referral of rehabilitation PT services to CC, evaluates CC costs for PT services, and analyzes utilization and cost trends among veterans within the VHA. Utilization data demonstrated a decrease in referrals from FY 2019 to FY 2020 and increases in referrals from FY 2020 to FY 2022 for most variables of interest, with cost data exhibiting similar trends. Results highlight the need for further investigation to address variations in PT referrals and costs across VISNs and eligibility reasons for CC referral.

Results demonstrated a noteworthy increase in PT CC referrals over time. The largest increase occurred from FY 2020 to FY 2021, with a smaller increase from FY 2021 to FY 2022. During this period, total enrollee numbers decreased by 3.0% across the 7 VISNs included in this analysis and by 1.6% across all VISNs, a trend that illustrates an overall decrease in enrollees as CC use increased. Results align with the implementation of the MISSION Act of 2018, which further expanded veterans’ options to use CC.1,6,7 Results also align with the onset of the COVID-19 pandemic, which disrupted care access for many veterans, placed a larger emphasis on the use of telehealth, and increased opportunities to stay within the VA for care by rapidly shifting to telehealth and leveraging telerehabilitation investments and initiatives (such as TR-EWI).20,31

VISN 8, VISN 19, and VISN 22, accounted for more than half of PT referrals. These VISNs had higher enrollee counts compared to the other VISNs.32 VISN 8 consistently had high levels of referrals, whereas VISN 19 and VISN 22 saw dramatic increases in FY 2021 and FY 2022. In contrast, VISN 4 and VISN 12 gradually decreased referrals during the study. VISN 2 had the lowest referral numbers during the study period, and all stations with the lowest individual referral numbers were located within VISN 2. Of the VISNs included in this study, VISN 2 had the second lowest number of enrollees (324,042).32 Reasons for increases and decreases over time could not be determined based on data collected in this study.

There were more urban than rural PT CC referrals; however, both exhibited an increase in referrals over time. This is consistent with population trends showing that most VHA patients (62.6%) and veterans (75.9%) reside in urban areas, which could explain some of the trends in this study.33 Some VISNs have larger urban catchment areas (eg, VISN 8 and VISN 22), and some have larger rural catchment areas (eg, VISN 15 and VISN 19), which could partially explain the rural-urban differences by VISN.32 Rural-urban referral trends might also reflect existing health care delivery system deficits in rural areas and known challenges associated with accessing health care for veterans living in rural communities.8,9

This study found larger differences in rural and urban PT CC referrals for younger age groups, with more than twice as many urban referrals in veterans aged 20 to 29 years and aged 30 to 39 years, and roughly 1.8 times as many urban referrals in veterans aged 40 to 49 years. However, there were similar numbers of rural and urban referrals in those aged 70 to 79 years and aged 80 to 89 years. These trends are consistent with data showing veterans residing in rural communities are older than their urban counterparts.23,34 Data suggest that older veteran populations might seek PT at higher rates than younger veteran populations. Moreover, data suggest there could be differences in PT-seeking rates for younger veteran populations who reside in rural vs urban areas. Additional research is needed to understand these trends.

Distance and timeliness of care were the predominant reasons for referral among eligibility groups, which is consistent with the MISSION Act goals.1,6,7 The most common eligibility reason for rural referrals was distance; timeliness of care was most common for urban referrals. This finding is expected, as veterans living in rural communities are farther away from VHA facilities and have longer drive times, whereas veterans living in urban communities might live closer, yet experience longer wait times due to services and/or appointment availability. Best medical interest accounted for almost 20% of referrals, which does not provide detailed insights into why those veterans were referred to CC.

The top PT diagnoses referred to CC were related to bone, joint, or soft tissue disorders of the lower back, shoulder, and knee. This suggests that musculoskeletal-related issues are prevalent among veterans seeking PT care, which is consistent with research that found > 50% of veterans receiving VHA care have musculoskeletal disorders.35 The probability of experiencing musculoskeletal problems increases with age, as does the need for PT services. Amputations and fractures accounted for < 1% of CC referrals, which is consistent with the historic provision of VHA clinical specialized care to conditions prevalent among veterans. It may also represent VHA efforts to internally provide care for complex conditions requiring more extensive interdisciplinary coordination.

The total cost of referrals over time was about $221 million. VISN 8 accounted for the highest overall cost; VISN 2 had the lowest, mirroring referral utilization trends and aligning with VISN enrollee numbers. VISN 19 and VISN 22 reported large cost increases from FY 2020 to FY 2021. Total referral costs increased by $34.9 million from FY 2020 to FY 2021, which may be due to health care inflation (2.9% during FY 2019 to FY 2022), increased awareness of CC services, or increased VHA wait times.36 Additionally, there were limitations in care provided across health care systems during the COVID-19 pandemic, including the VA.5 The increase from FY 2020 to FY 2021 may reflect a rebound from restrictions in appointments across VA, CC, and the private sector.

While the increase in total referral cost may be partly attributed to inflation, the cost effectiveness and efficiency of referring veterans to CC vs keeping veterans within VHA care is an ongoing debate.5 Examining and addressing cost drivers within the top eligibility types and their respective VISNs is necessary to determine resource allocation and improve quality of care. This study found that best medical interest and unavailable services accounted for 33.4% of the total cost of CC referrals, highlighting the need for policies that strengthen in-house competencies and recruit personnel to provide PT services currently unavailable within the VA.

Future Directions

The VHA should explore opportunities for in-house care, especially for services appropriate for telehealth.18,20,37 Data indicated a smaller cost increase from FY 2021 to FY 2022 compared to the relatively large increase from FY 2020 to FY 2021. The increased telehealth usage across VHA by TR-EWI and non—TR-EWI sites within selected VISNs may have contributed to limiting the increase in CC costs. Future studies should investigate contextual factors of increased telehealth usage, which would offer guidance for implementation to optimize the integration of telehealth with PT rehabilitation provided in-house. Additionally, future studies can examine potential limitations experienced during PT telehealth visits, such as the inability to conduct hands-on assessments, challenges in viewing the quality of patient movement, ensuring patient safety in the remote environment, and the lack of PT equipment in homes for telehealth visits, and how these challenges are being addressed.38,39 Research is also needed to understand tradeoffs of CC vs VHA care and the potential and cost benefits of keeping veterans within VHA using programs like TR-EWI.5 Veterans living in rural communities may especially benefit from this as expanding telehealth options can provide access to PT care that may not be readily available, enabling them to stay connected and engaged in their care.18,40

Future studies could examine contributory factors to rising costs, such as demographic shifts, changes in PT service utilization, and policy. Researchers might also consider qualitative studies with clinicians and veterans within each VISN, which may provide insights into how local factors impact PT referral to the community.

Limitations

Due to its descriptive nature, this study can only speculate about factors influencing trends. Limitations include the inability to link the Palantir and CC Dashboard datasets for cost comparisons and potential data change over time on Palantir due to platform updates. The focus on VISNs with TREWI sites limited generalizability and this study did not compare CC PT vs VHA PT. Finally, there may have been cost drivers not identified in this study.

Conclusions

This descriptive study provides insights into the utilization and cost of PT CC referrals for selected VISNs. Cost trends underscore the financial commitment to providing PT services to veterans. Understanding what factors are driving this cost is necessary for VHA to optimally provide and manage the rehabilitation resources needed to serve veterans through traditional in-person care, telehealth, and CC options while ensuring timely, highquality care.

References
  1. Congressional Budget Office. The Veterans Community Care Program: Background and Early Effects. October 26, 2021. Accessed September 23, 2024. https://www.cbo.gov/publication/57257
  2. US Dept of Veterans Affairs. Providing Health Care for Veterans. Updated September 10, 2024. Accessed September 23, 2024. https://www.va.gov/health/
  3. Davila H, Rosen AK, Beilstein-Wedel E, Shwartz M, Chatelain LJ, Gurewich D. Rural veterans’ experiences with outpatient care in the Veterans Health Administration versus community care. Med Care. 2021;59(Suppl 3):S286-S291. doi:10.1097/MLR.0000000000001552
  4. Vanneman ME, Wagner TH, Shwartz M, et al. Veterans’ experiences with outpatient care: comparing the Veterans Affairs system with community-based care. Health Aff (Millwood). 2020;39(8):1368-1376. doi:10.1377/hlthaff.2019.01375
  5. Rasmussen P, Farmer CM. The promise and challenges of VA community care: veterans’ issues in focus. Rand Health Q. 2023;10(3):9.
  6. Feyman Y, Legler A, Griffith KN. Appointment wait time data for primary & specialty care in veterans health administration facilities vs. community medical centers. Data Brief. 2021;36:107134. doi:10.1016/j.dib.2021.107134
  7. Kelley AT, Greenstone CL, Kirsh SR. Defining access and the role of community care in the Veterans Health Administration. J Gen Intern Med. 2020;35(5):1584-1585. doi:10.1007/s11606-019-05358-z
  8. Garvin LA, Pugatch M, Gurewich D, Pendergast JN, Miller CJ. Interorganizational care coordination of rural veterans by Veterans Affairs and community care programs: a systematic review. Med Care. 2021;59(Suppl 3):S259-S269. doi:10.1097/MLR.0000000000001542
  9. US Dept of Veterans Affairs, Office of Rural Health. Rural Veterans: Rural Veteran Health Care Challenges. Updated May 14, 2024. Accessed September 23, 2024. https:// www.ruralhealth.va.gov/aboutus/ruralvets.asp
  10. Ohl ME, Carrell M, Thurman A, et al. “Availability of healthcare providers for rural veterans eligible for purchased care under the veterans choice act.” BMC Health Serv Res. 2018;18(1):315. doi:10.1186/s12913-018-3108-8
  11. Mattocks KM, Cunningham KJ, Greenstone C, Atkins D, Rosen AK, Upton M. Innovations in community care programs, policies, and research. Med Care. 2021;59(Suppl 3):S229-S231. doi:10.1097/MLR.0000000000001550
  12. Doyle JM, Streeter RA. Veterans’ location in health professional shortage areas: implications for access to care and workforce supply. Health Serv Res. 2017;52 Suppl 1(Suppl 1):459-480. doi:10.1111/1475-6773.12633
  13. Patzel M, Barnes C, Ramalingam N, et al. Jumping through hoops: community care clinician and staff experiences providing primary care to rural veterans. J Gen Intern Med. 2023;38(Suppl 3):821-828. doi:10.1007/s11606-023-08126-2
  14. Mattocks KM, Kroll-Desrosiers A, Kinney R, Elwy AR, Cunningham KJ, Mengeling MA. Understanding VA’s use of and relationships with community care providers under the MISSION Act. Med Care. 2021;59(Suppl 3):S252-S258. doi:10.1097/MLR.0000000000001545
  15. Olenick M, Flowers M, Diaz VJ. US veterans and their unique issues: enhancing health care professional awareness. Adv Med Educ Pract. 2015;6:635-639. doi:10.2147/AMEP.S89479
  16. Campbell P, Pope R, Simas V, Canetti E, Schram B, Orr R. The effects of early physiotherapy treatment on musculoskeletal injury outcomes in military personnel: a narrative review. Int J Environ Res Public Health. 2022;19(20):13416. doi:10.3390/ijerph192013416
  17. Gurewich D, Shwartz M, Beilstein-Wedel E, Davila H, Rosen AK. Did access to care improve since passage of the veterans choice act? Differences between rural and urban veterans. Med Care. 2021;59(Suppl 3):S270-S278. doi:10.1097/MLR.0000000000001490
  18. Myers US, Birks A, Grubaugh AL, Axon RN. Flattening the curve by getting ahead of it: how the VA healthcare system is leveraging telehealth to provide continued access to care for rural veterans. J Rural Health. 2021;37(1):194-196. doi:10.1111/jrh.12449
  19. Hale-Gallardo JL, Kreider CM, Jia H, et al. Telerehabilitation for rural veterans: a qualitative assessment of barriers and facilitators to implementation. J Multidiscip Healthc. 2020;13:559-570. doi:10.2147/JMDH.S247267
  20. Kreider CM, Hale-Gallardo J, Kramer JC, et al. Providers’ shift to telerehabilitation at the U.S. Veterans Health Administration during COVID-19: practical applications. Front Public Health. 2022;10:831762. doi:10.3389/fpubh.2022.831762
  21. Cowper-Ripley DC, Jia H, Wang X, et al. Trends in VA telerehabilitation patients and encounters over time and by rurality. Fed Pract. 2019;36(3):122-128.
  22. US Dept of Veterans Affairs, Office of Rural Health. VHA Office of Rural Health. Updated August 30, 2024. Accessed September 23, 2024. https://www.ruralhealth.va.gov/index.asp
  23. National Center for Veterans Analysis and Statistics. Rural Veterans: 2021-2023. April 2023. Accessed September 23, 2024. https://www.datahub.va.gov/stories/s/Rural-Veterans-FY2021-2023/kkh2-eymp/
  24. U.S. Department of Veterans Affairs, Office of Research & Development. Program Guide: 1200.21, VHA Operations Activities That May Constitute Research. January 9, 2019. https://www.research.va.gov/resources/policies/ProgramGuide-1200-21-VHA-Operations-Activities.pdf
  25. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. J Nurs Care Qual. 2016;31(1):1-8. doi:10.1097/NCQ.0000000000000153
  26. US Dept of Veterans Affairs. Veterans Health Administration: Veterans Integrated Service Networks (VISNs). Updated January 29, 2024. Accessed September 23, 2024. https://www.va.gov/HEALTH/visns.asp
  27. Stomberg C, Frost A, Becker C, Stang H, Windschitl M, Carrier E. Community Care referral dashboard [Data dashboard]. https://app.powerbigov.us/groups/me/reports/090d22a7-0e1f-4cc5-bea8-0a1b87aa0bd9/ReportSectionacfd03cdebd76ffca9ec [Source not verified]
  28. US Dept of Veterans Affairs. Eligibility for community care outside VA. Updated May 30, 2024. Accessed September 23, 2024. https://www.va.gov/COMMUNITYCARE/programs/veterans/General_Care.asp
  29. US Department of Veterans Affairs, Office of Rural Health. How to define rurality fact sheet. Updated December 2023. Accessed January 28, 2025. https://www.ruralhealth.va.gov/docs/ORH_RuralityFactSheet_508.pdf
  30. Rural-Urban Commuting Area Codes. Economic Research Service, US Dept of Agriculture. Updated September 25, 2023. Accessed September 23, 2024. https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes.aspx
  31. Gurewich D, Beilstein-Wedel E, Shwartz M, Davila H, Rosen AK. Disparities in wait times for care among US veterans by race and ethnici t y. JAMA Netw Open. 2023;6(1):e2252061. doi:10.1001/jamanetworkopen.2022.52061
  32. U.S. Department of Veterans Affairs, VA Office of Rural Health, Veterans Rural Health Resource Center-Gainesville, GeoSpatial Outcomes Division. VA and Community Healthcare, and VHA Rurality web map application. Published 2023. https://portal.vhagis.inv.vaec.va.gov/arcgis/apps/webappbuilder/index.html [source not verified]
  33. Chartbook on Healthcare for Veterans: National Healthcare Quality and Disparities Report. Agency for Healthcare Research and Quality; November 2020. Accessed September 23, 2024. https://www.ahrq.gov/research/findings/nhqrdr/chartbooks/veterans/index.html
  34. Lum HD, Nearing K, Pimentel CB, Levy CR, Hung WW. Anywhere to anywhere: use of telehealth to increase health care access for older, rural veterans. Public Policy Aging Rep. 2020;30(1):12-18. doi:10.1093/ppar/prz030
  35. Goulet JL, Kerns RD, Bair M, et al. The musculoskeletal diagnosis cohort: examining pain and pain care among veterans. Pain. 2016;157(8):1696-1703. doi:10.1097/j.pain.0000000000000567
  36. US Inflation Calculator. Health Care Inflation in the United States (1948-2024). Accessed September 23, 2024. https://www.usinflationcalculator.com/inflation/health-care-inflation-in-the-united-states/
  37. Cottrell MA, Galea OA, O’Leary SP, Hill AJ, Russell TG. Real-time telerehabilitation for the treatment of musculoskeletal conditions is effective and comparable to standard practice: a systematic review and meta-analysis. Clin Rehabil. 2017;31(5):625-638. doi:10.1177/0269215516645148
  38. Elor A, Conde S, Powel l M, Robbins A, Chen NN, Kurniawan S. Physical therapist impressions of telehealth and virtual reality needs amidst a pandemic. Front Virtual Real. 2022;3. doi:10.3389/frvir.2022.915332
  39. Lee AC, Harada N. Telehealth as a means of health care delivery for physical therapist practice. Phys Ther. 2012;92(3):463-468. doi:10.2522/ptj.20110100
  40. Hynes DM, Edwards S, Hickok A, et al. Veterans’ use of Veterans Health Administration primary care in an era of expanding choice. Med Care. 2021;59(Suppl 3):S292- S300. doi:10.1097/MLR.0000000000001554
Article PDF
Author and Disclosure Information

Kelsea LeBeau, PhD, MPHa; Zaccheus J. Ahonle, PhD, CRCa,b; Sharon N. Mburu, PT, MSa,c; Sergio Romero, PhDa; Keith J. Myers, DPT, MBAa

Author affiliations:
aVeterans Rural Health Resource Center, Gainesville, Florida
bMississippi State University, Starkville
cUniversity of Florida, Gainesville

Author disclosures: The authors report no actual or potential conflicts of interest concerning this article.

Correspondence: Kelsea LeBeau ([email protected])

Fed Pract. 2025;42(2). Published online February 18. doi:10.12788/fp.0556

Issue
Federal Practitioner - 42(2)
Publications
Topics
Page Number
1-15
Sections
Author and Disclosure Information

Kelsea LeBeau, PhD, MPHa; Zaccheus J. Ahonle, PhD, CRCa,b; Sharon N. Mburu, PT, MSa,c; Sergio Romero, PhDa; Keith J. Myers, DPT, MBAa

Author affiliations:
aVeterans Rural Health Resource Center, Gainesville, Florida
bMississippi State University, Starkville
cUniversity of Florida, Gainesville

Author disclosures: The authors report no actual or potential conflicts of interest concerning this article.

Correspondence: Kelsea LeBeau ([email protected])

Fed Pract. 2025;42(2). Published online February 18. doi:10.12788/fp.0556

Author and Disclosure Information

Kelsea LeBeau, PhD, MPHa; Zaccheus J. Ahonle, PhD, CRCa,b; Sharon N. Mburu, PT, MSa,c; Sergio Romero, PhDa; Keith J. Myers, DPT, MBAa

Author affiliations:
aVeterans Rural Health Resource Center, Gainesville, Florida
bMississippi State University, Starkville
cUniversity of Florida, Gainesville

Author disclosures: The authors report no actual or potential conflicts of interest concerning this article.

Correspondence: Kelsea LeBeau ([email protected])

Fed Pract. 2025;42(2). Published online February 18. doi:10.12788/fp.0556

Article PDF
Article PDF

 

The Veterans Health Administration (VHA) is the largest US integrated health system, providing care to veterans through VHA and non-VHA practitioners and facilities.1,2 Providing high-quality, timely, and veteran-centric care remains a priority for the VHA. Legislative efforts have expanded opportunities for eligible veterans to receive care in the community purchased by VHA, known as community care (CC).1 The Veterans Access, Choice, and Accountability Act of 2014 came in response to reports of long wait times and drive times for patients.3-5 The MISSION Act of 2018 expanded access to CC by streamlining it and broadening eligibility criteria, especially for veterans in rural communities who often experience more barriers in accessing care than veterans living in urban communities.1,6-10 Since the implementation of the Choice and MISSION Acts, > 2.7 million veterans have received care through community practitioners within the VHA CC network.11

Background

Increased access to CC could benefit veterans living in rural communities by increasing care options and circumventing challenges to accessing VHA care (ie, geographic, transportation, and distance barriers, practitioner and specialist shortages, and hospital closures). 5,9,10,12,13 However, health care system deficits in rural areas could also limit CC effectiveness for veterans living in those communities. 3 Other challenges posed by using CC include care coordination, information sharing, care continuity, delayed payments to CC practitioners, and mixed findings regarding CC quality.5,8,13,14 VHA practitioners are specifically trained to meet the multifaceted needs unique to veterans’ health and subculture, training CC practitioners may not receive.5,15

CC offers services for primary care and a broad range of specialties, including rehabilitation services such as physical therapy (PT).6 PT is used for the effective treatment of various conditions veterans experience and promote wellbeing and independence.16 US Department of Veterans Affairs (VA) databases reveal a high prevalence of veterans receiving PT services through CC; PT is one of the most frequently used CC outpatient specialty services by veterans living in rural communities.14,17

Telerehabitltation Enterprisewide Initiative

VHA has greatly invested in delivering care virtually, especially for veterans living in rural communities.18 In 2017, the VHA Office of Rural Health funded the Telerehabilitation Enterprise-Wide Initiative (TR-EWI) in partnership with the Physical Medicine and Rehabilitation Services national program office to increase access to specialized rehabilitation services for veterans living in rural communities by leveraging telehealth technologies.18-21 This alternative mode of health care delivery allows clinicians to overcome access barriers by delivering rehabilitation therapies directly to veterans' homes or nearby community-based outpatient clinics. TR-EWI was conceived as a hub-and-spoke model, where rehabilitation expertise at the hub was virtually delivered to spoke sites that did not have in-house expertise. In subsequent years, the TR-EWI also evolved to provide targeted telerehabilitation programs within rural-serving community-based outpatient clinics, including PT as a predominant service.19,20

As TR-EWI progressed—and in conjunction with the uptake of telehealth across VHA during the COVID-19 pandemic—there has been increased focus on PT telerehabilitation, especially for the 4.6 million veterans in rural communities.18,22,23 Because health care delivery system deficits in rural areas could limit the effective use of CC, many TR-EWI sites hope to reduce their CC referrals by providing telehealth PT services to veterans who might otherwise need to be referred to CC. This strategy aligns with VHA goals of providing high-quality and timely care. To better understand opportunities for programs like TR-EWI to provide rehabilitation services for veterans and reduce care sent to the community, research that examines CC referral trends for PT over time is warranted.

This study examines CC from a rehabilitation perspective with a focus on CC referral trends for PT, specifically for Veterans Integrated Service Networks (VISNs) where TREWI sites are located. The study’s objectives were to describe rehabilitation PT services being referred to CC and examine associated CC costs for PT services. Two research questions guided the study. First, what are the utilization trends for CC PT referrals from fiscal year (FY) 2019 to FY 2022? Secondly, what is the cost breakdown of CC for PT referrals from FY 2020 to FY 2022?

Methods

This study was conducted by a multidisciplinary team comprised of public health, disability, rehabilitation counseling, and PT professionals. It was deemed a quality improvement project under VA guidance and followed the SQUIRE guidelines for quality improvement reporting.24,25 The study used the VA Common Operating Platform (Palantir) to obtain individual-level CC referral data from the HealthShare Referral Manager (HSRM) database and consult data from the Computerized Patient Record System. Palantir is used to store and integrate VA data derived from the VA Corporate Data Warehouse and VHA Support Service Center. Referrals are authorizations for care to be delivered by a CC practitioner.

TR-EWI is comprised of 7 sites: VISN 2, VISN 4, VISN 8, VISN 12, VISN 15, VISN 19, and VISN 22. Each site provides telerehabilitation services with an emphasis on reaching veterans living in rural communities. We joined the referrals and consults cubes in Palantir to extract PT referrals for FY 2019 to FY 2022 for the 7 VISNs with TR-EWI sites and obtain referral-specific information and demographic characteristics. 26 Data were extracted in October 2022.

The VHA Community Care Referral Dashboard (CC Dashboard) provided nonindividual level CC cost data.27 The CC Dashboard provides insights into the costs of CC services for VHA enrollees by category of care, standardized episode of care, and eligibility. Data are based on nationallevel HSRM referrals that are not suspended or linked to a canceled or discontinued consult. Data were aggregated by VISN. The dashboard only includes referrals dating back to FY 2020; therefore, PT data from FY 2020 through FY 2022 for VISNs with TR-EWI sites were collected. Data were extracted in December 2022.

This study examined CC referrals, station name, eligibility types, clinical diagnoses (International Classification of Diseases, Tenth Revision codes), and demographic information in the Palantir dataset. Six eligibility criteria can qualify a veteran to receive CC.28 Within clinical diagnoses, the variable of interest was the provisional diagnosis. Patient demographics included age, gender, and rurality of residence, as determined by the Rural-Urban Commuting Area system.29,30 Rural and highly rural categories were combined for analysis. For the CC cost dataset, this study examined CC referrals, referral cost, and eligibility type.

Analysis

For the first research question, we examined referral data from FY 2019 to FY 2022 using the Palantir dataset, performed descriptive statistical analysis for all variables, and analyzed data to identify trends. Descriptive statistics were completed using IBM SPSS Statistics for Windows Version 29.0.0.0.

A qualitative analysis of provisional diagnosis data revealed what is being referred to CC for PT. A preliminary overview of provisional diagnosis data was conducted to familiarize coders with the data. We developed a coding framework to categorize diagnoses based on anatomical location, body structure, and clinical areas of interest. Data were reviewed individually and grouped into categories within the coding framework before meeting as a team to achieve group consensus on categorization. We then totaled the frequency of occurrence for provisional diagnoses within each category. Qualitative analyses were completed using Microsoft Excel.

For the second research question, the study used the CC cost dataset to examine the cost breakdown of CC PT referrals from FY 2020 to FY 2022. We calculated the number and cost of PT referrals across eligibility groups for each FY and VISN. Data were analyzed using SPSS to identify cost trends.

Results

There were 344,406 referrals to CC for PT from FY 2019 to FY 2022 for the 7 VISNs analyzed (Table 1). Of these, 22.5% were from FY 2019, 19.1% from FY 2020, 28.2% from FY 2021, and 30.3% from FY 2022. VISN 8 and VISN 22 reported the most overall PT referrals, with VISN 8 comprising 22.2% and VISN 22 comprising 18.1% of all referrals. VISN 2 reported the least overall referrals (3.7%). VISN 4 and VISN 12 had decreases in referrals over time. VISN 2 and VISN 15 had decreases in referrals from FY 2019 to FY 2021 and slight increases from FY 2021 to FY 2022. VISN 19 and VISN 22 both saw slight increases from FY 2019 to FY 2020 and substantial increases from FY 2020 to FY 2022, with FY 2022 accounting for 40.0% and 42.3% of all referrals for VISN 19 and VISN 20, respectively (Figure 1).

0225FED-ePT-T10225FED-ePT-F1

For FY 2019 and FY 2020, VISN 8 had the highest percentage of referrals (26.7% and 23.2%, respectively), whereas VISN 22 was among the lowest (7.3% and 11.4%, respectively). However, for FY 2021 and FY 2022, VISN 22 reported the highest percentage of referrals (23.5% and 25.3%, respectively) compared to all other VISNs. VISN 2 consistently reported the lowest percentage of referrals across all years.

There were 56 stations analyzed across the 7 VISNs (Appendix 1). Nine stations each accounted for ≥ 3.0% of the total PT referrals and only 2 stations accounted for > 5.0% of referrals. Orlando, Florida (6.0%), Philadelphia, Pennsylvania (5.2%), Tampa, Florida (4.9%), Aurora, Colorado (4.9%), and Gainesville, Florida (4.4%) reported the top 5 highest referrals, with 3 being from VISN 8 (Orlando, Tampa, Gainesville). Stations with the lowest reported referrals were all in VISN 2 in New York: The Bronx, (0%), New York Harbor (0%), Hudson Valley (0.1%) and Finger Lakes (0.2%).

0225FED-ePT-A1
Rurality

Urban stations comprised 56.2% and rural stations comprised 39.8% of PT CC referrals, while 0.2% of referrals were from insular isle US territories: Guam, American Samoa, Northern Marianas, and the Virgin Islands. The sample had missing or unknown data for 3.8% of referrals. FY 2022 had the largest difference in rural and urban referrals. Additionally, there was an overall trend of more referrals over time for rural and urban, with a large increase in rural (+40.0%) and urban (+62.7%) referrals from FY 2020 to FY 2021 and a modest increase from FY 2021 to FY 2022 (+5.2% for rural and +9.1% for urban). There was a decrease in rural (-7.0%) and urban (-3.5%) referrals from FY 2019 to FY 2020 (Figure 2).

0225FED-ePT-F2

There were differences in referrals by rurality and VISN (Table 2). VISN 12, VISN 15, and VISN 19 reported more rural than urban referrals, whereas VISN 4, VISN 8, and VISN 22 reported more urban than rural referrals. VISN 2 reported similar numbers for both, with slightly more urban than rural referrals. When reviewing trends over time for each FY, VISN 12, VISN 15, and VISN 19 reported more rural than urban referrals and VISN 4, VISN 8, and VISN 22 had more urban than rural referrals. In FY 2019 and FY 2020, VISN 2 reported slightly more urban than rural referrals but almost the same number of referrals in FY 2021 and FY 2022 (Appendix 2).

0225FED-ePT-T20225FED-ePT-A2
Demographics

The mean (SD) age was 61.2 (15.8) years (range, 20-105). Most PT CC referrals were for veterans aged 70 to 79 years (26.9%), followed by 60 to 69 years (20.7%), and 50 to 59 years (16.4%) (Appendix 3). Trends were consistent across VISNs. There was less of a difference between rural and urban referral percentages as the population aged. Veterans aged < 49 years residing in more urban areas accounted for more referrals to CC compared to their rural counterparts. This difference was less apparent in the 70 to 79 years and 80 to 89 years age brackets.

0225FED-ePT-A3

Most PT CC referrals (81.2%) were male and 14.8% were female. About 3.6% of referral data were missing sex information, and there was a smaller difference between male veterans living in rural communities and male veterans living in urban communities compared with female veterans. A total of 42.9% of male veterans resided in rural areas compared to 56.8% in urban areas; 32.7% of female veterans resided in rural areas compared to 66.9% in urban areas (Appendix 3).

Other Criteria

Of the 334,406 referrals, 114,983 (34.4%) had eligibility data, mostly from FY 2021 and FY 2022 (Table 3). Available eligibility data were likely affected by the MISSION Act and new regulations for reporting CC eligibility. Distance (33.4%) was the most common eligibility criteria, followed by timeliness of care (28.8%), and best medical interest (19.8%); 40.4% were rural and 59.5% were urban. Distance (55.4%) was most common for rural veterans, while timeliness of care (39.7%) was most common for urban veterans. For both groups, the second most common eligibility reason was best medical interest (Appendix 4).

0225FED-ePT-T30225FED-ePT-A4

Bone, joint, or soft tissue disorders were common diagnoses, with 25.2% located in the lower back, 14.7% in the shoulder, and 12.8% in the knee (Appendix 5). Amputations of the upper and lower limbs, fractures, cancer-related diagnoses, integumentary system disorders, thoracic and abdominal injuries and disorders, and other medical and mental health conditions each accounted for < 1% of the total diagnoses.

0225FED-ePT-A5
Costs

At time of analysis, the CC Dashboard had cost data available for 200,204 CC PT referrals from FY 2020 to FY 2022. The difference in referral numbers for the 2 datasets is likely attributed to several factors: CC cost data is exclusively from the HSRM, whereas Palantir includes other data sources; how VA cleans data pulled into Palantir; how the CC Dashboard algorithm populates data; and variances based on timing of reporting and/or if referrals are eventually canceled.

The total cost of PT CC referrals from FY 2020 to FY 2022 in selected VISNs was about $220,615,399 (Appendix 6). Appendix 7 details the methodology for determining the average standardized episode- of-care cost by VISN and how referral costs are calculated. Data show a continuous increase in total estimated cost from $46.8 million in FY 2020 to $92.1 million in FY 2022. From FY 2020 to FY 2022, aggregate costs ranged from $6,758,053 in VISN 2 to $47,209,162 in VISN 8 (Figure 3). The total referral cost for PT was highest at VISN 4 in FY 2020 ($10,447,140) and highest at VISN 22 in FY 2021 ($18,835,657) and FY 2022 ($22,962,438) (Figure 4). For referral costs from FY 2020 to FY 2022, distance accounted for $75,561,948 (34.3%), timeliness of care accounted for $60,413,496 (27.3%), and best medical interest accounted for $46,291,390 (21.0%) (Table 4).

0225FED-ePT-A70225FED-ePT-A6

 

0225FED-ePT-F30225FED-ePT-F40225FED-ePT-T4

Overall costs were primarily driven by specific VISNs within each eligibility type (Appendix 8; Figure 5). VISN 19, VISN 22, and VISN 15 accounted for the highest referral costs for distance; VISN 22, VISN 8, and VISN 19 accounted for the secondhighest referral cost, timeliness of care; and VISN 4, VISN 8, and VISN 12 accounted for the third-highest referral cost, best medical interest (Figure 5). VISN 2, VISN 4, VISN 12, VISN 15, and VISN 22 had service unavailable as an eligibility type with 1 of the top 3 associated referral costs, which was higher in cost than timeliness of care for VISN 2, VISN 4, VISN 12, and VISN 15.

0225FED-ePT-A280225FED-ePT-F5

Discussion

This study examines the referral of rehabilitation PT services to CC, evaluates CC costs for PT services, and analyzes utilization and cost trends among veterans within the VHA. Utilization data demonstrated a decrease in referrals from FY 2019 to FY 2020 and increases in referrals from FY 2020 to FY 2022 for most variables of interest, with cost data exhibiting similar trends. Results highlight the need for further investigation to address variations in PT referrals and costs across VISNs and eligibility reasons for CC referral.

Results demonstrated a noteworthy increase in PT CC referrals over time. The largest increase occurred from FY 2020 to FY 2021, with a smaller increase from FY 2021 to FY 2022. During this period, total enrollee numbers decreased by 3.0% across the 7 VISNs included in this analysis and by 1.6% across all VISNs, a trend that illustrates an overall decrease in enrollees as CC use increased. Results align with the implementation of the MISSION Act of 2018, which further expanded veterans’ options to use CC.1,6,7 Results also align with the onset of the COVID-19 pandemic, which disrupted care access for many veterans, placed a larger emphasis on the use of telehealth, and increased opportunities to stay within the VA for care by rapidly shifting to telehealth and leveraging telerehabilitation investments and initiatives (such as TR-EWI).20,31

VISN 8, VISN 19, and VISN 22, accounted for more than half of PT referrals. These VISNs had higher enrollee counts compared to the other VISNs.32 VISN 8 consistently had high levels of referrals, whereas VISN 19 and VISN 22 saw dramatic increases in FY 2021 and FY 2022. In contrast, VISN 4 and VISN 12 gradually decreased referrals during the study. VISN 2 had the lowest referral numbers during the study period, and all stations with the lowest individual referral numbers were located within VISN 2. Of the VISNs included in this study, VISN 2 had the second lowest number of enrollees (324,042).32 Reasons for increases and decreases over time could not be determined based on data collected in this study.

There were more urban than rural PT CC referrals; however, both exhibited an increase in referrals over time. This is consistent with population trends showing that most VHA patients (62.6%) and veterans (75.9%) reside in urban areas, which could explain some of the trends in this study.33 Some VISNs have larger urban catchment areas (eg, VISN 8 and VISN 22), and some have larger rural catchment areas (eg, VISN 15 and VISN 19), which could partially explain the rural-urban differences by VISN.32 Rural-urban referral trends might also reflect existing health care delivery system deficits in rural areas and known challenges associated with accessing health care for veterans living in rural communities.8,9

This study found larger differences in rural and urban PT CC referrals for younger age groups, with more than twice as many urban referrals in veterans aged 20 to 29 years and aged 30 to 39 years, and roughly 1.8 times as many urban referrals in veterans aged 40 to 49 years. However, there were similar numbers of rural and urban referrals in those aged 70 to 79 years and aged 80 to 89 years. These trends are consistent with data showing veterans residing in rural communities are older than their urban counterparts.23,34 Data suggest that older veteran populations might seek PT at higher rates than younger veteran populations. Moreover, data suggest there could be differences in PT-seeking rates for younger veteran populations who reside in rural vs urban areas. Additional research is needed to understand these trends.

Distance and timeliness of care were the predominant reasons for referral among eligibility groups, which is consistent with the MISSION Act goals.1,6,7 The most common eligibility reason for rural referrals was distance; timeliness of care was most common for urban referrals. This finding is expected, as veterans living in rural communities are farther away from VHA facilities and have longer drive times, whereas veterans living in urban communities might live closer, yet experience longer wait times due to services and/or appointment availability. Best medical interest accounted for almost 20% of referrals, which does not provide detailed insights into why those veterans were referred to CC.

The top PT diagnoses referred to CC were related to bone, joint, or soft tissue disorders of the lower back, shoulder, and knee. This suggests that musculoskeletal-related issues are prevalent among veterans seeking PT care, which is consistent with research that found > 50% of veterans receiving VHA care have musculoskeletal disorders.35 The probability of experiencing musculoskeletal problems increases with age, as does the need for PT services. Amputations and fractures accounted for < 1% of CC referrals, which is consistent with the historic provision of VHA clinical specialized care to conditions prevalent among veterans. It may also represent VHA efforts to internally provide care for complex conditions requiring more extensive interdisciplinary coordination.

The total cost of referrals over time was about $221 million. VISN 8 accounted for the highest overall cost; VISN 2 had the lowest, mirroring referral utilization trends and aligning with VISN enrollee numbers. VISN 19 and VISN 22 reported large cost increases from FY 2020 to FY 2021. Total referral costs increased by $34.9 million from FY 2020 to FY 2021, which may be due to health care inflation (2.9% during FY 2019 to FY 2022), increased awareness of CC services, or increased VHA wait times.36 Additionally, there were limitations in care provided across health care systems during the COVID-19 pandemic, including the VA.5 The increase from FY 2020 to FY 2021 may reflect a rebound from restrictions in appointments across VA, CC, and the private sector.

While the increase in total referral cost may be partly attributed to inflation, the cost effectiveness and efficiency of referring veterans to CC vs keeping veterans within VHA care is an ongoing debate.5 Examining and addressing cost drivers within the top eligibility types and their respective VISNs is necessary to determine resource allocation and improve quality of care. This study found that best medical interest and unavailable services accounted for 33.4% of the total cost of CC referrals, highlighting the need for policies that strengthen in-house competencies and recruit personnel to provide PT services currently unavailable within the VA.

Future Directions

The VHA should explore opportunities for in-house care, especially for services appropriate for telehealth.18,20,37 Data indicated a smaller cost increase from FY 2021 to FY 2022 compared to the relatively large increase from FY 2020 to FY 2021. The increased telehealth usage across VHA by TR-EWI and non—TR-EWI sites within selected VISNs may have contributed to limiting the increase in CC costs. Future studies should investigate contextual factors of increased telehealth usage, which would offer guidance for implementation to optimize the integration of telehealth with PT rehabilitation provided in-house. Additionally, future studies can examine potential limitations experienced during PT telehealth visits, such as the inability to conduct hands-on assessments, challenges in viewing the quality of patient movement, ensuring patient safety in the remote environment, and the lack of PT equipment in homes for telehealth visits, and how these challenges are being addressed.38,39 Research is also needed to understand tradeoffs of CC vs VHA care and the potential and cost benefits of keeping veterans within VHA using programs like TR-EWI.5 Veterans living in rural communities may especially benefit from this as expanding telehealth options can provide access to PT care that may not be readily available, enabling them to stay connected and engaged in their care.18,40

Future studies could examine contributory factors to rising costs, such as demographic shifts, changes in PT service utilization, and policy. Researchers might also consider qualitative studies with clinicians and veterans within each VISN, which may provide insights into how local factors impact PT referral to the community.

Limitations

Due to its descriptive nature, this study can only speculate about factors influencing trends. Limitations include the inability to link the Palantir and CC Dashboard datasets for cost comparisons and potential data change over time on Palantir due to platform updates. The focus on VISNs with TREWI sites limited generalizability and this study did not compare CC PT vs VHA PT. Finally, there may have been cost drivers not identified in this study.

Conclusions

This descriptive study provides insights into the utilization and cost of PT CC referrals for selected VISNs. Cost trends underscore the financial commitment to providing PT services to veterans. Understanding what factors are driving this cost is necessary for VHA to optimally provide and manage the rehabilitation resources needed to serve veterans through traditional in-person care, telehealth, and CC options while ensuring timely, highquality care.

 

The Veterans Health Administration (VHA) is the largest US integrated health system, providing care to veterans through VHA and non-VHA practitioners and facilities.1,2 Providing high-quality, timely, and veteran-centric care remains a priority for the VHA. Legislative efforts have expanded opportunities for eligible veterans to receive care in the community purchased by VHA, known as community care (CC).1 The Veterans Access, Choice, and Accountability Act of 2014 came in response to reports of long wait times and drive times for patients.3-5 The MISSION Act of 2018 expanded access to CC by streamlining it and broadening eligibility criteria, especially for veterans in rural communities who often experience more barriers in accessing care than veterans living in urban communities.1,6-10 Since the implementation of the Choice and MISSION Acts, > 2.7 million veterans have received care through community practitioners within the VHA CC network.11

Background

Increased access to CC could benefit veterans living in rural communities by increasing care options and circumventing challenges to accessing VHA care (ie, geographic, transportation, and distance barriers, practitioner and specialist shortages, and hospital closures). 5,9,10,12,13 However, health care system deficits in rural areas could also limit CC effectiveness for veterans living in those communities. 3 Other challenges posed by using CC include care coordination, information sharing, care continuity, delayed payments to CC practitioners, and mixed findings regarding CC quality.5,8,13,14 VHA practitioners are specifically trained to meet the multifaceted needs unique to veterans’ health and subculture, training CC practitioners may not receive.5,15

CC offers services for primary care and a broad range of specialties, including rehabilitation services such as physical therapy (PT).6 PT is used for the effective treatment of various conditions veterans experience and promote wellbeing and independence.16 US Department of Veterans Affairs (VA) databases reveal a high prevalence of veterans receiving PT services through CC; PT is one of the most frequently used CC outpatient specialty services by veterans living in rural communities.14,17

Telerehabitltation Enterprisewide Initiative

VHA has greatly invested in delivering care virtually, especially for veterans living in rural communities.18 In 2017, the VHA Office of Rural Health funded the Telerehabilitation Enterprise-Wide Initiative (TR-EWI) in partnership with the Physical Medicine and Rehabilitation Services national program office to increase access to specialized rehabilitation services for veterans living in rural communities by leveraging telehealth technologies.18-21 This alternative mode of health care delivery allows clinicians to overcome access barriers by delivering rehabilitation therapies directly to veterans' homes or nearby community-based outpatient clinics. TR-EWI was conceived as a hub-and-spoke model, where rehabilitation expertise at the hub was virtually delivered to spoke sites that did not have in-house expertise. In subsequent years, the TR-EWI also evolved to provide targeted telerehabilitation programs within rural-serving community-based outpatient clinics, including PT as a predominant service.19,20

As TR-EWI progressed—and in conjunction with the uptake of telehealth across VHA during the COVID-19 pandemic—there has been increased focus on PT telerehabilitation, especially for the 4.6 million veterans in rural communities.18,22,23 Because health care delivery system deficits in rural areas could limit the effective use of CC, many TR-EWI sites hope to reduce their CC referrals by providing telehealth PT services to veterans who might otherwise need to be referred to CC. This strategy aligns with VHA goals of providing high-quality and timely care. To better understand opportunities for programs like TR-EWI to provide rehabilitation services for veterans and reduce care sent to the community, research that examines CC referral trends for PT over time is warranted.

This study examines CC from a rehabilitation perspective with a focus on CC referral trends for PT, specifically for Veterans Integrated Service Networks (VISNs) where TREWI sites are located. The study’s objectives were to describe rehabilitation PT services being referred to CC and examine associated CC costs for PT services. Two research questions guided the study. First, what are the utilization trends for CC PT referrals from fiscal year (FY) 2019 to FY 2022? Secondly, what is the cost breakdown of CC for PT referrals from FY 2020 to FY 2022?

Methods

This study was conducted by a multidisciplinary team comprised of public health, disability, rehabilitation counseling, and PT professionals. It was deemed a quality improvement project under VA guidance and followed the SQUIRE guidelines for quality improvement reporting.24,25 The study used the VA Common Operating Platform (Palantir) to obtain individual-level CC referral data from the HealthShare Referral Manager (HSRM) database and consult data from the Computerized Patient Record System. Palantir is used to store and integrate VA data derived from the VA Corporate Data Warehouse and VHA Support Service Center. Referrals are authorizations for care to be delivered by a CC practitioner.

TR-EWI is comprised of 7 sites: VISN 2, VISN 4, VISN 8, VISN 12, VISN 15, VISN 19, and VISN 22. Each site provides telerehabilitation services with an emphasis on reaching veterans living in rural communities. We joined the referrals and consults cubes in Palantir to extract PT referrals for FY 2019 to FY 2022 for the 7 VISNs with TR-EWI sites and obtain referral-specific information and demographic characteristics. 26 Data were extracted in October 2022.

The VHA Community Care Referral Dashboard (CC Dashboard) provided nonindividual level CC cost data.27 The CC Dashboard provides insights into the costs of CC services for VHA enrollees by category of care, standardized episode of care, and eligibility. Data are based on nationallevel HSRM referrals that are not suspended or linked to a canceled or discontinued consult. Data were aggregated by VISN. The dashboard only includes referrals dating back to FY 2020; therefore, PT data from FY 2020 through FY 2022 for VISNs with TR-EWI sites were collected. Data were extracted in December 2022.

This study examined CC referrals, station name, eligibility types, clinical diagnoses (International Classification of Diseases, Tenth Revision codes), and demographic information in the Palantir dataset. Six eligibility criteria can qualify a veteran to receive CC.28 Within clinical diagnoses, the variable of interest was the provisional diagnosis. Patient demographics included age, gender, and rurality of residence, as determined by the Rural-Urban Commuting Area system.29,30 Rural and highly rural categories were combined for analysis. For the CC cost dataset, this study examined CC referrals, referral cost, and eligibility type.

Analysis

For the first research question, we examined referral data from FY 2019 to FY 2022 using the Palantir dataset, performed descriptive statistical analysis for all variables, and analyzed data to identify trends. Descriptive statistics were completed using IBM SPSS Statistics for Windows Version 29.0.0.0.

A qualitative analysis of provisional diagnosis data revealed what is being referred to CC for PT. A preliminary overview of provisional diagnosis data was conducted to familiarize coders with the data. We developed a coding framework to categorize diagnoses based on anatomical location, body structure, and clinical areas of interest. Data were reviewed individually and grouped into categories within the coding framework before meeting as a team to achieve group consensus on categorization. We then totaled the frequency of occurrence for provisional diagnoses within each category. Qualitative analyses were completed using Microsoft Excel.

For the second research question, the study used the CC cost dataset to examine the cost breakdown of CC PT referrals from FY 2020 to FY 2022. We calculated the number and cost of PT referrals across eligibility groups for each FY and VISN. Data were analyzed using SPSS to identify cost trends.

Results

There were 344,406 referrals to CC for PT from FY 2019 to FY 2022 for the 7 VISNs analyzed (Table 1). Of these, 22.5% were from FY 2019, 19.1% from FY 2020, 28.2% from FY 2021, and 30.3% from FY 2022. VISN 8 and VISN 22 reported the most overall PT referrals, with VISN 8 comprising 22.2% and VISN 22 comprising 18.1% of all referrals. VISN 2 reported the least overall referrals (3.7%). VISN 4 and VISN 12 had decreases in referrals over time. VISN 2 and VISN 15 had decreases in referrals from FY 2019 to FY 2021 and slight increases from FY 2021 to FY 2022. VISN 19 and VISN 22 both saw slight increases from FY 2019 to FY 2020 and substantial increases from FY 2020 to FY 2022, with FY 2022 accounting for 40.0% and 42.3% of all referrals for VISN 19 and VISN 20, respectively (Figure 1).

0225FED-ePT-T10225FED-ePT-F1

For FY 2019 and FY 2020, VISN 8 had the highest percentage of referrals (26.7% and 23.2%, respectively), whereas VISN 22 was among the lowest (7.3% and 11.4%, respectively). However, for FY 2021 and FY 2022, VISN 22 reported the highest percentage of referrals (23.5% and 25.3%, respectively) compared to all other VISNs. VISN 2 consistently reported the lowest percentage of referrals across all years.

There were 56 stations analyzed across the 7 VISNs (Appendix 1). Nine stations each accounted for ≥ 3.0% of the total PT referrals and only 2 stations accounted for > 5.0% of referrals. Orlando, Florida (6.0%), Philadelphia, Pennsylvania (5.2%), Tampa, Florida (4.9%), Aurora, Colorado (4.9%), and Gainesville, Florida (4.4%) reported the top 5 highest referrals, with 3 being from VISN 8 (Orlando, Tampa, Gainesville). Stations with the lowest reported referrals were all in VISN 2 in New York: The Bronx, (0%), New York Harbor (0%), Hudson Valley (0.1%) and Finger Lakes (0.2%).

0225FED-ePT-A1
Rurality

Urban stations comprised 56.2% and rural stations comprised 39.8% of PT CC referrals, while 0.2% of referrals were from insular isle US territories: Guam, American Samoa, Northern Marianas, and the Virgin Islands. The sample had missing or unknown data for 3.8% of referrals. FY 2022 had the largest difference in rural and urban referrals. Additionally, there was an overall trend of more referrals over time for rural and urban, with a large increase in rural (+40.0%) and urban (+62.7%) referrals from FY 2020 to FY 2021 and a modest increase from FY 2021 to FY 2022 (+5.2% for rural and +9.1% for urban). There was a decrease in rural (-7.0%) and urban (-3.5%) referrals from FY 2019 to FY 2020 (Figure 2).

0225FED-ePT-F2

There were differences in referrals by rurality and VISN (Table 2). VISN 12, VISN 15, and VISN 19 reported more rural than urban referrals, whereas VISN 4, VISN 8, and VISN 22 reported more urban than rural referrals. VISN 2 reported similar numbers for both, with slightly more urban than rural referrals. When reviewing trends over time for each FY, VISN 12, VISN 15, and VISN 19 reported more rural than urban referrals and VISN 4, VISN 8, and VISN 22 had more urban than rural referrals. In FY 2019 and FY 2020, VISN 2 reported slightly more urban than rural referrals but almost the same number of referrals in FY 2021 and FY 2022 (Appendix 2).

0225FED-ePT-T20225FED-ePT-A2
Demographics

The mean (SD) age was 61.2 (15.8) years (range, 20-105). Most PT CC referrals were for veterans aged 70 to 79 years (26.9%), followed by 60 to 69 years (20.7%), and 50 to 59 years (16.4%) (Appendix 3). Trends were consistent across VISNs. There was less of a difference between rural and urban referral percentages as the population aged. Veterans aged < 49 years residing in more urban areas accounted for more referrals to CC compared to their rural counterparts. This difference was less apparent in the 70 to 79 years and 80 to 89 years age brackets.

0225FED-ePT-A3

Most PT CC referrals (81.2%) were male and 14.8% were female. About 3.6% of referral data were missing sex information, and there was a smaller difference between male veterans living in rural communities and male veterans living in urban communities compared with female veterans. A total of 42.9% of male veterans resided in rural areas compared to 56.8% in urban areas; 32.7% of female veterans resided in rural areas compared to 66.9% in urban areas (Appendix 3).

Other Criteria

Of the 334,406 referrals, 114,983 (34.4%) had eligibility data, mostly from FY 2021 and FY 2022 (Table 3). Available eligibility data were likely affected by the MISSION Act and new regulations for reporting CC eligibility. Distance (33.4%) was the most common eligibility criteria, followed by timeliness of care (28.8%), and best medical interest (19.8%); 40.4% were rural and 59.5% were urban. Distance (55.4%) was most common for rural veterans, while timeliness of care (39.7%) was most common for urban veterans. For both groups, the second most common eligibility reason was best medical interest (Appendix 4).

0225FED-ePT-T30225FED-ePT-A4

Bone, joint, or soft tissue disorders were common diagnoses, with 25.2% located in the lower back, 14.7% in the shoulder, and 12.8% in the knee (Appendix 5). Amputations of the upper and lower limbs, fractures, cancer-related diagnoses, integumentary system disorders, thoracic and abdominal injuries and disorders, and other medical and mental health conditions each accounted for < 1% of the total diagnoses.

0225FED-ePT-A5
Costs

At time of analysis, the CC Dashboard had cost data available for 200,204 CC PT referrals from FY 2020 to FY 2022. The difference in referral numbers for the 2 datasets is likely attributed to several factors: CC cost data is exclusively from the HSRM, whereas Palantir includes other data sources; how VA cleans data pulled into Palantir; how the CC Dashboard algorithm populates data; and variances based on timing of reporting and/or if referrals are eventually canceled.

The total cost of PT CC referrals from FY 2020 to FY 2022 in selected VISNs was about $220,615,399 (Appendix 6). Appendix 7 details the methodology for determining the average standardized episode- of-care cost by VISN and how referral costs are calculated. Data show a continuous increase in total estimated cost from $46.8 million in FY 2020 to $92.1 million in FY 2022. From FY 2020 to FY 2022, aggregate costs ranged from $6,758,053 in VISN 2 to $47,209,162 in VISN 8 (Figure 3). The total referral cost for PT was highest at VISN 4 in FY 2020 ($10,447,140) and highest at VISN 22 in FY 2021 ($18,835,657) and FY 2022 ($22,962,438) (Figure 4). For referral costs from FY 2020 to FY 2022, distance accounted for $75,561,948 (34.3%), timeliness of care accounted for $60,413,496 (27.3%), and best medical interest accounted for $46,291,390 (21.0%) (Table 4).

0225FED-ePT-A70225FED-ePT-A6

 

0225FED-ePT-F30225FED-ePT-F40225FED-ePT-T4

Overall costs were primarily driven by specific VISNs within each eligibility type (Appendix 8; Figure 5). VISN 19, VISN 22, and VISN 15 accounted for the highest referral costs for distance; VISN 22, VISN 8, and VISN 19 accounted for the secondhighest referral cost, timeliness of care; and VISN 4, VISN 8, and VISN 12 accounted for the third-highest referral cost, best medical interest (Figure 5). VISN 2, VISN 4, VISN 12, VISN 15, and VISN 22 had service unavailable as an eligibility type with 1 of the top 3 associated referral costs, which was higher in cost than timeliness of care for VISN 2, VISN 4, VISN 12, and VISN 15.

0225FED-ePT-A280225FED-ePT-F5

Discussion

This study examines the referral of rehabilitation PT services to CC, evaluates CC costs for PT services, and analyzes utilization and cost trends among veterans within the VHA. Utilization data demonstrated a decrease in referrals from FY 2019 to FY 2020 and increases in referrals from FY 2020 to FY 2022 for most variables of interest, with cost data exhibiting similar trends. Results highlight the need for further investigation to address variations in PT referrals and costs across VISNs and eligibility reasons for CC referral.

Results demonstrated a noteworthy increase in PT CC referrals over time. The largest increase occurred from FY 2020 to FY 2021, with a smaller increase from FY 2021 to FY 2022. During this period, total enrollee numbers decreased by 3.0% across the 7 VISNs included in this analysis and by 1.6% across all VISNs, a trend that illustrates an overall decrease in enrollees as CC use increased. Results align with the implementation of the MISSION Act of 2018, which further expanded veterans’ options to use CC.1,6,7 Results also align with the onset of the COVID-19 pandemic, which disrupted care access for many veterans, placed a larger emphasis on the use of telehealth, and increased opportunities to stay within the VA for care by rapidly shifting to telehealth and leveraging telerehabilitation investments and initiatives (such as TR-EWI).20,31

VISN 8, VISN 19, and VISN 22, accounted for more than half of PT referrals. These VISNs had higher enrollee counts compared to the other VISNs.32 VISN 8 consistently had high levels of referrals, whereas VISN 19 and VISN 22 saw dramatic increases in FY 2021 and FY 2022. In contrast, VISN 4 and VISN 12 gradually decreased referrals during the study. VISN 2 had the lowest referral numbers during the study period, and all stations with the lowest individual referral numbers were located within VISN 2. Of the VISNs included in this study, VISN 2 had the second lowest number of enrollees (324,042).32 Reasons for increases and decreases over time could not be determined based on data collected in this study.

There were more urban than rural PT CC referrals; however, both exhibited an increase in referrals over time. This is consistent with population trends showing that most VHA patients (62.6%) and veterans (75.9%) reside in urban areas, which could explain some of the trends in this study.33 Some VISNs have larger urban catchment areas (eg, VISN 8 and VISN 22), and some have larger rural catchment areas (eg, VISN 15 and VISN 19), which could partially explain the rural-urban differences by VISN.32 Rural-urban referral trends might also reflect existing health care delivery system deficits in rural areas and known challenges associated with accessing health care for veterans living in rural communities.8,9

This study found larger differences in rural and urban PT CC referrals for younger age groups, with more than twice as many urban referrals in veterans aged 20 to 29 years and aged 30 to 39 years, and roughly 1.8 times as many urban referrals in veterans aged 40 to 49 years. However, there were similar numbers of rural and urban referrals in those aged 70 to 79 years and aged 80 to 89 years. These trends are consistent with data showing veterans residing in rural communities are older than their urban counterparts.23,34 Data suggest that older veteran populations might seek PT at higher rates than younger veteran populations. Moreover, data suggest there could be differences in PT-seeking rates for younger veteran populations who reside in rural vs urban areas. Additional research is needed to understand these trends.

Distance and timeliness of care were the predominant reasons for referral among eligibility groups, which is consistent with the MISSION Act goals.1,6,7 The most common eligibility reason for rural referrals was distance; timeliness of care was most common for urban referrals. This finding is expected, as veterans living in rural communities are farther away from VHA facilities and have longer drive times, whereas veterans living in urban communities might live closer, yet experience longer wait times due to services and/or appointment availability. Best medical interest accounted for almost 20% of referrals, which does not provide detailed insights into why those veterans were referred to CC.

The top PT diagnoses referred to CC were related to bone, joint, or soft tissue disorders of the lower back, shoulder, and knee. This suggests that musculoskeletal-related issues are prevalent among veterans seeking PT care, which is consistent with research that found > 50% of veterans receiving VHA care have musculoskeletal disorders.35 The probability of experiencing musculoskeletal problems increases with age, as does the need for PT services. Amputations and fractures accounted for < 1% of CC referrals, which is consistent with the historic provision of VHA clinical specialized care to conditions prevalent among veterans. It may also represent VHA efforts to internally provide care for complex conditions requiring more extensive interdisciplinary coordination.

The total cost of referrals over time was about $221 million. VISN 8 accounted for the highest overall cost; VISN 2 had the lowest, mirroring referral utilization trends and aligning with VISN enrollee numbers. VISN 19 and VISN 22 reported large cost increases from FY 2020 to FY 2021. Total referral costs increased by $34.9 million from FY 2020 to FY 2021, which may be due to health care inflation (2.9% during FY 2019 to FY 2022), increased awareness of CC services, or increased VHA wait times.36 Additionally, there were limitations in care provided across health care systems during the COVID-19 pandemic, including the VA.5 The increase from FY 2020 to FY 2021 may reflect a rebound from restrictions in appointments across VA, CC, and the private sector.

While the increase in total referral cost may be partly attributed to inflation, the cost effectiveness and efficiency of referring veterans to CC vs keeping veterans within VHA care is an ongoing debate.5 Examining and addressing cost drivers within the top eligibility types and their respective VISNs is necessary to determine resource allocation and improve quality of care. This study found that best medical interest and unavailable services accounted for 33.4% of the total cost of CC referrals, highlighting the need for policies that strengthen in-house competencies and recruit personnel to provide PT services currently unavailable within the VA.

Future Directions

The VHA should explore opportunities for in-house care, especially for services appropriate for telehealth.18,20,37 Data indicated a smaller cost increase from FY 2021 to FY 2022 compared to the relatively large increase from FY 2020 to FY 2021. The increased telehealth usage across VHA by TR-EWI and non—TR-EWI sites within selected VISNs may have contributed to limiting the increase in CC costs. Future studies should investigate contextual factors of increased telehealth usage, which would offer guidance for implementation to optimize the integration of telehealth with PT rehabilitation provided in-house. Additionally, future studies can examine potential limitations experienced during PT telehealth visits, such as the inability to conduct hands-on assessments, challenges in viewing the quality of patient movement, ensuring patient safety in the remote environment, and the lack of PT equipment in homes for telehealth visits, and how these challenges are being addressed.38,39 Research is also needed to understand tradeoffs of CC vs VHA care and the potential and cost benefits of keeping veterans within VHA using programs like TR-EWI.5 Veterans living in rural communities may especially benefit from this as expanding telehealth options can provide access to PT care that may not be readily available, enabling them to stay connected and engaged in their care.18,40

Future studies could examine contributory factors to rising costs, such as demographic shifts, changes in PT service utilization, and policy. Researchers might also consider qualitative studies with clinicians and veterans within each VISN, which may provide insights into how local factors impact PT referral to the community.

Limitations

Due to its descriptive nature, this study can only speculate about factors influencing trends. Limitations include the inability to link the Palantir and CC Dashboard datasets for cost comparisons and potential data change over time on Palantir due to platform updates. The focus on VISNs with TREWI sites limited generalizability and this study did not compare CC PT vs VHA PT. Finally, there may have been cost drivers not identified in this study.

Conclusions

This descriptive study provides insights into the utilization and cost of PT CC referrals for selected VISNs. Cost trends underscore the financial commitment to providing PT services to veterans. Understanding what factors are driving this cost is necessary for VHA to optimally provide and manage the rehabilitation resources needed to serve veterans through traditional in-person care, telehealth, and CC options while ensuring timely, highquality care.

References
  1. Congressional Budget Office. The Veterans Community Care Program: Background and Early Effects. October 26, 2021. Accessed September 23, 2024. https://www.cbo.gov/publication/57257
  2. US Dept of Veterans Affairs. Providing Health Care for Veterans. Updated September 10, 2024. Accessed September 23, 2024. https://www.va.gov/health/
  3. Davila H, Rosen AK, Beilstein-Wedel E, Shwartz M, Chatelain LJ, Gurewich D. Rural veterans’ experiences with outpatient care in the Veterans Health Administration versus community care. Med Care. 2021;59(Suppl 3):S286-S291. doi:10.1097/MLR.0000000000001552
  4. Vanneman ME, Wagner TH, Shwartz M, et al. Veterans’ experiences with outpatient care: comparing the Veterans Affairs system with community-based care. Health Aff (Millwood). 2020;39(8):1368-1376. doi:10.1377/hlthaff.2019.01375
  5. Rasmussen P, Farmer CM. The promise and challenges of VA community care: veterans’ issues in focus. Rand Health Q. 2023;10(3):9.
  6. Feyman Y, Legler A, Griffith KN. Appointment wait time data for primary & specialty care in veterans health administration facilities vs. community medical centers. Data Brief. 2021;36:107134. doi:10.1016/j.dib.2021.107134
  7. Kelley AT, Greenstone CL, Kirsh SR. Defining access and the role of community care in the Veterans Health Administration. J Gen Intern Med. 2020;35(5):1584-1585. doi:10.1007/s11606-019-05358-z
  8. Garvin LA, Pugatch M, Gurewich D, Pendergast JN, Miller CJ. Interorganizational care coordination of rural veterans by Veterans Affairs and community care programs: a systematic review. Med Care. 2021;59(Suppl 3):S259-S269. doi:10.1097/MLR.0000000000001542
  9. US Dept of Veterans Affairs, Office of Rural Health. Rural Veterans: Rural Veteran Health Care Challenges. Updated May 14, 2024. Accessed September 23, 2024. https:// www.ruralhealth.va.gov/aboutus/ruralvets.asp
  10. Ohl ME, Carrell M, Thurman A, et al. “Availability of healthcare providers for rural veterans eligible for purchased care under the veterans choice act.” BMC Health Serv Res. 2018;18(1):315. doi:10.1186/s12913-018-3108-8
  11. Mattocks KM, Cunningham KJ, Greenstone C, Atkins D, Rosen AK, Upton M. Innovations in community care programs, policies, and research. Med Care. 2021;59(Suppl 3):S229-S231. doi:10.1097/MLR.0000000000001550
  12. Doyle JM, Streeter RA. Veterans’ location in health professional shortage areas: implications for access to care and workforce supply. Health Serv Res. 2017;52 Suppl 1(Suppl 1):459-480. doi:10.1111/1475-6773.12633
  13. Patzel M, Barnes C, Ramalingam N, et al. Jumping through hoops: community care clinician and staff experiences providing primary care to rural veterans. J Gen Intern Med. 2023;38(Suppl 3):821-828. doi:10.1007/s11606-023-08126-2
  14. Mattocks KM, Kroll-Desrosiers A, Kinney R, Elwy AR, Cunningham KJ, Mengeling MA. Understanding VA’s use of and relationships with community care providers under the MISSION Act. Med Care. 2021;59(Suppl 3):S252-S258. doi:10.1097/MLR.0000000000001545
  15. Olenick M, Flowers M, Diaz VJ. US veterans and their unique issues: enhancing health care professional awareness. Adv Med Educ Pract. 2015;6:635-639. doi:10.2147/AMEP.S89479
  16. Campbell P, Pope R, Simas V, Canetti E, Schram B, Orr R. The effects of early physiotherapy treatment on musculoskeletal injury outcomes in military personnel: a narrative review. Int J Environ Res Public Health. 2022;19(20):13416. doi:10.3390/ijerph192013416
  17. Gurewich D, Shwartz M, Beilstein-Wedel E, Davila H, Rosen AK. Did access to care improve since passage of the veterans choice act? Differences between rural and urban veterans. Med Care. 2021;59(Suppl 3):S270-S278. doi:10.1097/MLR.0000000000001490
  18. Myers US, Birks A, Grubaugh AL, Axon RN. Flattening the curve by getting ahead of it: how the VA healthcare system is leveraging telehealth to provide continued access to care for rural veterans. J Rural Health. 2021;37(1):194-196. doi:10.1111/jrh.12449
  19. Hale-Gallardo JL, Kreider CM, Jia H, et al. Telerehabilitation for rural veterans: a qualitative assessment of barriers and facilitators to implementation. J Multidiscip Healthc. 2020;13:559-570. doi:10.2147/JMDH.S247267
  20. Kreider CM, Hale-Gallardo J, Kramer JC, et al. Providers’ shift to telerehabilitation at the U.S. Veterans Health Administration during COVID-19: practical applications. Front Public Health. 2022;10:831762. doi:10.3389/fpubh.2022.831762
  21. Cowper-Ripley DC, Jia H, Wang X, et al. Trends in VA telerehabilitation patients and encounters over time and by rurality. Fed Pract. 2019;36(3):122-128.
  22. US Dept of Veterans Affairs, Office of Rural Health. VHA Office of Rural Health. Updated August 30, 2024. Accessed September 23, 2024. https://www.ruralhealth.va.gov/index.asp
  23. National Center for Veterans Analysis and Statistics. Rural Veterans: 2021-2023. April 2023. Accessed September 23, 2024. https://www.datahub.va.gov/stories/s/Rural-Veterans-FY2021-2023/kkh2-eymp/
  24. U.S. Department of Veterans Affairs, Office of Research & Development. Program Guide: 1200.21, VHA Operations Activities That May Constitute Research. January 9, 2019. https://www.research.va.gov/resources/policies/ProgramGuide-1200-21-VHA-Operations-Activities.pdf
  25. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. J Nurs Care Qual. 2016;31(1):1-8. doi:10.1097/NCQ.0000000000000153
  26. US Dept of Veterans Affairs. Veterans Health Administration: Veterans Integrated Service Networks (VISNs). Updated January 29, 2024. Accessed September 23, 2024. https://www.va.gov/HEALTH/visns.asp
  27. Stomberg C, Frost A, Becker C, Stang H, Windschitl M, Carrier E. Community Care referral dashboard [Data dashboard]. https://app.powerbigov.us/groups/me/reports/090d22a7-0e1f-4cc5-bea8-0a1b87aa0bd9/ReportSectionacfd03cdebd76ffca9ec [Source not verified]
  28. US Dept of Veterans Affairs. Eligibility for community care outside VA. Updated May 30, 2024. Accessed September 23, 2024. https://www.va.gov/COMMUNITYCARE/programs/veterans/General_Care.asp
  29. US Department of Veterans Affairs, Office of Rural Health. How to define rurality fact sheet. Updated December 2023. Accessed January 28, 2025. https://www.ruralhealth.va.gov/docs/ORH_RuralityFactSheet_508.pdf
  30. Rural-Urban Commuting Area Codes. Economic Research Service, US Dept of Agriculture. Updated September 25, 2023. Accessed September 23, 2024. https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes.aspx
  31. Gurewich D, Beilstein-Wedel E, Shwartz M, Davila H, Rosen AK. Disparities in wait times for care among US veterans by race and ethnici t y. JAMA Netw Open. 2023;6(1):e2252061. doi:10.1001/jamanetworkopen.2022.52061
  32. U.S. Department of Veterans Affairs, VA Office of Rural Health, Veterans Rural Health Resource Center-Gainesville, GeoSpatial Outcomes Division. VA and Community Healthcare, and VHA Rurality web map application. Published 2023. https://portal.vhagis.inv.vaec.va.gov/arcgis/apps/webappbuilder/index.html [source not verified]
  33. Chartbook on Healthcare for Veterans: National Healthcare Quality and Disparities Report. Agency for Healthcare Research and Quality; November 2020. Accessed September 23, 2024. https://www.ahrq.gov/research/findings/nhqrdr/chartbooks/veterans/index.html
  34. Lum HD, Nearing K, Pimentel CB, Levy CR, Hung WW. Anywhere to anywhere: use of telehealth to increase health care access for older, rural veterans. Public Policy Aging Rep. 2020;30(1):12-18. doi:10.1093/ppar/prz030
  35. Goulet JL, Kerns RD, Bair M, et al. The musculoskeletal diagnosis cohort: examining pain and pain care among veterans. Pain. 2016;157(8):1696-1703. doi:10.1097/j.pain.0000000000000567
  36. US Inflation Calculator. Health Care Inflation in the United States (1948-2024). Accessed September 23, 2024. https://www.usinflationcalculator.com/inflation/health-care-inflation-in-the-united-states/
  37. Cottrell MA, Galea OA, O’Leary SP, Hill AJ, Russell TG. Real-time telerehabilitation for the treatment of musculoskeletal conditions is effective and comparable to standard practice: a systematic review and meta-analysis. Clin Rehabil. 2017;31(5):625-638. doi:10.1177/0269215516645148
  38. Elor A, Conde S, Powel l M, Robbins A, Chen NN, Kurniawan S. Physical therapist impressions of telehealth and virtual reality needs amidst a pandemic. Front Virtual Real. 2022;3. doi:10.3389/frvir.2022.915332
  39. Lee AC, Harada N. Telehealth as a means of health care delivery for physical therapist practice. Phys Ther. 2012;92(3):463-468. doi:10.2522/ptj.20110100
  40. Hynes DM, Edwards S, Hickok A, et al. Veterans’ use of Veterans Health Administration primary care in an era of expanding choice. Med Care. 2021;59(Suppl 3):S292- S300. doi:10.1097/MLR.0000000000001554
References
  1. Congressional Budget Office. The Veterans Community Care Program: Background and Early Effects. October 26, 2021. Accessed September 23, 2024. https://www.cbo.gov/publication/57257
  2. US Dept of Veterans Affairs. Providing Health Care for Veterans. Updated September 10, 2024. Accessed September 23, 2024. https://www.va.gov/health/
  3. Davila H, Rosen AK, Beilstein-Wedel E, Shwartz M, Chatelain LJ, Gurewich D. Rural veterans’ experiences with outpatient care in the Veterans Health Administration versus community care. Med Care. 2021;59(Suppl 3):S286-S291. doi:10.1097/MLR.0000000000001552
  4. Vanneman ME, Wagner TH, Shwartz M, et al. Veterans’ experiences with outpatient care: comparing the Veterans Affairs system with community-based care. Health Aff (Millwood). 2020;39(8):1368-1376. doi:10.1377/hlthaff.2019.01375
  5. Rasmussen P, Farmer CM. The promise and challenges of VA community care: veterans’ issues in focus. Rand Health Q. 2023;10(3):9.
  6. Feyman Y, Legler A, Griffith KN. Appointment wait time data for primary & specialty care in veterans health administration facilities vs. community medical centers. Data Brief. 2021;36:107134. doi:10.1016/j.dib.2021.107134
  7. Kelley AT, Greenstone CL, Kirsh SR. Defining access and the role of community care in the Veterans Health Administration. J Gen Intern Med. 2020;35(5):1584-1585. doi:10.1007/s11606-019-05358-z
  8. Garvin LA, Pugatch M, Gurewich D, Pendergast JN, Miller CJ. Interorganizational care coordination of rural veterans by Veterans Affairs and community care programs: a systematic review. Med Care. 2021;59(Suppl 3):S259-S269. doi:10.1097/MLR.0000000000001542
  9. US Dept of Veterans Affairs, Office of Rural Health. Rural Veterans: Rural Veteran Health Care Challenges. Updated May 14, 2024. Accessed September 23, 2024. https:// www.ruralhealth.va.gov/aboutus/ruralvets.asp
  10. Ohl ME, Carrell M, Thurman A, et al. “Availability of healthcare providers for rural veterans eligible for purchased care under the veterans choice act.” BMC Health Serv Res. 2018;18(1):315. doi:10.1186/s12913-018-3108-8
  11. Mattocks KM, Cunningham KJ, Greenstone C, Atkins D, Rosen AK, Upton M. Innovations in community care programs, policies, and research. Med Care. 2021;59(Suppl 3):S229-S231. doi:10.1097/MLR.0000000000001550
  12. Doyle JM, Streeter RA. Veterans’ location in health professional shortage areas: implications for access to care and workforce supply. Health Serv Res. 2017;52 Suppl 1(Suppl 1):459-480. doi:10.1111/1475-6773.12633
  13. Patzel M, Barnes C, Ramalingam N, et al. Jumping through hoops: community care clinician and staff experiences providing primary care to rural veterans. J Gen Intern Med. 2023;38(Suppl 3):821-828. doi:10.1007/s11606-023-08126-2
  14. Mattocks KM, Kroll-Desrosiers A, Kinney R, Elwy AR, Cunningham KJ, Mengeling MA. Understanding VA’s use of and relationships with community care providers under the MISSION Act. Med Care. 2021;59(Suppl 3):S252-S258. doi:10.1097/MLR.0000000000001545
  15. Olenick M, Flowers M, Diaz VJ. US veterans and their unique issues: enhancing health care professional awareness. Adv Med Educ Pract. 2015;6:635-639. doi:10.2147/AMEP.S89479
  16. Campbell P, Pope R, Simas V, Canetti E, Schram B, Orr R. The effects of early physiotherapy treatment on musculoskeletal injury outcomes in military personnel: a narrative review. Int J Environ Res Public Health. 2022;19(20):13416. doi:10.3390/ijerph192013416
  17. Gurewich D, Shwartz M, Beilstein-Wedel E, Davila H, Rosen AK. Did access to care improve since passage of the veterans choice act? Differences between rural and urban veterans. Med Care. 2021;59(Suppl 3):S270-S278. doi:10.1097/MLR.0000000000001490
  18. Myers US, Birks A, Grubaugh AL, Axon RN. Flattening the curve by getting ahead of it: how the VA healthcare system is leveraging telehealth to provide continued access to care for rural veterans. J Rural Health. 2021;37(1):194-196. doi:10.1111/jrh.12449
  19. Hale-Gallardo JL, Kreider CM, Jia H, et al. Telerehabilitation for rural veterans: a qualitative assessment of barriers and facilitators to implementation. J Multidiscip Healthc. 2020;13:559-570. doi:10.2147/JMDH.S247267
  20. Kreider CM, Hale-Gallardo J, Kramer JC, et al. Providers’ shift to telerehabilitation at the U.S. Veterans Health Administration during COVID-19: practical applications. Front Public Health. 2022;10:831762. doi:10.3389/fpubh.2022.831762
  21. Cowper-Ripley DC, Jia H, Wang X, et al. Trends in VA telerehabilitation patients and encounters over time and by rurality. Fed Pract. 2019;36(3):122-128.
  22. US Dept of Veterans Affairs, Office of Rural Health. VHA Office of Rural Health. Updated August 30, 2024. Accessed September 23, 2024. https://www.ruralhealth.va.gov/index.asp
  23. National Center for Veterans Analysis and Statistics. Rural Veterans: 2021-2023. April 2023. Accessed September 23, 2024. https://www.datahub.va.gov/stories/s/Rural-Veterans-FY2021-2023/kkh2-eymp/
  24. U.S. Department of Veterans Affairs, Office of Research & Development. Program Guide: 1200.21, VHA Operations Activities That May Constitute Research. January 9, 2019. https://www.research.va.gov/resources/policies/ProgramGuide-1200-21-VHA-Operations-Activities.pdf
  25. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. J Nurs Care Qual. 2016;31(1):1-8. doi:10.1097/NCQ.0000000000000153
  26. US Dept of Veterans Affairs. Veterans Health Administration: Veterans Integrated Service Networks (VISNs). Updated January 29, 2024. Accessed September 23, 2024. https://www.va.gov/HEALTH/visns.asp
  27. Stomberg C, Frost A, Becker C, Stang H, Windschitl M, Carrier E. Community Care referral dashboard [Data dashboard]. https://app.powerbigov.us/groups/me/reports/090d22a7-0e1f-4cc5-bea8-0a1b87aa0bd9/ReportSectionacfd03cdebd76ffca9ec [Source not verified]
  28. US Dept of Veterans Affairs. Eligibility for community care outside VA. Updated May 30, 2024. Accessed September 23, 2024. https://www.va.gov/COMMUNITYCARE/programs/veterans/General_Care.asp
  29. US Department of Veterans Affairs, Office of Rural Health. How to define rurality fact sheet. Updated December 2023. Accessed January 28, 2025. https://www.ruralhealth.va.gov/docs/ORH_RuralityFactSheet_508.pdf
  30. Rural-Urban Commuting Area Codes. Economic Research Service, US Dept of Agriculture. Updated September 25, 2023. Accessed September 23, 2024. https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes.aspx
  31. Gurewich D, Beilstein-Wedel E, Shwartz M, Davila H, Rosen AK. Disparities in wait times for care among US veterans by race and ethnici t y. JAMA Netw Open. 2023;6(1):e2252061. doi:10.1001/jamanetworkopen.2022.52061
  32. U.S. Department of Veterans Affairs, VA Office of Rural Health, Veterans Rural Health Resource Center-Gainesville, GeoSpatial Outcomes Division. VA and Community Healthcare, and VHA Rurality web map application. Published 2023. https://portal.vhagis.inv.vaec.va.gov/arcgis/apps/webappbuilder/index.html [source not verified]
  33. Chartbook on Healthcare for Veterans: National Healthcare Quality and Disparities Report. Agency for Healthcare Research and Quality; November 2020. Accessed September 23, 2024. https://www.ahrq.gov/research/findings/nhqrdr/chartbooks/veterans/index.html
  34. Lum HD, Nearing K, Pimentel CB, Levy CR, Hung WW. Anywhere to anywhere: use of telehealth to increase health care access for older, rural veterans. Public Policy Aging Rep. 2020;30(1):12-18. doi:10.1093/ppar/prz030
  35. Goulet JL, Kerns RD, Bair M, et al. The musculoskeletal diagnosis cohort: examining pain and pain care among veterans. Pain. 2016;157(8):1696-1703. doi:10.1097/j.pain.0000000000000567
  36. US Inflation Calculator. Health Care Inflation in the United States (1948-2024). Accessed September 23, 2024. https://www.usinflationcalculator.com/inflation/health-care-inflation-in-the-united-states/
  37. Cottrell MA, Galea OA, O’Leary SP, Hill AJ, Russell TG. Real-time telerehabilitation for the treatment of musculoskeletal conditions is effective and comparable to standard practice: a systematic review and meta-analysis. Clin Rehabil. 2017;31(5):625-638. doi:10.1177/0269215516645148
  38. Elor A, Conde S, Powel l M, Robbins A, Chen NN, Kurniawan S. Physical therapist impressions of telehealth and virtual reality needs amidst a pandemic. Front Virtual Real. 2022;3. doi:10.3389/frvir.2022.915332
  39. Lee AC, Harada N. Telehealth as a means of health care delivery for physical therapist practice. Phys Ther. 2012;92(3):463-468. doi:10.2522/ptj.20110100
  40. Hynes DM, Edwards S, Hickok A, et al. Veterans’ use of Veterans Health Administration primary care in an era of expanding choice. Med Care. 2021;59(Suppl 3):S292- S300. doi:10.1097/MLR.0000000000001554
Issue
Federal Practitioner - 42(2)
Issue
Federal Practitioner - 42(2)
Page Number
1-15
Page Number
1-15
Publications
Publications
Topics
Article Type
Display Headline

Utilization and Cost of Veterans Health Administration Referrals to Community Care-Based Physical Therapy

Display Headline

Utilization and Cost of Veterans Health Administration Referrals to Community Care-Based Physical Therapy

Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Fri, 02/21/2025 - 14:57
Un-Gate On Date
Fri, 02/21/2025 - 14:57
Use ProPublica
CFC Schedule Remove Status
Fri, 02/21/2025 - 14:57
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Fri, 02/21/2025 - 14:57

Impact of 3 Months of Supervised Exercise on Function by Arthritis Status

Article Type
Changed
Tue, 02/11/2025 - 13:39
Display Headline

Impact of 3 Months of Supervised Exercise on Function by Arthritis Status

About half of US adults aged ≥ 65 years report arthritis, and of those, 44% have an arthritis-attributable activity limitation.1,2 Arthritis is a significant health issue for veterans, with veterans reporting higher rates of disability compared with the civilian population.3

Osteoarthritis (OA) is the most common type of arthritis.4 Among individuals aged ≥ 40 years, the incidence of OA is nearly twice as high among veterans compared with civilians and is a leading cause of separation from military service and disability.5,6 OA pain and disability have been shown to be associated with increases in health care and medication use, including opioids, nonsteroidal anti-inflammatory medications, and muscle relaxants.7,8 Because OA is chronic and has no cure, safe and effective management strategies—such as exercise— are critical to minimize pain and maintain physical function.9

Exercise can reduce pain and disability associated with OA and is a first-line recommendation in guidelines for the treatment of knee and hip OA.9 Given the limited exercise and high levels of physical inactivity among veterans with OA, there is a need to identify opportunities that support veterans with OA engaging in regular exercise.

Gerofit, an outpatient clinical exercise program available at 30 Veterans Health Administration (VHA) sites, may provide an opportunity for older veterans with arthritis to engage in exercise.10 Gerofit is specifically designed for veterans aged ≥ 65 years. It is not disease-specific and supports older veterans with multiple chronic conditions, including OA. Veterans aged ≥ 65 years with a referral from a VA clinician are eligible for Gerofit. Those who are unable to perform activities of daily living; unable to independently function without assistance; have a history of unstable angina, proliferative diabetic retinopathy, oxygen dependence, volatile behavioral issues, or are unable to work successfully in a group environment/setting; experience active substance abuse, homelessness, or uncontrolled incontinence; and have open wounds that cannot be appropriately dressed are excluded from Gerofit. Exercise sessions are held 3 times per week and last from 60 to 90 minutes. Sessions are supervised by Gerofit staff and include personalized exercise prescriptions based on functional assessments. Exercise prescriptions include aerobic, resistance, and balance/flexibility components and are modified by the Gerofit program staff as needed. Gerofit adopts a functional fitness approach and includes individual progression as appropriate according to evidence-based guidelines, using the Borg ratings of perceived exertion. 11 Assessments are performed at baseline, 3 months, 6 months, and annually thereafter. Clinical staff conduct all assessments, including physical function testing, and record them in a database. Assessments are reviewed with the veteran to chart progress and identify future goals or needs. Veterans perform personalized self-paced exercises in the Gerofit group setting. Exercise prescriptions are continuously modified to meet individualized needs and goals. Veterans may participate continuously with no end date.

Participation in supervised exercise is associated with improved physical function and individuals with arthritis can improve function even though their baseline functional status is lower than individuals without arthritis. 12 In this analysis, we examine the impact of exercise on the status and location of arthritis (upper body, lower body, or both). Lower body arthritis is more common than upper body arthritis and lower extremity function is associated with increased ability to perform activities of daily living, resulting in independence among older adults.13,14 We also include upper body strength measures to capture important functional movements such as reaching and pulling.15 Among those who participate in Gerofit, the greatest gains in physical function occur during the initial 3 months, which tend to be sustained over 12 months.16 For this reason, this study focused on the initial 3 months of the program.

Older adults with arthritis may have pain and functional limitations that exceed those of the general older adult population. Exercise programs for older adults that do not specifically target arthritis but are able to improve physical function among those with arthritis could potentially increase access to exercise for older adults living with arthritis. Therefore, the purpose of this study was to determine whether change in physical function with participation in Gerofit for 3 months varies by arthritis status, including no arthritis, any arthritis, lower body arthritis, or both upper and lower body arthritis compared with no arthritis.

Methods

This is a secondary analysis of previously collected data from 10 VHA Gerofit sites (Ann Arbor, Baltimore, Greater Los Angeles, Canandaigua, Cincinnati, Miami, Honolulu, Denver, Durham, and Pittsburgh) from 2002 to 2019. Implementation data regarding the consistency of the program delivery at Gerofit expansion sites have been previously published.16 Although the delivery of Gerofit transitioned to telehealth due to COVID-19, data for this analysis were collected from in-person exercise sessions prior to the pandemic.17 Data were collected for clinical purposes. This project was part of the Gerofit quality improvement initiative and was reviewed and approved by the Durham Institutional Review Board as quality improvement.

Participants in Gerofit who completed baseline and 3-month assessments were included to analyze the effects of exercise on physical function. At each of the time points, physical functional assessments included: (1) usual gait speed (> 10 meters [m/s], or 10- meter walk test [10MWT]); (2) lower body strength (chair stands [number completed in 30 seconds]); (3) upper body strength (number of arm curls [5-lb for females/8-lb for males] completed in 30 seconds); and (4) 6-minute walk distance [6MWD] in meters to measure aerobic endurance). These measures have been validated in older adults.18-21 Arm curls were added to the physical function assessments after the 10MWT, chair stands, and 6MWD; therefore, fewer participants had data for this measure. Participants self-reported at baseline on 45 common medical conditions, including arthritis or rheumatism (both upper body and lower body were offered as choices). Self-reporting has been shown to be an acceptable method of identifying arthritis in adults.22

Descriptive statistics at baseline were calculated for all participants. One-way analysis of variance and X2 tests were used to determine differences in baseline characteristics across arthritis status. The primary outcomes were changes in physical function measures from baseline to 3 months by arthritis status. Arthritis status was defined as: any arthritis, which includes individuals who reported upper body arthritis, lower body arthritis, or both; and arthritis status individuals reporting either upper body arthritis, lower body arthritis, or both. Categories of arthritis for arthritis status were mutually exclusive. Two separate linear models were constructed for each of the 4 physical function measures, with change from baseline to 3 months as the outcome (dependent variable) and arthritis status, age, and body mass index (BMI) as predictors (independent variables). The first model compared any arthritis with no arthritis and the second model compared arthritis status (both upper and lower body arthritis vs lower body arthritis) with no arthritis. These models were used to obtain mean changes and 95% CIs in physical function and to test for differences in the change in physical function measures by arthritis status. Statistical analyses were performed using R software, version 4.0.3.

Results

Baseline and 3-month data were available for 737 Gerofit participants and included in the analysis. The mean (SD) age was 73.5 (7.1) years. A total of 707 participants were male (95.9%) and 322 (43.6%) reported some arthritis, with arthritis in both the upper and lower body being reported by 168 participants (52.2%) (Table 1). There were no differences in age, sex, or race for those with any arthritis compared with those with no arthritis, but BMI was significantly higher in those reporting any arthritis compared with no arthritis. For the baseline functional measures, statistically significant differences were observed between those with no arthritis and those reporting any arthritis for the 10MWT (P = .001), chair stands (P = .046), and 6MWD (P = .001), but not for arm curls (P = .77), with those with no arthritis performing better.

FDP04202100_T1

All 4 arthritis status groups showed improvements in each of the physical function measures over 3 months. For the 10MWT the mean change (95% CI) in gait speed (m/s) was 0.06 (0.04-0.08) for patients with no arthritis, 0.07 (0.05- 0.08) for any arthritis, 0.07 (0.04-0.11) for lower body arthritis, and 0.07 (0.04- 0.09) for both lower and upper body arthritis. For the number of arm curls in 30 seconds the mean change (95% CI) was 2.3 (1.8-2.8) for patients with no arthritis, 2.1 (1.5-2.6) for any arthritis, 2.0 (1.1-3.0) for lower body arthritis, and 1.9 (1.1-2.7) for both lower and upper body arthritis. For the number of chair stands in 30 seconds the mean change (95% CI) was 2.1 (1.7-2.4) for patients with no arthritis, 2.2 (1.8-2.6) for any arthritis, 2.3 (1.6-2.9), for lower body arthritis, and 2.0 (1.5-2.5) for both lower and upper body arthritis. For the 6MWD distance in meters the mean change (95% CI) was 21.5 (15.5-27.4) for patients with no arthritis, 28.6 (21.9-35.3) for any arthritis, 30.4 (19.5-41.3) for lower body arthritis, and 28.6 (19.2-38.0) for both lower and upper body arthritis (Figure).

FDP04202100_F1

We used 2 models to measure the change from baseline to 3 months for each of the arthritis groups. Model 1 compared any arthritis vs no arthritis and model 2 compared lower body arthritis and both upper and lower body arthritis vs no arthritis for each physical function measure (Table 2). There were no statistically significant differences in 3-month change in physical function for any of the physical function measures between arthritis groups after adjusting for age and BMI.

FDP04202100_T2

Discussion

Participation in Gerofit was associated with functional gains among all participants over 3 months, regardless of arthritis status. Older veterans reporting any arthritis had significantly lower physical function scores upon enrollment into Gerofit compared with those veterans reporting no arthritis. However, compared with individuals who reported no arthritis, individuals who reported arthritis (any arthritis, lower body arthritis only, or both lower and upper body arthritis) experienced similar improvements (ie, no statistically significant differences in mean change from baseline to follow-up among those with and without arthritis). This study suggests that progressive, multicomponent exercise programs for older adults may be beneficial for those with arthritis.

Involvement of multiple sites of arthritis is associated with moderate to severe functional limitations as well as lower healthrelated quality of life.23 While it has been found that individuals with arthritis can improve function with supervised exercise, even though their baseline functional status is lower than individuals without arthritis, it was not clear whether individuals with multiple joint involvement also would benefit.12 The results of this study suggest that these individuals can improve across various domains of physical function despite variation in arthritis location and status. As incidence of arthritis increases with age, targeting older adults for exercise programs such as Gerofit may improve functional limitations and health-related quality of life associated with arthritis.2

We evaluated physical function using multiple measures to assess upper (arm curls) and lower (chair stands, 10MWT) extremity physical function and aerobic endurance (6MWD). Participants in this study reached clinically meaningful changes with 3 months of participation in Gerofit for most of the physical function measures. Gerofit participants had a mean gait speed improvement of 0.05 to 0.07 m/s compared with 0.10 to 0.30 m/s, which was reported previously. 24,25 In this study, nearly all groups achieved the clinically important improvements in the chair stand in 30 seconds (2.0 to 2.6) and the 6MWD (21.8 to 59.1 m) that have been reported in the literature.24-26

The Osteoarthritis Research Society International recommends the chair stand and 6MWD performance-based tests for individuals with hip and knee arthritis because they align with patient-reported outcomes and represent the types of activities relevant to this population.27 The findings of this study suggest that improvement in these physical function measures with participation in exercise align with data from arthritis-specific exercise programs designed for wide implementation. Hughes and colleagues reported improvements in the 6MWD after the 8-week Fit and Strong exercise intervention, which included walking and lower body resistance training.28 The Arthritis Foundation’s Walk With Ease program is a 6-week walking program that has shown improvements in chair stands and gait speed.29 Another Arthritis Foundation program, People with Arthritis Can Exercise, is an 8-week course consisting of a variety of resistance, aerobic, and balance activities. This program has been associated with increases in chair stands but not gait speed or 6MWD.30,31

This study found that participation in a VHA outpatient clinical supervised exercise program results in improvements in physical function that can be realized by older adults regardless of arthritis burden. Gerofit programs typically require 1.5 to 2.0 dedicated full-time equivalent employees to run the program effectively and additional administrative support, depending on size of the program.32 The cost savings generated by the program include reductions in hospitalization rates, emergency department visits, days in hospital, and medication use and provide a compelling argument for the program’s financial viability to health care systems through long-term savings and improved health outcomes for older adults.33-36

While evidenced-based arthritis programs exist, this study illustrates that an exercise program without a focus on arthritis also improves physical function, potentially reducing the risk of disability related to arthritis. The clinical implication for these findings is that arthritis-specific exercise programs may not be needed to achieve functional improvements in individuals with arthritis. This is critical for under-resourced or exercise- limited health care systems or communities. Therefore, if exercise programming is limited, or arthritis-specific programs and interventions are not available, nonspecific exercise programs will also be beneficial to individuals with arthritis. Thus, individuals with arthritis should be encouraged to participate in any available exercise programming to achieve improvements in physical function. In addition, many older adults have multiple comorbidities, most of which improve with participation in exercise. 37 Disease-specific exercise programs can offer tailored exercises and coaching related to common barriers in participation, such as joint pain for arthritis.31 It is unclear whether these additional programmatic components are associated with greater improvements in outcomes, such as physical function. More research is needed to explore the benefits of disease-specific tailored exercise programs compared with general exercise programs.

Strengths and Limitations

This study demonstrated the effect of participation in a clinical, supervised exercise program in a real-world setting. It suggests that even exercise programs not specifically targeted for arthritis populations can improve physical function among those with arthritis.

As a VHA clinical supervised exercise program, Gerofit may not be generalizable to all older adults or other exercise programs. In addition, this analysis only included a veteran population that was > 95% male and may not be generalizable to other populations. Arthritis status was defined by self-report and not verified in the health record. However, this approach has been shown to be acceptable in this setting and the most common type of arthritis in this population (OA) is a painful musculoskeletal condition associated with functional limitations.4,22,38,39 Self-reported arthritis or rheumatism is associated with functional limitations.1 Therefore, it is unlikely that the results would differ for physician-diagnosed or radiographically defined OA. Additionally, the study did not have data on the total number of joints with arthritis or arthritis severity but rather used upper body, lower body, and both upper and lower body arthritis as a proxy for arthritis status. While our models were adjusted for age and BMI, 2 known confounding factors for the association between arthritis and physical function, there are other potential confounding factors that were not included in the models. 40,41 Finally, this study only included individuals with completed baseline and 3-month follow-up assessments, and the individuals who participated for longer or shorter periods may have had different physical function outcomes than individuals included in this study.

Conclusions

Participation in 3 months VHA Gerofit outpatient supervised exercise programs can improve physical function for all older adults, regardless of arthritis status. These programs may increase access to exercise programming that is beneficial for common conditions affecting older adults, such as arthritis.

References
  1. Centers for Disease Control and Prevention. Prevalence and most common causes of disability among adults- -United States, 2005. MMWR Morb Mortal Wkly Rep. 2009;58:421-426.
  2. Theis KA, Murphy LB, Guglielmo D, et al. Prevalence of arthritis and arthritis-attributable activity limitation—United States, 2016–2018. MMWR Morb Mortal Wkly Rep. 2021;70:1401-1407. doi:10.15585/mmwr.mm7040a2
  3. Murphy LB, Helmick CG, Allen KD, et al. Arthritis among veterans—United States, 2011–2013. MMWR Morb Mortal Wkly Rep. 2014;63:999-1003.
  4. Park J, Mendy A, Vieira ER. Various types of arthritis in the United States: prevalence and age-related trends from 1999 to 2014. Am J Public Health. 2018;108:256-258.
  5. Cameron KL, Hsiao MS, Owens BD, Burks R, Svoboda SJ. Incidence of physician-diagnosed osteoarthritis among active duty United States military service members. Arthritis Rheum. 2011;63:2974-2982. doi:10.1002/art.30498
  6. Patzkowski JC, Rivera JC, Ficke JR, Wenke JC. The changing face of disability in the US Army: the Operation Enduring Freedom and Operation Iraqi Freedom effect. J Am Acad Orthop Surg. 2012;20(suppl 1):S23-S30. doi:10.5435/JAAOS-20-08-S23
  7. Rivera JC, Amuan ME, Morris RM, Johnson AE, Pugh MJ. Arthritis, comorbidities, and care utilization in veterans of Operations Enduring and Iraqi Freedom. J Orthop Res. 2017;35:682-687. doi:10.1002/jor.23323
  8. Singh JA, Nelson DB, Fink HA, Nichol KL. Health-related quality of life predicts future health care utilization and mortality in veterans with self-reported physician-diagnosed arthritis: the Veterans Arthritis Quality of Life Study. Semin Arthritis Rheum. 2005;34:755- 765. doi:10.1016/j.semarthrit.2004.08.001
  9. Nelson AE, Allen KD, Golightly YM, Goode AP, Jordan JM. A systematic review of recommendations and guidelines for the management of osteoarthritis: the Chronic Osteoarthritis Management Initiative of the U.S. Bone and Joint Initiative. Semin Arthritis Rheum. 2014;43:701-712. doi:10.1016/j.semarthrit.2013.11.012
  10. Morey MC, Crowley GM, Robbins MS, Cowper PA, Sullivan RJ Jr. The Gerofit Program: a VA innovation. South Med J. 1994;87:S83-S87.
  11. Chen MJ, Fan X, Moe ST. Criterion-related validity of the Borg ratings of perceived exertion scale in healthy individuals: a meta-analysis. J Sports Sci. 2002;20:873-899. doi:10.1080/026404102320761787
  12. Morey MC, Pieper CF, Sullivan RJ Jr, Crowley GM, Cowper PA, Robbins MS. Five-year performance trends for older exercisers: a hierarchical model of endurance, strength, and flexibility. J Am Geriatr Soc. 1996;44:1226-1231. doi:10.1111/j.1532-5415.1996.tb01374.x
  13. Allen KD, Gol ight ly YM. State of the evidence. Curr Opin Rheumatol. 2015;27:276-283. doi:10.1097/BOR.0000000000000161
  14. den Ouden MEM, Schuurmans MJ, Arts IEMA, van der Schouw YT. Association between physical performance characteristics and independence in activities of daily living in middle-aged and elderly men. Geriatr Gerontol Int. 2013;13:274-280. doi:10.1111/j.1447-0594.2012.00890.x
  15. Daly M, Vidt ME, Eggebeen JD, et al. Upper extremity muscle volumes and functional strength after resistance training in older adults. J Aging Phys Act. 2013;21:186-207. doi:10.1123/japa.21.2.186
  16. Morey MC, Lee CC, Castle S, et al. Should structured exercise be promoted as a model of care? Dissemination of the Department of Veterans Affairs Gerofit Program. J Am Geriatr Soc. 2018;66:1009-1016. doi:10.1111/jgs.15276
  17. Jennings SC, Manning KM, Bettger JP, et al. Rapid transition to telehealth group exercise and functional assessments in response to COVID-19. Gerontol Geriatr Med. 2020;6:2333721420980313. doi:10.1177/ 2333721420980313
  18. Studenski S, Perera S, Wallace D, et al. Physical performance measures in the clinical setting. J Am Geriatr Soc. 2003;51:314-322. doi:10.1046/j.1532-5415.2003.51104.x
  19. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community residing older adults. Res Q Exerc Sport. 1999;70:113- 119. doi:10.1080/02701367.1999.10608028
  20. Rikli RE, Jones CJ. Development and validation of a functional fitness test for community-residing older adults. J Aging Phys Act. 1999;7:129-161. doi:10.1123/japa.7.2.129
  21. Harada ND, Chiu V, Stewart AL. Mobility-related function in older adults: assessment with a 6-minute walk test. Arch Phys Med Rehabil. 1999;80:837-841. doi:10.1016/s0003-9993(99)90236-8
  22. Peeters GGME, Alshurafa M, Schaap L, de Vet HCW. Diagnostic accuracy of self-reported arthritis in the general adult population is acceptable. J Clin Epidemiol. 2015;68:452-459. doi:10.1016/j.jclinepi.2014.09.019
  23. Cuperus N, Vliet Vlieland TPM, Mahler EAM, Kersten CC, Hoogeboom TJ, van den Ende CHM. The clinical burden of generalized osteoarthritis represented by self-reported health-related quality of life and activity limitations: a cross-sectional study. Rheumatol Int. 2015;35:871-877. doi:10.1007/s00296-014-3149-1
  24. Coleman G, Dobson F, Hinman RS, Bennell K, White DK. Measures of physical performance. Arthritis Care Res (Hoboken). 2020;72(suppl 10):452-485. doi:10.1002/acr.24373
  25. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54:743-749. doi:10.1111/j.1532-5415.2006.00701.x
  26. Wright AA, Cook CE, Baxter GD, Dockerty JD, Abbott JH. A comparison of 3 methodological approaches to defining major clinically important improvement of 4 performance measures in patients with hip osteoarthritis. J Orthop Sports Phys Ther. 2011;41:319-327. doi:10.2519/jospt.2011.3515
  27. Dobson F, Hinman R, Roos EM, et al. OARSI recommended performance-based tests to assess physical function in people diagnosed with hip or knee osteoarthritis. Osteoarthritis Cartilage. 2013;21:1042- 1052. doi:10.1016/j.joca.2013.05.002
  28. Hughes SL, Seymour RB, Campbell R, Pollak N, Huber G, Sharma L. Impact of the fit and strong intervention on older adults with osteoarthritis. Gerontologist. 2004;44:217-228. doi:10.1093/geront/44.2.217
  29. Callahan LF, Shreffler JH, Altpeter M, et al. Evaluation of group and self-directed formats of the Arthritis Foundation's Walk With Ease Program. Arthritis Care Res (Hoboken). 2011;63:1098-1107. doi:10.1002/acr.20490
  30. Boutaugh ML. Arthritis Foundation community-based physical activity programs: effectiveness and implementation issues. Arthritis Rheum. 2003;49:463-470. doi:10.1002/art.11050
  31. Callahan LF, Mielenz T, Freburger J, et al. A randomized controlled trial of the People with Arthritis Can Exercise Program: symptoms, function, physical activity, and psychosocial outcomes. Arthritis Rheum. 2008;59:92-101. doi:10.1002/art.23239
  32. Hall KS, Jennings SC, Pearson MP. Outpatient care models: the Gerofit model of care for exercise promotion in older adults. In: Malone ML, Boltz M, Macias Tejada J, White H, eds. Geriatrics Models of Care. Springer; 2024:205-213. doi:10.1007/978-3-031-56204-4_21
  33. Pepin MJ, Valencia WM, Bettger JP, et al. Impact of supervised exercise on one-year medication use in older veterans with multiple morbidities. Gerontol Geriatr Med. 2020;6:2333721420956751. doi:10.1177/ 2333721420956751
  34. Abbate L, Li J, Veazie P, et al. Does Gerofit exercise reduce veterans’ use of emergency department and inpatient care? Innov Aging. 2020;4(suppl 1):771. doi:10.1093/geroni/igaa057.2786
  35. Morey MC, Pieper CF, Crowley GM, Sullivan RJ Jr, Puglisi CM. Exercise adherence and 10-year mortality in chronically ill older adults. J Am Geriatr Soc. 2002;50:1929-1933. doi:10.1046/j.1532-5415.2002.50602.x
  36. Manning KM, Hall KS, Sloane R, et al. Longitudinal analysis of physical function in older adults: the effects of physical inactivity and exercise training. Aging Cell. 2024;23:e13987. doi:10.1111/acel.13987
  37. Bean JF, Vora A, Frontera WR. Benefits of exercise for community-dwelling older adults. Arch Phys Med Rehabil. 2004;85(7 suppl 3):S31-S42; quiz S3-S4. doi:10.1016/j.apmr.2004.03.010
  38. Covinsky KE, Lindquist K, Dunlop DD, Yelin E. Pain, functional limitations, and aging. J Am Geriatr Soc. 2009; 57:1556-1561. doi:10.1111/j.1532-5415.2009.02388.x
  39. Katz JN, Wright EA, Baron JA, Losina E. Development and validation of an index of musculoskeletal functional limitations. BMC Musculoskelet Disord. 2009;10:62. doi:10.1186/1471-2474-10-62
  40. Allen KD, Thoma LM, Golightly YM. Epidemiology of osteoarthritis. Osteoarthritis Cartilage. 2022;30:184-195. doi:10.1016/j.joca.2021.04.020
  41. Riebe D, Blissmer BJ, Greaney ML, Ewing Garber C, Lees FD, Clark PG. The relationship between obesity, physical activity, and physical function in older adults. J Aging Health. 2009;21:1159-1178. doi:10.1177/0898264309350076
Article PDF
Author and Disclosure Information

Lauren M. Abbate, MD, PhDa,b; Kelli D. Allen, PhDc,d; P. Michael Ho, MD, PhDe; Steven C. Castle, MDf,g; Cathy C. Lee, MSf,g; Leslie I. Katzel, MD, PhDh,i; Jamie Giffuni, MAh; Teresa Kopp, MBA, PTj; Michelle McDonald, BS, OTR/Lk; Megan Pearson, MAc; Richard Sloane, MPHl; Vanessa Richardson, MSa; Katherine S. Hall, PhD, MSc,l; Miriam C. Morey, PhDc,l

Author affiliations
aVeterans Affairs Eastern Colorado Geriatric Research Education and Clinical Center, Aurora
bUniversity of Colorado, Aurora
cVeterans Affairs Durham Health Care System, North Carolina
dUniversity of North Carolina, Chapel Hill
eVeterans Affairs Eastern Colorado Health Care System, Aurora
fVeterans Affairs Greater Los Angeles Health Care System, California
gDavid Geffen School of Medicine at UCLA, Los Angeles, California
hVeterans Affairs Maryland Health Care System, Baltimore
iUniversity of Maryland School of Medicine, Baltimore
jCanandaigua Veterans Affairs Medical Center, New York
kVeterans Affairs Pacific Islands Health Care System, Honolulu, Hawaii
lDuke University Medical Center, Durham, North Carolina

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Correspondence: Lauren Abbate ([email protected])

Fed Pract. 2025;42(2). Published online February 15. doi:10.12788/fp.0549

Issue
Federal Practitioner - 42(2)
Publications
Topics
Page Number
100-106
Sections
Author and Disclosure Information

Lauren M. Abbate, MD, PhDa,b; Kelli D. Allen, PhDc,d; P. Michael Ho, MD, PhDe; Steven C. Castle, MDf,g; Cathy C. Lee, MSf,g; Leslie I. Katzel, MD, PhDh,i; Jamie Giffuni, MAh; Teresa Kopp, MBA, PTj; Michelle McDonald, BS, OTR/Lk; Megan Pearson, MAc; Richard Sloane, MPHl; Vanessa Richardson, MSa; Katherine S. Hall, PhD, MSc,l; Miriam C. Morey, PhDc,l

Author affiliations
aVeterans Affairs Eastern Colorado Geriatric Research Education and Clinical Center, Aurora
bUniversity of Colorado, Aurora
cVeterans Affairs Durham Health Care System, North Carolina
dUniversity of North Carolina, Chapel Hill
eVeterans Affairs Eastern Colorado Health Care System, Aurora
fVeterans Affairs Greater Los Angeles Health Care System, California
gDavid Geffen School of Medicine at UCLA, Los Angeles, California
hVeterans Affairs Maryland Health Care System, Baltimore
iUniversity of Maryland School of Medicine, Baltimore
jCanandaigua Veterans Affairs Medical Center, New York
kVeterans Affairs Pacific Islands Health Care System, Honolulu, Hawaii
lDuke University Medical Center, Durham, North Carolina

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Correspondence: Lauren Abbate ([email protected])

Fed Pract. 2025;42(2). Published online February 15. doi:10.12788/fp.0549

Author and Disclosure Information

Lauren M. Abbate, MD, PhDa,b; Kelli D. Allen, PhDc,d; P. Michael Ho, MD, PhDe; Steven C. Castle, MDf,g; Cathy C. Lee, MSf,g; Leslie I. Katzel, MD, PhDh,i; Jamie Giffuni, MAh; Teresa Kopp, MBA, PTj; Michelle McDonald, BS, OTR/Lk; Megan Pearson, MAc; Richard Sloane, MPHl; Vanessa Richardson, MSa; Katherine S. Hall, PhD, MSc,l; Miriam C. Morey, PhDc,l

Author affiliations
aVeterans Affairs Eastern Colorado Geriatric Research Education and Clinical Center, Aurora
bUniversity of Colorado, Aurora
cVeterans Affairs Durham Health Care System, North Carolina
dUniversity of North Carolina, Chapel Hill
eVeterans Affairs Eastern Colorado Health Care System, Aurora
fVeterans Affairs Greater Los Angeles Health Care System, California
gDavid Geffen School of Medicine at UCLA, Los Angeles, California
hVeterans Affairs Maryland Health Care System, Baltimore
iUniversity of Maryland School of Medicine, Baltimore
jCanandaigua Veterans Affairs Medical Center, New York
kVeterans Affairs Pacific Islands Health Care System, Honolulu, Hawaii
lDuke University Medical Center, Durham, North Carolina

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Correspondence: Lauren Abbate ([email protected])

Fed Pract. 2025;42(2). Published online February 15. doi:10.12788/fp.0549

Article PDF
Article PDF

About half of US adults aged ≥ 65 years report arthritis, and of those, 44% have an arthritis-attributable activity limitation.1,2 Arthritis is a significant health issue for veterans, with veterans reporting higher rates of disability compared with the civilian population.3

Osteoarthritis (OA) is the most common type of arthritis.4 Among individuals aged ≥ 40 years, the incidence of OA is nearly twice as high among veterans compared with civilians and is a leading cause of separation from military service and disability.5,6 OA pain and disability have been shown to be associated with increases in health care and medication use, including opioids, nonsteroidal anti-inflammatory medications, and muscle relaxants.7,8 Because OA is chronic and has no cure, safe and effective management strategies—such as exercise— are critical to minimize pain and maintain physical function.9

Exercise can reduce pain and disability associated with OA and is a first-line recommendation in guidelines for the treatment of knee and hip OA.9 Given the limited exercise and high levels of physical inactivity among veterans with OA, there is a need to identify opportunities that support veterans with OA engaging in regular exercise.

Gerofit, an outpatient clinical exercise program available at 30 Veterans Health Administration (VHA) sites, may provide an opportunity for older veterans with arthritis to engage in exercise.10 Gerofit is specifically designed for veterans aged ≥ 65 years. It is not disease-specific and supports older veterans with multiple chronic conditions, including OA. Veterans aged ≥ 65 years with a referral from a VA clinician are eligible for Gerofit. Those who are unable to perform activities of daily living; unable to independently function without assistance; have a history of unstable angina, proliferative diabetic retinopathy, oxygen dependence, volatile behavioral issues, or are unable to work successfully in a group environment/setting; experience active substance abuse, homelessness, or uncontrolled incontinence; and have open wounds that cannot be appropriately dressed are excluded from Gerofit. Exercise sessions are held 3 times per week and last from 60 to 90 minutes. Sessions are supervised by Gerofit staff and include personalized exercise prescriptions based on functional assessments. Exercise prescriptions include aerobic, resistance, and balance/flexibility components and are modified by the Gerofit program staff as needed. Gerofit adopts a functional fitness approach and includes individual progression as appropriate according to evidence-based guidelines, using the Borg ratings of perceived exertion. 11 Assessments are performed at baseline, 3 months, 6 months, and annually thereafter. Clinical staff conduct all assessments, including physical function testing, and record them in a database. Assessments are reviewed with the veteran to chart progress and identify future goals or needs. Veterans perform personalized self-paced exercises in the Gerofit group setting. Exercise prescriptions are continuously modified to meet individualized needs and goals. Veterans may participate continuously with no end date.

Participation in supervised exercise is associated with improved physical function and individuals with arthritis can improve function even though their baseline functional status is lower than individuals without arthritis. 12 In this analysis, we examine the impact of exercise on the status and location of arthritis (upper body, lower body, or both). Lower body arthritis is more common than upper body arthritis and lower extremity function is associated with increased ability to perform activities of daily living, resulting in independence among older adults.13,14 We also include upper body strength measures to capture important functional movements such as reaching and pulling.15 Among those who participate in Gerofit, the greatest gains in physical function occur during the initial 3 months, which tend to be sustained over 12 months.16 For this reason, this study focused on the initial 3 months of the program.

Older adults with arthritis may have pain and functional limitations that exceed those of the general older adult population. Exercise programs for older adults that do not specifically target arthritis but are able to improve physical function among those with arthritis could potentially increase access to exercise for older adults living with arthritis. Therefore, the purpose of this study was to determine whether change in physical function with participation in Gerofit for 3 months varies by arthritis status, including no arthritis, any arthritis, lower body arthritis, or both upper and lower body arthritis compared with no arthritis.

Methods

This is a secondary analysis of previously collected data from 10 VHA Gerofit sites (Ann Arbor, Baltimore, Greater Los Angeles, Canandaigua, Cincinnati, Miami, Honolulu, Denver, Durham, and Pittsburgh) from 2002 to 2019. Implementation data regarding the consistency of the program delivery at Gerofit expansion sites have been previously published.16 Although the delivery of Gerofit transitioned to telehealth due to COVID-19, data for this analysis were collected from in-person exercise sessions prior to the pandemic.17 Data were collected for clinical purposes. This project was part of the Gerofit quality improvement initiative and was reviewed and approved by the Durham Institutional Review Board as quality improvement.

Participants in Gerofit who completed baseline and 3-month assessments were included to analyze the effects of exercise on physical function. At each of the time points, physical functional assessments included: (1) usual gait speed (> 10 meters [m/s], or 10- meter walk test [10MWT]); (2) lower body strength (chair stands [number completed in 30 seconds]); (3) upper body strength (number of arm curls [5-lb for females/8-lb for males] completed in 30 seconds); and (4) 6-minute walk distance [6MWD] in meters to measure aerobic endurance). These measures have been validated in older adults.18-21 Arm curls were added to the physical function assessments after the 10MWT, chair stands, and 6MWD; therefore, fewer participants had data for this measure. Participants self-reported at baseline on 45 common medical conditions, including arthritis or rheumatism (both upper body and lower body were offered as choices). Self-reporting has been shown to be an acceptable method of identifying arthritis in adults.22

Descriptive statistics at baseline were calculated for all participants. One-way analysis of variance and X2 tests were used to determine differences in baseline characteristics across arthritis status. The primary outcomes were changes in physical function measures from baseline to 3 months by arthritis status. Arthritis status was defined as: any arthritis, which includes individuals who reported upper body arthritis, lower body arthritis, or both; and arthritis status individuals reporting either upper body arthritis, lower body arthritis, or both. Categories of arthritis for arthritis status were mutually exclusive. Two separate linear models were constructed for each of the 4 physical function measures, with change from baseline to 3 months as the outcome (dependent variable) and arthritis status, age, and body mass index (BMI) as predictors (independent variables). The first model compared any arthritis with no arthritis and the second model compared arthritis status (both upper and lower body arthritis vs lower body arthritis) with no arthritis. These models were used to obtain mean changes and 95% CIs in physical function and to test for differences in the change in physical function measures by arthritis status. Statistical analyses were performed using R software, version 4.0.3.

Results

Baseline and 3-month data were available for 737 Gerofit participants and included in the analysis. The mean (SD) age was 73.5 (7.1) years. A total of 707 participants were male (95.9%) and 322 (43.6%) reported some arthritis, with arthritis in both the upper and lower body being reported by 168 participants (52.2%) (Table 1). There were no differences in age, sex, or race for those with any arthritis compared with those with no arthritis, but BMI was significantly higher in those reporting any arthritis compared with no arthritis. For the baseline functional measures, statistically significant differences were observed between those with no arthritis and those reporting any arthritis for the 10MWT (P = .001), chair stands (P = .046), and 6MWD (P = .001), but not for arm curls (P = .77), with those with no arthritis performing better.

FDP04202100_T1

All 4 arthritis status groups showed improvements in each of the physical function measures over 3 months. For the 10MWT the mean change (95% CI) in gait speed (m/s) was 0.06 (0.04-0.08) for patients with no arthritis, 0.07 (0.05- 0.08) for any arthritis, 0.07 (0.04-0.11) for lower body arthritis, and 0.07 (0.04- 0.09) for both lower and upper body arthritis. For the number of arm curls in 30 seconds the mean change (95% CI) was 2.3 (1.8-2.8) for patients with no arthritis, 2.1 (1.5-2.6) for any arthritis, 2.0 (1.1-3.0) for lower body arthritis, and 1.9 (1.1-2.7) for both lower and upper body arthritis. For the number of chair stands in 30 seconds the mean change (95% CI) was 2.1 (1.7-2.4) for patients with no arthritis, 2.2 (1.8-2.6) for any arthritis, 2.3 (1.6-2.9), for lower body arthritis, and 2.0 (1.5-2.5) for both lower and upper body arthritis. For the 6MWD distance in meters the mean change (95% CI) was 21.5 (15.5-27.4) for patients with no arthritis, 28.6 (21.9-35.3) for any arthritis, 30.4 (19.5-41.3) for lower body arthritis, and 28.6 (19.2-38.0) for both lower and upper body arthritis (Figure).

FDP04202100_F1

We used 2 models to measure the change from baseline to 3 months for each of the arthritis groups. Model 1 compared any arthritis vs no arthritis and model 2 compared lower body arthritis and both upper and lower body arthritis vs no arthritis for each physical function measure (Table 2). There were no statistically significant differences in 3-month change in physical function for any of the physical function measures between arthritis groups after adjusting for age and BMI.

FDP04202100_T2

Discussion

Participation in Gerofit was associated with functional gains among all participants over 3 months, regardless of arthritis status. Older veterans reporting any arthritis had significantly lower physical function scores upon enrollment into Gerofit compared with those veterans reporting no arthritis. However, compared with individuals who reported no arthritis, individuals who reported arthritis (any arthritis, lower body arthritis only, or both lower and upper body arthritis) experienced similar improvements (ie, no statistically significant differences in mean change from baseline to follow-up among those with and without arthritis). This study suggests that progressive, multicomponent exercise programs for older adults may be beneficial for those with arthritis.

Involvement of multiple sites of arthritis is associated with moderate to severe functional limitations as well as lower healthrelated quality of life.23 While it has been found that individuals with arthritis can improve function with supervised exercise, even though their baseline functional status is lower than individuals without arthritis, it was not clear whether individuals with multiple joint involvement also would benefit.12 The results of this study suggest that these individuals can improve across various domains of physical function despite variation in arthritis location and status. As incidence of arthritis increases with age, targeting older adults for exercise programs such as Gerofit may improve functional limitations and health-related quality of life associated with arthritis.2

We evaluated physical function using multiple measures to assess upper (arm curls) and lower (chair stands, 10MWT) extremity physical function and aerobic endurance (6MWD). Participants in this study reached clinically meaningful changes with 3 months of participation in Gerofit for most of the physical function measures. Gerofit participants had a mean gait speed improvement of 0.05 to 0.07 m/s compared with 0.10 to 0.30 m/s, which was reported previously. 24,25 In this study, nearly all groups achieved the clinically important improvements in the chair stand in 30 seconds (2.0 to 2.6) and the 6MWD (21.8 to 59.1 m) that have been reported in the literature.24-26

The Osteoarthritis Research Society International recommends the chair stand and 6MWD performance-based tests for individuals with hip and knee arthritis because they align with patient-reported outcomes and represent the types of activities relevant to this population.27 The findings of this study suggest that improvement in these physical function measures with participation in exercise align with data from arthritis-specific exercise programs designed for wide implementation. Hughes and colleagues reported improvements in the 6MWD after the 8-week Fit and Strong exercise intervention, which included walking and lower body resistance training.28 The Arthritis Foundation’s Walk With Ease program is a 6-week walking program that has shown improvements in chair stands and gait speed.29 Another Arthritis Foundation program, People with Arthritis Can Exercise, is an 8-week course consisting of a variety of resistance, aerobic, and balance activities. This program has been associated with increases in chair stands but not gait speed or 6MWD.30,31

This study found that participation in a VHA outpatient clinical supervised exercise program results in improvements in physical function that can be realized by older adults regardless of arthritis burden. Gerofit programs typically require 1.5 to 2.0 dedicated full-time equivalent employees to run the program effectively and additional administrative support, depending on size of the program.32 The cost savings generated by the program include reductions in hospitalization rates, emergency department visits, days in hospital, and medication use and provide a compelling argument for the program’s financial viability to health care systems through long-term savings and improved health outcomes for older adults.33-36

While evidenced-based arthritis programs exist, this study illustrates that an exercise program without a focus on arthritis also improves physical function, potentially reducing the risk of disability related to arthritis. The clinical implication for these findings is that arthritis-specific exercise programs may not be needed to achieve functional improvements in individuals with arthritis. This is critical for under-resourced or exercise- limited health care systems or communities. Therefore, if exercise programming is limited, or arthritis-specific programs and interventions are not available, nonspecific exercise programs will also be beneficial to individuals with arthritis. Thus, individuals with arthritis should be encouraged to participate in any available exercise programming to achieve improvements in physical function. In addition, many older adults have multiple comorbidities, most of which improve with participation in exercise. 37 Disease-specific exercise programs can offer tailored exercises and coaching related to common barriers in participation, such as joint pain for arthritis.31 It is unclear whether these additional programmatic components are associated with greater improvements in outcomes, such as physical function. More research is needed to explore the benefits of disease-specific tailored exercise programs compared with general exercise programs.

Strengths and Limitations

This study demonstrated the effect of participation in a clinical, supervised exercise program in a real-world setting. It suggests that even exercise programs not specifically targeted for arthritis populations can improve physical function among those with arthritis.

As a VHA clinical supervised exercise program, Gerofit may not be generalizable to all older adults or other exercise programs. In addition, this analysis only included a veteran population that was > 95% male and may not be generalizable to other populations. Arthritis status was defined by self-report and not verified in the health record. However, this approach has been shown to be acceptable in this setting and the most common type of arthritis in this population (OA) is a painful musculoskeletal condition associated with functional limitations.4,22,38,39 Self-reported arthritis or rheumatism is associated with functional limitations.1 Therefore, it is unlikely that the results would differ for physician-diagnosed or radiographically defined OA. Additionally, the study did not have data on the total number of joints with arthritis or arthritis severity but rather used upper body, lower body, and both upper and lower body arthritis as a proxy for arthritis status. While our models were adjusted for age and BMI, 2 known confounding factors for the association between arthritis and physical function, there are other potential confounding factors that were not included in the models. 40,41 Finally, this study only included individuals with completed baseline and 3-month follow-up assessments, and the individuals who participated for longer or shorter periods may have had different physical function outcomes than individuals included in this study.

Conclusions

Participation in 3 months VHA Gerofit outpatient supervised exercise programs can improve physical function for all older adults, regardless of arthritis status. These programs may increase access to exercise programming that is beneficial for common conditions affecting older adults, such as arthritis.

About half of US adults aged ≥ 65 years report arthritis, and of those, 44% have an arthritis-attributable activity limitation.1,2 Arthritis is a significant health issue for veterans, with veterans reporting higher rates of disability compared with the civilian population.3

Osteoarthritis (OA) is the most common type of arthritis.4 Among individuals aged ≥ 40 years, the incidence of OA is nearly twice as high among veterans compared with civilians and is a leading cause of separation from military service and disability.5,6 OA pain and disability have been shown to be associated with increases in health care and medication use, including opioids, nonsteroidal anti-inflammatory medications, and muscle relaxants.7,8 Because OA is chronic and has no cure, safe and effective management strategies—such as exercise— are critical to minimize pain and maintain physical function.9

Exercise can reduce pain and disability associated with OA and is a first-line recommendation in guidelines for the treatment of knee and hip OA.9 Given the limited exercise and high levels of physical inactivity among veterans with OA, there is a need to identify opportunities that support veterans with OA engaging in regular exercise.

Gerofit, an outpatient clinical exercise program available at 30 Veterans Health Administration (VHA) sites, may provide an opportunity for older veterans with arthritis to engage in exercise.10 Gerofit is specifically designed for veterans aged ≥ 65 years. It is not disease-specific and supports older veterans with multiple chronic conditions, including OA. Veterans aged ≥ 65 years with a referral from a VA clinician are eligible for Gerofit. Those who are unable to perform activities of daily living; unable to independently function without assistance; have a history of unstable angina, proliferative diabetic retinopathy, oxygen dependence, volatile behavioral issues, or are unable to work successfully in a group environment/setting; experience active substance abuse, homelessness, or uncontrolled incontinence; and have open wounds that cannot be appropriately dressed are excluded from Gerofit. Exercise sessions are held 3 times per week and last from 60 to 90 minutes. Sessions are supervised by Gerofit staff and include personalized exercise prescriptions based on functional assessments. Exercise prescriptions include aerobic, resistance, and balance/flexibility components and are modified by the Gerofit program staff as needed. Gerofit adopts a functional fitness approach and includes individual progression as appropriate according to evidence-based guidelines, using the Borg ratings of perceived exertion. 11 Assessments are performed at baseline, 3 months, 6 months, and annually thereafter. Clinical staff conduct all assessments, including physical function testing, and record them in a database. Assessments are reviewed with the veteran to chart progress and identify future goals or needs. Veterans perform personalized self-paced exercises in the Gerofit group setting. Exercise prescriptions are continuously modified to meet individualized needs and goals. Veterans may participate continuously with no end date.

Participation in supervised exercise is associated with improved physical function and individuals with arthritis can improve function even though their baseline functional status is lower than individuals without arthritis. 12 In this analysis, we examine the impact of exercise on the status and location of arthritis (upper body, lower body, or both). Lower body arthritis is more common than upper body arthritis and lower extremity function is associated with increased ability to perform activities of daily living, resulting in independence among older adults.13,14 We also include upper body strength measures to capture important functional movements such as reaching and pulling.15 Among those who participate in Gerofit, the greatest gains in physical function occur during the initial 3 months, which tend to be sustained over 12 months.16 For this reason, this study focused on the initial 3 months of the program.

Older adults with arthritis may have pain and functional limitations that exceed those of the general older adult population. Exercise programs for older adults that do not specifically target arthritis but are able to improve physical function among those with arthritis could potentially increase access to exercise for older adults living with arthritis. Therefore, the purpose of this study was to determine whether change in physical function with participation in Gerofit for 3 months varies by arthritis status, including no arthritis, any arthritis, lower body arthritis, or both upper and lower body arthritis compared with no arthritis.

Methods

This is a secondary analysis of previously collected data from 10 VHA Gerofit sites (Ann Arbor, Baltimore, Greater Los Angeles, Canandaigua, Cincinnati, Miami, Honolulu, Denver, Durham, and Pittsburgh) from 2002 to 2019. Implementation data regarding the consistency of the program delivery at Gerofit expansion sites have been previously published.16 Although the delivery of Gerofit transitioned to telehealth due to COVID-19, data for this analysis were collected from in-person exercise sessions prior to the pandemic.17 Data were collected for clinical purposes. This project was part of the Gerofit quality improvement initiative and was reviewed and approved by the Durham Institutional Review Board as quality improvement.

Participants in Gerofit who completed baseline and 3-month assessments were included to analyze the effects of exercise on physical function. At each of the time points, physical functional assessments included: (1) usual gait speed (> 10 meters [m/s], or 10- meter walk test [10MWT]); (2) lower body strength (chair stands [number completed in 30 seconds]); (3) upper body strength (number of arm curls [5-lb for females/8-lb for males] completed in 30 seconds); and (4) 6-minute walk distance [6MWD] in meters to measure aerobic endurance). These measures have been validated in older adults.18-21 Arm curls were added to the physical function assessments after the 10MWT, chair stands, and 6MWD; therefore, fewer participants had data for this measure. Participants self-reported at baseline on 45 common medical conditions, including arthritis or rheumatism (both upper body and lower body were offered as choices). Self-reporting has been shown to be an acceptable method of identifying arthritis in adults.22

Descriptive statistics at baseline were calculated for all participants. One-way analysis of variance and X2 tests were used to determine differences in baseline characteristics across arthritis status. The primary outcomes were changes in physical function measures from baseline to 3 months by arthritis status. Arthritis status was defined as: any arthritis, which includes individuals who reported upper body arthritis, lower body arthritis, or both; and arthritis status individuals reporting either upper body arthritis, lower body arthritis, or both. Categories of arthritis for arthritis status were mutually exclusive. Two separate linear models were constructed for each of the 4 physical function measures, with change from baseline to 3 months as the outcome (dependent variable) and arthritis status, age, and body mass index (BMI) as predictors (independent variables). The first model compared any arthritis with no arthritis and the second model compared arthritis status (both upper and lower body arthritis vs lower body arthritis) with no arthritis. These models were used to obtain mean changes and 95% CIs in physical function and to test for differences in the change in physical function measures by arthritis status. Statistical analyses were performed using R software, version 4.0.3.

Results

Baseline and 3-month data were available for 737 Gerofit participants and included in the analysis. The mean (SD) age was 73.5 (7.1) years. A total of 707 participants were male (95.9%) and 322 (43.6%) reported some arthritis, with arthritis in both the upper and lower body being reported by 168 participants (52.2%) (Table 1). There were no differences in age, sex, or race for those with any arthritis compared with those with no arthritis, but BMI was significantly higher in those reporting any arthritis compared with no arthritis. For the baseline functional measures, statistically significant differences were observed between those with no arthritis and those reporting any arthritis for the 10MWT (P = .001), chair stands (P = .046), and 6MWD (P = .001), but not for arm curls (P = .77), with those with no arthritis performing better.

FDP04202100_T1

All 4 arthritis status groups showed improvements in each of the physical function measures over 3 months. For the 10MWT the mean change (95% CI) in gait speed (m/s) was 0.06 (0.04-0.08) for patients with no arthritis, 0.07 (0.05- 0.08) for any arthritis, 0.07 (0.04-0.11) for lower body arthritis, and 0.07 (0.04- 0.09) for both lower and upper body arthritis. For the number of arm curls in 30 seconds the mean change (95% CI) was 2.3 (1.8-2.8) for patients with no arthritis, 2.1 (1.5-2.6) for any arthritis, 2.0 (1.1-3.0) for lower body arthritis, and 1.9 (1.1-2.7) for both lower and upper body arthritis. For the number of chair stands in 30 seconds the mean change (95% CI) was 2.1 (1.7-2.4) for patients with no arthritis, 2.2 (1.8-2.6) for any arthritis, 2.3 (1.6-2.9), for lower body arthritis, and 2.0 (1.5-2.5) for both lower and upper body arthritis. For the 6MWD distance in meters the mean change (95% CI) was 21.5 (15.5-27.4) for patients with no arthritis, 28.6 (21.9-35.3) for any arthritis, 30.4 (19.5-41.3) for lower body arthritis, and 28.6 (19.2-38.0) for both lower and upper body arthritis (Figure).

FDP04202100_F1

We used 2 models to measure the change from baseline to 3 months for each of the arthritis groups. Model 1 compared any arthritis vs no arthritis and model 2 compared lower body arthritis and both upper and lower body arthritis vs no arthritis for each physical function measure (Table 2). There were no statistically significant differences in 3-month change in physical function for any of the physical function measures between arthritis groups after adjusting for age and BMI.

FDP04202100_T2

Discussion

Participation in Gerofit was associated with functional gains among all participants over 3 months, regardless of arthritis status. Older veterans reporting any arthritis had significantly lower physical function scores upon enrollment into Gerofit compared with those veterans reporting no arthritis. However, compared with individuals who reported no arthritis, individuals who reported arthritis (any arthritis, lower body arthritis only, or both lower and upper body arthritis) experienced similar improvements (ie, no statistically significant differences in mean change from baseline to follow-up among those with and without arthritis). This study suggests that progressive, multicomponent exercise programs for older adults may be beneficial for those with arthritis.

Involvement of multiple sites of arthritis is associated with moderate to severe functional limitations as well as lower healthrelated quality of life.23 While it has been found that individuals with arthritis can improve function with supervised exercise, even though their baseline functional status is lower than individuals without arthritis, it was not clear whether individuals with multiple joint involvement also would benefit.12 The results of this study suggest that these individuals can improve across various domains of physical function despite variation in arthritis location and status. As incidence of arthritis increases with age, targeting older adults for exercise programs such as Gerofit may improve functional limitations and health-related quality of life associated with arthritis.2

We evaluated physical function using multiple measures to assess upper (arm curls) and lower (chair stands, 10MWT) extremity physical function and aerobic endurance (6MWD). Participants in this study reached clinically meaningful changes with 3 months of participation in Gerofit for most of the physical function measures. Gerofit participants had a mean gait speed improvement of 0.05 to 0.07 m/s compared with 0.10 to 0.30 m/s, which was reported previously. 24,25 In this study, nearly all groups achieved the clinically important improvements in the chair stand in 30 seconds (2.0 to 2.6) and the 6MWD (21.8 to 59.1 m) that have been reported in the literature.24-26

The Osteoarthritis Research Society International recommends the chair stand and 6MWD performance-based tests for individuals with hip and knee arthritis because they align with patient-reported outcomes and represent the types of activities relevant to this population.27 The findings of this study suggest that improvement in these physical function measures with participation in exercise align with data from arthritis-specific exercise programs designed for wide implementation. Hughes and colleagues reported improvements in the 6MWD after the 8-week Fit and Strong exercise intervention, which included walking and lower body resistance training.28 The Arthritis Foundation’s Walk With Ease program is a 6-week walking program that has shown improvements in chair stands and gait speed.29 Another Arthritis Foundation program, People with Arthritis Can Exercise, is an 8-week course consisting of a variety of resistance, aerobic, and balance activities. This program has been associated with increases in chair stands but not gait speed or 6MWD.30,31

This study found that participation in a VHA outpatient clinical supervised exercise program results in improvements in physical function that can be realized by older adults regardless of arthritis burden. Gerofit programs typically require 1.5 to 2.0 dedicated full-time equivalent employees to run the program effectively and additional administrative support, depending on size of the program.32 The cost savings generated by the program include reductions in hospitalization rates, emergency department visits, days in hospital, and medication use and provide a compelling argument for the program’s financial viability to health care systems through long-term savings and improved health outcomes for older adults.33-36

While evidenced-based arthritis programs exist, this study illustrates that an exercise program without a focus on arthritis also improves physical function, potentially reducing the risk of disability related to arthritis. The clinical implication for these findings is that arthritis-specific exercise programs may not be needed to achieve functional improvements in individuals with arthritis. This is critical for under-resourced or exercise- limited health care systems or communities. Therefore, if exercise programming is limited, or arthritis-specific programs and interventions are not available, nonspecific exercise programs will also be beneficial to individuals with arthritis. Thus, individuals with arthritis should be encouraged to participate in any available exercise programming to achieve improvements in physical function. In addition, many older adults have multiple comorbidities, most of which improve with participation in exercise. 37 Disease-specific exercise programs can offer tailored exercises and coaching related to common barriers in participation, such as joint pain for arthritis.31 It is unclear whether these additional programmatic components are associated with greater improvements in outcomes, such as physical function. More research is needed to explore the benefits of disease-specific tailored exercise programs compared with general exercise programs.

Strengths and Limitations

This study demonstrated the effect of participation in a clinical, supervised exercise program in a real-world setting. It suggests that even exercise programs not specifically targeted for arthritis populations can improve physical function among those with arthritis.

As a VHA clinical supervised exercise program, Gerofit may not be generalizable to all older adults or other exercise programs. In addition, this analysis only included a veteran population that was > 95% male and may not be generalizable to other populations. Arthritis status was defined by self-report and not verified in the health record. However, this approach has been shown to be acceptable in this setting and the most common type of arthritis in this population (OA) is a painful musculoskeletal condition associated with functional limitations.4,22,38,39 Self-reported arthritis or rheumatism is associated with functional limitations.1 Therefore, it is unlikely that the results would differ for physician-diagnosed or radiographically defined OA. Additionally, the study did not have data on the total number of joints with arthritis or arthritis severity but rather used upper body, lower body, and both upper and lower body arthritis as a proxy for arthritis status. While our models were adjusted for age and BMI, 2 known confounding factors for the association between arthritis and physical function, there are other potential confounding factors that were not included in the models. 40,41 Finally, this study only included individuals with completed baseline and 3-month follow-up assessments, and the individuals who participated for longer or shorter periods may have had different physical function outcomes than individuals included in this study.

Conclusions

Participation in 3 months VHA Gerofit outpatient supervised exercise programs can improve physical function for all older adults, regardless of arthritis status. These programs may increase access to exercise programming that is beneficial for common conditions affecting older adults, such as arthritis.

References
  1. Centers for Disease Control and Prevention. Prevalence and most common causes of disability among adults- -United States, 2005. MMWR Morb Mortal Wkly Rep. 2009;58:421-426.
  2. Theis KA, Murphy LB, Guglielmo D, et al. Prevalence of arthritis and arthritis-attributable activity limitation—United States, 2016–2018. MMWR Morb Mortal Wkly Rep. 2021;70:1401-1407. doi:10.15585/mmwr.mm7040a2
  3. Murphy LB, Helmick CG, Allen KD, et al. Arthritis among veterans—United States, 2011–2013. MMWR Morb Mortal Wkly Rep. 2014;63:999-1003.
  4. Park J, Mendy A, Vieira ER. Various types of arthritis in the United States: prevalence and age-related trends from 1999 to 2014. Am J Public Health. 2018;108:256-258.
  5. Cameron KL, Hsiao MS, Owens BD, Burks R, Svoboda SJ. Incidence of physician-diagnosed osteoarthritis among active duty United States military service members. Arthritis Rheum. 2011;63:2974-2982. doi:10.1002/art.30498
  6. Patzkowski JC, Rivera JC, Ficke JR, Wenke JC. The changing face of disability in the US Army: the Operation Enduring Freedom and Operation Iraqi Freedom effect. J Am Acad Orthop Surg. 2012;20(suppl 1):S23-S30. doi:10.5435/JAAOS-20-08-S23
  7. Rivera JC, Amuan ME, Morris RM, Johnson AE, Pugh MJ. Arthritis, comorbidities, and care utilization in veterans of Operations Enduring and Iraqi Freedom. J Orthop Res. 2017;35:682-687. doi:10.1002/jor.23323
  8. Singh JA, Nelson DB, Fink HA, Nichol KL. Health-related quality of life predicts future health care utilization and mortality in veterans with self-reported physician-diagnosed arthritis: the Veterans Arthritis Quality of Life Study. Semin Arthritis Rheum. 2005;34:755- 765. doi:10.1016/j.semarthrit.2004.08.001
  9. Nelson AE, Allen KD, Golightly YM, Goode AP, Jordan JM. A systematic review of recommendations and guidelines for the management of osteoarthritis: the Chronic Osteoarthritis Management Initiative of the U.S. Bone and Joint Initiative. Semin Arthritis Rheum. 2014;43:701-712. doi:10.1016/j.semarthrit.2013.11.012
  10. Morey MC, Crowley GM, Robbins MS, Cowper PA, Sullivan RJ Jr. The Gerofit Program: a VA innovation. South Med J. 1994;87:S83-S87.
  11. Chen MJ, Fan X, Moe ST. Criterion-related validity of the Borg ratings of perceived exertion scale in healthy individuals: a meta-analysis. J Sports Sci. 2002;20:873-899. doi:10.1080/026404102320761787
  12. Morey MC, Pieper CF, Sullivan RJ Jr, Crowley GM, Cowper PA, Robbins MS. Five-year performance trends for older exercisers: a hierarchical model of endurance, strength, and flexibility. J Am Geriatr Soc. 1996;44:1226-1231. doi:10.1111/j.1532-5415.1996.tb01374.x
  13. Allen KD, Gol ight ly YM. State of the evidence. Curr Opin Rheumatol. 2015;27:276-283. doi:10.1097/BOR.0000000000000161
  14. den Ouden MEM, Schuurmans MJ, Arts IEMA, van der Schouw YT. Association between physical performance characteristics and independence in activities of daily living in middle-aged and elderly men. Geriatr Gerontol Int. 2013;13:274-280. doi:10.1111/j.1447-0594.2012.00890.x
  15. Daly M, Vidt ME, Eggebeen JD, et al. Upper extremity muscle volumes and functional strength after resistance training in older adults. J Aging Phys Act. 2013;21:186-207. doi:10.1123/japa.21.2.186
  16. Morey MC, Lee CC, Castle S, et al. Should structured exercise be promoted as a model of care? Dissemination of the Department of Veterans Affairs Gerofit Program. J Am Geriatr Soc. 2018;66:1009-1016. doi:10.1111/jgs.15276
  17. Jennings SC, Manning KM, Bettger JP, et al. Rapid transition to telehealth group exercise and functional assessments in response to COVID-19. Gerontol Geriatr Med. 2020;6:2333721420980313. doi:10.1177/ 2333721420980313
  18. Studenski S, Perera S, Wallace D, et al. Physical performance measures in the clinical setting. J Am Geriatr Soc. 2003;51:314-322. doi:10.1046/j.1532-5415.2003.51104.x
  19. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community residing older adults. Res Q Exerc Sport. 1999;70:113- 119. doi:10.1080/02701367.1999.10608028
  20. Rikli RE, Jones CJ. Development and validation of a functional fitness test for community-residing older adults. J Aging Phys Act. 1999;7:129-161. doi:10.1123/japa.7.2.129
  21. Harada ND, Chiu V, Stewart AL. Mobility-related function in older adults: assessment with a 6-minute walk test. Arch Phys Med Rehabil. 1999;80:837-841. doi:10.1016/s0003-9993(99)90236-8
  22. Peeters GGME, Alshurafa M, Schaap L, de Vet HCW. Diagnostic accuracy of self-reported arthritis in the general adult population is acceptable. J Clin Epidemiol. 2015;68:452-459. doi:10.1016/j.jclinepi.2014.09.019
  23. Cuperus N, Vliet Vlieland TPM, Mahler EAM, Kersten CC, Hoogeboom TJ, van den Ende CHM. The clinical burden of generalized osteoarthritis represented by self-reported health-related quality of life and activity limitations: a cross-sectional study. Rheumatol Int. 2015;35:871-877. doi:10.1007/s00296-014-3149-1
  24. Coleman G, Dobson F, Hinman RS, Bennell K, White DK. Measures of physical performance. Arthritis Care Res (Hoboken). 2020;72(suppl 10):452-485. doi:10.1002/acr.24373
  25. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54:743-749. doi:10.1111/j.1532-5415.2006.00701.x
  26. Wright AA, Cook CE, Baxter GD, Dockerty JD, Abbott JH. A comparison of 3 methodological approaches to defining major clinically important improvement of 4 performance measures in patients with hip osteoarthritis. J Orthop Sports Phys Ther. 2011;41:319-327. doi:10.2519/jospt.2011.3515
  27. Dobson F, Hinman R, Roos EM, et al. OARSI recommended performance-based tests to assess physical function in people diagnosed with hip or knee osteoarthritis. Osteoarthritis Cartilage. 2013;21:1042- 1052. doi:10.1016/j.joca.2013.05.002
  28. Hughes SL, Seymour RB, Campbell R, Pollak N, Huber G, Sharma L. Impact of the fit and strong intervention on older adults with osteoarthritis. Gerontologist. 2004;44:217-228. doi:10.1093/geront/44.2.217
  29. Callahan LF, Shreffler JH, Altpeter M, et al. Evaluation of group and self-directed formats of the Arthritis Foundation's Walk With Ease Program. Arthritis Care Res (Hoboken). 2011;63:1098-1107. doi:10.1002/acr.20490
  30. Boutaugh ML. Arthritis Foundation community-based physical activity programs: effectiveness and implementation issues. Arthritis Rheum. 2003;49:463-470. doi:10.1002/art.11050
  31. Callahan LF, Mielenz T, Freburger J, et al. A randomized controlled trial of the People with Arthritis Can Exercise Program: symptoms, function, physical activity, and psychosocial outcomes. Arthritis Rheum. 2008;59:92-101. doi:10.1002/art.23239
  32. Hall KS, Jennings SC, Pearson MP. Outpatient care models: the Gerofit model of care for exercise promotion in older adults. In: Malone ML, Boltz M, Macias Tejada J, White H, eds. Geriatrics Models of Care. Springer; 2024:205-213. doi:10.1007/978-3-031-56204-4_21
  33. Pepin MJ, Valencia WM, Bettger JP, et al. Impact of supervised exercise on one-year medication use in older veterans with multiple morbidities. Gerontol Geriatr Med. 2020;6:2333721420956751. doi:10.1177/ 2333721420956751
  34. Abbate L, Li J, Veazie P, et al. Does Gerofit exercise reduce veterans’ use of emergency department and inpatient care? Innov Aging. 2020;4(suppl 1):771. doi:10.1093/geroni/igaa057.2786
  35. Morey MC, Pieper CF, Crowley GM, Sullivan RJ Jr, Puglisi CM. Exercise adherence and 10-year mortality in chronically ill older adults. J Am Geriatr Soc. 2002;50:1929-1933. doi:10.1046/j.1532-5415.2002.50602.x
  36. Manning KM, Hall KS, Sloane R, et al. Longitudinal analysis of physical function in older adults: the effects of physical inactivity and exercise training. Aging Cell. 2024;23:e13987. doi:10.1111/acel.13987
  37. Bean JF, Vora A, Frontera WR. Benefits of exercise for community-dwelling older adults. Arch Phys Med Rehabil. 2004;85(7 suppl 3):S31-S42; quiz S3-S4. doi:10.1016/j.apmr.2004.03.010
  38. Covinsky KE, Lindquist K, Dunlop DD, Yelin E. Pain, functional limitations, and aging. J Am Geriatr Soc. 2009; 57:1556-1561. doi:10.1111/j.1532-5415.2009.02388.x
  39. Katz JN, Wright EA, Baron JA, Losina E. Development and validation of an index of musculoskeletal functional limitations. BMC Musculoskelet Disord. 2009;10:62. doi:10.1186/1471-2474-10-62
  40. Allen KD, Thoma LM, Golightly YM. Epidemiology of osteoarthritis. Osteoarthritis Cartilage. 2022;30:184-195. doi:10.1016/j.joca.2021.04.020
  41. Riebe D, Blissmer BJ, Greaney ML, Ewing Garber C, Lees FD, Clark PG. The relationship between obesity, physical activity, and physical function in older adults. J Aging Health. 2009;21:1159-1178. doi:10.1177/0898264309350076
References
  1. Centers for Disease Control and Prevention. Prevalence and most common causes of disability among adults- -United States, 2005. MMWR Morb Mortal Wkly Rep. 2009;58:421-426.
  2. Theis KA, Murphy LB, Guglielmo D, et al. Prevalence of arthritis and arthritis-attributable activity limitation—United States, 2016–2018. MMWR Morb Mortal Wkly Rep. 2021;70:1401-1407. doi:10.15585/mmwr.mm7040a2
  3. Murphy LB, Helmick CG, Allen KD, et al. Arthritis among veterans—United States, 2011–2013. MMWR Morb Mortal Wkly Rep. 2014;63:999-1003.
  4. Park J, Mendy A, Vieira ER. Various types of arthritis in the United States: prevalence and age-related trends from 1999 to 2014. Am J Public Health. 2018;108:256-258.
  5. Cameron KL, Hsiao MS, Owens BD, Burks R, Svoboda SJ. Incidence of physician-diagnosed osteoarthritis among active duty United States military service members. Arthritis Rheum. 2011;63:2974-2982. doi:10.1002/art.30498
  6. Patzkowski JC, Rivera JC, Ficke JR, Wenke JC. The changing face of disability in the US Army: the Operation Enduring Freedom and Operation Iraqi Freedom effect. J Am Acad Orthop Surg. 2012;20(suppl 1):S23-S30. doi:10.5435/JAAOS-20-08-S23
  7. Rivera JC, Amuan ME, Morris RM, Johnson AE, Pugh MJ. Arthritis, comorbidities, and care utilization in veterans of Operations Enduring and Iraqi Freedom. J Orthop Res. 2017;35:682-687. doi:10.1002/jor.23323
  8. Singh JA, Nelson DB, Fink HA, Nichol KL. Health-related quality of life predicts future health care utilization and mortality in veterans with self-reported physician-diagnosed arthritis: the Veterans Arthritis Quality of Life Study. Semin Arthritis Rheum. 2005;34:755- 765. doi:10.1016/j.semarthrit.2004.08.001
  9. Nelson AE, Allen KD, Golightly YM, Goode AP, Jordan JM. A systematic review of recommendations and guidelines for the management of osteoarthritis: the Chronic Osteoarthritis Management Initiative of the U.S. Bone and Joint Initiative. Semin Arthritis Rheum. 2014;43:701-712. doi:10.1016/j.semarthrit.2013.11.012
  10. Morey MC, Crowley GM, Robbins MS, Cowper PA, Sullivan RJ Jr. The Gerofit Program: a VA innovation. South Med J. 1994;87:S83-S87.
  11. Chen MJ, Fan X, Moe ST. Criterion-related validity of the Borg ratings of perceived exertion scale in healthy individuals: a meta-analysis. J Sports Sci. 2002;20:873-899. doi:10.1080/026404102320761787
  12. Morey MC, Pieper CF, Sullivan RJ Jr, Crowley GM, Cowper PA, Robbins MS. Five-year performance trends for older exercisers: a hierarchical model of endurance, strength, and flexibility. J Am Geriatr Soc. 1996;44:1226-1231. doi:10.1111/j.1532-5415.1996.tb01374.x
  13. Allen KD, Gol ight ly YM. State of the evidence. Curr Opin Rheumatol. 2015;27:276-283. doi:10.1097/BOR.0000000000000161
  14. den Ouden MEM, Schuurmans MJ, Arts IEMA, van der Schouw YT. Association between physical performance characteristics and independence in activities of daily living in middle-aged and elderly men. Geriatr Gerontol Int. 2013;13:274-280. doi:10.1111/j.1447-0594.2012.00890.x
  15. Daly M, Vidt ME, Eggebeen JD, et al. Upper extremity muscle volumes and functional strength after resistance training in older adults. J Aging Phys Act. 2013;21:186-207. doi:10.1123/japa.21.2.186
  16. Morey MC, Lee CC, Castle S, et al. Should structured exercise be promoted as a model of care? Dissemination of the Department of Veterans Affairs Gerofit Program. J Am Geriatr Soc. 2018;66:1009-1016. doi:10.1111/jgs.15276
  17. Jennings SC, Manning KM, Bettger JP, et al. Rapid transition to telehealth group exercise and functional assessments in response to COVID-19. Gerontol Geriatr Med. 2020;6:2333721420980313. doi:10.1177/ 2333721420980313
  18. Studenski S, Perera S, Wallace D, et al. Physical performance measures in the clinical setting. J Am Geriatr Soc. 2003;51:314-322. doi:10.1046/j.1532-5415.2003.51104.x
  19. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community residing older adults. Res Q Exerc Sport. 1999;70:113- 119. doi:10.1080/02701367.1999.10608028
  20. Rikli RE, Jones CJ. Development and validation of a functional fitness test for community-residing older adults. J Aging Phys Act. 1999;7:129-161. doi:10.1123/japa.7.2.129
  21. Harada ND, Chiu V, Stewart AL. Mobility-related function in older adults: assessment with a 6-minute walk test. Arch Phys Med Rehabil. 1999;80:837-841. doi:10.1016/s0003-9993(99)90236-8
  22. Peeters GGME, Alshurafa M, Schaap L, de Vet HCW. Diagnostic accuracy of self-reported arthritis in the general adult population is acceptable. J Clin Epidemiol. 2015;68:452-459. doi:10.1016/j.jclinepi.2014.09.019
  23. Cuperus N, Vliet Vlieland TPM, Mahler EAM, Kersten CC, Hoogeboom TJ, van den Ende CHM. The clinical burden of generalized osteoarthritis represented by self-reported health-related quality of life and activity limitations: a cross-sectional study. Rheumatol Int. 2015;35:871-877. doi:10.1007/s00296-014-3149-1
  24. Coleman G, Dobson F, Hinman RS, Bennell K, White DK. Measures of physical performance. Arthritis Care Res (Hoboken). 2020;72(suppl 10):452-485. doi:10.1002/acr.24373
  25. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54:743-749. doi:10.1111/j.1532-5415.2006.00701.x
  26. Wright AA, Cook CE, Baxter GD, Dockerty JD, Abbott JH. A comparison of 3 methodological approaches to defining major clinically important improvement of 4 performance measures in patients with hip osteoarthritis. J Orthop Sports Phys Ther. 2011;41:319-327. doi:10.2519/jospt.2011.3515
  27. Dobson F, Hinman R, Roos EM, et al. OARSI recommended performance-based tests to assess physical function in people diagnosed with hip or knee osteoarthritis. Osteoarthritis Cartilage. 2013;21:1042- 1052. doi:10.1016/j.joca.2013.05.002
  28. Hughes SL, Seymour RB, Campbell R, Pollak N, Huber G, Sharma L. Impact of the fit and strong intervention on older adults with osteoarthritis. Gerontologist. 2004;44:217-228. doi:10.1093/geront/44.2.217
  29. Callahan LF, Shreffler JH, Altpeter M, et al. Evaluation of group and self-directed formats of the Arthritis Foundation's Walk With Ease Program. Arthritis Care Res (Hoboken). 2011;63:1098-1107. doi:10.1002/acr.20490
  30. Boutaugh ML. Arthritis Foundation community-based physical activity programs: effectiveness and implementation issues. Arthritis Rheum. 2003;49:463-470. doi:10.1002/art.11050
  31. Callahan LF, Mielenz T, Freburger J, et al. A randomized controlled trial of the People with Arthritis Can Exercise Program: symptoms, function, physical activity, and psychosocial outcomes. Arthritis Rheum. 2008;59:92-101. doi:10.1002/art.23239
  32. Hall KS, Jennings SC, Pearson MP. Outpatient care models: the Gerofit model of care for exercise promotion in older adults. In: Malone ML, Boltz M, Macias Tejada J, White H, eds. Geriatrics Models of Care. Springer; 2024:205-213. doi:10.1007/978-3-031-56204-4_21
  33. Pepin MJ, Valencia WM, Bettger JP, et al. Impact of supervised exercise on one-year medication use in older veterans with multiple morbidities. Gerontol Geriatr Med. 2020;6:2333721420956751. doi:10.1177/ 2333721420956751
  34. Abbate L, Li J, Veazie P, et al. Does Gerofit exercise reduce veterans’ use of emergency department and inpatient care? Innov Aging. 2020;4(suppl 1):771. doi:10.1093/geroni/igaa057.2786
  35. Morey MC, Pieper CF, Crowley GM, Sullivan RJ Jr, Puglisi CM. Exercise adherence and 10-year mortality in chronically ill older adults. J Am Geriatr Soc. 2002;50:1929-1933. doi:10.1046/j.1532-5415.2002.50602.x
  36. Manning KM, Hall KS, Sloane R, et al. Longitudinal analysis of physical function in older adults: the effects of physical inactivity and exercise training. Aging Cell. 2024;23:e13987. doi:10.1111/acel.13987
  37. Bean JF, Vora A, Frontera WR. Benefits of exercise for community-dwelling older adults. Arch Phys Med Rehabil. 2004;85(7 suppl 3):S31-S42; quiz S3-S4. doi:10.1016/j.apmr.2004.03.010
  38. Covinsky KE, Lindquist K, Dunlop DD, Yelin E. Pain, functional limitations, and aging. J Am Geriatr Soc. 2009; 57:1556-1561. doi:10.1111/j.1532-5415.2009.02388.x
  39. Katz JN, Wright EA, Baron JA, Losina E. Development and validation of an index of musculoskeletal functional limitations. BMC Musculoskelet Disord. 2009;10:62. doi:10.1186/1471-2474-10-62
  40. Allen KD, Thoma LM, Golightly YM. Epidemiology of osteoarthritis. Osteoarthritis Cartilage. 2022;30:184-195. doi:10.1016/j.joca.2021.04.020
  41. Riebe D, Blissmer BJ, Greaney ML, Ewing Garber C, Lees FD, Clark PG. The relationship between obesity, physical activity, and physical function in older adults. J Aging Health. 2009;21:1159-1178. doi:10.1177/0898264309350076
Issue
Federal Practitioner - 42(2)
Issue
Federal Practitioner - 42(2)
Page Number
100-106
Page Number
100-106
Publications
Publications
Topics
Article Type
Display Headline

Impact of 3 Months of Supervised Exercise on Function by Arthritis Status

Display Headline

Impact of 3 Months of Supervised Exercise on Function by Arthritis Status

Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Wed, 02/05/2025 - 17:42
Un-Gate On Date
Wed, 02/05/2025 - 17:42
Use ProPublica
CFC Schedule Remove Status
Wed, 02/05/2025 - 17:42
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Wed, 02/05/2025 - 17:42

Improving High-Risk Osteoporosis Medication Adherence and Safety With an Automated Dashboard

Article Type
Changed
Wed, 03/05/2025 - 08:21
Display Headline

Improving High-Risk Osteoporosis Medication Adherence and Safety With an Automated Dashboard

Osteoporotic fragility fractures constitute a significant public health concern, with 1 in 2 women and 1 in 5 men aged > 50 years sustaining an osteoporotic fracture.1 Osteoporotic fractures are costly and associated with reduced quality of life and impaired survival.2-6 Many interventions including fall mitigation, calcium, vitamin D supplementation, and osteoporosis—specific medications reduce fracture risk.7 New medications for treating osteoporosis, including anabolic therapies, are costly and require clinical oversight to ensure safe delivery. This includes laboratory monitoring, timing of in-clinic dosing and provision of sequence therapy.8,9 COVID-19 introduced numerous barriers to osteoporosis care, raising concerns for medication interruption and patients lost to follow-up, which made monitoring these high risk and costly medications even more important.

The US Department of Veterans Affairs (VA) was an early adopter of using the electronic health record to analyze and implement system-wide processes for population management and quality improvement.10 This enabled the creation of clinical dashboards to display key performance indicator data that support quality improvement and patient care initiatives.11-15 The VA Puget Sound Health Care System (VAPSHCS) has a dedicated osteoporosis clinic focused on preventing and treating veterans at high risk for fracture. Considering the growing utilization of osteoporosis medications, particularly those requiring timed sequential therapy to prevent bone mineral density loss and rebound osteoporotic fractures, close monitoring and follow-up is required. The COVID-19 pandemic made clear the need for proactive osteoporosis management. This article describes the creation and use of an automated clinic dashboard to identify and contact veterans with osteoporosis-related care needs, such as prescription refills, laboratory tests, and clinical visits.

Methods

An automated dashboard was created in partnership with VA pharmacy clinical informatics to display the osteoporosis medication prescription (including last refill), monitoring laboratory test values and most recent osteoporosis clinic visit for each clinic patient. Data from the VA Corporate Data Warehouse were extracted. The resulting tables were used to create a patient cohort with ≥ 1 active medication for alendronate, zoledronic acid, the parathyroid hormone analogues (PTH) teriparatide or abaloparatide, denosumab, or romosozumab. Notably, alendronate was the only oral bisphosphonate prescribed in the clinic. These data were formatted and displayed using Microsoft SQL Server Reporting Services. The secure and encrypted dashboard alerts the clinic staff when prescriptions, appointments, or laboratory tests, such as estimated glomerular filtration rate, 25-hydroxy vitamin D, calcium, and PTH are overdue or out of reference range. The dashboard tracked the most recent clinic visit or dual-energy X-ray absorptiometry (DXA) scan if performed within the VA. Overdue laboratory test alerts for bisphosphonates were flagged if delayed 12 months and 6 months for all other medications.

On March 20, 2021, the VAPSHCS osteoporosis clinic was staffed by 1 endocrinologist, 1 geriatrician, 1 rheumatologist, and 1 registered nurse (RN) coordinator. Overdue or out-of-range alerts were reviewed weekly by the RN coordinator, who addressed alerts. For any overdue laboratory work or prescription refills, the RN coordinator alerted the primary osteoporosis physician via the electronic health record for updated orders. Patients were contacted by phone to schedule a clinic visit, complete ordered laboratory work, or discuss osteoporosis medication refills based on the need identified by the dashboard. A letter was mailed to the patient requesting they contact the osteoporosis clinic for patients who could not be reached by phone after 2 attempts. If 3 attempts (2 phone calls and a letter) were unsuccessful, the osteoporosis physician was alerted so they could either call the patient, alert the primary referring clinician, or discontinue the osteoporosis medication.

Results

As of March 20, 2021, 139 patients were included on the dashboard. Ninety-two patients (66%) had unmet care needs and 29% were female. Ages ranged from 40 to 100 years (Table). The dashboard alerted the team to 3 patients lost to follow-up, all of whom had transferred to care outside the clinic. Twenty-three patients (17%) had overdue medications, including 2 (9%) who had not refilled oral bisphosphonate and 18 (78%) who were overdue for intravenous bisphosphonate treatment. One veteran flagged as overdue for their denosumab injection was unable to receive it due to a significant change in health status. Two veterans were overdue for a PTH analogue refill, 1 of whom had completed their course and transitioned to bisphosphonate.

FDP04202096_T1

The most common alert was 40 patients (29%) with overdue laboratory tests, 37 of which were receiving bisphosphonates. One patient included on the dashboard was taking romosozumab and all their monitoring parameters were up to date, thus their data were not included in the Table to prevent possible identification.

Discussion

A dashboard alerted the osteoporosis clinic team to veterans who were overdue for visits, laboratory work, and prescription renewals. Overall, 92 patients (66%) had unmet care needs identified by the dashboard, all of which were addressed with phone calls and/or letters. Most of the overdue medication refills and laboratory tests were for patients taking bisphosphonates avoiding VAPSHCS during the COVID-19 pandemic. The dashboard enabled the RN coordinator to promptly contact the patient, facilitate coordination of care requirements, and guarantee the safe and efficient delivery of osteoporosis care.

The VA has historically been a leader in the creation of clinical dashboards to support health campaigns.11,12 These dashboards have successfully improved quality metrics towards the treatment of hepatitis C virus, heart failure, and highrisk opioid prescribing.13-15 Data have shown that successful clinical dashboard implementation must be done in conjunction with protected time or staff to support care improvements.16 Additionally, the time required for clinical dashboards can limit their sustainability and feasibility.17 A study aimed at improving osteoporosis care for patients with Parkinson disease found that weekly multidisciplinary review of at-risk patients resulted in all new patients and 91% of follow-up patients receiving evidence- based osteoporosis treatments.17 However, despite the benefits, the intervention required significant time and resources. In contrast, the osteoporosis dashboard implemented at VAPSHCS was not time or resource intensive, requiring about 1 hour per week for the RN coordinator to review the dashboard and coordinate patient care needs.

Limitations

This study setting is unique from other health care organizations or VA health care systems. Implementation of a similar dashboard in other clinical settings where patients receive medical care in multiple health care systems may differ. The VA dedicates resources to support veteran population health management, which may not be available in other health care systems.11,12 These issues may pose a barrier to implementing a similar osteoporosis dashboard in non-VA facilities. In addition, it is significant that while the dashboard can be reconfigured and adapted to track veterans across different VA facilities, certain complexities arise if essential data, such as laboratory tests and DXA imaging, are conducted outside of VA facilities. In such cases, manual entry of this information into the dashboard would be necessary. Because the dashboard was quickly developed during the COVID-19 pandemic, this study lacked preimplementation data on laboratory testing, medication refills, and DXA imaging, which would have enabled a comparison of adherence before and after dashboard implementation. Finally, we acknowledge the delay in publishing these findings; however, we believe sharing innovative approaches to providing care for high-risk populations is essential, as demonstrated during the COVID-19 pandemic.

Conclusions

An osteoporosis clinic dashboard served as a valuable clinical support tool to ensure safe and effective osteoporosis medication delivery at VAPSHCS. Considering the growing utilization of osteoporosis medications, this dashboard plays a vital role in facilitating care coordination for patients receiving these high-risk treatments.18 Use of the dashboard supported the effective use of high-cost osteoporosis medications and is likely to improve clinical osteoporosis outcomes.

Despite the known fracture risk reduction, osteoporosis medication adherence is low.19,20 Maintaining consistent pharmacotherapy for osteoporosis is essential not only for fracture prevention but also reducing health care costs related to osteoporosis and preserving patient independence and functionality.21-24 While initially developed in response to the COVID-19 pandemic, the dashboard remains useful. The VAPSHCS osteoporosis clinic is now staffed by 2 physicians (endocrine and rheumatology) and the dashboard is still in use. The RN coordinator spends about 15 minutes per week using the dashboard and managing the 67 veterans on osteoporosis therapy. This dashboard represents a sustainable clinical tool with the capacity to minimize osteoporosis care gaps and improve outcomes.

References
  1. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005;16(suppl 2):S3-S7. doi:10.1007/s00198-004-1702-6
  2. van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone. 2001;29:517-522. doi:10.1016/s8756-3282(01)00614-7
  3. Dennison E, Cooper C. Epidemiology of osteoporotic fractures. Horm Res. 2000;54(suppl 1):58-63. doi:10.1159/000063449
  4. Cooper C. Epidemiology and public health impact of osteoporosis. Baillieres Clin Rheumatol. 1993;7:459-477. doi:10.1016/s0950-3579(05)80073-1
  5. Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int. 1998;8:611-617. doi:10.1007/s001980050107
  6. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-475. doi:10.1359/jbmr.061113
  7. Palacios S. Medical treatment of osteoporosis. Climacteric. 2022;25:43-49. doi:10.1080/13697137.2021.1951697
  8. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104:1595-1622. doi:10.1210/jc.2019-00221
  9. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:1802-1822. doi:10.1210/jc.2011-3045
  10. Lau MK, Bounthavong M, Kay CL, Harvey MA, Christopher MLD. Clinical dashboard development and use for academic detailing in the U.S. Department of Veterans Affairs. J Am Pharm Assoc (2003). 2019;59(2S):S96-S103.e3. doi:10.1016/j.japh.2018.12.006
  11. Mould DR, D’Haens G, Upton RN. Clinical decision support tools: the evolution of a revolution. Clin Pharmacol Ther. 2016;99:405-418. doi:10.1002/cpt.334
  12. Kizer KW, Fonseca ML, Long LM. The veterans healthcare system: preparing for the twenty-first century. Hosp Health Serv Adm. 1997;42:283-298.
  13. Park A, Gonzalez R, Chartier M, et al. Screening and treating hepatitis c in the VA: achieving excellence using lean and system redesign. Fed Pract. 2018;35:24-29.
  14. Brownell N, Kay C, Parra D, et al. Development and optimization of the Veterans Affairs’ national heart failure dashboard for population health management. J Card Fail. 2024;30:452-459. doi:10.1016/j.cardfail.2023.08.024
  15. Lin LA, Bohnert ASB, Kerns RD, Clay MA, Ganoczy D, Ilgen MA. Impact of the opioid safety initiative on opioidrelated prescribing in veterans. Pain. 2017;158:833-839. doi:10.1097/j.pain.0000000000000837
  16. Twohig PA, Rivington JR, Gunzler D, Daprano J, Margolius D. Clinician dashboard views and improvement in preventative health outcome measures: a retrospective analysis. BMC Health Serv Res. 2019;19:475. doi:10.1186/s12913-019-4327-3
  17. Singh I, Fletcher R, Scanlon L, Tyler M, Aithal S. A quality improvement initiative on the management of osteoporosis in older people with Parkinsonism. BMJ Qual Improv Rep. 2016;5:u210921.w5756. doi:10.1136/bmjquality.u210921.w5756
  18. Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A. Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med. 2021;10:152. doi:10.3390/jcm10010152
  19. Sharman Moser S, Yu J, Goldshtein I, et al. Cost and consequences of nonadherence with oral bisphosphonate therapy: findings from a real-world data analysis. Ann Pharmacother. 2016;50:262-269. doi:10.1177/1060028015626935
  20. Olsen KR, Hansen C, Abrahamsen B. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases. Osteoporos Int. 2013;24:2639-2647. doi:10.1007/s00198-013-2365-y
  21. Blouin J, Dragomir A, Fredette M, Ste-Marie LG, Fernandes JC, Perreault S. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporos Int. 2009;20:1571-1581. doi:10.1007/s00198-008-0818-5
  22. Cotté F-E, De Pouvourville G. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France. BMC Health Serv Res. 2011;11:151. doi:10.1186/1472-6963-11-151
  23. Cho H, Byun J-H, Song I, et al. Effect of improved medication adherence on health care costs in osteoporosis patients. Medicine (Baltimore). 2018;97:e11470. doi:10.1097/MD.0000000000011470
  24. Li N, Cornelissen D, Silverman S, et al. An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics. 2021;39:181-209. doi:10.1007/s40273-020-00965-9
Article PDF
Author and Disclosure Information

Danielle H. Tran, MDa; Radhika Narla, MDb,c; Magdalena Wojtowicz, RNc; Patrick Spoutz, PharmD, BCPSd; Katherine D. Wysham, MDb,c

Author affiliations
aUniversity of Washington, Seattle
bUniversity of Washington Medical Center, Seattle
cVA Puget Sound Health Care System, Seattle, Washington
dVeteran Affairs Integrated Service Network 20, Vancouver, Washington

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Correspondence: Katherine Wysham ([email protected])

Fed Pract. 2025;42(2). Published online February 15. doi:10.12788/fp.0551

Issue
Federal Practitioner - 42(2)
Publications
Topics
Page Number
96-99
Sections
Author and Disclosure Information

Danielle H. Tran, MDa; Radhika Narla, MDb,c; Magdalena Wojtowicz, RNc; Patrick Spoutz, PharmD, BCPSd; Katherine D. Wysham, MDb,c

Author affiliations
aUniversity of Washington, Seattle
bUniversity of Washington Medical Center, Seattle
cVA Puget Sound Health Care System, Seattle, Washington
dVeteran Affairs Integrated Service Network 20, Vancouver, Washington

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Correspondence: Katherine Wysham ([email protected])

Fed Pract. 2025;42(2). Published online February 15. doi:10.12788/fp.0551

Author and Disclosure Information

Danielle H. Tran, MDa; Radhika Narla, MDb,c; Magdalena Wojtowicz, RNc; Patrick Spoutz, PharmD, BCPSd; Katherine D. Wysham, MDb,c

Author affiliations
aUniversity of Washington, Seattle
bUniversity of Washington Medical Center, Seattle
cVA Puget Sound Health Care System, Seattle, Washington
dVeteran Affairs Integrated Service Network 20, Vancouver, Washington

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Correspondence: Katherine Wysham ([email protected])

Fed Pract. 2025;42(2). Published online February 15. doi:10.12788/fp.0551

Article PDF
Article PDF

Osteoporotic fragility fractures constitute a significant public health concern, with 1 in 2 women and 1 in 5 men aged > 50 years sustaining an osteoporotic fracture.1 Osteoporotic fractures are costly and associated with reduced quality of life and impaired survival.2-6 Many interventions including fall mitigation, calcium, vitamin D supplementation, and osteoporosis—specific medications reduce fracture risk.7 New medications for treating osteoporosis, including anabolic therapies, are costly and require clinical oversight to ensure safe delivery. This includes laboratory monitoring, timing of in-clinic dosing and provision of sequence therapy.8,9 COVID-19 introduced numerous barriers to osteoporosis care, raising concerns for medication interruption and patients lost to follow-up, which made monitoring these high risk and costly medications even more important.

The US Department of Veterans Affairs (VA) was an early adopter of using the electronic health record to analyze and implement system-wide processes for population management and quality improvement.10 This enabled the creation of clinical dashboards to display key performance indicator data that support quality improvement and patient care initiatives.11-15 The VA Puget Sound Health Care System (VAPSHCS) has a dedicated osteoporosis clinic focused on preventing and treating veterans at high risk for fracture. Considering the growing utilization of osteoporosis medications, particularly those requiring timed sequential therapy to prevent bone mineral density loss and rebound osteoporotic fractures, close monitoring and follow-up is required. The COVID-19 pandemic made clear the need for proactive osteoporosis management. This article describes the creation and use of an automated clinic dashboard to identify and contact veterans with osteoporosis-related care needs, such as prescription refills, laboratory tests, and clinical visits.

Methods

An automated dashboard was created in partnership with VA pharmacy clinical informatics to display the osteoporosis medication prescription (including last refill), monitoring laboratory test values and most recent osteoporosis clinic visit for each clinic patient. Data from the VA Corporate Data Warehouse were extracted. The resulting tables were used to create a patient cohort with ≥ 1 active medication for alendronate, zoledronic acid, the parathyroid hormone analogues (PTH) teriparatide or abaloparatide, denosumab, or romosozumab. Notably, alendronate was the only oral bisphosphonate prescribed in the clinic. These data were formatted and displayed using Microsoft SQL Server Reporting Services. The secure and encrypted dashboard alerts the clinic staff when prescriptions, appointments, or laboratory tests, such as estimated glomerular filtration rate, 25-hydroxy vitamin D, calcium, and PTH are overdue or out of reference range. The dashboard tracked the most recent clinic visit or dual-energy X-ray absorptiometry (DXA) scan if performed within the VA. Overdue laboratory test alerts for bisphosphonates were flagged if delayed 12 months and 6 months for all other medications.

On March 20, 2021, the VAPSHCS osteoporosis clinic was staffed by 1 endocrinologist, 1 geriatrician, 1 rheumatologist, and 1 registered nurse (RN) coordinator. Overdue or out-of-range alerts were reviewed weekly by the RN coordinator, who addressed alerts. For any overdue laboratory work or prescription refills, the RN coordinator alerted the primary osteoporosis physician via the electronic health record for updated orders. Patients were contacted by phone to schedule a clinic visit, complete ordered laboratory work, or discuss osteoporosis medication refills based on the need identified by the dashboard. A letter was mailed to the patient requesting they contact the osteoporosis clinic for patients who could not be reached by phone after 2 attempts. If 3 attempts (2 phone calls and a letter) were unsuccessful, the osteoporosis physician was alerted so they could either call the patient, alert the primary referring clinician, or discontinue the osteoporosis medication.

Results

As of March 20, 2021, 139 patients were included on the dashboard. Ninety-two patients (66%) had unmet care needs and 29% were female. Ages ranged from 40 to 100 years (Table). The dashboard alerted the team to 3 patients lost to follow-up, all of whom had transferred to care outside the clinic. Twenty-three patients (17%) had overdue medications, including 2 (9%) who had not refilled oral bisphosphonate and 18 (78%) who were overdue for intravenous bisphosphonate treatment. One veteran flagged as overdue for their denosumab injection was unable to receive it due to a significant change in health status. Two veterans were overdue for a PTH analogue refill, 1 of whom had completed their course and transitioned to bisphosphonate.

FDP04202096_T1

The most common alert was 40 patients (29%) with overdue laboratory tests, 37 of which were receiving bisphosphonates. One patient included on the dashboard was taking romosozumab and all their monitoring parameters were up to date, thus their data were not included in the Table to prevent possible identification.

Discussion

A dashboard alerted the osteoporosis clinic team to veterans who were overdue for visits, laboratory work, and prescription renewals. Overall, 92 patients (66%) had unmet care needs identified by the dashboard, all of which were addressed with phone calls and/or letters. Most of the overdue medication refills and laboratory tests were for patients taking bisphosphonates avoiding VAPSHCS during the COVID-19 pandemic. The dashboard enabled the RN coordinator to promptly contact the patient, facilitate coordination of care requirements, and guarantee the safe and efficient delivery of osteoporosis care.

The VA has historically been a leader in the creation of clinical dashboards to support health campaigns.11,12 These dashboards have successfully improved quality metrics towards the treatment of hepatitis C virus, heart failure, and highrisk opioid prescribing.13-15 Data have shown that successful clinical dashboard implementation must be done in conjunction with protected time or staff to support care improvements.16 Additionally, the time required for clinical dashboards can limit their sustainability and feasibility.17 A study aimed at improving osteoporosis care for patients with Parkinson disease found that weekly multidisciplinary review of at-risk patients resulted in all new patients and 91% of follow-up patients receiving evidence- based osteoporosis treatments.17 However, despite the benefits, the intervention required significant time and resources. In contrast, the osteoporosis dashboard implemented at VAPSHCS was not time or resource intensive, requiring about 1 hour per week for the RN coordinator to review the dashboard and coordinate patient care needs.

Limitations

This study setting is unique from other health care organizations or VA health care systems. Implementation of a similar dashboard in other clinical settings where patients receive medical care in multiple health care systems may differ. The VA dedicates resources to support veteran population health management, which may not be available in other health care systems.11,12 These issues may pose a barrier to implementing a similar osteoporosis dashboard in non-VA facilities. In addition, it is significant that while the dashboard can be reconfigured and adapted to track veterans across different VA facilities, certain complexities arise if essential data, such as laboratory tests and DXA imaging, are conducted outside of VA facilities. In such cases, manual entry of this information into the dashboard would be necessary. Because the dashboard was quickly developed during the COVID-19 pandemic, this study lacked preimplementation data on laboratory testing, medication refills, and DXA imaging, which would have enabled a comparison of adherence before and after dashboard implementation. Finally, we acknowledge the delay in publishing these findings; however, we believe sharing innovative approaches to providing care for high-risk populations is essential, as demonstrated during the COVID-19 pandemic.

Conclusions

An osteoporosis clinic dashboard served as a valuable clinical support tool to ensure safe and effective osteoporosis medication delivery at VAPSHCS. Considering the growing utilization of osteoporosis medications, this dashboard plays a vital role in facilitating care coordination for patients receiving these high-risk treatments.18 Use of the dashboard supported the effective use of high-cost osteoporosis medications and is likely to improve clinical osteoporosis outcomes.

Despite the known fracture risk reduction, osteoporosis medication adherence is low.19,20 Maintaining consistent pharmacotherapy for osteoporosis is essential not only for fracture prevention but also reducing health care costs related to osteoporosis and preserving patient independence and functionality.21-24 While initially developed in response to the COVID-19 pandemic, the dashboard remains useful. The VAPSHCS osteoporosis clinic is now staffed by 2 physicians (endocrine and rheumatology) and the dashboard is still in use. The RN coordinator spends about 15 minutes per week using the dashboard and managing the 67 veterans on osteoporosis therapy. This dashboard represents a sustainable clinical tool with the capacity to minimize osteoporosis care gaps and improve outcomes.

Osteoporotic fragility fractures constitute a significant public health concern, with 1 in 2 women and 1 in 5 men aged > 50 years sustaining an osteoporotic fracture.1 Osteoporotic fractures are costly and associated with reduced quality of life and impaired survival.2-6 Many interventions including fall mitigation, calcium, vitamin D supplementation, and osteoporosis—specific medications reduce fracture risk.7 New medications for treating osteoporosis, including anabolic therapies, are costly and require clinical oversight to ensure safe delivery. This includes laboratory monitoring, timing of in-clinic dosing and provision of sequence therapy.8,9 COVID-19 introduced numerous barriers to osteoporosis care, raising concerns for medication interruption and patients lost to follow-up, which made monitoring these high risk and costly medications even more important.

The US Department of Veterans Affairs (VA) was an early adopter of using the electronic health record to analyze and implement system-wide processes for population management and quality improvement.10 This enabled the creation of clinical dashboards to display key performance indicator data that support quality improvement and patient care initiatives.11-15 The VA Puget Sound Health Care System (VAPSHCS) has a dedicated osteoporosis clinic focused on preventing and treating veterans at high risk for fracture. Considering the growing utilization of osteoporosis medications, particularly those requiring timed sequential therapy to prevent bone mineral density loss and rebound osteoporotic fractures, close monitoring and follow-up is required. The COVID-19 pandemic made clear the need for proactive osteoporosis management. This article describes the creation and use of an automated clinic dashboard to identify and contact veterans with osteoporosis-related care needs, such as prescription refills, laboratory tests, and clinical visits.

Methods

An automated dashboard was created in partnership with VA pharmacy clinical informatics to display the osteoporosis medication prescription (including last refill), monitoring laboratory test values and most recent osteoporosis clinic visit for each clinic patient. Data from the VA Corporate Data Warehouse were extracted. The resulting tables were used to create a patient cohort with ≥ 1 active medication for alendronate, zoledronic acid, the parathyroid hormone analogues (PTH) teriparatide or abaloparatide, denosumab, or romosozumab. Notably, alendronate was the only oral bisphosphonate prescribed in the clinic. These data were formatted and displayed using Microsoft SQL Server Reporting Services. The secure and encrypted dashboard alerts the clinic staff when prescriptions, appointments, or laboratory tests, such as estimated glomerular filtration rate, 25-hydroxy vitamin D, calcium, and PTH are overdue or out of reference range. The dashboard tracked the most recent clinic visit or dual-energy X-ray absorptiometry (DXA) scan if performed within the VA. Overdue laboratory test alerts for bisphosphonates were flagged if delayed 12 months and 6 months for all other medications.

On March 20, 2021, the VAPSHCS osteoporosis clinic was staffed by 1 endocrinologist, 1 geriatrician, 1 rheumatologist, and 1 registered nurse (RN) coordinator. Overdue or out-of-range alerts were reviewed weekly by the RN coordinator, who addressed alerts. For any overdue laboratory work or prescription refills, the RN coordinator alerted the primary osteoporosis physician via the electronic health record for updated orders. Patients were contacted by phone to schedule a clinic visit, complete ordered laboratory work, or discuss osteoporosis medication refills based on the need identified by the dashboard. A letter was mailed to the patient requesting they contact the osteoporosis clinic for patients who could not be reached by phone after 2 attempts. If 3 attempts (2 phone calls and a letter) were unsuccessful, the osteoporosis physician was alerted so they could either call the patient, alert the primary referring clinician, or discontinue the osteoporosis medication.

Results

As of March 20, 2021, 139 patients were included on the dashboard. Ninety-two patients (66%) had unmet care needs and 29% were female. Ages ranged from 40 to 100 years (Table). The dashboard alerted the team to 3 patients lost to follow-up, all of whom had transferred to care outside the clinic. Twenty-three patients (17%) had overdue medications, including 2 (9%) who had not refilled oral bisphosphonate and 18 (78%) who were overdue for intravenous bisphosphonate treatment. One veteran flagged as overdue for their denosumab injection was unable to receive it due to a significant change in health status. Two veterans were overdue for a PTH analogue refill, 1 of whom had completed their course and transitioned to bisphosphonate.

FDP04202096_T1

The most common alert was 40 patients (29%) with overdue laboratory tests, 37 of which were receiving bisphosphonates. One patient included on the dashboard was taking romosozumab and all their monitoring parameters were up to date, thus their data were not included in the Table to prevent possible identification.

Discussion

A dashboard alerted the osteoporosis clinic team to veterans who were overdue for visits, laboratory work, and prescription renewals. Overall, 92 patients (66%) had unmet care needs identified by the dashboard, all of which were addressed with phone calls and/or letters. Most of the overdue medication refills and laboratory tests were for patients taking bisphosphonates avoiding VAPSHCS during the COVID-19 pandemic. The dashboard enabled the RN coordinator to promptly contact the patient, facilitate coordination of care requirements, and guarantee the safe and efficient delivery of osteoporosis care.

The VA has historically been a leader in the creation of clinical dashboards to support health campaigns.11,12 These dashboards have successfully improved quality metrics towards the treatment of hepatitis C virus, heart failure, and highrisk opioid prescribing.13-15 Data have shown that successful clinical dashboard implementation must be done in conjunction with protected time or staff to support care improvements.16 Additionally, the time required for clinical dashboards can limit their sustainability and feasibility.17 A study aimed at improving osteoporosis care for patients with Parkinson disease found that weekly multidisciplinary review of at-risk patients resulted in all new patients and 91% of follow-up patients receiving evidence- based osteoporosis treatments.17 However, despite the benefits, the intervention required significant time and resources. In contrast, the osteoporosis dashboard implemented at VAPSHCS was not time or resource intensive, requiring about 1 hour per week for the RN coordinator to review the dashboard and coordinate patient care needs.

Limitations

This study setting is unique from other health care organizations or VA health care systems. Implementation of a similar dashboard in other clinical settings where patients receive medical care in multiple health care systems may differ. The VA dedicates resources to support veteran population health management, which may not be available in other health care systems.11,12 These issues may pose a barrier to implementing a similar osteoporosis dashboard in non-VA facilities. In addition, it is significant that while the dashboard can be reconfigured and adapted to track veterans across different VA facilities, certain complexities arise if essential data, such as laboratory tests and DXA imaging, are conducted outside of VA facilities. In such cases, manual entry of this information into the dashboard would be necessary. Because the dashboard was quickly developed during the COVID-19 pandemic, this study lacked preimplementation data on laboratory testing, medication refills, and DXA imaging, which would have enabled a comparison of adherence before and after dashboard implementation. Finally, we acknowledge the delay in publishing these findings; however, we believe sharing innovative approaches to providing care for high-risk populations is essential, as demonstrated during the COVID-19 pandemic.

Conclusions

An osteoporosis clinic dashboard served as a valuable clinical support tool to ensure safe and effective osteoporosis medication delivery at VAPSHCS. Considering the growing utilization of osteoporosis medications, this dashboard plays a vital role in facilitating care coordination for patients receiving these high-risk treatments.18 Use of the dashboard supported the effective use of high-cost osteoporosis medications and is likely to improve clinical osteoporosis outcomes.

Despite the known fracture risk reduction, osteoporosis medication adherence is low.19,20 Maintaining consistent pharmacotherapy for osteoporosis is essential not only for fracture prevention but also reducing health care costs related to osteoporosis and preserving patient independence and functionality.21-24 While initially developed in response to the COVID-19 pandemic, the dashboard remains useful. The VAPSHCS osteoporosis clinic is now staffed by 2 physicians (endocrine and rheumatology) and the dashboard is still in use. The RN coordinator spends about 15 minutes per week using the dashboard and managing the 67 veterans on osteoporosis therapy. This dashboard represents a sustainable clinical tool with the capacity to minimize osteoporosis care gaps and improve outcomes.

References
  1. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005;16(suppl 2):S3-S7. doi:10.1007/s00198-004-1702-6
  2. van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone. 2001;29:517-522. doi:10.1016/s8756-3282(01)00614-7
  3. Dennison E, Cooper C. Epidemiology of osteoporotic fractures. Horm Res. 2000;54(suppl 1):58-63. doi:10.1159/000063449
  4. Cooper C. Epidemiology and public health impact of osteoporosis. Baillieres Clin Rheumatol. 1993;7:459-477. doi:10.1016/s0950-3579(05)80073-1
  5. Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int. 1998;8:611-617. doi:10.1007/s001980050107
  6. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-475. doi:10.1359/jbmr.061113
  7. Palacios S. Medical treatment of osteoporosis. Climacteric. 2022;25:43-49. doi:10.1080/13697137.2021.1951697
  8. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104:1595-1622. doi:10.1210/jc.2019-00221
  9. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:1802-1822. doi:10.1210/jc.2011-3045
  10. Lau MK, Bounthavong M, Kay CL, Harvey MA, Christopher MLD. Clinical dashboard development and use for academic detailing in the U.S. Department of Veterans Affairs. J Am Pharm Assoc (2003). 2019;59(2S):S96-S103.e3. doi:10.1016/j.japh.2018.12.006
  11. Mould DR, D’Haens G, Upton RN. Clinical decision support tools: the evolution of a revolution. Clin Pharmacol Ther. 2016;99:405-418. doi:10.1002/cpt.334
  12. Kizer KW, Fonseca ML, Long LM. The veterans healthcare system: preparing for the twenty-first century. Hosp Health Serv Adm. 1997;42:283-298.
  13. Park A, Gonzalez R, Chartier M, et al. Screening and treating hepatitis c in the VA: achieving excellence using lean and system redesign. Fed Pract. 2018;35:24-29.
  14. Brownell N, Kay C, Parra D, et al. Development and optimization of the Veterans Affairs’ national heart failure dashboard for population health management. J Card Fail. 2024;30:452-459. doi:10.1016/j.cardfail.2023.08.024
  15. Lin LA, Bohnert ASB, Kerns RD, Clay MA, Ganoczy D, Ilgen MA. Impact of the opioid safety initiative on opioidrelated prescribing in veterans. Pain. 2017;158:833-839. doi:10.1097/j.pain.0000000000000837
  16. Twohig PA, Rivington JR, Gunzler D, Daprano J, Margolius D. Clinician dashboard views and improvement in preventative health outcome measures: a retrospective analysis. BMC Health Serv Res. 2019;19:475. doi:10.1186/s12913-019-4327-3
  17. Singh I, Fletcher R, Scanlon L, Tyler M, Aithal S. A quality improvement initiative on the management of osteoporosis in older people with Parkinsonism. BMJ Qual Improv Rep. 2016;5:u210921.w5756. doi:10.1136/bmjquality.u210921.w5756
  18. Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A. Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med. 2021;10:152. doi:10.3390/jcm10010152
  19. Sharman Moser S, Yu J, Goldshtein I, et al. Cost and consequences of nonadherence with oral bisphosphonate therapy: findings from a real-world data analysis. Ann Pharmacother. 2016;50:262-269. doi:10.1177/1060028015626935
  20. Olsen KR, Hansen C, Abrahamsen B. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases. Osteoporos Int. 2013;24:2639-2647. doi:10.1007/s00198-013-2365-y
  21. Blouin J, Dragomir A, Fredette M, Ste-Marie LG, Fernandes JC, Perreault S. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporos Int. 2009;20:1571-1581. doi:10.1007/s00198-008-0818-5
  22. Cotté F-E, De Pouvourville G. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France. BMC Health Serv Res. 2011;11:151. doi:10.1186/1472-6963-11-151
  23. Cho H, Byun J-H, Song I, et al. Effect of improved medication adherence on health care costs in osteoporosis patients. Medicine (Baltimore). 2018;97:e11470. doi:10.1097/MD.0000000000011470
  24. Li N, Cornelissen D, Silverman S, et al. An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics. 2021;39:181-209. doi:10.1007/s40273-020-00965-9
References
  1. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005;16(suppl 2):S3-S7. doi:10.1007/s00198-004-1702-6
  2. van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone. 2001;29:517-522. doi:10.1016/s8756-3282(01)00614-7
  3. Dennison E, Cooper C. Epidemiology of osteoporotic fractures. Horm Res. 2000;54(suppl 1):58-63. doi:10.1159/000063449
  4. Cooper C. Epidemiology and public health impact of osteoporosis. Baillieres Clin Rheumatol. 1993;7:459-477. doi:10.1016/s0950-3579(05)80073-1
  5. Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int. 1998;8:611-617. doi:10.1007/s001980050107
  6. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-475. doi:10.1359/jbmr.061113
  7. Palacios S. Medical treatment of osteoporosis. Climacteric. 2022;25:43-49. doi:10.1080/13697137.2021.1951697
  8. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104:1595-1622. doi:10.1210/jc.2019-00221
  9. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:1802-1822. doi:10.1210/jc.2011-3045
  10. Lau MK, Bounthavong M, Kay CL, Harvey MA, Christopher MLD. Clinical dashboard development and use for academic detailing in the U.S. Department of Veterans Affairs. J Am Pharm Assoc (2003). 2019;59(2S):S96-S103.e3. doi:10.1016/j.japh.2018.12.006
  11. Mould DR, D’Haens G, Upton RN. Clinical decision support tools: the evolution of a revolution. Clin Pharmacol Ther. 2016;99:405-418. doi:10.1002/cpt.334
  12. Kizer KW, Fonseca ML, Long LM. The veterans healthcare system: preparing for the twenty-first century. Hosp Health Serv Adm. 1997;42:283-298.
  13. Park A, Gonzalez R, Chartier M, et al. Screening and treating hepatitis c in the VA: achieving excellence using lean and system redesign. Fed Pract. 2018;35:24-29.
  14. Brownell N, Kay C, Parra D, et al. Development and optimization of the Veterans Affairs’ national heart failure dashboard for population health management. J Card Fail. 2024;30:452-459. doi:10.1016/j.cardfail.2023.08.024
  15. Lin LA, Bohnert ASB, Kerns RD, Clay MA, Ganoczy D, Ilgen MA. Impact of the opioid safety initiative on opioidrelated prescribing in veterans. Pain. 2017;158:833-839. doi:10.1097/j.pain.0000000000000837
  16. Twohig PA, Rivington JR, Gunzler D, Daprano J, Margolius D. Clinician dashboard views and improvement in preventative health outcome measures: a retrospective analysis. BMC Health Serv Res. 2019;19:475. doi:10.1186/s12913-019-4327-3
  17. Singh I, Fletcher R, Scanlon L, Tyler M, Aithal S. A quality improvement initiative on the management of osteoporosis in older people with Parkinsonism. BMJ Qual Improv Rep. 2016;5:u210921.w5756. doi:10.1136/bmjquality.u210921.w5756
  18. Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A. Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med. 2021;10:152. doi:10.3390/jcm10010152
  19. Sharman Moser S, Yu J, Goldshtein I, et al. Cost and consequences of nonadherence with oral bisphosphonate therapy: findings from a real-world data analysis. Ann Pharmacother. 2016;50:262-269. doi:10.1177/1060028015626935
  20. Olsen KR, Hansen C, Abrahamsen B. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases. Osteoporos Int. 2013;24:2639-2647. doi:10.1007/s00198-013-2365-y
  21. Blouin J, Dragomir A, Fredette M, Ste-Marie LG, Fernandes JC, Perreault S. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporos Int. 2009;20:1571-1581. doi:10.1007/s00198-008-0818-5
  22. Cotté F-E, De Pouvourville G. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France. BMC Health Serv Res. 2011;11:151. doi:10.1186/1472-6963-11-151
  23. Cho H, Byun J-H, Song I, et al. Effect of improved medication adherence on health care costs in osteoporosis patients. Medicine (Baltimore). 2018;97:e11470. doi:10.1097/MD.0000000000011470
  24. Li N, Cornelissen D, Silverman S, et al. An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics. 2021;39:181-209. doi:10.1007/s40273-020-00965-9
Issue
Federal Practitioner - 42(2)
Issue
Federal Practitioner - 42(2)
Page Number
96-99
Page Number
96-99
Publications
Publications
Topics
Article Type
Display Headline

Improving High-Risk Osteoporosis Medication Adherence and Safety With an Automated Dashboard

Display Headline

Improving High-Risk Osteoporosis Medication Adherence and Safety With an Automated Dashboard

Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Wed, 02/05/2025 - 16:54
Un-Gate On Date
Wed, 02/05/2025 - 16:54
Use ProPublica
CFC Schedule Remove Status
Wed, 02/05/2025 - 16:54
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Wed, 02/05/2025 - 16:54

Efficacy of Anti-Obesity Medications in Adult and Older Adult Veteran Populations

Article Type
Changed
Tue, 02/11/2025 - 11:07
Display Headline

Efficacy of Anti-Obesity Medications in Adult and Older Adult Veteran Populations

The impact of obesity in the United States is significant. Between August 2021 and August 2023, the prevalence of obesity (body mass index ≥ 30) in US adults was 40.3%.1 The prevalence of obesity in adults aged 40 to 59 years was 46.4%, higher than the prevalence in adults aged 20 to 39 years (35.5%) and those aged ≥ 60 years (38.9%).1 The excess annual medical costs associated with obesity in the US are estimated at nearly $173 billion.2

The first-line treatment for obesity is lifestyle modifications, including a healthy diet and exercise. When lifestyle modifications are not enough to achieve weight-loss goals, bariatric surgery and anti-obesity medications (AOMs) are often considered. Five medications were approved for the long-term tretament of obesity by the US Food and Drug Administration (FDA) between 2021 and 2023, when this study was conducted: semaglutide (Wegovy), liraglutide (Saxenda), phentermine and topiramate, naltrexone and bupropion, and orlistat. The clinically meaningful (and commonly accepted) weight-loss target for these medications is ≥ 5% from baseline by week 12 of the maximally tolerated dose of therapy. A 5% weight loss has been shown to be clinically significant in improving cardiometabolic risk factors.3,4 These medications are intended to be used as an adjunct to healthy diet and exercise. Of note, semaglutide and liraglutide carry brand names, which are associated with different dosing for the treatment of type 2 diabetes mellitus (T2DM).

All 5 FDA-approved AOMs were available at the Veterans Affairs Sioux Falls Health Care System (VASFHCS) for the treatment of obesity at the time of the study. To qualify for an AOM, a veteran at VASFHCS must first work with a dietitian or be enrolled in the MOVE! clinic to participate in the weight management program, which focuses on dietary, exercise, and behavioral changes. At VASFHCS, AOMs are prescribed by primary care practitioners, clinical pharmacy providers, and advanced practitioners within the MOVE! program.

Ample data exist for the efficacy of AOMs. However, no published research has reported on AOM efficacy by age group (Appendix).5-11 While most of the AOM clinical trials included older adults, the average age of participants was typically between 40 and 50 years. It is well-known that pharmacokinetic and pharmacodynamic changes occur as age increases. Renal and hepatic clearance is reduced while the volume distribution and sensitivities to some medications may increase. 12 Although this study did not focus on specific pharmacokinetic and pharmacodynamic changes with respect to AOM, it is important to recognize that this may play a role in the efficacy and safety of AOMs in older adults.

FDP04202090_A1

Methods

This retrospective single-center chart review was performed using the VASFHCS Computerized Patient Record System to compare the efficacy of AOMs in older adults (aged ≥ 65 years) vs adults (aged < 65 years). The primary endpoint was the percent change in body weight from baseline to 6 and 12 months after initiation of AOM therapy in the older adult vs adult population. Secondary endpoints included changes in low-density lipoprotein (LDL), hemoglobin A1c (HbA1c), and blood pressure (BP) from baseline compared to 12 months on AOM therapy. HbA1c was assessed in patients with T2DM or prediabetes at the time of AOM initiation. Two safety endpoints were also explored to determine the incidence of medication adverse events (AEs) and subsequent discontinuation of AOM. A subset analysis was performed to determine whether there was a difference in percent change in body weight between patients in 3 age groups: 18 to 40 years, 41 to 64 years, and ≥ 65 years.

The study population included patients who were prescribed an AOM between January 1, 2021, and June 30, 2023. Patients were excluded if they did not continue AOM therapy for ≥ 6 months after initiation or if they underwent gastric bypass surgery while undergoing AOM therapy. Patients taking semaglutide (Ozempic) or liraglutide (Victoza) for both T2DM and weight loss who were eventually switched to the weight loss formulations (Wegovy or Saxenda) were included. Patients who switched between semaglutide and liraglutide for weight loss were also included. Those taking semaglutide or liraglutide solely for T2DM treatment were excluded because they are dosed differently.

Collected data included age, gender, race, weight (baseline, 6 and 12 months after initiation of AOM), metabolic laboratory values/vital signs (HbA1c, LDL, and BP at baseline and 12 months after initiation of AOM), diagnosis of T2DM or prediabetes, reported AEs associated with AOM therapy, and date of AOM initiation and discontinuation (if applicable). Baseline values were defined at the time of medication initiation or values documented within 6 months prior to medication initiation if true baseline data were not reported. If values were not recorded at months 6 and 12 after AOM initiation, values documented closest to those targets were used. Weights were used for baseline, 6-, and 12-month data unless they were unavailable due to use of virtual care modalities. In these cases, patient-reported weights were used. Patients were included in the 6-month data, but not the 12-month data, if they were taking AOMs for > 6 months but not for 12 months. If patients had been on multiple AOMs, baseline data were recorded at the start of the first medication that was used for 6 months or longer. Twelve-month data were recorded after subsequent medication change. Twelve-month metabolic laboratory values/vital signs were recorded for patients included in the study even if they did not complete ≥ 12 months of AOM therapy.

Statistical Analysis

Data from patients who were prescribed an AOM from January 2021 to June 2023 and who remained on the medication for ≥ 6 months were analyzed. Baseline characteristics were analyzed using descriptive statistics. The primary and secondary endpoints were evaluated using the t test. The safety endpoints were analyzed using descriptive statistics. An analysis of variance test was used for the subset analysis. Results with P < .05 were statistically significant.

Results

A total of 144 participants were included in this study, 116 in the adult group (aged < 65 years) and 28 in the older adult group (aged ≥ 65 years). Sixty-seven patients were excluded due to prespecified inclusion and exclusion criteria.

Other than the predetermined mean age differences (48 years vs 71 years), there were multiple differences in patient baseline characteristics. When comparing older adults and adults, average weight (283 lb vs 269 lb) and White race (89% vs 87%) were slightly higher in the older adult group. Also, a higher prevalence of T2DM (54% and 18%) and a lower prevalence of prediabetes (21% and 33%) was noted in the older adult group. HbA1c and BP were similar between both groups at baseline, while LDL was slightly lower in the older adult group (Table 1).

FDP04202090_T1

Patients in the adult group lost a mean 7.0% and 8.7% of body weight at 6 and 12 months, respectively, while the older adult group lost 5.0% and 6.6% body weight at 6 and 12 months, respectively. The difference in percent change in body weight was not statistically different at 6 (P = .08) or 12 (P = .26) months between patients in the adult group vs the older adult group or in the specific age groups (18-40 years, 41-64 years, ≥ 65 years) at 6 months (P = .24) or 12 months (P = .53) (Figure).

FDP04202090_F

At 12 months, the difference between the adult group vs the older adult group was not statistically significant for HbA1c in patients with T2DM or prediabetes (P = .73), LDL (P = .95), systolic BP (P = .58), or diastolic BP (P = .51) (Table 2).

FDP04202090_T2

For the safety endpoint, the incidence of AEs was found to be different between groups. There were more reported AEs (61.2% vs 39.3%) and a greater increase in therapy discontinuation due to AEs (6.0% vs 0%) in the adult group compared to the older adult group (Table 3).

FDP04202090_T3

Discussion

Patients taking AOMs revealed no statistically significant difference in percent change in body weight at 6 or 12 months between adults aged < 65 years and older adults aged ≥ 65 years. The subset analysis also showed no statistically significant difference in change in percent body weight between more narrowly defined age groups of 18 to 40 years, 41 to 64 years, and ≥ 65 years. This suggests that AOM may have similar efficacy for weight loss in all ages of adults.

Secondary endpoint findings showed no statistically significant difference in HbA1c (in patients with T2DM or prediabetes), LDL, or BP at 12 months between the 2 groups. Although this study did not differentiate secondary outcomes based on the individual AOM, the change in HbA1c in both groups was expected, given that 70% of the patients included in this study were taking a glucagon-like peptide-1 agonist (liraglutide and semaglutide) at some point during the study. It’s also worth noting that secondary endpoints were collected for patients who discontinued the AOM between 6 and 12 months. Therefore, the patients’ HbA1c, LDL, and BP may not have accurately reflected the change that could have been expected if they had continued AOM therapy beyond the 12-month period.

Due to the different mechanisms and range in efficacy that AOMs have in regard to weight loss, changes in all outcomes, including weight, HbA1c, LDL, and BP were expected to vary as patients were included even after switching AOM (collection of data started after ≥ 6 months on a single AOM). Switching of AOM after the first 6 months of therapy was recorded in 25% of the patients in the ≥ 65 years group and 330% of the patients in the < 65 years group.

The incidence of AEs and subsequent discontinuation of AOMs in this study was higher in the adult group. This study excluded patients who did not continue taking an AOM for at least 6 months. As a result, the incidence of AEs between the 2 groups within the first 6 months of AOM therapy remains unknown. It is possible that during the first 6 months of therapy, patients aged < 65 years were more willing to tolerate or had fewer severe AEs compared with the older adult group. It’s also possible that the smaller number of patients in the older adult group was due to increased AEs that led them to discontinue early (before completion of 6 months of therapy) and/or prescriber discomfort in using AOMs in the older adult population. In addition, because the specific medication(s) taken by patients in each group were not detailed, it is unknown whether the adult group was taking AOMs associated with a greater number of AEs.

Limitations

This was a retrospective study with a relatively small sample size. A larger sample size may have shown more precise differences between age groups and may be more representative of the general population. Additionally, data were reliant on appropriate documentation, and adherence to AOM therapy was not assessed due to the retrospective nature of this study. At times, the study relied on patient reported data points, such as weight, if a clinic weight was not available. Also, this study did not account for many potential confounding factors such as other medications taken by the patient, which can affect outcomes including weight, HbA1c, LDL, blood pressure, and AEs.

Conclusions

This retrospective study of patients taking AOMs showed no statistically significant difference in weight loss at 6 or 12 months between adults aged < 65 years and older adults aged ≥ 65 years. A subset analysis found no statistically significant difference in change in body weight between specific age groups (18-40 years, 41-64 years, and ≥ 65 years). There was also no statistically significant difference in secondary outcomes, including change in HbA1c (in patients with T2DM or prediabetes), LDL or BP between age groups. The safety endpoints showed a higher incidence of medication AEs in the adult group, with more of these adults discontinuing therapy due to AEs. This study indicates that AOM may have similar outcomes for weight loss and metabolic laboratory values/vital sign changes between adults and older adults. Also, our findings suggest that patients aged < 65 years may experience more AEs than patients aged ≥ 65 years after ≥ 6 months of AOM therapy. Larger studies are needed to further evaluate these age-specific findings.

References
  1. Emmerich SD, Fryar CD, Stierman B, Ogden CL. Obesity and severe obesity prevalence in adults: United States, August 2021-August 2023. NCHS Data Brief No. 508. National Center for Health Statistics; 2024. Accessed December 11, 2024. https://www.cdc.gov/nchs/products/databriefs/db508.htm
  2. Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass index with health care expenditures in the United States by age and sex. PLoS One. 2021;16(3):e0247307. doi:10.1371/journal.pone.0247307
  3. Horn DB, Almandoz JP, Look M. What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. Postgrad Med. 2022;134(4):359-375. doi:10.1080/00325481.2022.2051366
  4. American Diabetes Association (ADA). Standards of care in diabetes–2023. Diabetes Care. 2023;46(suppl 1):S128- S2139. doi:10.2337/dc23-S008
  5. Wilding JPH, Batterham RL, Calanna S, et al. Onceweekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
  6. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892
  7. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330-342. doi:10.1038/oby.2011.330
  8. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352. doi:10.1016/S0140-6736(11)60205-5
  9. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297-308. doi:10.3945/ajcn.111.024927
  10. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605. doi:10.1016/S0140-6736(10)60888-4
  11. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352(9123):167-172. doi:10.1016s0140-6736(97)11509-4
  12. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6-14. doi:10.1046/j.1365-2125.2003.02007.x
Article PDF
Author and Disclosure Information

Haley Smit, PharmDa; Krista Hayen, PharmDa; Kathryn Schartz, PharmD, BCACPa; Justin Metzger, PharmDa; Meghan Perry, PharmDa

Author affiliations
aVeterans Affairs Sioux Falls Health Care System

Author disclosures The authors report no actual or potential conflicts of interest or outside sources of funding with regard to this article.

Correspondence: Haley Smit ([email protected])

Fed Pract. 2025;42(2). Published online February 15. doi:10.12788/fp.0553

Issue
Federal Practitioner - 42(2)
Publications
Topics
Page Number
90-94
Sections
Author and Disclosure Information

Haley Smit, PharmDa; Krista Hayen, PharmDa; Kathryn Schartz, PharmD, BCACPa; Justin Metzger, PharmDa; Meghan Perry, PharmDa

Author affiliations
aVeterans Affairs Sioux Falls Health Care System

Author disclosures The authors report no actual or potential conflicts of interest or outside sources of funding with regard to this article.

Correspondence: Haley Smit ([email protected])

Fed Pract. 2025;42(2). Published online February 15. doi:10.12788/fp.0553

Author and Disclosure Information

Haley Smit, PharmDa; Krista Hayen, PharmDa; Kathryn Schartz, PharmD, BCACPa; Justin Metzger, PharmDa; Meghan Perry, PharmDa

Author affiliations
aVeterans Affairs Sioux Falls Health Care System

Author disclosures The authors report no actual or potential conflicts of interest or outside sources of funding with regard to this article.

Correspondence: Haley Smit ([email protected])

Fed Pract. 2025;42(2). Published online February 15. doi:10.12788/fp.0553

Article PDF
Article PDF

The impact of obesity in the United States is significant. Between August 2021 and August 2023, the prevalence of obesity (body mass index ≥ 30) in US adults was 40.3%.1 The prevalence of obesity in adults aged 40 to 59 years was 46.4%, higher than the prevalence in adults aged 20 to 39 years (35.5%) and those aged ≥ 60 years (38.9%).1 The excess annual medical costs associated with obesity in the US are estimated at nearly $173 billion.2

The first-line treatment for obesity is lifestyle modifications, including a healthy diet and exercise. When lifestyle modifications are not enough to achieve weight-loss goals, bariatric surgery and anti-obesity medications (AOMs) are often considered. Five medications were approved for the long-term tretament of obesity by the US Food and Drug Administration (FDA) between 2021 and 2023, when this study was conducted: semaglutide (Wegovy), liraglutide (Saxenda), phentermine and topiramate, naltrexone and bupropion, and orlistat. The clinically meaningful (and commonly accepted) weight-loss target for these medications is ≥ 5% from baseline by week 12 of the maximally tolerated dose of therapy. A 5% weight loss has been shown to be clinically significant in improving cardiometabolic risk factors.3,4 These medications are intended to be used as an adjunct to healthy diet and exercise. Of note, semaglutide and liraglutide carry brand names, which are associated with different dosing for the treatment of type 2 diabetes mellitus (T2DM).

All 5 FDA-approved AOMs were available at the Veterans Affairs Sioux Falls Health Care System (VASFHCS) for the treatment of obesity at the time of the study. To qualify for an AOM, a veteran at VASFHCS must first work with a dietitian or be enrolled in the MOVE! clinic to participate in the weight management program, which focuses on dietary, exercise, and behavioral changes. At VASFHCS, AOMs are prescribed by primary care practitioners, clinical pharmacy providers, and advanced practitioners within the MOVE! program.

Ample data exist for the efficacy of AOMs. However, no published research has reported on AOM efficacy by age group (Appendix).5-11 While most of the AOM clinical trials included older adults, the average age of participants was typically between 40 and 50 years. It is well-known that pharmacokinetic and pharmacodynamic changes occur as age increases. Renal and hepatic clearance is reduced while the volume distribution and sensitivities to some medications may increase. 12 Although this study did not focus on specific pharmacokinetic and pharmacodynamic changes with respect to AOM, it is important to recognize that this may play a role in the efficacy and safety of AOMs in older adults.

FDP04202090_A1

Methods

This retrospective single-center chart review was performed using the VASFHCS Computerized Patient Record System to compare the efficacy of AOMs in older adults (aged ≥ 65 years) vs adults (aged < 65 years). The primary endpoint was the percent change in body weight from baseline to 6 and 12 months after initiation of AOM therapy in the older adult vs adult population. Secondary endpoints included changes in low-density lipoprotein (LDL), hemoglobin A1c (HbA1c), and blood pressure (BP) from baseline compared to 12 months on AOM therapy. HbA1c was assessed in patients with T2DM or prediabetes at the time of AOM initiation. Two safety endpoints were also explored to determine the incidence of medication adverse events (AEs) and subsequent discontinuation of AOM. A subset analysis was performed to determine whether there was a difference in percent change in body weight between patients in 3 age groups: 18 to 40 years, 41 to 64 years, and ≥ 65 years.

The study population included patients who were prescribed an AOM between January 1, 2021, and June 30, 2023. Patients were excluded if they did not continue AOM therapy for ≥ 6 months after initiation or if they underwent gastric bypass surgery while undergoing AOM therapy. Patients taking semaglutide (Ozempic) or liraglutide (Victoza) for both T2DM and weight loss who were eventually switched to the weight loss formulations (Wegovy or Saxenda) were included. Patients who switched between semaglutide and liraglutide for weight loss were also included. Those taking semaglutide or liraglutide solely for T2DM treatment were excluded because they are dosed differently.

Collected data included age, gender, race, weight (baseline, 6 and 12 months after initiation of AOM), metabolic laboratory values/vital signs (HbA1c, LDL, and BP at baseline and 12 months after initiation of AOM), diagnosis of T2DM or prediabetes, reported AEs associated with AOM therapy, and date of AOM initiation and discontinuation (if applicable). Baseline values were defined at the time of medication initiation or values documented within 6 months prior to medication initiation if true baseline data were not reported. If values were not recorded at months 6 and 12 after AOM initiation, values documented closest to those targets were used. Weights were used for baseline, 6-, and 12-month data unless they were unavailable due to use of virtual care modalities. In these cases, patient-reported weights were used. Patients were included in the 6-month data, but not the 12-month data, if they were taking AOMs for > 6 months but not for 12 months. If patients had been on multiple AOMs, baseline data were recorded at the start of the first medication that was used for 6 months or longer. Twelve-month data were recorded after subsequent medication change. Twelve-month metabolic laboratory values/vital signs were recorded for patients included in the study even if they did not complete ≥ 12 months of AOM therapy.

Statistical Analysis

Data from patients who were prescribed an AOM from January 2021 to June 2023 and who remained on the medication for ≥ 6 months were analyzed. Baseline characteristics were analyzed using descriptive statistics. The primary and secondary endpoints were evaluated using the t test. The safety endpoints were analyzed using descriptive statistics. An analysis of variance test was used for the subset analysis. Results with P < .05 were statistically significant.

Results

A total of 144 participants were included in this study, 116 in the adult group (aged < 65 years) and 28 in the older adult group (aged ≥ 65 years). Sixty-seven patients were excluded due to prespecified inclusion and exclusion criteria.

Other than the predetermined mean age differences (48 years vs 71 years), there were multiple differences in patient baseline characteristics. When comparing older adults and adults, average weight (283 lb vs 269 lb) and White race (89% vs 87%) were slightly higher in the older adult group. Also, a higher prevalence of T2DM (54% and 18%) and a lower prevalence of prediabetes (21% and 33%) was noted in the older adult group. HbA1c and BP were similar between both groups at baseline, while LDL was slightly lower in the older adult group (Table 1).

FDP04202090_T1

Patients in the adult group lost a mean 7.0% and 8.7% of body weight at 6 and 12 months, respectively, while the older adult group lost 5.0% and 6.6% body weight at 6 and 12 months, respectively. The difference in percent change in body weight was not statistically different at 6 (P = .08) or 12 (P = .26) months between patients in the adult group vs the older adult group or in the specific age groups (18-40 years, 41-64 years, ≥ 65 years) at 6 months (P = .24) or 12 months (P = .53) (Figure).

FDP04202090_F

At 12 months, the difference between the adult group vs the older adult group was not statistically significant for HbA1c in patients with T2DM or prediabetes (P = .73), LDL (P = .95), systolic BP (P = .58), or diastolic BP (P = .51) (Table 2).

FDP04202090_T2

For the safety endpoint, the incidence of AEs was found to be different between groups. There were more reported AEs (61.2% vs 39.3%) and a greater increase in therapy discontinuation due to AEs (6.0% vs 0%) in the adult group compared to the older adult group (Table 3).

FDP04202090_T3

Discussion

Patients taking AOMs revealed no statistically significant difference in percent change in body weight at 6 or 12 months between adults aged < 65 years and older adults aged ≥ 65 years. The subset analysis also showed no statistically significant difference in change in percent body weight between more narrowly defined age groups of 18 to 40 years, 41 to 64 years, and ≥ 65 years. This suggests that AOM may have similar efficacy for weight loss in all ages of adults.

Secondary endpoint findings showed no statistically significant difference in HbA1c (in patients with T2DM or prediabetes), LDL, or BP at 12 months between the 2 groups. Although this study did not differentiate secondary outcomes based on the individual AOM, the change in HbA1c in both groups was expected, given that 70% of the patients included in this study were taking a glucagon-like peptide-1 agonist (liraglutide and semaglutide) at some point during the study. It’s also worth noting that secondary endpoints were collected for patients who discontinued the AOM between 6 and 12 months. Therefore, the patients’ HbA1c, LDL, and BP may not have accurately reflected the change that could have been expected if they had continued AOM therapy beyond the 12-month period.

Due to the different mechanisms and range in efficacy that AOMs have in regard to weight loss, changes in all outcomes, including weight, HbA1c, LDL, and BP were expected to vary as patients were included even after switching AOM (collection of data started after ≥ 6 months on a single AOM). Switching of AOM after the first 6 months of therapy was recorded in 25% of the patients in the ≥ 65 years group and 330% of the patients in the < 65 years group.

The incidence of AEs and subsequent discontinuation of AOMs in this study was higher in the adult group. This study excluded patients who did not continue taking an AOM for at least 6 months. As a result, the incidence of AEs between the 2 groups within the first 6 months of AOM therapy remains unknown. It is possible that during the first 6 months of therapy, patients aged < 65 years were more willing to tolerate or had fewer severe AEs compared with the older adult group. It’s also possible that the smaller number of patients in the older adult group was due to increased AEs that led them to discontinue early (before completion of 6 months of therapy) and/or prescriber discomfort in using AOMs in the older adult population. In addition, because the specific medication(s) taken by patients in each group were not detailed, it is unknown whether the adult group was taking AOMs associated with a greater number of AEs.

Limitations

This was a retrospective study with a relatively small sample size. A larger sample size may have shown more precise differences between age groups and may be more representative of the general population. Additionally, data were reliant on appropriate documentation, and adherence to AOM therapy was not assessed due to the retrospective nature of this study. At times, the study relied on patient reported data points, such as weight, if a clinic weight was not available. Also, this study did not account for many potential confounding factors such as other medications taken by the patient, which can affect outcomes including weight, HbA1c, LDL, blood pressure, and AEs.

Conclusions

This retrospective study of patients taking AOMs showed no statistically significant difference in weight loss at 6 or 12 months between adults aged < 65 years and older adults aged ≥ 65 years. A subset analysis found no statistically significant difference in change in body weight between specific age groups (18-40 years, 41-64 years, and ≥ 65 years). There was also no statistically significant difference in secondary outcomes, including change in HbA1c (in patients with T2DM or prediabetes), LDL or BP between age groups. The safety endpoints showed a higher incidence of medication AEs in the adult group, with more of these adults discontinuing therapy due to AEs. This study indicates that AOM may have similar outcomes for weight loss and metabolic laboratory values/vital sign changes between adults and older adults. Also, our findings suggest that patients aged < 65 years may experience more AEs than patients aged ≥ 65 years after ≥ 6 months of AOM therapy. Larger studies are needed to further evaluate these age-specific findings.

The impact of obesity in the United States is significant. Between August 2021 and August 2023, the prevalence of obesity (body mass index ≥ 30) in US adults was 40.3%.1 The prevalence of obesity in adults aged 40 to 59 years was 46.4%, higher than the prevalence in adults aged 20 to 39 years (35.5%) and those aged ≥ 60 years (38.9%).1 The excess annual medical costs associated with obesity in the US are estimated at nearly $173 billion.2

The first-line treatment for obesity is lifestyle modifications, including a healthy diet and exercise. When lifestyle modifications are not enough to achieve weight-loss goals, bariatric surgery and anti-obesity medications (AOMs) are often considered. Five medications were approved for the long-term tretament of obesity by the US Food and Drug Administration (FDA) between 2021 and 2023, when this study was conducted: semaglutide (Wegovy), liraglutide (Saxenda), phentermine and topiramate, naltrexone and bupropion, and orlistat. The clinically meaningful (and commonly accepted) weight-loss target for these medications is ≥ 5% from baseline by week 12 of the maximally tolerated dose of therapy. A 5% weight loss has been shown to be clinically significant in improving cardiometabolic risk factors.3,4 These medications are intended to be used as an adjunct to healthy diet and exercise. Of note, semaglutide and liraglutide carry brand names, which are associated with different dosing for the treatment of type 2 diabetes mellitus (T2DM).

All 5 FDA-approved AOMs were available at the Veterans Affairs Sioux Falls Health Care System (VASFHCS) for the treatment of obesity at the time of the study. To qualify for an AOM, a veteran at VASFHCS must first work with a dietitian or be enrolled in the MOVE! clinic to participate in the weight management program, which focuses on dietary, exercise, and behavioral changes. At VASFHCS, AOMs are prescribed by primary care practitioners, clinical pharmacy providers, and advanced practitioners within the MOVE! program.

Ample data exist for the efficacy of AOMs. However, no published research has reported on AOM efficacy by age group (Appendix).5-11 While most of the AOM clinical trials included older adults, the average age of participants was typically between 40 and 50 years. It is well-known that pharmacokinetic and pharmacodynamic changes occur as age increases. Renal and hepatic clearance is reduced while the volume distribution and sensitivities to some medications may increase. 12 Although this study did not focus on specific pharmacokinetic and pharmacodynamic changes with respect to AOM, it is important to recognize that this may play a role in the efficacy and safety of AOMs in older adults.

FDP04202090_A1

Methods

This retrospective single-center chart review was performed using the VASFHCS Computerized Patient Record System to compare the efficacy of AOMs in older adults (aged ≥ 65 years) vs adults (aged < 65 years). The primary endpoint was the percent change in body weight from baseline to 6 and 12 months after initiation of AOM therapy in the older adult vs adult population. Secondary endpoints included changes in low-density lipoprotein (LDL), hemoglobin A1c (HbA1c), and blood pressure (BP) from baseline compared to 12 months on AOM therapy. HbA1c was assessed in patients with T2DM or prediabetes at the time of AOM initiation. Two safety endpoints were also explored to determine the incidence of medication adverse events (AEs) and subsequent discontinuation of AOM. A subset analysis was performed to determine whether there was a difference in percent change in body weight between patients in 3 age groups: 18 to 40 years, 41 to 64 years, and ≥ 65 years.

The study population included patients who were prescribed an AOM between January 1, 2021, and June 30, 2023. Patients were excluded if they did not continue AOM therapy for ≥ 6 months after initiation or if they underwent gastric bypass surgery while undergoing AOM therapy. Patients taking semaglutide (Ozempic) or liraglutide (Victoza) for both T2DM and weight loss who were eventually switched to the weight loss formulations (Wegovy or Saxenda) were included. Patients who switched between semaglutide and liraglutide for weight loss were also included. Those taking semaglutide or liraglutide solely for T2DM treatment were excluded because they are dosed differently.

Collected data included age, gender, race, weight (baseline, 6 and 12 months after initiation of AOM), metabolic laboratory values/vital signs (HbA1c, LDL, and BP at baseline and 12 months after initiation of AOM), diagnosis of T2DM or prediabetes, reported AEs associated with AOM therapy, and date of AOM initiation and discontinuation (if applicable). Baseline values were defined at the time of medication initiation or values documented within 6 months prior to medication initiation if true baseline data were not reported. If values were not recorded at months 6 and 12 after AOM initiation, values documented closest to those targets were used. Weights were used for baseline, 6-, and 12-month data unless they were unavailable due to use of virtual care modalities. In these cases, patient-reported weights were used. Patients were included in the 6-month data, but not the 12-month data, if they were taking AOMs for > 6 months but not for 12 months. If patients had been on multiple AOMs, baseline data were recorded at the start of the first medication that was used for 6 months or longer. Twelve-month data were recorded after subsequent medication change. Twelve-month metabolic laboratory values/vital signs were recorded for patients included in the study even if they did not complete ≥ 12 months of AOM therapy.

Statistical Analysis

Data from patients who were prescribed an AOM from January 2021 to June 2023 and who remained on the medication for ≥ 6 months were analyzed. Baseline characteristics were analyzed using descriptive statistics. The primary and secondary endpoints were evaluated using the t test. The safety endpoints were analyzed using descriptive statistics. An analysis of variance test was used for the subset analysis. Results with P < .05 were statistically significant.

Results

A total of 144 participants were included in this study, 116 in the adult group (aged < 65 years) and 28 in the older adult group (aged ≥ 65 years). Sixty-seven patients were excluded due to prespecified inclusion and exclusion criteria.

Other than the predetermined mean age differences (48 years vs 71 years), there were multiple differences in patient baseline characteristics. When comparing older adults and adults, average weight (283 lb vs 269 lb) and White race (89% vs 87%) were slightly higher in the older adult group. Also, a higher prevalence of T2DM (54% and 18%) and a lower prevalence of prediabetes (21% and 33%) was noted in the older adult group. HbA1c and BP were similar between both groups at baseline, while LDL was slightly lower in the older adult group (Table 1).

FDP04202090_T1

Patients in the adult group lost a mean 7.0% and 8.7% of body weight at 6 and 12 months, respectively, while the older adult group lost 5.0% and 6.6% body weight at 6 and 12 months, respectively. The difference in percent change in body weight was not statistically different at 6 (P = .08) or 12 (P = .26) months between patients in the adult group vs the older adult group or in the specific age groups (18-40 years, 41-64 years, ≥ 65 years) at 6 months (P = .24) or 12 months (P = .53) (Figure).

FDP04202090_F

At 12 months, the difference between the adult group vs the older adult group was not statistically significant for HbA1c in patients with T2DM or prediabetes (P = .73), LDL (P = .95), systolic BP (P = .58), or diastolic BP (P = .51) (Table 2).

FDP04202090_T2

For the safety endpoint, the incidence of AEs was found to be different between groups. There were more reported AEs (61.2% vs 39.3%) and a greater increase in therapy discontinuation due to AEs (6.0% vs 0%) in the adult group compared to the older adult group (Table 3).

FDP04202090_T3

Discussion

Patients taking AOMs revealed no statistically significant difference in percent change in body weight at 6 or 12 months between adults aged < 65 years and older adults aged ≥ 65 years. The subset analysis also showed no statistically significant difference in change in percent body weight between more narrowly defined age groups of 18 to 40 years, 41 to 64 years, and ≥ 65 years. This suggests that AOM may have similar efficacy for weight loss in all ages of adults.

Secondary endpoint findings showed no statistically significant difference in HbA1c (in patients with T2DM or prediabetes), LDL, or BP at 12 months between the 2 groups. Although this study did not differentiate secondary outcomes based on the individual AOM, the change in HbA1c in both groups was expected, given that 70% of the patients included in this study were taking a glucagon-like peptide-1 agonist (liraglutide and semaglutide) at some point during the study. It’s also worth noting that secondary endpoints were collected for patients who discontinued the AOM between 6 and 12 months. Therefore, the patients’ HbA1c, LDL, and BP may not have accurately reflected the change that could have been expected if they had continued AOM therapy beyond the 12-month period.

Due to the different mechanisms and range in efficacy that AOMs have in regard to weight loss, changes in all outcomes, including weight, HbA1c, LDL, and BP were expected to vary as patients were included even after switching AOM (collection of data started after ≥ 6 months on a single AOM). Switching of AOM after the first 6 months of therapy was recorded in 25% of the patients in the ≥ 65 years group and 330% of the patients in the < 65 years group.

The incidence of AEs and subsequent discontinuation of AOMs in this study was higher in the adult group. This study excluded patients who did not continue taking an AOM for at least 6 months. As a result, the incidence of AEs between the 2 groups within the first 6 months of AOM therapy remains unknown. It is possible that during the first 6 months of therapy, patients aged < 65 years were more willing to tolerate or had fewer severe AEs compared with the older adult group. It’s also possible that the smaller number of patients in the older adult group was due to increased AEs that led them to discontinue early (before completion of 6 months of therapy) and/or prescriber discomfort in using AOMs in the older adult population. In addition, because the specific medication(s) taken by patients in each group were not detailed, it is unknown whether the adult group was taking AOMs associated with a greater number of AEs.

Limitations

This was a retrospective study with a relatively small sample size. A larger sample size may have shown more precise differences between age groups and may be more representative of the general population. Additionally, data were reliant on appropriate documentation, and adherence to AOM therapy was not assessed due to the retrospective nature of this study. At times, the study relied on patient reported data points, such as weight, if a clinic weight was not available. Also, this study did not account for many potential confounding factors such as other medications taken by the patient, which can affect outcomes including weight, HbA1c, LDL, blood pressure, and AEs.

Conclusions

This retrospective study of patients taking AOMs showed no statistically significant difference in weight loss at 6 or 12 months between adults aged < 65 years and older adults aged ≥ 65 years. A subset analysis found no statistically significant difference in change in body weight between specific age groups (18-40 years, 41-64 years, and ≥ 65 years). There was also no statistically significant difference in secondary outcomes, including change in HbA1c (in patients with T2DM or prediabetes), LDL or BP between age groups. The safety endpoints showed a higher incidence of medication AEs in the adult group, with more of these adults discontinuing therapy due to AEs. This study indicates that AOM may have similar outcomes for weight loss and metabolic laboratory values/vital sign changes between adults and older adults. Also, our findings suggest that patients aged < 65 years may experience more AEs than patients aged ≥ 65 years after ≥ 6 months of AOM therapy. Larger studies are needed to further evaluate these age-specific findings.

References
  1. Emmerich SD, Fryar CD, Stierman B, Ogden CL. Obesity and severe obesity prevalence in adults: United States, August 2021-August 2023. NCHS Data Brief No. 508. National Center for Health Statistics; 2024. Accessed December 11, 2024. https://www.cdc.gov/nchs/products/databriefs/db508.htm
  2. Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass index with health care expenditures in the United States by age and sex. PLoS One. 2021;16(3):e0247307. doi:10.1371/journal.pone.0247307
  3. Horn DB, Almandoz JP, Look M. What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. Postgrad Med. 2022;134(4):359-375. doi:10.1080/00325481.2022.2051366
  4. American Diabetes Association (ADA). Standards of care in diabetes–2023. Diabetes Care. 2023;46(suppl 1):S128- S2139. doi:10.2337/dc23-S008
  5. Wilding JPH, Batterham RL, Calanna S, et al. Onceweekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
  6. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892
  7. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330-342. doi:10.1038/oby.2011.330
  8. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352. doi:10.1016/S0140-6736(11)60205-5
  9. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297-308. doi:10.3945/ajcn.111.024927
  10. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605. doi:10.1016/S0140-6736(10)60888-4
  11. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352(9123):167-172. doi:10.1016s0140-6736(97)11509-4
  12. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6-14. doi:10.1046/j.1365-2125.2003.02007.x
References
  1. Emmerich SD, Fryar CD, Stierman B, Ogden CL. Obesity and severe obesity prevalence in adults: United States, August 2021-August 2023. NCHS Data Brief No. 508. National Center for Health Statistics; 2024. Accessed December 11, 2024. https://www.cdc.gov/nchs/products/databriefs/db508.htm
  2. Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass index with health care expenditures in the United States by age and sex. PLoS One. 2021;16(3):e0247307. doi:10.1371/journal.pone.0247307
  3. Horn DB, Almandoz JP, Look M. What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. Postgrad Med. 2022;134(4):359-375. doi:10.1080/00325481.2022.2051366
  4. American Diabetes Association (ADA). Standards of care in diabetes–2023. Diabetes Care. 2023;46(suppl 1):S128- S2139. doi:10.2337/dc23-S008
  5. Wilding JPH, Batterham RL, Calanna S, et al. Onceweekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
  6. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892
  7. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330-342. doi:10.1038/oby.2011.330
  8. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352. doi:10.1016/S0140-6736(11)60205-5
  9. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297-308. doi:10.3945/ajcn.111.024927
  10. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605. doi:10.1016/S0140-6736(10)60888-4
  11. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352(9123):167-172. doi:10.1016s0140-6736(97)11509-4
  12. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6-14. doi:10.1046/j.1365-2125.2003.02007.x
Issue
Federal Practitioner - 42(2)
Issue
Federal Practitioner - 42(2)
Page Number
90-94
Page Number
90-94
Publications
Publications
Topics
Article Type
Display Headline

Efficacy of Anti-Obesity Medications in Adult and Older Adult Veteran Populations

Display Headline

Efficacy of Anti-Obesity Medications in Adult and Older Adult Veteran Populations

Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Wed, 02/05/2025 - 14:51
Un-Gate On Date
Wed, 02/05/2025 - 14:51
Use ProPublica
CFC Schedule Remove Status
Wed, 02/05/2025 - 14:51
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Wed, 02/05/2025 - 14:51

Resident Participation Impact on Operative Time and Outcomes in Veterans Undergoing Total Laryngectomy

Article Type
Changed
Wed, 02/19/2025 - 08:47
Display Headline

Resident Participation Impact on Operative Time and Outcomes in Veterans Undergoing Total Laryngectomy

The US Department of Veterans Affairs (VA) has been integral in resident training. Resident surgical training requires a balance of supervision and autonomy, along with procedure repetition and appropriate feedback.1-3 Non-VA research has found that resident participation across various otolaryngology procedures, including thyroidectomy, neck dissection, and laryngectomy, does not increase patient morbidity.4-7 However, resident involvement in private and academic settings that included nonhead and neck procedures was linked to increased operative time and reduced productivity, as determined by work relative value units (wRVUs).7-13 This has also been identified in other specialties, including general surgery, orthopedics, and ophthalmology.14-16

Unlike the private sector, surgeon compensation at the VA is not as closely linked to operative productivity, offering a unique setting for resident training. While VA integration in otolaryngology residency programs increases resident case numbers, particularly in head and neck cases, the impact on VA patient outcomes and productivity is unknown.17 The use of larynxpreserving treatment modalities for laryngeal cancer has led to a decline in the number of total laryngectomies performed, which could potentially impact resident operative training for laryngectomies.18-20

This study sought to determine the impact of resident participation on operative time, wRVUs, and patient outcomes in veterans who underwent a total laryngectomy. This study was reviewed and approved by the MedStar Georgetown University Hospital Institutional Review Board and Research and Development Committee (#1595672).

Methods

A retrospective cohort of veterans nationwide who underwent total laryngectomy between 2001 and 2021, with or without neck dissection, was identified from the Veterans Affairs Surgical Quality Improvement Program (VASQIP). Data were extracted via the VA Informatics and Computing Infrastructure and patients were included based on Current Procedural Terminology codes for total laryngectomy, with or without neck dissection (31320, 31360, 31365). Laryngopharyngectomies, partial laryngectomies, and minimally invasive laryngectomies were excluded. VASQIP nurse data managers reviewed patient data for operative data, postoperative outcomes (including 30- day morbidity and mortality), and preoperative risk factors (Appendix).21

The VASQIP data provide the highest resident or postgraduate year (PGY) per surgery. PGY 1, 2, and 3 were considered junior residents and PGY ≥4, surgical fellows, and individuals who took research years during residency were considered senior residents. Cases performed by attending physicians alone were compared with those involving junior or senior residents.

Patient demographic data included age, body mass index, smoking and alcohol use, weight loss, and functional status. Consumption of any tobacco products within 12 months of surgery was considered tobacco use. Drinking on average ≥2 alcoholic beverages daily was considered alcohol use. Weight loss was defined as a 10% reduction in body weight within the 6 months before surgery, excluding patients enrolled in a weight loss program. Functional status was categorized as independent, partially dependent, totally dependent, and unknown.

Primary outcomes included operative time, wRVUs generated, and wRVUs generated per hour of operative time. Postoperative complications were recorded both as a continuous variable and as a binary variable for presence or absence of a complication. Additional outcome variables included length of postoperative hospital stay, return to the operating room (OR), and death within 30 days of surgery.

Statistical Analysis

Data were summarized using frequency and percentage for categorical variables and median with IQR for continuous variables. Data were also summarized based on resident involvement in the surgery and the PGY level of the residents involved. The occurrence of total laryngectomy, rate of complications, and patient return to the OR were summarized by year.

Univariate associations between resident involvement and surgical outcomes were analyzed using the Kruskal-Wallis test for continuous variables and the ÷2 test for categorical variables. A Fisher exact test was used when the cell count in the contingency table was < 5. The univariate associations between surgical outcomes and demographic/preoperative variables were examined using 2-sided Wilcoxon ranksum tests or Kruskal-Wallis tests between continuous variables and categorical variables, X2 or Fisher exact test between 2 categorical variables, and 2-sided Spearman correlation test between 2 continuous variables. A false-discovery rate approach was used for simultaneous posthoc tests to determine the adjusted P values for wRVUs generated/operative time for attending physicians alone vs with junior residents and for attending physicians alone vs with senior residents. Models were used to evaluate the effects of resident involvement on surgical outcomes, adjusting for variables that showed significant univariate associations. Linear regression models were used for operative time, wRVUs generated, wRVUs generated/operative time, and length of postoperative stay. A logistic regression model was used for death within 30 days. Models were not built for postoperative complications or patient return to the OR, as these were only statistically significantly associated with the patient’s preoperative functional status. A finding was considered significant if P < .05. All analyses were performed using statistical software RStudio Version 2023.03.0.

Results

Between 2001 and 2021, 1857 patients who underwent total laryngectomy were identified from the VASQIP database nationwide. Most of the total laryngectomies were staffed by an attending physician with a senior resident (n = 1190, 64%), 446 (24%) were conducted by the attending physician alone, and 221 (12%) by an attending physician with a junior resident (Table 1). The mean operating time for an attending physician alone was 378 minutes, 384 minutes for an attending physician with a senior resident, and 432 minutes for an attending physician with a junior resident (Table 2). There was a statistically significant increase in operating time for laryngectomies with resident participation compared to attending physicians operating alone (P < .001).

FDP04202082_T1FDP04202082_T2

When the wRVUs generated/operative time was analyzed, there was a statistically significant difference between comparison groups. Total laryngectomies performed by attending physicians alone had the highest wRVUs generated/operative time (5.5), followed by laryngectomies performed by attending physicians with senior residents and laryngectomies performed by attending physicians with junior residents (5.2 and 4.8, respectively; P = .002). Table 3 describes adjusted P values for wRVUs generated/ operative time for total laryngectomies performed by attending physicians alone vs with junior residents (P = .003) and for attending physicians alone vs with senior residents (P = .02). Resident participation in total laryngectomies did not significantly impact the development or number of postoperative complications or the rate of return to the OR.

FDP04202082_T3

The number of laryngectomies performed in a single fiscal year peaked in 2010 at 170 cases (Figure 1). Between 2001 and 2021, the mean rates of postoperative complications (21.3%) and patient return to the OR (14.6%) did not significantly change. Resident participation in total laryngectomies also peaked in 2010 at 89.0% but has significantly declined, falling to a low of 43.6% in 2021 (Figure 2). From 2001 to 2011, the mean resident participation rate in total laryngectomies was 80.6%, compared with 68.3% from 2012 to 2021 (P < .001).

FDP04202082_F1FDP04202082_F2

The effect of various demographic and preoperative characteristics on surgical outcomes was also analyzed. A linear regression model accounted for each variable significantly associated with operative time. On multivariable analysis, when all other variables were held constant, Table 4 shows the estimated change in operative time based on certain criteria. For instance, the operative time for attendings with junior residents surgeries was 40 minutes longer (95% CI, 16 to 64) than that of attending alone surgeries (P = .001). Furthermore, operative time decreased by 1.1 minutes (95% CI, 0.30 to 2.04) for each 1-year increase in patient age (P = .009).

FDP04202082_T4

A multivariable logistic regression model evaluated the effect of resident involvement on 30-day mortality rates. Senior resident involvement (P = .02), partially dependent functional status (P = .01), totally dependent functional status (P < .001), and advanced age (P = .02) all were significantly associated with 30-day mortality (Table 5). When other variables remained constant, the odds of death for totally dependent patients were 10.4 times higher than that of patients with independent functional status. Thus, totally dependent functional status appeared to have a greater impact on this outcome than resident participation. The linear regression model for postoperative length of stay demonstrated that senior resident involvement (P = .04), functional status (partially dependent vs independent P < .001), and age (P = .03) were significantly associated with prolonged length of stay.

FDP04202082_T5

Discussion

Otolaryngology residency training is designed to educate future otolaryngologists through hands-on learning, adequate feedback, and supervision.1 Although this exposure is paramount for resident education, balancing appropriate supervision and autonomy while mitigating patient risk has been difficult. Numerous non-VA studies have reviewed the impact of resident participation on patient outcomes in various specialties, ranging from a single institution to the National Surgical Quality Improvement Program (NSQIP).4,5,7,22 This study is the first to describe the nationwide impact of resident participation on outcomes in veterans undergoing total laryngectomy.

This study found that resident participation increases operative time and decreases wRVUs generated/operative time without impacting complication rates or patient return to the OR. This reinforces the notion that under close supervision, resident participation does not negatively impact patient outcomes. Resident operative training requires time and dedication by the attending physician and surgical team, thereby increasing operative time. Because VA physician compensation is not linked with productivity as closely as it is in other private and academic settings, surgeons can dedicate more time to operative teaching. This study found that a total laryngectomy involving a junior resident took about 45 minutes longer than an attending physician working alone.

As expected, with longer operative times, the wRVUs generated/operative time ratio was lower in cases with resident participation. Even though resident participation leads to lower OR efficiency, their participation may not significantly impact ancillary costs.23 However, a recent study from NSQIP found an opportunity cost of $60.44 per hour for surgeons operating with a resident in head and neck cases.13

Postoperative complications and mortality are key measures of surgical outcomes in addition to operative time and efficiency. This study found that neither junior nor senior resident participation significantly increased complication rates or patient return to the OR. Despite declining resident involvement and the number of total laryngectomy surgeries in the VA, the complication rate has remained steady. The 30-day mortality rate was significantly higher in cases involving senior residents compared to cases with attending physicians alone. This could be a result of senior resident participation in more challenging cases, such as laryngectomies performed as salvage surgery following radiation. Residents are more often involved in cases with greater complexity at teaching institutions.24-26 Therefore, the higher mortality seen among laryngectomies with senior resident involvement is likely due to the higher complexity of those cases.

The proportion of resident involvement in laryngectomies at VA medical centers has been decreasing over time. Due to the single payer nature of the VA health care system and the number of complex and comorbid patients, the VA offers an invaluable space for resident education in the OR. The fact that less than half of laryngectomies in 2021 involved resident participation is noteworthy for residency training programs. As wRVU compensation models evolve, VA attending surgeons may face less pressure to move the case along, leading to a high potential for operative teaching. Therefore, complex cases, such as laryngectomies, are often ideal for resident participation in the VA.

The steady decline in total laryngectomies at the VA parallels the recent decrease seen in non-VA settings.20 This is due in part to the use of larynx-preserving treatment modalities for laryngeal cancer as well as decreases in the incidence of laryngeal cancer due to population level changes in smoking behaviors. 18,19 Although a laryngectomy is not a key indicator case as determined by the Accreditation Council for Graduate Medical Education, it is important for otolaryngology residents to be exposed to these cases and have a thorough understanding of the operative technique.27 Total laryngectomy was selected for this study because it is a complex and time-consuming surgery with somewhat standardized surgical steps. Unlike microvascular surgery that is very rarely performed by an attending physician alone, laryngectomies can be performed by attending physicians alone or with a resident.28

Limitations

Since this was a retrospective study, it was susceptible to errors in data entry and data extraction from the VASQIP database. Another limitation is the lack of preoperative treatment data on tumor stage and prior nonoperative treatment. For example, a salvage laryngectomy after treatment with radiation and/or chemoradiation is a higher risk procedure than an upfront laryngectomy. Senior resident involvement may be more common in patients undergoing salvage laryngectomy due to the high risk of postoperative fistula and other complications. This may have contributed to the association identified between senior resident participation and 30-day mortality.

Since we could not account for residents who took research years or were fellows, a senior resident may have been mislabeled as a junior resident or vice versa. However, because most research years occur following the third year of residency. We are confident that PGY-1, PGY-2, and PGY-3 is likely to capture junior residents. Other factors, such as coattending surgeon cases, medical student assistance, and fellow involvement may have also impacted the results of this study.

Conclusions

This study is the first to investigate the impact of resident participation on operative time, wRVUs generated, and complication rates in head and neck surgery at VA medical centers. It found that resident participation in total laryngectomies among veterans increased operative time and reduced wRVUs generated per hour but did not impact complication rate or patient return to the OR. The VA offers a unique and invaluable space for resident education and operative training, and the recent decline in resident participation among laryngectomies is important for residency programs to acknowledge and potentially address moving forward.

In contrast to oral cavity resections which can vary from partial glossectomies to composite resections, laryngectomy represents a homogenous procedure from which to draw meaningful conclusions about complication rates, operative time, and outcome. Future directions should include studying other types of head and neck surgery in the VA to determine whether the impact of resident participation mirrors the findings of this study.

References
  1. Chung RS. How much time do surgical residents need to learn operative surgery? Am J Surg. 2005;190(3):351-353. doi:10.1016/j.amjsurg.2005.06.035
  2. S, Darzi A. Defining quality in surgical training: perceptions of the profession. Am J Surg. 2014;207(4):628-636. doi:10.1016/j.amjsurg.2013.07.044
  3. Bhatti NI, Ahmed A, Choi SS. Identifying quality indicators of surgical of surgical training: a national survey. Laryngoscope. 2015;125(12):2685-2689. doi:10.1002/lary.25262
  4. Abt NB, Reh DD, Eisele DW, Francis HW, Gourin CG. Does resident participation influence otolaryngology-head and neck surgery morbidity and mortality? Laryngoscope. 2016;126(10):2263-2269. doi:10.1002/lary.25973
  5. Jubbal KT, Chang D, Izaddoost SA, Pederson W, Zavlin D, Echo A. Resident involvement in microsurgery: an American College of Surgeons national surgical quality improvement program analysis. J Surg Educ. 2017;74(6):1124-1132. doi:10.1016/j.jsurg.2017.05.017
  6. Kshirsagar RS, Chandy Z, Mahboubi H, Verma SP. Does resident involvement in thyroid surgery lead to increased postoperative complications? Laryngoscope. 2017;127(5):1242-1246. doi:10.1002/lary.26176
  7. Vieira BL, Hernandez DJ, Qin C, Smith SS, Kim JY, Dutra JC. The impact of resident involvement on otolaryngology surgical outcomes. Laryngoscope. 2016;126(3):602-607. doi:10.1002/lary.25046
  8. Advani V, Ahad S, Gonczy C, Markwell S, Hassan I. Does resident involvement effect surgical times and complication rates during laparoscopic appendectomy for uncomplicated appendicitis? An analysis of 16,849 cases from the ACS-NSQIP. Am J Surg. 2012;203(3):347-352. doi:10.1016/j.amjsurg.2011.08.015
  9. Quinn NA, Alt JA, Ashby S, Orlandi RR. Time, resident involvement, and supply drive cost variability in septoplasty with turbinate reduction. Otolaryngol Head Neck Surg. 2018;159(2):310-314. doi:10.1177/0194599818765099
  10. Leader BA, Wiebracht ND, Meinzen-Derr J, Ishman SL. The impact of resident involvement on tonsillectomy outcomes and surgical time. Laryngoscope. 2020;130(10):2481-2486. doi:10.1002/lary.28427
  11. Muelleman T, Shew M, Muelleman RJ, et al. Impact of resident participation on operative time and outcomes in otologic surgery. Otolaryngol Head Neck Surg. 2018;158(1):151-154. doi:10.1177/0194599817737270
  12. Puram SV, Kozin ED, Sethi R, et al. Impact of resident surgeons on procedure length based on common pediatric otolaryngology cases. Laryngoscope. 2015;125(4):991 -997. doi:10.1002/lary.24912
  13. Chow MS, Gordon AJ, Talwar A, Lydiatt WM, Yueh B, Givi B. The RVU compensation model and head and neck surgical education. Laryngoscope. 2024;134(1):113-119. doi:10.1002/lary.30807
  14. Papandria D, Rhee D, Ortega G, et al. Assessing trainee impact on operative time for common general surgical procedures in ACS-NSQIP. J Surg Educ. 2012;69(2):149-155. doi:10.1016/j.jsurg.2011.08.003
  15. Pugely AJ, Gao Y, Martin CT, Callagh JJ, Weinstein SL, Marsh JL. The effect of resident participation on short-term outcomes after orthopaedic surgery. Clin Orthop Relat Res. 2014;472(7):2290-2300. doi:10.1007/s11999-014-3567-0
  16. Hosler MR, Scott IU, Kunselman AR, Wolford KR, Oltra EZ, Murray WB. Impact of resident participation in cataract surgery on operative time and cost. Ophthalmology. 2012;119(1):95-98. doi:10.1016/j.ophtha.2011.06.026
  17. Lanigan A, Spaw M, Donaghe C, Brennan J. The impact of the Veteran’s Affairs medical system on an otolaryngology residency training program. Mil Med. 2018;183(11-12):e671-e675. doi:10.1093/milmed/usy041
  18. American Society of Clinical Oncology, Pfister DG, Laurie SA, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006;24(22):3693-3704. doi:10.1200/JCO.2006.07.4559
  19. Forastiere AA, Ismaila N, Lewin JS, et al. Use of larynxpreservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36(11):1143-1169. doi:10.1200/JCO.2017.75.7385
  20. Verma SP, Mahboubi H. The changing landscape of total laryngectomy surgery. Otolaryngol Head Neck Surg. 2014;150(3):413-418. doi:10.1177/0194599813514515
  21. Habermann EB, Harris AHS, Giori NJ. Large surgical databases with direct data abstraction: VASQIP and ACSNSQIP. J Bone Joint Surg Am. 2022;104(suppl 3):9-14. doi:10.2106/JBJS.22.00596
  22. Benito DA, Mamidi I, Pasick LJ, et al. Evaluating resident involvement and the ‘July effect’ in parotidectomy. J Laryngol Otol. 2021;135(5):452-457. doi:10.1017/S0022215121000578
  23. Hwang CS, Wichterman KA, Alfrey EJ. The cost of resident education. J Surg Res. 2010;163(1):18-23. doi:10.1016/j.jss.2010.03.013
  24. Saliba AN, Taher AT, Tamim H, et al. Impact of resident involvement in surgery (IRIS-NSQIP): looking at the bigger picture based on the American College of Surgeons- NSQIP database. J Am Coll Surg. 2016; 222(1):30-40. doi:10.1016/j.jamcollsurg.2015.10.011
  25. Khuri SF, Najjar SF, Daley J, et al. Comparison of surgical outcomes between teaching and nonteaching hospitals in the Department of Veterans Affairs. Ann Surg. 2001;234(3):370-383. doi:10.1097/00000658-200109000-00011
  26. Relles DM, Burkhart RA, Pucci MJ et al. Does resident experience affect outcomes in complex abdominal surgery? Pancreaticoduodenectomy as an example. J Gastrointest Surg. 2014;18(2):279-285. doi:10.1007/s11605-013-2372-5
  27. Accreditation Council for Graduate Medical Education. Required minimum number of key indicator procedures for graduating residents. June 2019. Accessed January 2, 2025. https://www.acgme.org/globalassets/pfassets/programresources/280_core_case_log_minimums.pdf
  28. Brady JS, Crippen MM, Filimonov A, et al. The effect of training level on complications after free flap surgery of the head and neck. Am J Otolaryngol. 2017;38(5):560-564. doi:10.1016/j.amjoto.2017.06.001
Article PDF
Author and Disclosure Information

John Andersona; Xue Geng, MSb; Jessica H. Maxwell, MD, MPHc,d

Author disclosures: The authors report no actual or potential conflicts of interest with regard to this article.

Author affiliationsL
aGeorgetown University, Washington, District of Columbia
bMedStar Georgetown University Hospital, Washington, District of Columbia
cUniversity of Pittsburgh Medical Center, Pennsylvania
dVeterans Affairs Pittsburgh Healthcare System, Pennsylvania

Correspondence: Jessica Maxwell ([email protected])

Fed Pract. 2025;42(2). Published online February 15. doi:10.12788/fp.0550

Issue
Federal Practitioner - 42(2)
Publications
Topics
Page Number
82-89
Sections
Author and Disclosure Information

John Andersona; Xue Geng, MSb; Jessica H. Maxwell, MD, MPHc,d

Author disclosures: The authors report no actual or potential conflicts of interest with regard to this article.

Author affiliationsL
aGeorgetown University, Washington, District of Columbia
bMedStar Georgetown University Hospital, Washington, District of Columbia
cUniversity of Pittsburgh Medical Center, Pennsylvania
dVeterans Affairs Pittsburgh Healthcare System, Pennsylvania

Correspondence: Jessica Maxwell ([email protected])

Fed Pract. 2025;42(2). Published online February 15. doi:10.12788/fp.0550

Author and Disclosure Information

John Andersona; Xue Geng, MSb; Jessica H. Maxwell, MD, MPHc,d

Author disclosures: The authors report no actual or potential conflicts of interest with regard to this article.

Author affiliationsL
aGeorgetown University, Washington, District of Columbia
bMedStar Georgetown University Hospital, Washington, District of Columbia
cUniversity of Pittsburgh Medical Center, Pennsylvania
dVeterans Affairs Pittsburgh Healthcare System, Pennsylvania

Correspondence: Jessica Maxwell ([email protected])

Fed Pract. 2025;42(2). Published online February 15. doi:10.12788/fp.0550

Article PDF
Article PDF

The US Department of Veterans Affairs (VA) has been integral in resident training. Resident surgical training requires a balance of supervision and autonomy, along with procedure repetition and appropriate feedback.1-3 Non-VA research has found that resident participation across various otolaryngology procedures, including thyroidectomy, neck dissection, and laryngectomy, does not increase patient morbidity.4-7 However, resident involvement in private and academic settings that included nonhead and neck procedures was linked to increased operative time and reduced productivity, as determined by work relative value units (wRVUs).7-13 This has also been identified in other specialties, including general surgery, orthopedics, and ophthalmology.14-16

Unlike the private sector, surgeon compensation at the VA is not as closely linked to operative productivity, offering a unique setting for resident training. While VA integration in otolaryngology residency programs increases resident case numbers, particularly in head and neck cases, the impact on VA patient outcomes and productivity is unknown.17 The use of larynxpreserving treatment modalities for laryngeal cancer has led to a decline in the number of total laryngectomies performed, which could potentially impact resident operative training for laryngectomies.18-20

This study sought to determine the impact of resident participation on operative time, wRVUs, and patient outcomes in veterans who underwent a total laryngectomy. This study was reviewed and approved by the MedStar Georgetown University Hospital Institutional Review Board and Research and Development Committee (#1595672).

Methods

A retrospective cohort of veterans nationwide who underwent total laryngectomy between 2001 and 2021, with or without neck dissection, was identified from the Veterans Affairs Surgical Quality Improvement Program (VASQIP). Data were extracted via the VA Informatics and Computing Infrastructure and patients were included based on Current Procedural Terminology codes for total laryngectomy, with or without neck dissection (31320, 31360, 31365). Laryngopharyngectomies, partial laryngectomies, and minimally invasive laryngectomies were excluded. VASQIP nurse data managers reviewed patient data for operative data, postoperative outcomes (including 30- day morbidity and mortality), and preoperative risk factors (Appendix).21

The VASQIP data provide the highest resident or postgraduate year (PGY) per surgery. PGY 1, 2, and 3 were considered junior residents and PGY ≥4, surgical fellows, and individuals who took research years during residency were considered senior residents. Cases performed by attending physicians alone were compared with those involving junior or senior residents.

Patient demographic data included age, body mass index, smoking and alcohol use, weight loss, and functional status. Consumption of any tobacco products within 12 months of surgery was considered tobacco use. Drinking on average ≥2 alcoholic beverages daily was considered alcohol use. Weight loss was defined as a 10% reduction in body weight within the 6 months before surgery, excluding patients enrolled in a weight loss program. Functional status was categorized as independent, partially dependent, totally dependent, and unknown.

Primary outcomes included operative time, wRVUs generated, and wRVUs generated per hour of operative time. Postoperative complications were recorded both as a continuous variable and as a binary variable for presence or absence of a complication. Additional outcome variables included length of postoperative hospital stay, return to the operating room (OR), and death within 30 days of surgery.

Statistical Analysis

Data were summarized using frequency and percentage for categorical variables and median with IQR for continuous variables. Data were also summarized based on resident involvement in the surgery and the PGY level of the residents involved. The occurrence of total laryngectomy, rate of complications, and patient return to the OR were summarized by year.

Univariate associations between resident involvement and surgical outcomes were analyzed using the Kruskal-Wallis test for continuous variables and the ÷2 test for categorical variables. A Fisher exact test was used when the cell count in the contingency table was < 5. The univariate associations between surgical outcomes and demographic/preoperative variables were examined using 2-sided Wilcoxon ranksum tests or Kruskal-Wallis tests between continuous variables and categorical variables, X2 or Fisher exact test between 2 categorical variables, and 2-sided Spearman correlation test between 2 continuous variables. A false-discovery rate approach was used for simultaneous posthoc tests to determine the adjusted P values for wRVUs generated/operative time for attending physicians alone vs with junior residents and for attending physicians alone vs with senior residents. Models were used to evaluate the effects of resident involvement on surgical outcomes, adjusting for variables that showed significant univariate associations. Linear regression models were used for operative time, wRVUs generated, wRVUs generated/operative time, and length of postoperative stay. A logistic regression model was used for death within 30 days. Models were not built for postoperative complications or patient return to the OR, as these were only statistically significantly associated with the patient’s preoperative functional status. A finding was considered significant if P < .05. All analyses were performed using statistical software RStudio Version 2023.03.0.

Results

Between 2001 and 2021, 1857 patients who underwent total laryngectomy were identified from the VASQIP database nationwide. Most of the total laryngectomies were staffed by an attending physician with a senior resident (n = 1190, 64%), 446 (24%) were conducted by the attending physician alone, and 221 (12%) by an attending physician with a junior resident (Table 1). The mean operating time for an attending physician alone was 378 minutes, 384 minutes for an attending physician with a senior resident, and 432 minutes for an attending physician with a junior resident (Table 2). There was a statistically significant increase in operating time for laryngectomies with resident participation compared to attending physicians operating alone (P < .001).

FDP04202082_T1FDP04202082_T2

When the wRVUs generated/operative time was analyzed, there was a statistically significant difference between comparison groups. Total laryngectomies performed by attending physicians alone had the highest wRVUs generated/operative time (5.5), followed by laryngectomies performed by attending physicians with senior residents and laryngectomies performed by attending physicians with junior residents (5.2 and 4.8, respectively; P = .002). Table 3 describes adjusted P values for wRVUs generated/ operative time for total laryngectomies performed by attending physicians alone vs with junior residents (P = .003) and for attending physicians alone vs with senior residents (P = .02). Resident participation in total laryngectomies did not significantly impact the development or number of postoperative complications or the rate of return to the OR.

FDP04202082_T3

The number of laryngectomies performed in a single fiscal year peaked in 2010 at 170 cases (Figure 1). Between 2001 and 2021, the mean rates of postoperative complications (21.3%) and patient return to the OR (14.6%) did not significantly change. Resident participation in total laryngectomies also peaked in 2010 at 89.0% but has significantly declined, falling to a low of 43.6% in 2021 (Figure 2). From 2001 to 2011, the mean resident participation rate in total laryngectomies was 80.6%, compared with 68.3% from 2012 to 2021 (P < .001).

FDP04202082_F1FDP04202082_F2

The effect of various demographic and preoperative characteristics on surgical outcomes was also analyzed. A linear regression model accounted for each variable significantly associated with operative time. On multivariable analysis, when all other variables were held constant, Table 4 shows the estimated change in operative time based on certain criteria. For instance, the operative time for attendings with junior residents surgeries was 40 minutes longer (95% CI, 16 to 64) than that of attending alone surgeries (P = .001). Furthermore, operative time decreased by 1.1 minutes (95% CI, 0.30 to 2.04) for each 1-year increase in patient age (P = .009).

FDP04202082_T4

A multivariable logistic regression model evaluated the effect of resident involvement on 30-day mortality rates. Senior resident involvement (P = .02), partially dependent functional status (P = .01), totally dependent functional status (P < .001), and advanced age (P = .02) all were significantly associated with 30-day mortality (Table 5). When other variables remained constant, the odds of death for totally dependent patients were 10.4 times higher than that of patients with independent functional status. Thus, totally dependent functional status appeared to have a greater impact on this outcome than resident participation. The linear regression model for postoperative length of stay demonstrated that senior resident involvement (P = .04), functional status (partially dependent vs independent P < .001), and age (P = .03) were significantly associated with prolonged length of stay.

FDP04202082_T5

Discussion

Otolaryngology residency training is designed to educate future otolaryngologists through hands-on learning, adequate feedback, and supervision.1 Although this exposure is paramount for resident education, balancing appropriate supervision and autonomy while mitigating patient risk has been difficult. Numerous non-VA studies have reviewed the impact of resident participation on patient outcomes in various specialties, ranging from a single institution to the National Surgical Quality Improvement Program (NSQIP).4,5,7,22 This study is the first to describe the nationwide impact of resident participation on outcomes in veterans undergoing total laryngectomy.

This study found that resident participation increases operative time and decreases wRVUs generated/operative time without impacting complication rates or patient return to the OR. This reinforces the notion that under close supervision, resident participation does not negatively impact patient outcomes. Resident operative training requires time and dedication by the attending physician and surgical team, thereby increasing operative time. Because VA physician compensation is not linked with productivity as closely as it is in other private and academic settings, surgeons can dedicate more time to operative teaching. This study found that a total laryngectomy involving a junior resident took about 45 minutes longer than an attending physician working alone.

As expected, with longer operative times, the wRVUs generated/operative time ratio was lower in cases with resident participation. Even though resident participation leads to lower OR efficiency, their participation may not significantly impact ancillary costs.23 However, a recent study from NSQIP found an opportunity cost of $60.44 per hour for surgeons operating with a resident in head and neck cases.13

Postoperative complications and mortality are key measures of surgical outcomes in addition to operative time and efficiency. This study found that neither junior nor senior resident participation significantly increased complication rates or patient return to the OR. Despite declining resident involvement and the number of total laryngectomy surgeries in the VA, the complication rate has remained steady. The 30-day mortality rate was significantly higher in cases involving senior residents compared to cases with attending physicians alone. This could be a result of senior resident participation in more challenging cases, such as laryngectomies performed as salvage surgery following radiation. Residents are more often involved in cases with greater complexity at teaching institutions.24-26 Therefore, the higher mortality seen among laryngectomies with senior resident involvement is likely due to the higher complexity of those cases.

The proportion of resident involvement in laryngectomies at VA medical centers has been decreasing over time. Due to the single payer nature of the VA health care system and the number of complex and comorbid patients, the VA offers an invaluable space for resident education in the OR. The fact that less than half of laryngectomies in 2021 involved resident participation is noteworthy for residency training programs. As wRVU compensation models evolve, VA attending surgeons may face less pressure to move the case along, leading to a high potential for operative teaching. Therefore, complex cases, such as laryngectomies, are often ideal for resident participation in the VA.

The steady decline in total laryngectomies at the VA parallels the recent decrease seen in non-VA settings.20 This is due in part to the use of larynx-preserving treatment modalities for laryngeal cancer as well as decreases in the incidence of laryngeal cancer due to population level changes in smoking behaviors. 18,19 Although a laryngectomy is not a key indicator case as determined by the Accreditation Council for Graduate Medical Education, it is important for otolaryngology residents to be exposed to these cases and have a thorough understanding of the operative technique.27 Total laryngectomy was selected for this study because it is a complex and time-consuming surgery with somewhat standardized surgical steps. Unlike microvascular surgery that is very rarely performed by an attending physician alone, laryngectomies can be performed by attending physicians alone or with a resident.28

Limitations

Since this was a retrospective study, it was susceptible to errors in data entry and data extraction from the VASQIP database. Another limitation is the lack of preoperative treatment data on tumor stage and prior nonoperative treatment. For example, a salvage laryngectomy after treatment with radiation and/or chemoradiation is a higher risk procedure than an upfront laryngectomy. Senior resident involvement may be more common in patients undergoing salvage laryngectomy due to the high risk of postoperative fistula and other complications. This may have contributed to the association identified between senior resident participation and 30-day mortality.

Since we could not account for residents who took research years or were fellows, a senior resident may have been mislabeled as a junior resident or vice versa. However, because most research years occur following the third year of residency. We are confident that PGY-1, PGY-2, and PGY-3 is likely to capture junior residents. Other factors, such as coattending surgeon cases, medical student assistance, and fellow involvement may have also impacted the results of this study.

Conclusions

This study is the first to investigate the impact of resident participation on operative time, wRVUs generated, and complication rates in head and neck surgery at VA medical centers. It found that resident participation in total laryngectomies among veterans increased operative time and reduced wRVUs generated per hour but did not impact complication rate or patient return to the OR. The VA offers a unique and invaluable space for resident education and operative training, and the recent decline in resident participation among laryngectomies is important for residency programs to acknowledge and potentially address moving forward.

In contrast to oral cavity resections which can vary from partial glossectomies to composite resections, laryngectomy represents a homogenous procedure from which to draw meaningful conclusions about complication rates, operative time, and outcome. Future directions should include studying other types of head and neck surgery in the VA to determine whether the impact of resident participation mirrors the findings of this study.

The US Department of Veterans Affairs (VA) has been integral in resident training. Resident surgical training requires a balance of supervision and autonomy, along with procedure repetition and appropriate feedback.1-3 Non-VA research has found that resident participation across various otolaryngology procedures, including thyroidectomy, neck dissection, and laryngectomy, does not increase patient morbidity.4-7 However, resident involvement in private and academic settings that included nonhead and neck procedures was linked to increased operative time and reduced productivity, as determined by work relative value units (wRVUs).7-13 This has also been identified in other specialties, including general surgery, orthopedics, and ophthalmology.14-16

Unlike the private sector, surgeon compensation at the VA is not as closely linked to operative productivity, offering a unique setting for resident training. While VA integration in otolaryngology residency programs increases resident case numbers, particularly in head and neck cases, the impact on VA patient outcomes and productivity is unknown.17 The use of larynxpreserving treatment modalities for laryngeal cancer has led to a decline in the number of total laryngectomies performed, which could potentially impact resident operative training for laryngectomies.18-20

This study sought to determine the impact of resident participation on operative time, wRVUs, and patient outcomes in veterans who underwent a total laryngectomy. This study was reviewed and approved by the MedStar Georgetown University Hospital Institutional Review Board and Research and Development Committee (#1595672).

Methods

A retrospective cohort of veterans nationwide who underwent total laryngectomy between 2001 and 2021, with or without neck dissection, was identified from the Veterans Affairs Surgical Quality Improvement Program (VASQIP). Data were extracted via the VA Informatics and Computing Infrastructure and patients were included based on Current Procedural Terminology codes for total laryngectomy, with or without neck dissection (31320, 31360, 31365). Laryngopharyngectomies, partial laryngectomies, and minimally invasive laryngectomies were excluded. VASQIP nurse data managers reviewed patient data for operative data, postoperative outcomes (including 30- day morbidity and mortality), and preoperative risk factors (Appendix).21

The VASQIP data provide the highest resident or postgraduate year (PGY) per surgery. PGY 1, 2, and 3 were considered junior residents and PGY ≥4, surgical fellows, and individuals who took research years during residency were considered senior residents. Cases performed by attending physicians alone were compared with those involving junior or senior residents.

Patient demographic data included age, body mass index, smoking and alcohol use, weight loss, and functional status. Consumption of any tobacco products within 12 months of surgery was considered tobacco use. Drinking on average ≥2 alcoholic beverages daily was considered alcohol use. Weight loss was defined as a 10% reduction in body weight within the 6 months before surgery, excluding patients enrolled in a weight loss program. Functional status was categorized as independent, partially dependent, totally dependent, and unknown.

Primary outcomes included operative time, wRVUs generated, and wRVUs generated per hour of operative time. Postoperative complications were recorded both as a continuous variable and as a binary variable for presence or absence of a complication. Additional outcome variables included length of postoperative hospital stay, return to the operating room (OR), and death within 30 days of surgery.

Statistical Analysis

Data were summarized using frequency and percentage for categorical variables and median with IQR for continuous variables. Data were also summarized based on resident involvement in the surgery and the PGY level of the residents involved. The occurrence of total laryngectomy, rate of complications, and patient return to the OR were summarized by year.

Univariate associations between resident involvement and surgical outcomes were analyzed using the Kruskal-Wallis test for continuous variables and the ÷2 test for categorical variables. A Fisher exact test was used when the cell count in the contingency table was < 5. The univariate associations between surgical outcomes and demographic/preoperative variables were examined using 2-sided Wilcoxon ranksum tests or Kruskal-Wallis tests between continuous variables and categorical variables, X2 or Fisher exact test between 2 categorical variables, and 2-sided Spearman correlation test between 2 continuous variables. A false-discovery rate approach was used for simultaneous posthoc tests to determine the adjusted P values for wRVUs generated/operative time for attending physicians alone vs with junior residents and for attending physicians alone vs with senior residents. Models were used to evaluate the effects of resident involvement on surgical outcomes, adjusting for variables that showed significant univariate associations. Linear regression models were used for operative time, wRVUs generated, wRVUs generated/operative time, and length of postoperative stay. A logistic regression model was used for death within 30 days. Models were not built for postoperative complications or patient return to the OR, as these were only statistically significantly associated with the patient’s preoperative functional status. A finding was considered significant if P < .05. All analyses were performed using statistical software RStudio Version 2023.03.0.

Results

Between 2001 and 2021, 1857 patients who underwent total laryngectomy were identified from the VASQIP database nationwide. Most of the total laryngectomies were staffed by an attending physician with a senior resident (n = 1190, 64%), 446 (24%) were conducted by the attending physician alone, and 221 (12%) by an attending physician with a junior resident (Table 1). The mean operating time for an attending physician alone was 378 minutes, 384 minutes for an attending physician with a senior resident, and 432 minutes for an attending physician with a junior resident (Table 2). There was a statistically significant increase in operating time for laryngectomies with resident participation compared to attending physicians operating alone (P < .001).

FDP04202082_T1FDP04202082_T2

When the wRVUs generated/operative time was analyzed, there was a statistically significant difference between comparison groups. Total laryngectomies performed by attending physicians alone had the highest wRVUs generated/operative time (5.5), followed by laryngectomies performed by attending physicians with senior residents and laryngectomies performed by attending physicians with junior residents (5.2 and 4.8, respectively; P = .002). Table 3 describes adjusted P values for wRVUs generated/ operative time for total laryngectomies performed by attending physicians alone vs with junior residents (P = .003) and for attending physicians alone vs with senior residents (P = .02). Resident participation in total laryngectomies did not significantly impact the development or number of postoperative complications or the rate of return to the OR.

FDP04202082_T3

The number of laryngectomies performed in a single fiscal year peaked in 2010 at 170 cases (Figure 1). Between 2001 and 2021, the mean rates of postoperative complications (21.3%) and patient return to the OR (14.6%) did not significantly change. Resident participation in total laryngectomies also peaked in 2010 at 89.0% but has significantly declined, falling to a low of 43.6% in 2021 (Figure 2). From 2001 to 2011, the mean resident participation rate in total laryngectomies was 80.6%, compared with 68.3% from 2012 to 2021 (P < .001).

FDP04202082_F1FDP04202082_F2

The effect of various demographic and preoperative characteristics on surgical outcomes was also analyzed. A linear regression model accounted for each variable significantly associated with operative time. On multivariable analysis, when all other variables were held constant, Table 4 shows the estimated change in operative time based on certain criteria. For instance, the operative time for attendings with junior residents surgeries was 40 minutes longer (95% CI, 16 to 64) than that of attending alone surgeries (P = .001). Furthermore, operative time decreased by 1.1 minutes (95% CI, 0.30 to 2.04) for each 1-year increase in patient age (P = .009).

FDP04202082_T4

A multivariable logistic regression model evaluated the effect of resident involvement on 30-day mortality rates. Senior resident involvement (P = .02), partially dependent functional status (P = .01), totally dependent functional status (P < .001), and advanced age (P = .02) all were significantly associated with 30-day mortality (Table 5). When other variables remained constant, the odds of death for totally dependent patients were 10.4 times higher than that of patients with independent functional status. Thus, totally dependent functional status appeared to have a greater impact on this outcome than resident participation. The linear regression model for postoperative length of stay demonstrated that senior resident involvement (P = .04), functional status (partially dependent vs independent P < .001), and age (P = .03) were significantly associated with prolonged length of stay.

FDP04202082_T5

Discussion

Otolaryngology residency training is designed to educate future otolaryngologists through hands-on learning, adequate feedback, and supervision.1 Although this exposure is paramount for resident education, balancing appropriate supervision and autonomy while mitigating patient risk has been difficult. Numerous non-VA studies have reviewed the impact of resident participation on patient outcomes in various specialties, ranging from a single institution to the National Surgical Quality Improvement Program (NSQIP).4,5,7,22 This study is the first to describe the nationwide impact of resident participation on outcomes in veterans undergoing total laryngectomy.

This study found that resident participation increases operative time and decreases wRVUs generated/operative time without impacting complication rates or patient return to the OR. This reinforces the notion that under close supervision, resident participation does not negatively impact patient outcomes. Resident operative training requires time and dedication by the attending physician and surgical team, thereby increasing operative time. Because VA physician compensation is not linked with productivity as closely as it is in other private and academic settings, surgeons can dedicate more time to operative teaching. This study found that a total laryngectomy involving a junior resident took about 45 minutes longer than an attending physician working alone.

As expected, with longer operative times, the wRVUs generated/operative time ratio was lower in cases with resident participation. Even though resident participation leads to lower OR efficiency, their participation may not significantly impact ancillary costs.23 However, a recent study from NSQIP found an opportunity cost of $60.44 per hour for surgeons operating with a resident in head and neck cases.13

Postoperative complications and mortality are key measures of surgical outcomes in addition to operative time and efficiency. This study found that neither junior nor senior resident participation significantly increased complication rates or patient return to the OR. Despite declining resident involvement and the number of total laryngectomy surgeries in the VA, the complication rate has remained steady. The 30-day mortality rate was significantly higher in cases involving senior residents compared to cases with attending physicians alone. This could be a result of senior resident participation in more challenging cases, such as laryngectomies performed as salvage surgery following radiation. Residents are more often involved in cases with greater complexity at teaching institutions.24-26 Therefore, the higher mortality seen among laryngectomies with senior resident involvement is likely due to the higher complexity of those cases.

The proportion of resident involvement in laryngectomies at VA medical centers has been decreasing over time. Due to the single payer nature of the VA health care system and the number of complex and comorbid patients, the VA offers an invaluable space for resident education in the OR. The fact that less than half of laryngectomies in 2021 involved resident participation is noteworthy for residency training programs. As wRVU compensation models evolve, VA attending surgeons may face less pressure to move the case along, leading to a high potential for operative teaching. Therefore, complex cases, such as laryngectomies, are often ideal for resident participation in the VA.

The steady decline in total laryngectomies at the VA parallels the recent decrease seen in non-VA settings.20 This is due in part to the use of larynx-preserving treatment modalities for laryngeal cancer as well as decreases in the incidence of laryngeal cancer due to population level changes in smoking behaviors. 18,19 Although a laryngectomy is not a key indicator case as determined by the Accreditation Council for Graduate Medical Education, it is important for otolaryngology residents to be exposed to these cases and have a thorough understanding of the operative technique.27 Total laryngectomy was selected for this study because it is a complex and time-consuming surgery with somewhat standardized surgical steps. Unlike microvascular surgery that is very rarely performed by an attending physician alone, laryngectomies can be performed by attending physicians alone or with a resident.28

Limitations

Since this was a retrospective study, it was susceptible to errors in data entry and data extraction from the VASQIP database. Another limitation is the lack of preoperative treatment data on tumor stage and prior nonoperative treatment. For example, a salvage laryngectomy after treatment with radiation and/or chemoradiation is a higher risk procedure than an upfront laryngectomy. Senior resident involvement may be more common in patients undergoing salvage laryngectomy due to the high risk of postoperative fistula and other complications. This may have contributed to the association identified between senior resident participation and 30-day mortality.

Since we could not account for residents who took research years or were fellows, a senior resident may have been mislabeled as a junior resident or vice versa. However, because most research years occur following the third year of residency. We are confident that PGY-1, PGY-2, and PGY-3 is likely to capture junior residents. Other factors, such as coattending surgeon cases, medical student assistance, and fellow involvement may have also impacted the results of this study.

Conclusions

This study is the first to investigate the impact of resident participation on operative time, wRVUs generated, and complication rates in head and neck surgery at VA medical centers. It found that resident participation in total laryngectomies among veterans increased operative time and reduced wRVUs generated per hour but did not impact complication rate or patient return to the OR. The VA offers a unique and invaluable space for resident education and operative training, and the recent decline in resident participation among laryngectomies is important for residency programs to acknowledge and potentially address moving forward.

In contrast to oral cavity resections which can vary from partial glossectomies to composite resections, laryngectomy represents a homogenous procedure from which to draw meaningful conclusions about complication rates, operative time, and outcome. Future directions should include studying other types of head and neck surgery in the VA to determine whether the impact of resident participation mirrors the findings of this study.

References
  1. Chung RS. How much time do surgical residents need to learn operative surgery? Am J Surg. 2005;190(3):351-353. doi:10.1016/j.amjsurg.2005.06.035
  2. S, Darzi A. Defining quality in surgical training: perceptions of the profession. Am J Surg. 2014;207(4):628-636. doi:10.1016/j.amjsurg.2013.07.044
  3. Bhatti NI, Ahmed A, Choi SS. Identifying quality indicators of surgical of surgical training: a national survey. Laryngoscope. 2015;125(12):2685-2689. doi:10.1002/lary.25262
  4. Abt NB, Reh DD, Eisele DW, Francis HW, Gourin CG. Does resident participation influence otolaryngology-head and neck surgery morbidity and mortality? Laryngoscope. 2016;126(10):2263-2269. doi:10.1002/lary.25973
  5. Jubbal KT, Chang D, Izaddoost SA, Pederson W, Zavlin D, Echo A. Resident involvement in microsurgery: an American College of Surgeons national surgical quality improvement program analysis. J Surg Educ. 2017;74(6):1124-1132. doi:10.1016/j.jsurg.2017.05.017
  6. Kshirsagar RS, Chandy Z, Mahboubi H, Verma SP. Does resident involvement in thyroid surgery lead to increased postoperative complications? Laryngoscope. 2017;127(5):1242-1246. doi:10.1002/lary.26176
  7. Vieira BL, Hernandez DJ, Qin C, Smith SS, Kim JY, Dutra JC. The impact of resident involvement on otolaryngology surgical outcomes. Laryngoscope. 2016;126(3):602-607. doi:10.1002/lary.25046
  8. Advani V, Ahad S, Gonczy C, Markwell S, Hassan I. Does resident involvement effect surgical times and complication rates during laparoscopic appendectomy for uncomplicated appendicitis? An analysis of 16,849 cases from the ACS-NSQIP. Am J Surg. 2012;203(3):347-352. doi:10.1016/j.amjsurg.2011.08.015
  9. Quinn NA, Alt JA, Ashby S, Orlandi RR. Time, resident involvement, and supply drive cost variability in septoplasty with turbinate reduction. Otolaryngol Head Neck Surg. 2018;159(2):310-314. doi:10.1177/0194599818765099
  10. Leader BA, Wiebracht ND, Meinzen-Derr J, Ishman SL. The impact of resident involvement on tonsillectomy outcomes and surgical time. Laryngoscope. 2020;130(10):2481-2486. doi:10.1002/lary.28427
  11. Muelleman T, Shew M, Muelleman RJ, et al. Impact of resident participation on operative time and outcomes in otologic surgery. Otolaryngol Head Neck Surg. 2018;158(1):151-154. doi:10.1177/0194599817737270
  12. Puram SV, Kozin ED, Sethi R, et al. Impact of resident surgeons on procedure length based on common pediatric otolaryngology cases. Laryngoscope. 2015;125(4):991 -997. doi:10.1002/lary.24912
  13. Chow MS, Gordon AJ, Talwar A, Lydiatt WM, Yueh B, Givi B. The RVU compensation model and head and neck surgical education. Laryngoscope. 2024;134(1):113-119. doi:10.1002/lary.30807
  14. Papandria D, Rhee D, Ortega G, et al. Assessing trainee impact on operative time for common general surgical procedures in ACS-NSQIP. J Surg Educ. 2012;69(2):149-155. doi:10.1016/j.jsurg.2011.08.003
  15. Pugely AJ, Gao Y, Martin CT, Callagh JJ, Weinstein SL, Marsh JL. The effect of resident participation on short-term outcomes after orthopaedic surgery. Clin Orthop Relat Res. 2014;472(7):2290-2300. doi:10.1007/s11999-014-3567-0
  16. Hosler MR, Scott IU, Kunselman AR, Wolford KR, Oltra EZ, Murray WB. Impact of resident participation in cataract surgery on operative time and cost. Ophthalmology. 2012;119(1):95-98. doi:10.1016/j.ophtha.2011.06.026
  17. Lanigan A, Spaw M, Donaghe C, Brennan J. The impact of the Veteran’s Affairs medical system on an otolaryngology residency training program. Mil Med. 2018;183(11-12):e671-e675. doi:10.1093/milmed/usy041
  18. American Society of Clinical Oncology, Pfister DG, Laurie SA, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006;24(22):3693-3704. doi:10.1200/JCO.2006.07.4559
  19. Forastiere AA, Ismaila N, Lewin JS, et al. Use of larynxpreservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36(11):1143-1169. doi:10.1200/JCO.2017.75.7385
  20. Verma SP, Mahboubi H. The changing landscape of total laryngectomy surgery. Otolaryngol Head Neck Surg. 2014;150(3):413-418. doi:10.1177/0194599813514515
  21. Habermann EB, Harris AHS, Giori NJ. Large surgical databases with direct data abstraction: VASQIP and ACSNSQIP. J Bone Joint Surg Am. 2022;104(suppl 3):9-14. doi:10.2106/JBJS.22.00596
  22. Benito DA, Mamidi I, Pasick LJ, et al. Evaluating resident involvement and the ‘July effect’ in parotidectomy. J Laryngol Otol. 2021;135(5):452-457. doi:10.1017/S0022215121000578
  23. Hwang CS, Wichterman KA, Alfrey EJ. The cost of resident education. J Surg Res. 2010;163(1):18-23. doi:10.1016/j.jss.2010.03.013
  24. Saliba AN, Taher AT, Tamim H, et al. Impact of resident involvement in surgery (IRIS-NSQIP): looking at the bigger picture based on the American College of Surgeons- NSQIP database. J Am Coll Surg. 2016; 222(1):30-40. doi:10.1016/j.jamcollsurg.2015.10.011
  25. Khuri SF, Najjar SF, Daley J, et al. Comparison of surgical outcomes between teaching and nonteaching hospitals in the Department of Veterans Affairs. Ann Surg. 2001;234(3):370-383. doi:10.1097/00000658-200109000-00011
  26. Relles DM, Burkhart RA, Pucci MJ et al. Does resident experience affect outcomes in complex abdominal surgery? Pancreaticoduodenectomy as an example. J Gastrointest Surg. 2014;18(2):279-285. doi:10.1007/s11605-013-2372-5
  27. Accreditation Council for Graduate Medical Education. Required minimum number of key indicator procedures for graduating residents. June 2019. Accessed January 2, 2025. https://www.acgme.org/globalassets/pfassets/programresources/280_core_case_log_minimums.pdf
  28. Brady JS, Crippen MM, Filimonov A, et al. The effect of training level on complications after free flap surgery of the head and neck. Am J Otolaryngol. 2017;38(5):560-564. doi:10.1016/j.amjoto.2017.06.001
References
  1. Chung RS. How much time do surgical residents need to learn operative surgery? Am J Surg. 2005;190(3):351-353. doi:10.1016/j.amjsurg.2005.06.035
  2. S, Darzi A. Defining quality in surgical training: perceptions of the profession. Am J Surg. 2014;207(4):628-636. doi:10.1016/j.amjsurg.2013.07.044
  3. Bhatti NI, Ahmed A, Choi SS. Identifying quality indicators of surgical of surgical training: a national survey. Laryngoscope. 2015;125(12):2685-2689. doi:10.1002/lary.25262
  4. Abt NB, Reh DD, Eisele DW, Francis HW, Gourin CG. Does resident participation influence otolaryngology-head and neck surgery morbidity and mortality? Laryngoscope. 2016;126(10):2263-2269. doi:10.1002/lary.25973
  5. Jubbal KT, Chang D, Izaddoost SA, Pederson W, Zavlin D, Echo A. Resident involvement in microsurgery: an American College of Surgeons national surgical quality improvement program analysis. J Surg Educ. 2017;74(6):1124-1132. doi:10.1016/j.jsurg.2017.05.017
  6. Kshirsagar RS, Chandy Z, Mahboubi H, Verma SP. Does resident involvement in thyroid surgery lead to increased postoperative complications? Laryngoscope. 2017;127(5):1242-1246. doi:10.1002/lary.26176
  7. Vieira BL, Hernandez DJ, Qin C, Smith SS, Kim JY, Dutra JC. The impact of resident involvement on otolaryngology surgical outcomes. Laryngoscope. 2016;126(3):602-607. doi:10.1002/lary.25046
  8. Advani V, Ahad S, Gonczy C, Markwell S, Hassan I. Does resident involvement effect surgical times and complication rates during laparoscopic appendectomy for uncomplicated appendicitis? An analysis of 16,849 cases from the ACS-NSQIP. Am J Surg. 2012;203(3):347-352. doi:10.1016/j.amjsurg.2011.08.015
  9. Quinn NA, Alt JA, Ashby S, Orlandi RR. Time, resident involvement, and supply drive cost variability in septoplasty with turbinate reduction. Otolaryngol Head Neck Surg. 2018;159(2):310-314. doi:10.1177/0194599818765099
  10. Leader BA, Wiebracht ND, Meinzen-Derr J, Ishman SL. The impact of resident involvement on tonsillectomy outcomes and surgical time. Laryngoscope. 2020;130(10):2481-2486. doi:10.1002/lary.28427
  11. Muelleman T, Shew M, Muelleman RJ, et al. Impact of resident participation on operative time and outcomes in otologic surgery. Otolaryngol Head Neck Surg. 2018;158(1):151-154. doi:10.1177/0194599817737270
  12. Puram SV, Kozin ED, Sethi R, et al. Impact of resident surgeons on procedure length based on common pediatric otolaryngology cases. Laryngoscope. 2015;125(4):991 -997. doi:10.1002/lary.24912
  13. Chow MS, Gordon AJ, Talwar A, Lydiatt WM, Yueh B, Givi B. The RVU compensation model and head and neck surgical education. Laryngoscope. 2024;134(1):113-119. doi:10.1002/lary.30807
  14. Papandria D, Rhee D, Ortega G, et al. Assessing trainee impact on operative time for common general surgical procedures in ACS-NSQIP. J Surg Educ. 2012;69(2):149-155. doi:10.1016/j.jsurg.2011.08.003
  15. Pugely AJ, Gao Y, Martin CT, Callagh JJ, Weinstein SL, Marsh JL. The effect of resident participation on short-term outcomes after orthopaedic surgery. Clin Orthop Relat Res. 2014;472(7):2290-2300. doi:10.1007/s11999-014-3567-0
  16. Hosler MR, Scott IU, Kunselman AR, Wolford KR, Oltra EZ, Murray WB. Impact of resident participation in cataract surgery on operative time and cost. Ophthalmology. 2012;119(1):95-98. doi:10.1016/j.ophtha.2011.06.026
  17. Lanigan A, Spaw M, Donaghe C, Brennan J. The impact of the Veteran’s Affairs medical system on an otolaryngology residency training program. Mil Med. 2018;183(11-12):e671-e675. doi:10.1093/milmed/usy041
  18. American Society of Clinical Oncology, Pfister DG, Laurie SA, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006;24(22):3693-3704. doi:10.1200/JCO.2006.07.4559
  19. Forastiere AA, Ismaila N, Lewin JS, et al. Use of larynxpreservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36(11):1143-1169. doi:10.1200/JCO.2017.75.7385
  20. Verma SP, Mahboubi H. The changing landscape of total laryngectomy surgery. Otolaryngol Head Neck Surg. 2014;150(3):413-418. doi:10.1177/0194599813514515
  21. Habermann EB, Harris AHS, Giori NJ. Large surgical databases with direct data abstraction: VASQIP and ACSNSQIP. J Bone Joint Surg Am. 2022;104(suppl 3):9-14. doi:10.2106/JBJS.22.00596
  22. Benito DA, Mamidi I, Pasick LJ, et al. Evaluating resident involvement and the ‘July effect’ in parotidectomy. J Laryngol Otol. 2021;135(5):452-457. doi:10.1017/S0022215121000578
  23. Hwang CS, Wichterman KA, Alfrey EJ. The cost of resident education. J Surg Res. 2010;163(1):18-23. doi:10.1016/j.jss.2010.03.013
  24. Saliba AN, Taher AT, Tamim H, et al. Impact of resident involvement in surgery (IRIS-NSQIP): looking at the bigger picture based on the American College of Surgeons- NSQIP database. J Am Coll Surg. 2016; 222(1):30-40. doi:10.1016/j.jamcollsurg.2015.10.011
  25. Khuri SF, Najjar SF, Daley J, et al. Comparison of surgical outcomes between teaching and nonteaching hospitals in the Department of Veterans Affairs. Ann Surg. 2001;234(3):370-383. doi:10.1097/00000658-200109000-00011
  26. Relles DM, Burkhart RA, Pucci MJ et al. Does resident experience affect outcomes in complex abdominal surgery? Pancreaticoduodenectomy as an example. J Gastrointest Surg. 2014;18(2):279-285. doi:10.1007/s11605-013-2372-5
  27. Accreditation Council for Graduate Medical Education. Required minimum number of key indicator procedures for graduating residents. June 2019. Accessed January 2, 2025. https://www.acgme.org/globalassets/pfassets/programresources/280_core_case_log_minimums.pdf
  28. Brady JS, Crippen MM, Filimonov A, et al. The effect of training level on complications after free flap surgery of the head and neck. Am J Otolaryngol. 2017;38(5):560-564. doi:10.1016/j.amjoto.2017.06.001
Issue
Federal Practitioner - 42(2)
Issue
Federal Practitioner - 42(2)
Page Number
82-89
Page Number
82-89
Publications
Publications
Topics
Article Type
Display Headline

Resident Participation Impact on Operative Time and Outcomes in Veterans Undergoing Total Laryngectomy

Display Headline

Resident Participation Impact on Operative Time and Outcomes in Veterans Undergoing Total Laryngectomy

Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Wed, 02/05/2025 - 13:20
Un-Gate On Date
Wed, 02/05/2025 - 13:20
Use ProPublica
CFC Schedule Remove Status
Wed, 02/05/2025 - 13:20
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Wed, 02/05/2025 - 13:20

Apremilast Treatment Outcomes and Adverse Events in Psoriasis Patients With HIV

Article Type
Changed
Wed, 02/19/2025 - 16:57
Display Headline

Apremilast Treatment Outcomes and Adverse Events in Psoriasis Patients With HIV

To the Editor:

Psoriasis is a chronic systemic inflammatory disease that affects 1% to 3% of the global population.1,2 Due to dysregulation of the immune system, patients with HIV who have concurrent moderate to severe psoriasis present a clinical therapeutic challenge for dermatologists. Recent guidelines from the American Academy of Dermatology recommended avoiding certain systemic treatments (eg, methotrexate, cyclosporine) in patients who are HIV positive due to their immunosuppressive effects, as well as cautious use of certain biologics in populations with HIV.3 Traditional therapies for managing psoriasis in patients with HIV have included topical agents, antiretroviral therapy (ART), phototherapy, and acitretin; however, phototherapy can be logistically cumbersome for patients, and in the setting of ART, acitretin has the potential to exacerbate hypertriglyceridemia as well as other undesirable adverse effects.3

Apremilast is a phosphodiesterase 4 inhibitor that has emerged as a promising alternative in patients with HIV who require treatment for psoriasis. It has demonstrated clinical efficacy in psoriasis and has minimal immunosuppressive risk.4 Despite its potential in this population, reports of apremilast used in patients who are HIV positive are rare, and these patients often are excluded from larges studies. In this study, we reviewed the literature to evaluate outcomes and adverse events in patients with HIV who underwent psoriasis treatment with apremilast.

A search of PubMed articles indexed for MEDLINE from the inception of the database through January 2023 was conducted using the terms psoriasis, human immunodeficiency virus, acquired immunodeficiency syndrome, therapy, apremilast, and adverse events. The inclusion criteria were articles that reported patients with HIV and psoriasis undergoing treatment with apremilast with subsequent follow-up to delineate potential outcomes and adverse effects. Non–English language articles were excluded.

Our search of the literature yielded 7 patients with HIV and psoriasis who were treated with apremilast (eTable).5-11 All of the patients were male and ranged in age from 31 to 55 years, and all had pretreatment CD4 cell counts greater than 450 cells/mm3. All but 1 patient were confirmed to have undergone ART prior to treatment with apremilast, and all were treated using the traditional apremilast titration from 10 mg to 30 mg orally twice daily.

CT115002066-eTable

The mean pretreatment Psoriasis Area and Severity Index (PASI) score in the patients we evaluated was 12.2, with an average reduction in PASI score of 9.3. This equated to achievement of PASI 75 or greater (ie, representing at least a 75% improvement in psoriasis) in 4 (57.1%) patients, with clinical improvement confirmed in all 7 patients (100.0%)(eTable). The average follow-up time was 9.7 months (range, 6 weeks to 24 months). Only 1 (14.3%) patient experienced any adverse effects, which included self-resolving diarrhea and respiratory infections (nonopportunistic) over a follow-up period of 2 years.6 Of note, gastrointestinal upset is common with apremilast and usually improves over time.12

Apremilast represents a safe and effective alternative systemic therapy for patients with HIV and psoriasis.4 As a phosphodiesterase 4 inhibitor, apremilast leads to increased levels of cyclic adenosine monophosphate, which restores an equilibrium between proinflammatory (eg, tumor necrosis factors, interferons, IL-2, IL-6, IL-12, IL-23) and anti-inflammatory (eg, IL-10) cytokines.13 Unlike most biologics that target and inhibit a specific proinflammatory cytokine, apremilast’s homeostatic mechanism may explain its minimal immunosuppressive adverse effects.

In the majority of patients we evaluated, initiation of apremilast led to documented clinical improvement. It is worth noting that some patients presented with a relevant medical history and/or comorbidities such as hepatitis and metabolic conditions (eg, obesity, type 2 diabetes mellitus, hypertriglyceridemia). Despite these comorbidities, initiation of apremilast therapy in these patients led to clinical improvement of psoriasis overall. Notable cases from our study included a 41-year-old man with concurrent hepatitis B and psoriatic arthritis who achieved PASI 90 after 24 weeks of apremilast therapy8; a 46-year-old man with concurrent hepatitis C who went from 8% to 1.5% body surface area affected after 5 months of treatment with apremilast5; and a 54-year-old man with concurrent obesity, type 2 diabetes mellitus, and hypertriglyceridemia who went from a PASI score of 10.2 to 4.1 after 3 months of apremilast treatment and maintained a PASI score of 2.7 at 2 years’ follow up (eTable).6

Limitations of this study included the small sample size and homogeneous demographic consisting only of adult males, which restrict the external validity of the findings. Despite limitations, apremilast was utilized effectively for patients with both psoriasis and psoriatic arthritis. The observed effectiveness of apremilast in multiple forms of psoriasis provides valuable insights into the drug’s versatility in this patient population.

The use of apremilast for treatment of psoriasis in patients with HIV represents an important therapeutic development. Its effectiveness in reducing psoriasis symptoms in these immunocompromised patients makes it a viable alternative to traditional systemic therapies that might be contraindicated in this population. While larger studies would be ideal, the exclusion of patients with HIV from clinical trials presents an obstacle and therefore makes case series and reviews helpful for clinicians in bridging the gap with respect to treatment options for these patients. Apremilast may be a safe and effective medication for patients with HIV and psoriasis who require systemic therapy to treat their skin disease.

References
  1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512-516. doi:10.1016/j.jaad.2013.11.013
  2. Parisi R, Symmons DP, Griffiths CE, et al; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377-385. doi:10.1038/jid.2012.339
  3. Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80:43-53. doi:10.1016/j.jaad.2018.06.056
  4. Crowley J, Thaci D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for >156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77:310-317.e1.
  5. Reddy SP, Shah VV, Wu JJ. Apremilast for a psoriasis patient with HIV and hepatitis C. J Eur Acad Dermatol Venereol. 2017;31:E481-E482. doi:10.1111/jdv.14301
  6. Zarbafian M, Cote B, Richer V. Treatment of moderate to severe psoriasis with apremilast over 2 years in the context of long-term treated HIV infection: a case report. SAGE Open Med Case Rep. 2019;7:2050313X19845193. doi:10.1177/2050313X19845193 doi:10.1016/j.jaad.2017.01.052
  7. Sacchelli L, Patrizi A, Ferrara F, et al. Apremilast as therapeutic option in a HIV positive patient with severe psoriasis. Dermatol Ther. 2018;31:E12719. doi:10.1111/dth.12719
  8. Manfreda V, Esposito M, Campione E, et al. Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. Postgrad Med. 2019;131:239-240. doi:10.1080/00325481.2019 .1575613
  9. Shah BJ, Mistry D, Chaudhary N. Apremilast in people living with HIV with psoriasis vulgaris: a case report. Indian J Dermatol. 2019;64:242- 244. doi:10.4103/ijd.IJD_633_18
  10. Reddy SP, Lee E, Wu JJ. Apremilast and phototherapy for treatment of psoriasis in a patient with human immunodeficiency virus. Cutis. 2019;103:E6-E7.
  11. Romita P, Foti C, Calianno G, et al. Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast. Dermatol Ther. 2022;35:E15610. doi:10.1111/dth.15610
  12. Zeb L, Mhaskar R, Lewis S, et al. Real-world drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center. Dermatol Ther. 2021;34:E14826. doi:10.1111/dth.14826
  13. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583-1590. doi:10.1016/j.bcp.2012.01.001
Article PDF
Author and Disclosure Information

Drs. Lauck, Columbus, and Tolkachjov are from Baylor University Medical Center, Dallas, Texas. Drs. Lauck and Tolkachjov are from the Department of Dermatology, and Drs. Columbus is from the Division of Infectious Diseases and the Department of Internal Medicine. Drs. Columbus and Tolkachjov also are from and Kaycee Nguyen is from the College of Medicine, Texas A&M University, Dallas. Dr. Tolkachjov also is from Epiphany Dermatology, Dallas, and the Department of Dermatology, University of Texas Southwestern Medical Center, Dallas.

Drs. Lauck and Columbus and Kaycee Nguyen have no relevant financial disclosures to report. Dr. Tolkachjov is a speaker/investigator for Castle Biosciences, Kerecis, and Boehringer Ingelheim.

Correspondence: Stanislav N. Tolkachjov, MD, 1640 FM 544, Ste 100, Lewisville, TX 75056 ([email protected]).

Cutis. 2025 February;115(2):66-67, E2. doi:10.12788/cutis.1166

Issue
Cutis - 115(2)
Publications
Topics
Page Number
66-67
Sections
Author and Disclosure Information

Drs. Lauck, Columbus, and Tolkachjov are from Baylor University Medical Center, Dallas, Texas. Drs. Lauck and Tolkachjov are from the Department of Dermatology, and Drs. Columbus is from the Division of Infectious Diseases and the Department of Internal Medicine. Drs. Columbus and Tolkachjov also are from and Kaycee Nguyen is from the College of Medicine, Texas A&M University, Dallas. Dr. Tolkachjov also is from Epiphany Dermatology, Dallas, and the Department of Dermatology, University of Texas Southwestern Medical Center, Dallas.

Drs. Lauck and Columbus and Kaycee Nguyen have no relevant financial disclosures to report. Dr. Tolkachjov is a speaker/investigator for Castle Biosciences, Kerecis, and Boehringer Ingelheim.

Correspondence: Stanislav N. Tolkachjov, MD, 1640 FM 544, Ste 100, Lewisville, TX 75056 ([email protected]).

Cutis. 2025 February;115(2):66-67, E2. doi:10.12788/cutis.1166

Author and Disclosure Information

Drs. Lauck, Columbus, and Tolkachjov are from Baylor University Medical Center, Dallas, Texas. Drs. Lauck and Tolkachjov are from the Department of Dermatology, and Drs. Columbus is from the Division of Infectious Diseases and the Department of Internal Medicine. Drs. Columbus and Tolkachjov also are from and Kaycee Nguyen is from the College of Medicine, Texas A&M University, Dallas. Dr. Tolkachjov also is from Epiphany Dermatology, Dallas, and the Department of Dermatology, University of Texas Southwestern Medical Center, Dallas.

Drs. Lauck and Columbus and Kaycee Nguyen have no relevant financial disclosures to report. Dr. Tolkachjov is a speaker/investigator for Castle Biosciences, Kerecis, and Boehringer Ingelheim.

Correspondence: Stanislav N. Tolkachjov, MD, 1640 FM 544, Ste 100, Lewisville, TX 75056 ([email protected]).

Cutis. 2025 February;115(2):66-67, E2. doi:10.12788/cutis.1166

Article PDF
Article PDF

To the Editor:

Psoriasis is a chronic systemic inflammatory disease that affects 1% to 3% of the global population.1,2 Due to dysregulation of the immune system, patients with HIV who have concurrent moderate to severe psoriasis present a clinical therapeutic challenge for dermatologists. Recent guidelines from the American Academy of Dermatology recommended avoiding certain systemic treatments (eg, methotrexate, cyclosporine) in patients who are HIV positive due to their immunosuppressive effects, as well as cautious use of certain biologics in populations with HIV.3 Traditional therapies for managing psoriasis in patients with HIV have included topical agents, antiretroviral therapy (ART), phototherapy, and acitretin; however, phototherapy can be logistically cumbersome for patients, and in the setting of ART, acitretin has the potential to exacerbate hypertriglyceridemia as well as other undesirable adverse effects.3

Apremilast is a phosphodiesterase 4 inhibitor that has emerged as a promising alternative in patients with HIV who require treatment for psoriasis. It has demonstrated clinical efficacy in psoriasis and has minimal immunosuppressive risk.4 Despite its potential in this population, reports of apremilast used in patients who are HIV positive are rare, and these patients often are excluded from larges studies. In this study, we reviewed the literature to evaluate outcomes and adverse events in patients with HIV who underwent psoriasis treatment with apremilast.

A search of PubMed articles indexed for MEDLINE from the inception of the database through January 2023 was conducted using the terms psoriasis, human immunodeficiency virus, acquired immunodeficiency syndrome, therapy, apremilast, and adverse events. The inclusion criteria were articles that reported patients with HIV and psoriasis undergoing treatment with apremilast with subsequent follow-up to delineate potential outcomes and adverse effects. Non–English language articles were excluded.

Our search of the literature yielded 7 patients with HIV and psoriasis who were treated with apremilast (eTable).5-11 All of the patients were male and ranged in age from 31 to 55 years, and all had pretreatment CD4 cell counts greater than 450 cells/mm3. All but 1 patient were confirmed to have undergone ART prior to treatment with apremilast, and all were treated using the traditional apremilast titration from 10 mg to 30 mg orally twice daily.

CT115002066-eTable

The mean pretreatment Psoriasis Area and Severity Index (PASI) score in the patients we evaluated was 12.2, with an average reduction in PASI score of 9.3. This equated to achievement of PASI 75 or greater (ie, representing at least a 75% improvement in psoriasis) in 4 (57.1%) patients, with clinical improvement confirmed in all 7 patients (100.0%)(eTable). The average follow-up time was 9.7 months (range, 6 weeks to 24 months). Only 1 (14.3%) patient experienced any adverse effects, which included self-resolving diarrhea and respiratory infections (nonopportunistic) over a follow-up period of 2 years.6 Of note, gastrointestinal upset is common with apremilast and usually improves over time.12

Apremilast represents a safe and effective alternative systemic therapy for patients with HIV and psoriasis.4 As a phosphodiesterase 4 inhibitor, apremilast leads to increased levels of cyclic adenosine monophosphate, which restores an equilibrium between proinflammatory (eg, tumor necrosis factors, interferons, IL-2, IL-6, IL-12, IL-23) and anti-inflammatory (eg, IL-10) cytokines.13 Unlike most biologics that target and inhibit a specific proinflammatory cytokine, apremilast’s homeostatic mechanism may explain its minimal immunosuppressive adverse effects.

In the majority of patients we evaluated, initiation of apremilast led to documented clinical improvement. It is worth noting that some patients presented with a relevant medical history and/or comorbidities such as hepatitis and metabolic conditions (eg, obesity, type 2 diabetes mellitus, hypertriglyceridemia). Despite these comorbidities, initiation of apremilast therapy in these patients led to clinical improvement of psoriasis overall. Notable cases from our study included a 41-year-old man with concurrent hepatitis B and psoriatic arthritis who achieved PASI 90 after 24 weeks of apremilast therapy8; a 46-year-old man with concurrent hepatitis C who went from 8% to 1.5% body surface area affected after 5 months of treatment with apremilast5; and a 54-year-old man with concurrent obesity, type 2 diabetes mellitus, and hypertriglyceridemia who went from a PASI score of 10.2 to 4.1 after 3 months of apremilast treatment and maintained a PASI score of 2.7 at 2 years’ follow up (eTable).6

Limitations of this study included the small sample size and homogeneous demographic consisting only of adult males, which restrict the external validity of the findings. Despite limitations, apremilast was utilized effectively for patients with both psoriasis and psoriatic arthritis. The observed effectiveness of apremilast in multiple forms of psoriasis provides valuable insights into the drug’s versatility in this patient population.

The use of apremilast for treatment of psoriasis in patients with HIV represents an important therapeutic development. Its effectiveness in reducing psoriasis symptoms in these immunocompromised patients makes it a viable alternative to traditional systemic therapies that might be contraindicated in this population. While larger studies would be ideal, the exclusion of patients with HIV from clinical trials presents an obstacle and therefore makes case series and reviews helpful for clinicians in bridging the gap with respect to treatment options for these patients. Apremilast may be a safe and effective medication for patients with HIV and psoriasis who require systemic therapy to treat their skin disease.

To the Editor:

Psoriasis is a chronic systemic inflammatory disease that affects 1% to 3% of the global population.1,2 Due to dysregulation of the immune system, patients with HIV who have concurrent moderate to severe psoriasis present a clinical therapeutic challenge for dermatologists. Recent guidelines from the American Academy of Dermatology recommended avoiding certain systemic treatments (eg, methotrexate, cyclosporine) in patients who are HIV positive due to their immunosuppressive effects, as well as cautious use of certain biologics in populations with HIV.3 Traditional therapies for managing psoriasis in patients with HIV have included topical agents, antiretroviral therapy (ART), phototherapy, and acitretin; however, phototherapy can be logistically cumbersome for patients, and in the setting of ART, acitretin has the potential to exacerbate hypertriglyceridemia as well as other undesirable adverse effects.3

Apremilast is a phosphodiesterase 4 inhibitor that has emerged as a promising alternative in patients with HIV who require treatment for psoriasis. It has demonstrated clinical efficacy in psoriasis and has minimal immunosuppressive risk.4 Despite its potential in this population, reports of apremilast used in patients who are HIV positive are rare, and these patients often are excluded from larges studies. In this study, we reviewed the literature to evaluate outcomes and adverse events in patients with HIV who underwent psoriasis treatment with apremilast.

A search of PubMed articles indexed for MEDLINE from the inception of the database through January 2023 was conducted using the terms psoriasis, human immunodeficiency virus, acquired immunodeficiency syndrome, therapy, apremilast, and adverse events. The inclusion criteria were articles that reported patients with HIV and psoriasis undergoing treatment with apremilast with subsequent follow-up to delineate potential outcomes and adverse effects. Non–English language articles were excluded.

Our search of the literature yielded 7 patients with HIV and psoriasis who were treated with apremilast (eTable).5-11 All of the patients were male and ranged in age from 31 to 55 years, and all had pretreatment CD4 cell counts greater than 450 cells/mm3. All but 1 patient were confirmed to have undergone ART prior to treatment with apremilast, and all were treated using the traditional apremilast titration from 10 mg to 30 mg orally twice daily.

CT115002066-eTable

The mean pretreatment Psoriasis Area and Severity Index (PASI) score in the patients we evaluated was 12.2, with an average reduction in PASI score of 9.3. This equated to achievement of PASI 75 or greater (ie, representing at least a 75% improvement in psoriasis) in 4 (57.1%) patients, with clinical improvement confirmed in all 7 patients (100.0%)(eTable). The average follow-up time was 9.7 months (range, 6 weeks to 24 months). Only 1 (14.3%) patient experienced any adverse effects, which included self-resolving diarrhea and respiratory infections (nonopportunistic) over a follow-up period of 2 years.6 Of note, gastrointestinal upset is common with apremilast and usually improves over time.12

Apremilast represents a safe and effective alternative systemic therapy for patients with HIV and psoriasis.4 As a phosphodiesterase 4 inhibitor, apremilast leads to increased levels of cyclic adenosine monophosphate, which restores an equilibrium between proinflammatory (eg, tumor necrosis factors, interferons, IL-2, IL-6, IL-12, IL-23) and anti-inflammatory (eg, IL-10) cytokines.13 Unlike most biologics that target and inhibit a specific proinflammatory cytokine, apremilast’s homeostatic mechanism may explain its minimal immunosuppressive adverse effects.

In the majority of patients we evaluated, initiation of apremilast led to documented clinical improvement. It is worth noting that some patients presented with a relevant medical history and/or comorbidities such as hepatitis and metabolic conditions (eg, obesity, type 2 diabetes mellitus, hypertriglyceridemia). Despite these comorbidities, initiation of apremilast therapy in these patients led to clinical improvement of psoriasis overall. Notable cases from our study included a 41-year-old man with concurrent hepatitis B and psoriatic arthritis who achieved PASI 90 after 24 weeks of apremilast therapy8; a 46-year-old man with concurrent hepatitis C who went from 8% to 1.5% body surface area affected after 5 months of treatment with apremilast5; and a 54-year-old man with concurrent obesity, type 2 diabetes mellitus, and hypertriglyceridemia who went from a PASI score of 10.2 to 4.1 after 3 months of apremilast treatment and maintained a PASI score of 2.7 at 2 years’ follow up (eTable).6

Limitations of this study included the small sample size and homogeneous demographic consisting only of adult males, which restrict the external validity of the findings. Despite limitations, apremilast was utilized effectively for patients with both psoriasis and psoriatic arthritis. The observed effectiveness of apremilast in multiple forms of psoriasis provides valuable insights into the drug’s versatility in this patient population.

The use of apremilast for treatment of psoriasis in patients with HIV represents an important therapeutic development. Its effectiveness in reducing psoriasis symptoms in these immunocompromised patients makes it a viable alternative to traditional systemic therapies that might be contraindicated in this population. While larger studies would be ideal, the exclusion of patients with HIV from clinical trials presents an obstacle and therefore makes case series and reviews helpful for clinicians in bridging the gap with respect to treatment options for these patients. Apremilast may be a safe and effective medication for patients with HIV and psoriasis who require systemic therapy to treat their skin disease.

References
  1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512-516. doi:10.1016/j.jaad.2013.11.013
  2. Parisi R, Symmons DP, Griffiths CE, et al; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377-385. doi:10.1038/jid.2012.339
  3. Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80:43-53. doi:10.1016/j.jaad.2018.06.056
  4. Crowley J, Thaci D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for >156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77:310-317.e1.
  5. Reddy SP, Shah VV, Wu JJ. Apremilast for a psoriasis patient with HIV and hepatitis C. J Eur Acad Dermatol Venereol. 2017;31:E481-E482. doi:10.1111/jdv.14301
  6. Zarbafian M, Cote B, Richer V. Treatment of moderate to severe psoriasis with apremilast over 2 years in the context of long-term treated HIV infection: a case report. SAGE Open Med Case Rep. 2019;7:2050313X19845193. doi:10.1177/2050313X19845193 doi:10.1016/j.jaad.2017.01.052
  7. Sacchelli L, Patrizi A, Ferrara F, et al. Apremilast as therapeutic option in a HIV positive patient with severe psoriasis. Dermatol Ther. 2018;31:E12719. doi:10.1111/dth.12719
  8. Manfreda V, Esposito M, Campione E, et al. Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. Postgrad Med. 2019;131:239-240. doi:10.1080/00325481.2019 .1575613
  9. Shah BJ, Mistry D, Chaudhary N. Apremilast in people living with HIV with psoriasis vulgaris: a case report. Indian J Dermatol. 2019;64:242- 244. doi:10.4103/ijd.IJD_633_18
  10. Reddy SP, Lee E, Wu JJ. Apremilast and phototherapy for treatment of psoriasis in a patient with human immunodeficiency virus. Cutis. 2019;103:E6-E7.
  11. Romita P, Foti C, Calianno G, et al. Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast. Dermatol Ther. 2022;35:E15610. doi:10.1111/dth.15610
  12. Zeb L, Mhaskar R, Lewis S, et al. Real-world drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center. Dermatol Ther. 2021;34:E14826. doi:10.1111/dth.14826
  13. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583-1590. doi:10.1016/j.bcp.2012.01.001
References
  1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512-516. doi:10.1016/j.jaad.2013.11.013
  2. Parisi R, Symmons DP, Griffiths CE, et al; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377-385. doi:10.1038/jid.2012.339
  3. Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80:43-53. doi:10.1016/j.jaad.2018.06.056
  4. Crowley J, Thaci D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for >156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77:310-317.e1.
  5. Reddy SP, Shah VV, Wu JJ. Apremilast for a psoriasis patient with HIV and hepatitis C. J Eur Acad Dermatol Venereol. 2017;31:E481-E482. doi:10.1111/jdv.14301
  6. Zarbafian M, Cote B, Richer V. Treatment of moderate to severe psoriasis with apremilast over 2 years in the context of long-term treated HIV infection: a case report. SAGE Open Med Case Rep. 2019;7:2050313X19845193. doi:10.1177/2050313X19845193 doi:10.1016/j.jaad.2017.01.052
  7. Sacchelli L, Patrizi A, Ferrara F, et al. Apremilast as therapeutic option in a HIV positive patient with severe psoriasis. Dermatol Ther. 2018;31:E12719. doi:10.1111/dth.12719
  8. Manfreda V, Esposito M, Campione E, et al. Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. Postgrad Med. 2019;131:239-240. doi:10.1080/00325481.2019 .1575613
  9. Shah BJ, Mistry D, Chaudhary N. Apremilast in people living with HIV with psoriasis vulgaris: a case report. Indian J Dermatol. 2019;64:242- 244. doi:10.4103/ijd.IJD_633_18
  10. Reddy SP, Lee E, Wu JJ. Apremilast and phototherapy for treatment of psoriasis in a patient with human immunodeficiency virus. Cutis. 2019;103:E6-E7.
  11. Romita P, Foti C, Calianno G, et al. Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast. Dermatol Ther. 2022;35:E15610. doi:10.1111/dth.15610
  12. Zeb L, Mhaskar R, Lewis S, et al. Real-world drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center. Dermatol Ther. 2021;34:E14826. doi:10.1111/dth.14826
  13. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583-1590. doi:10.1016/j.bcp.2012.01.001
Issue
Cutis - 115(2)
Issue
Cutis - 115(2)
Page Number
66-67
Page Number
66-67
Publications
Publications
Topics
Article Type
Display Headline

Apremilast Treatment Outcomes and Adverse Events in Psoriasis Patients With HIV

Display Headline

Apremilast Treatment Outcomes and Adverse Events in Psoriasis Patients With HIV

Sections
Inside the Article

PRACTICE POINT

  • For patients with HIV who require systemic therapy for psoriasis, apremilast may provide an effective and safe therapeutic option, with minimal immunosuppressive adverse effects.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Wed, 02/05/2025 - 11:42
Un-Gate On Date
Wed, 02/05/2025 - 11:42
Use ProPublica
CFC Schedule Remove Status
Wed, 02/05/2025 - 11:42
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Wed, 02/05/2025 - 11:42

Association Between Psoriasis and Sunburn Prevalence in US Adults

Article Type
Changed
Wed, 02/19/2025 - 17:01
Display Headline

Association Between Psoriasis and Sunburn Prevalence in US Adults

To the Editor:

UV light plays an essential role in various environmental and biological processes.1 Excessive exposure to UV radiation can lead to sunburn, which is marked by skin erythema and pain.2 A study of more than 31,000 individuals found that 34.2% of adults aged 18 years and older reported at least 1 sunburn during the survey year.3 A lack of research regarding the incidence of sunburns in patients with psoriasis is particularly important considering the heightened incidence of skin cancer observed in this population.4 Thus, the aim of our study was to analyze the prevalence of sunburns among US adults with psoriasis utilizing data from the National Health and Nutrition Examination Survey (NHANES) database.5

Our analysis initially included 11,842 participants ranging in age from 20 to 59 years; 35 did not respond to questions assessing psoriasis and sunburn prevalence and thus were excluded. Multivariable logistic regression analyses were performed using Stata/SE 18 (StataCorp LLC) to assess the relationship between psoriasis and sunburns. Our models controlled for patient age, sex, income, race, education, diabetes status, tobacco use, and body mass index. A P value <.05 was considered statistically significant. The study period from January 2009 to December 2014 was chosen based on the availability of the most recent and comprehensive psoriasis data within the NHANES database.

In the NHANES data we evaluated, psoriasis status was assessed by asking, “Have you ever been told by a doctor or other health professional that you had psoriasis?” History of sunburns in the survey year was assessed by the question, “How many times in the past year have you had sunburn?” Patients who reported 1 or more sunburns were included in the sunburn cohort, while those who did not report a sunburn were included in the no sunburn cohort.

In our analysis, the prevalence of at least 1 sunburn in the survey year in patients with psoriasis was 55.4% (weighted), compared to 45.6% (weighted) among those without psoriasis (eTable 1). Although there was no statistically significant relationship between psoriasis and history of sunburn in patients aged 20 to 59 years, a subgroup analysis revealed a significant association between psoriasis and sunburn in adults aged 20 to 39 years after adjusting for potential confounding variables (adjusted OR, 1.57 [95% CI, 1.00-2.45]; P=.049)(eTable 2). Further analysis of subgroups showed no statistically significant results with adjustment of the logistic regression model. Characterizing response rates is important for assessing the validity of survey studies. The NHANES response rate from 2009 to 2014 was 72.9%, enhancing the reliability of our findings.

CT115002063-eTable1CT115002063-eTable2

Our study revealed an increased prevalence of sunburn in US adults with psoriasis. A trend of increased sunburn prevalence among younger adults regardless of psoriasis status is corroborated by the literature. Surveys conducted in the United States in 2005, 2010, and 2015 showed that 43% to 50% of adults aged 18 to 39 years and 28% to 42% of those aged 40 to 59 years reported experiencing at least 1 sunburn within the respective survey year.6 Furthermore, in our study, patients with psoriasis reported higher rates of sunburn than their counterparts without psoriasis, both in those aged 20 to 39 years (psoriasis, 62.8% [73/136]; no psoriasis, 51.1% [2425/5840]) and those aged 40 to 59 years (psoriasis, 50.5% [n=75/179]; no psoriasis, 40.2% [1613/5652]), though it was only statistically significant in the 20-to-39 age group. This discrepancy may be attributed to differences in sun-protective behaviors in younger vs older adults. A study from the NHANES database found that, among individuals aged 20 to 39 years, 75.9% [4225/5493] reported staying in the shade, 50.0% [2346/5493] reported using sunscreen, and 31.2% [1874/5493] reported wearing sun-protective clothing.7 Interestingly, the likelihood of engaging in all 3 behaviors was 28% lower in the 20-to-39 age group vs the 40-to-59 age group (adjusted OR, 0.72; 95% CI, 0.62-0.83).7

While our analysis adjusted for age, race/ethnicity, and tobacco use to mitigate potential confounding, we acknowledge the statistically significant differences observed in these variables between study groups as presented in eTable 2. These differences may reflect inherent disparities in the study population. We employed multivariable regression analysis to control for these covariates in our primary analyses. Of note, there was a statistically significant difference associated with race/ethnicity when comparing non-Hispanic White individuals with psoriasis (77.0% [n=182/315]) and those without psoriasis (62.5% [n=4516/11,492])(P<.0001)(eTable 1). The higher proportion of non-Hispanic White patients in the psoriasis group may reflect an increased susceptibility to sunburn given their typically lighter skin pigmentation; however, our analysis controlled for race/ethnicity (eTable 2), thereby allowing us to isolate the effect of psoriasis on sunburn prevalence independent of racial/ethnic differences. There also were statistically significant differences in tobacco use (P=.0026) and age (P=.002) in our unadjusted findings (eTable 1). Again, our analysis controlled for these factors (eTable 2), thereby allowing us to isolate the effect of psoriasis on sunburn prevalence independent of tobacco use and age differences. This approach enhanced the reliability of our findings.

The association between psoriasis and skin cancer has previously been evaluated using the NHANES database—one study found that patients with psoriasis had a significantly higher prevalence of nonmelanoma skin cancer compared with those without psoriasis (3.0% vs 1.3%; relative risk, 2.29; P<.001).8 This difference remained significant after adjusting for confounding variables, as it was found that psoriasis was independently associated with a 1.5-fold increased risk for nonmelanoma skin cancer (adjusted relative risk, 2.06; P=.004).8

The relationship between psoriasis and sunburn may be due to behavioral choices, such as the use of phototherapy for managing psoriasis due to its recognized advantages.9 Patients may seek out both artificial and natural light sources more frequently, potentially increasing the risk for sunburn.10 Psoriasis-related sunburn susceptibility may stem from biological factors, including vitamin D insufficiency, as vitamin D is crucial for keratinocyte differentiation, immune function, and UV protection and repair.11 One study examined the effects of high-dose vitamin D3 on sunburn-induced inflammation.12 Patients who received high-dose vitamin D3 exhibited reduced skin inflammation, enhanced skin barrier repair, and increased anti-inflammatory response compared with those who did not receive the supplement. This improvement was associated with upregulation of arginase 1, an anti-inflammatory enzyme, leading to decreased levels of pro-inflammatory mediators such as tumor necrosis factor α and inducible nitric oxide synthase, thereby promoting tissue repair and reducing prolonged inflammation.12 These findings suggest that vitamin D insufficiency coupled with dysregulated immune responses may contribute to the heightened susceptibility of individuals with psoriasis to sunburn.

The established correlation between sunburn and skin cancer4,8 coupled with our findings of increased prevalence of sunburn in individuals with psoriasis underscores the need for additional research to clarify the underlying biological and behavioral factors that may contribute to a higher prevalence of sunburn in these patients, along with the implications for skin cancer development. Limitations of our study included potential recall bias, as individuals self-reported their clinical conditions and the inability to incorporate psoriasis severity into our analysis, as this was not consistently captured in the NHANES questionnaire during the study period.

References
  1. Blaustein AR, Searle C. Ultraviolet radiation. In: Levin SA, ed. Encyclopedia of Biodiversity. 2nd ed. Academic Press; 2013:296-303.
  2. D’Orazio J, Jarrett S, Amaro-Ortiz A, et al. UV radiation and the skin. Int J Mol Sci. 2013;14:12222-12248
  3. Holman DM, Ding H, Guy GP Jr, et al. Prevalence of sun protection use and sunburn and association of demographic and behavioral characteristics with sunburn among US adults. JAMA Dermatol. 2018;154:561-568.
  4. Balda A, Wani I, Roohi TF, et al. Psoriasis and skin cancer—is there a link? Int Immunopharmacol. 2023;121:110464.
  5. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. NHANES questionnaires, datasets, and related documentation. Accessed December 4, 2024. https://wwwn.cdc.gov/nchs/nhanes/Default.aspx
  6. Holman DM, Ding H, Berkowitz Z, et al. Sunburn prevalence among US adults, National Health Interview Survey 2005, 2010, and 2015. J Am Acad Dermatol. 2019;80:817-820.
  7. Challapalli SD, Shetty KR, Bui Q, et al. Sun protective behaviors among adolescents and young adults in the United States. J Natl Med Assoc. 2023;115:353-361.
  8. Herbosa CM, Hodges W, Mann C, et al. Risk of cancer in psoriasis: study of a nationally representative sample of the US population with comparison to a single]institution cohort. J Am Acad Dermatol Venereol. 2020;34:E529-E531.
  9. Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019;81:775-804.
  10. Åkerla P, Pukkala E, Helminen M, et al. Skin cancer risk of narrow-band UV-B (TL-01) phototherapy: a multi-center registry study with 4,815 patients. Acta Derm Venereol. 2024;104:adv39927.
  11. Filoni A, Vestita M, Congedo M, et al. Association between psoriasis and vitamin D: duration of disease correlates with decreased vitamin D serum levels: an observational case-control study. Medicine (Baltimore). 2018;97:E11185.
  12. Scott JF, Das LM, Ahsanuddin S, et al. Oral vitamin D rapidly attenuates inflammation from sunburn: an interventional study. J Invest Dermatol. 2017;137:2078-2086.
Article PDF
Author and Disclosure Information

Sara Osborne is from the University of Minnesota School of Medicine, Twin Cities. Olivia Kam is from the Renaissance School of Medicine at Stony Brook University, New York. Dr. Thacker is from the KPC Health Hemet Global Medical Center, California. Raquel Wescott is from the University of Nevada Reno School of Medicine. Carolynne Vo is from the University of California Riverside School of Medicine. Dr. Wu is from the University of Miami Miller School of Medicine, Florida.

Sara Osborne, Olivia Kam, Raquel Wescott, Carolynne Vo, and Dr. Thacker have no relevant financial disclosures to report. Dr. Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, DermTech, Dr. Reddy’s Laboratories, Eli Lilly & Company, EPI Health, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Pfizer, Regeneron, Samsung Bioepis, Sanofi Genzyme, Solius, Sun Pharmaceuticals, UCB, and Zerigo Health.

Correspondence: Jashin J. Wu, MD, University of Miami Miller School of Medicine, 1600 NW 10th Ave, RMSB, Room 2023-A, Miami, FL 33136 ([email protected]).

Cutis. 2025 February;115(2):63-64, E4-E5. doi:10.12788/cutis.1171

Issue
Cutis - 115(2)
Publications
Topics
Page Number
63-64
Sections
Author and Disclosure Information

Sara Osborne is from the University of Minnesota School of Medicine, Twin Cities. Olivia Kam is from the Renaissance School of Medicine at Stony Brook University, New York. Dr. Thacker is from the KPC Health Hemet Global Medical Center, California. Raquel Wescott is from the University of Nevada Reno School of Medicine. Carolynne Vo is from the University of California Riverside School of Medicine. Dr. Wu is from the University of Miami Miller School of Medicine, Florida.

Sara Osborne, Olivia Kam, Raquel Wescott, Carolynne Vo, and Dr. Thacker have no relevant financial disclosures to report. Dr. Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, DermTech, Dr. Reddy’s Laboratories, Eli Lilly & Company, EPI Health, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Pfizer, Regeneron, Samsung Bioepis, Sanofi Genzyme, Solius, Sun Pharmaceuticals, UCB, and Zerigo Health.

Correspondence: Jashin J. Wu, MD, University of Miami Miller School of Medicine, 1600 NW 10th Ave, RMSB, Room 2023-A, Miami, FL 33136 ([email protected]).

Cutis. 2025 February;115(2):63-64, E4-E5. doi:10.12788/cutis.1171

Author and Disclosure Information

Sara Osborne is from the University of Minnesota School of Medicine, Twin Cities. Olivia Kam is from the Renaissance School of Medicine at Stony Brook University, New York. Dr. Thacker is from the KPC Health Hemet Global Medical Center, California. Raquel Wescott is from the University of Nevada Reno School of Medicine. Carolynne Vo is from the University of California Riverside School of Medicine. Dr. Wu is from the University of Miami Miller School of Medicine, Florida.

Sara Osborne, Olivia Kam, Raquel Wescott, Carolynne Vo, and Dr. Thacker have no relevant financial disclosures to report. Dr. Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, DermTech, Dr. Reddy’s Laboratories, Eli Lilly & Company, EPI Health, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Pfizer, Regeneron, Samsung Bioepis, Sanofi Genzyme, Solius, Sun Pharmaceuticals, UCB, and Zerigo Health.

Correspondence: Jashin J. Wu, MD, University of Miami Miller School of Medicine, 1600 NW 10th Ave, RMSB, Room 2023-A, Miami, FL 33136 ([email protected]).

Cutis. 2025 February;115(2):63-64, E4-E5. doi:10.12788/cutis.1171

Article PDF
Article PDF

To the Editor:

UV light plays an essential role in various environmental and biological processes.1 Excessive exposure to UV radiation can lead to sunburn, which is marked by skin erythema and pain.2 A study of more than 31,000 individuals found that 34.2% of adults aged 18 years and older reported at least 1 sunburn during the survey year.3 A lack of research regarding the incidence of sunburns in patients with psoriasis is particularly important considering the heightened incidence of skin cancer observed in this population.4 Thus, the aim of our study was to analyze the prevalence of sunburns among US adults with psoriasis utilizing data from the National Health and Nutrition Examination Survey (NHANES) database.5

Our analysis initially included 11,842 participants ranging in age from 20 to 59 years; 35 did not respond to questions assessing psoriasis and sunburn prevalence and thus were excluded. Multivariable logistic regression analyses were performed using Stata/SE 18 (StataCorp LLC) to assess the relationship between psoriasis and sunburns. Our models controlled for patient age, sex, income, race, education, diabetes status, tobacco use, and body mass index. A P value <.05 was considered statistically significant. The study period from January 2009 to December 2014 was chosen based on the availability of the most recent and comprehensive psoriasis data within the NHANES database.

In the NHANES data we evaluated, psoriasis status was assessed by asking, “Have you ever been told by a doctor or other health professional that you had psoriasis?” History of sunburns in the survey year was assessed by the question, “How many times in the past year have you had sunburn?” Patients who reported 1 or more sunburns were included in the sunburn cohort, while those who did not report a sunburn were included in the no sunburn cohort.

In our analysis, the prevalence of at least 1 sunburn in the survey year in patients with psoriasis was 55.4% (weighted), compared to 45.6% (weighted) among those without psoriasis (eTable 1). Although there was no statistically significant relationship between psoriasis and history of sunburn in patients aged 20 to 59 years, a subgroup analysis revealed a significant association between psoriasis and sunburn in adults aged 20 to 39 years after adjusting for potential confounding variables (adjusted OR, 1.57 [95% CI, 1.00-2.45]; P=.049)(eTable 2). Further analysis of subgroups showed no statistically significant results with adjustment of the logistic regression model. Characterizing response rates is important for assessing the validity of survey studies. The NHANES response rate from 2009 to 2014 was 72.9%, enhancing the reliability of our findings.

CT115002063-eTable1CT115002063-eTable2

Our study revealed an increased prevalence of sunburn in US adults with psoriasis. A trend of increased sunburn prevalence among younger adults regardless of psoriasis status is corroborated by the literature. Surveys conducted in the United States in 2005, 2010, and 2015 showed that 43% to 50% of adults aged 18 to 39 years and 28% to 42% of those aged 40 to 59 years reported experiencing at least 1 sunburn within the respective survey year.6 Furthermore, in our study, patients with psoriasis reported higher rates of sunburn than their counterparts without psoriasis, both in those aged 20 to 39 years (psoriasis, 62.8% [73/136]; no psoriasis, 51.1% [2425/5840]) and those aged 40 to 59 years (psoriasis, 50.5% [n=75/179]; no psoriasis, 40.2% [1613/5652]), though it was only statistically significant in the 20-to-39 age group. This discrepancy may be attributed to differences in sun-protective behaviors in younger vs older adults. A study from the NHANES database found that, among individuals aged 20 to 39 years, 75.9% [4225/5493] reported staying in the shade, 50.0% [2346/5493] reported using sunscreen, and 31.2% [1874/5493] reported wearing sun-protective clothing.7 Interestingly, the likelihood of engaging in all 3 behaviors was 28% lower in the 20-to-39 age group vs the 40-to-59 age group (adjusted OR, 0.72; 95% CI, 0.62-0.83).7

While our analysis adjusted for age, race/ethnicity, and tobacco use to mitigate potential confounding, we acknowledge the statistically significant differences observed in these variables between study groups as presented in eTable 2. These differences may reflect inherent disparities in the study population. We employed multivariable regression analysis to control for these covariates in our primary analyses. Of note, there was a statistically significant difference associated with race/ethnicity when comparing non-Hispanic White individuals with psoriasis (77.0% [n=182/315]) and those without psoriasis (62.5% [n=4516/11,492])(P<.0001)(eTable 1). The higher proportion of non-Hispanic White patients in the psoriasis group may reflect an increased susceptibility to sunburn given their typically lighter skin pigmentation; however, our analysis controlled for race/ethnicity (eTable 2), thereby allowing us to isolate the effect of psoriasis on sunburn prevalence independent of racial/ethnic differences. There also were statistically significant differences in tobacco use (P=.0026) and age (P=.002) in our unadjusted findings (eTable 1). Again, our analysis controlled for these factors (eTable 2), thereby allowing us to isolate the effect of psoriasis on sunburn prevalence independent of tobacco use and age differences. This approach enhanced the reliability of our findings.

The association between psoriasis and skin cancer has previously been evaluated using the NHANES database—one study found that patients with psoriasis had a significantly higher prevalence of nonmelanoma skin cancer compared with those without psoriasis (3.0% vs 1.3%; relative risk, 2.29; P<.001).8 This difference remained significant after adjusting for confounding variables, as it was found that psoriasis was independently associated with a 1.5-fold increased risk for nonmelanoma skin cancer (adjusted relative risk, 2.06; P=.004).8

The relationship between psoriasis and sunburn may be due to behavioral choices, such as the use of phototherapy for managing psoriasis due to its recognized advantages.9 Patients may seek out both artificial and natural light sources more frequently, potentially increasing the risk for sunburn.10 Psoriasis-related sunburn susceptibility may stem from biological factors, including vitamin D insufficiency, as vitamin D is crucial for keratinocyte differentiation, immune function, and UV protection and repair.11 One study examined the effects of high-dose vitamin D3 on sunburn-induced inflammation.12 Patients who received high-dose vitamin D3 exhibited reduced skin inflammation, enhanced skin barrier repair, and increased anti-inflammatory response compared with those who did not receive the supplement. This improvement was associated with upregulation of arginase 1, an anti-inflammatory enzyme, leading to decreased levels of pro-inflammatory mediators such as tumor necrosis factor α and inducible nitric oxide synthase, thereby promoting tissue repair and reducing prolonged inflammation.12 These findings suggest that vitamin D insufficiency coupled with dysregulated immune responses may contribute to the heightened susceptibility of individuals with psoriasis to sunburn.

The established correlation between sunburn and skin cancer4,8 coupled with our findings of increased prevalence of sunburn in individuals with psoriasis underscores the need for additional research to clarify the underlying biological and behavioral factors that may contribute to a higher prevalence of sunburn in these patients, along with the implications for skin cancer development. Limitations of our study included potential recall bias, as individuals self-reported their clinical conditions and the inability to incorporate psoriasis severity into our analysis, as this was not consistently captured in the NHANES questionnaire during the study period.

To the Editor:

UV light plays an essential role in various environmental and biological processes.1 Excessive exposure to UV radiation can lead to sunburn, which is marked by skin erythema and pain.2 A study of more than 31,000 individuals found that 34.2% of adults aged 18 years and older reported at least 1 sunburn during the survey year.3 A lack of research regarding the incidence of sunburns in patients with psoriasis is particularly important considering the heightened incidence of skin cancer observed in this population.4 Thus, the aim of our study was to analyze the prevalence of sunburns among US adults with psoriasis utilizing data from the National Health and Nutrition Examination Survey (NHANES) database.5

Our analysis initially included 11,842 participants ranging in age from 20 to 59 years; 35 did not respond to questions assessing psoriasis and sunburn prevalence and thus were excluded. Multivariable logistic regression analyses were performed using Stata/SE 18 (StataCorp LLC) to assess the relationship between psoriasis and sunburns. Our models controlled for patient age, sex, income, race, education, diabetes status, tobacco use, and body mass index. A P value <.05 was considered statistically significant. The study period from January 2009 to December 2014 was chosen based on the availability of the most recent and comprehensive psoriasis data within the NHANES database.

In the NHANES data we evaluated, psoriasis status was assessed by asking, “Have you ever been told by a doctor or other health professional that you had psoriasis?” History of sunburns in the survey year was assessed by the question, “How many times in the past year have you had sunburn?” Patients who reported 1 or more sunburns were included in the sunburn cohort, while those who did not report a sunburn were included in the no sunburn cohort.

In our analysis, the prevalence of at least 1 sunburn in the survey year in patients with psoriasis was 55.4% (weighted), compared to 45.6% (weighted) among those without psoriasis (eTable 1). Although there was no statistically significant relationship between psoriasis and history of sunburn in patients aged 20 to 59 years, a subgroup analysis revealed a significant association between psoriasis and sunburn in adults aged 20 to 39 years after adjusting for potential confounding variables (adjusted OR, 1.57 [95% CI, 1.00-2.45]; P=.049)(eTable 2). Further analysis of subgroups showed no statistically significant results with adjustment of the logistic regression model. Characterizing response rates is important for assessing the validity of survey studies. The NHANES response rate from 2009 to 2014 was 72.9%, enhancing the reliability of our findings.

CT115002063-eTable1CT115002063-eTable2

Our study revealed an increased prevalence of sunburn in US adults with psoriasis. A trend of increased sunburn prevalence among younger adults regardless of psoriasis status is corroborated by the literature. Surveys conducted in the United States in 2005, 2010, and 2015 showed that 43% to 50% of adults aged 18 to 39 years and 28% to 42% of those aged 40 to 59 years reported experiencing at least 1 sunburn within the respective survey year.6 Furthermore, in our study, patients with psoriasis reported higher rates of sunburn than their counterparts without psoriasis, both in those aged 20 to 39 years (psoriasis, 62.8% [73/136]; no psoriasis, 51.1% [2425/5840]) and those aged 40 to 59 years (psoriasis, 50.5% [n=75/179]; no psoriasis, 40.2% [1613/5652]), though it was only statistically significant in the 20-to-39 age group. This discrepancy may be attributed to differences in sun-protective behaviors in younger vs older adults. A study from the NHANES database found that, among individuals aged 20 to 39 years, 75.9% [4225/5493] reported staying in the shade, 50.0% [2346/5493] reported using sunscreen, and 31.2% [1874/5493] reported wearing sun-protective clothing.7 Interestingly, the likelihood of engaging in all 3 behaviors was 28% lower in the 20-to-39 age group vs the 40-to-59 age group (adjusted OR, 0.72; 95% CI, 0.62-0.83).7

While our analysis adjusted for age, race/ethnicity, and tobacco use to mitigate potential confounding, we acknowledge the statistically significant differences observed in these variables between study groups as presented in eTable 2. These differences may reflect inherent disparities in the study population. We employed multivariable regression analysis to control for these covariates in our primary analyses. Of note, there was a statistically significant difference associated with race/ethnicity when comparing non-Hispanic White individuals with psoriasis (77.0% [n=182/315]) and those without psoriasis (62.5% [n=4516/11,492])(P<.0001)(eTable 1). The higher proportion of non-Hispanic White patients in the psoriasis group may reflect an increased susceptibility to sunburn given their typically lighter skin pigmentation; however, our analysis controlled for race/ethnicity (eTable 2), thereby allowing us to isolate the effect of psoriasis on sunburn prevalence independent of racial/ethnic differences. There also were statistically significant differences in tobacco use (P=.0026) and age (P=.002) in our unadjusted findings (eTable 1). Again, our analysis controlled for these factors (eTable 2), thereby allowing us to isolate the effect of psoriasis on sunburn prevalence independent of tobacco use and age differences. This approach enhanced the reliability of our findings.

The association between psoriasis and skin cancer has previously been evaluated using the NHANES database—one study found that patients with psoriasis had a significantly higher prevalence of nonmelanoma skin cancer compared with those without psoriasis (3.0% vs 1.3%; relative risk, 2.29; P<.001).8 This difference remained significant after adjusting for confounding variables, as it was found that psoriasis was independently associated with a 1.5-fold increased risk for nonmelanoma skin cancer (adjusted relative risk, 2.06; P=.004).8

The relationship between psoriasis and sunburn may be due to behavioral choices, such as the use of phototherapy for managing psoriasis due to its recognized advantages.9 Patients may seek out both artificial and natural light sources more frequently, potentially increasing the risk for sunburn.10 Psoriasis-related sunburn susceptibility may stem from biological factors, including vitamin D insufficiency, as vitamin D is crucial for keratinocyte differentiation, immune function, and UV protection and repair.11 One study examined the effects of high-dose vitamin D3 on sunburn-induced inflammation.12 Patients who received high-dose vitamin D3 exhibited reduced skin inflammation, enhanced skin barrier repair, and increased anti-inflammatory response compared with those who did not receive the supplement. This improvement was associated with upregulation of arginase 1, an anti-inflammatory enzyme, leading to decreased levels of pro-inflammatory mediators such as tumor necrosis factor α and inducible nitric oxide synthase, thereby promoting tissue repair and reducing prolonged inflammation.12 These findings suggest that vitamin D insufficiency coupled with dysregulated immune responses may contribute to the heightened susceptibility of individuals with psoriasis to sunburn.

The established correlation between sunburn and skin cancer4,8 coupled with our findings of increased prevalence of sunburn in individuals with psoriasis underscores the need for additional research to clarify the underlying biological and behavioral factors that may contribute to a higher prevalence of sunburn in these patients, along with the implications for skin cancer development. Limitations of our study included potential recall bias, as individuals self-reported their clinical conditions and the inability to incorporate psoriasis severity into our analysis, as this was not consistently captured in the NHANES questionnaire during the study period.

References
  1. Blaustein AR, Searle C. Ultraviolet radiation. In: Levin SA, ed. Encyclopedia of Biodiversity. 2nd ed. Academic Press; 2013:296-303.
  2. D’Orazio J, Jarrett S, Amaro-Ortiz A, et al. UV radiation and the skin. Int J Mol Sci. 2013;14:12222-12248
  3. Holman DM, Ding H, Guy GP Jr, et al. Prevalence of sun protection use and sunburn and association of demographic and behavioral characteristics with sunburn among US adults. JAMA Dermatol. 2018;154:561-568.
  4. Balda A, Wani I, Roohi TF, et al. Psoriasis and skin cancer—is there a link? Int Immunopharmacol. 2023;121:110464.
  5. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. NHANES questionnaires, datasets, and related documentation. Accessed December 4, 2024. https://wwwn.cdc.gov/nchs/nhanes/Default.aspx
  6. Holman DM, Ding H, Berkowitz Z, et al. Sunburn prevalence among US adults, National Health Interview Survey 2005, 2010, and 2015. J Am Acad Dermatol. 2019;80:817-820.
  7. Challapalli SD, Shetty KR, Bui Q, et al. Sun protective behaviors among adolescents and young adults in the United States. J Natl Med Assoc. 2023;115:353-361.
  8. Herbosa CM, Hodges W, Mann C, et al. Risk of cancer in psoriasis: study of a nationally representative sample of the US population with comparison to a single]institution cohort. J Am Acad Dermatol Venereol. 2020;34:E529-E531.
  9. Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019;81:775-804.
  10. Åkerla P, Pukkala E, Helminen M, et al. Skin cancer risk of narrow-band UV-B (TL-01) phototherapy: a multi-center registry study with 4,815 patients. Acta Derm Venereol. 2024;104:adv39927.
  11. Filoni A, Vestita M, Congedo M, et al. Association between psoriasis and vitamin D: duration of disease correlates with decreased vitamin D serum levels: an observational case-control study. Medicine (Baltimore). 2018;97:E11185.
  12. Scott JF, Das LM, Ahsanuddin S, et al. Oral vitamin D rapidly attenuates inflammation from sunburn: an interventional study. J Invest Dermatol. 2017;137:2078-2086.
References
  1. Blaustein AR, Searle C. Ultraviolet radiation. In: Levin SA, ed. Encyclopedia of Biodiversity. 2nd ed. Academic Press; 2013:296-303.
  2. D’Orazio J, Jarrett S, Amaro-Ortiz A, et al. UV radiation and the skin. Int J Mol Sci. 2013;14:12222-12248
  3. Holman DM, Ding H, Guy GP Jr, et al. Prevalence of sun protection use and sunburn and association of demographic and behavioral characteristics with sunburn among US adults. JAMA Dermatol. 2018;154:561-568.
  4. Balda A, Wani I, Roohi TF, et al. Psoriasis and skin cancer—is there a link? Int Immunopharmacol. 2023;121:110464.
  5. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. NHANES questionnaires, datasets, and related documentation. Accessed December 4, 2024. https://wwwn.cdc.gov/nchs/nhanes/Default.aspx
  6. Holman DM, Ding H, Berkowitz Z, et al. Sunburn prevalence among US adults, National Health Interview Survey 2005, 2010, and 2015. J Am Acad Dermatol. 2019;80:817-820.
  7. Challapalli SD, Shetty KR, Bui Q, et al. Sun protective behaviors among adolescents and young adults in the United States. J Natl Med Assoc. 2023;115:353-361.
  8. Herbosa CM, Hodges W, Mann C, et al. Risk of cancer in psoriasis: study of a nationally representative sample of the US population with comparison to a single]institution cohort. J Am Acad Dermatol Venereol. 2020;34:E529-E531.
  9. Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019;81:775-804.
  10. Åkerla P, Pukkala E, Helminen M, et al. Skin cancer risk of narrow-band UV-B (TL-01) phototherapy: a multi-center registry study with 4,815 patients. Acta Derm Venereol. 2024;104:adv39927.
  11. Filoni A, Vestita M, Congedo M, et al. Association between psoriasis and vitamin D: duration of disease correlates with decreased vitamin D serum levels: an observational case-control study. Medicine (Baltimore). 2018;97:E11185.
  12. Scott JF, Das LM, Ahsanuddin S, et al. Oral vitamin D rapidly attenuates inflammation from sunburn: an interventional study. J Invest Dermatol. 2017;137:2078-2086.
Issue
Cutis - 115(2)
Issue
Cutis - 115(2)
Page Number
63-64
Page Number
63-64
Publications
Publications
Topics
Article Type
Display Headline

Association Between Psoriasis and Sunburn Prevalence in US Adults

Display Headline

Association Between Psoriasis and Sunburn Prevalence in US Adults

Sections
Inside the Article

PRACTICE POINTS

  • It is important for dermatologists to encourage rigorous sun-safety practices in patients with psoriasis, particularly those aged 20 to 59 years.
  • A thorough sunburn history should be taken for skin cancer risk assessment in patients with psoriasis.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Mon, 02/03/2025 - 16:54
Un-Gate On Date
Mon, 02/03/2025 - 16:54
Use ProPublica
CFC Schedule Remove Status
Mon, 02/03/2025 - 16:54
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Mon, 02/03/2025 - 16:54